


**CUMULATIVE
SUPPLEMENT 8
AUGUST 2020**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

40th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2020

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

40th EDITION

**Cumulative Supplement 8
August 2020**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi

DRUG PRODUCT LISTS

Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

40th EDITION

CUMULATIVE SUPPLEMENT 8
AUGUST 2020

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ACP NIMBLE BUYER INC (ACP NIMBLE)	COSETTE PHARMACEUTICALS INC (COSETTE)
AMNEAL PHARMACEUTICALS CO GMBH (AMNEAL PHARMS CO)	AMNEAL EU LTD (AMNEAL EU)
AMERICAN ANTIBIOTICS INC (AM ANTIBIOTICS)	BELCHER PHARMACEUTICALS INC (BELCHER PHARMS)

AMERICAN ANTIBIOTICS LLC (AM ANTIBIOTICS)	BELCHER PHARMACEUTICALS INC (BELCHER PHARMS)
ANDA REPOSITORY LLC (ANDA REPOSITORY)	PHARMACEUTICS INTERNATIONAL INC (PII)
LUITPOLD PHARMACEUTICALS INC (LUITPOLD)	AMERICAN REGENT INC (AM REGENT)
SHIRE DEVELOPMENT INC (SHIRE)	TAKEDA PHARMACEUTICALS USA INC (TAKEDA PHARMS USA)
SHIRE DEVELOPMENT LLC (SHIRE DEV LLC)	TAKEDA PHARMACEUTICALS USA INC (TAKEDA PHARMS USA)
SHIRE DEVELOPMENT LLC (SHIRE LLC)	TAKEDA PHARMACEUTICALS USA INC (TAKEDA PHARMS USA)
SUVEN LIFE SCIENCES LTD (SUVEN LIFE)	SUVEN PHARMACEUTICALS LTD (SUVEN PHARMS)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN GROUP HOLDINGS 4 LLC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2019</u>	<u>MAR</u> <u>2020</u>	<u>JUN</u> <u>2020</u>	<u>SEP</u> <u>2020</u>	<u>DEC</u> <u>2020</u>
DRUG PRODUCTS	20567	20367	20382		
LISTED SINGLE	2743	2635	2660		
SOURCE	(13.3%)	(12.9%)	(13.1%)		
MULTISOURCE	17824	17732	17722		
	(86.7%)	(87.1%)	(86.9%)		
THERAPEUTICALLY	17740	17659	17649		
EQUIVALENT	(86.3%)	(86.7%)	(86.6%)		
NOT	84	73	73		
THERAPEUTICALLY	(0.4%)	(0.4%)	(0.4%)		
EQUIVALENT					
EXCEPTIONS ⁴	54	54	54		
	(0.3%)	(0.3%)	(0.3%)		
NEW MOLECULAR					
ENTITIES	17	24	25		
APPROVED					
NUMBER OF	1162	1166	1189		
APPLICANTS					

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >D>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code
CTNA	Change. Trade Name
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE

TABLET; ORAL

ABACAVIR SULFATE

>D>	AB	APOTEX INC	EQ 300MG BASE	A201570	001	Dec 17, 2012	Aug DISC
>A>		@	EQ 300MG BASE	A201570	001	Dec 17, 2012	Aug DISC

ABAMETAPIR

LOTION; TOPICAL

XEGLYZE

+	!	DR REDDYS LABS SA	0.74%	N206966	001	Jul 24, 2020	Jul NEWA
---	---	-------------------	-------	---------	-----	--------------	----------

ABIRATERONE ACETATE

TABLET; ORAL

ABIRATERONE ACETATE

AB		DR REDDYS LABS LTD	250MG	A208416	001	May 18, 2020	May NEWA
----	--	--------------------	-------	---------	-----	--------------	----------

ACARBOSE

TABLET; ORAL

ACARBOSE

		@ EMCURE PHARMS LTD	25MG	A202271	001	Feb 07, 2012	Mar DISC
		@	50MG	A202271	002	Feb 07, 2012	Mar DISC
		@	100MG	A202271	003	Feb 07, 2012	Mar DISC
>A>	AB	HANGZHOU ZHONGMEI	25MG	A213821	001	Aug 18, 2020	Aug NEWA
>A>	AB		50MG	A213821	002	Aug 18, 2020	Aug NEWA
>A>	AB		100MG	A213821	003	Aug 18, 2020	Aug NEWA

ACETAMINOPHEN

SOLUTION; INTRAVENOUS

ACETAMINOPHEN

AP		MYLAN	1GM/100ML (10MG/ML)	A213255	001	Aug 07, 2020	Jul NEWA
----	--	-------	---------------------	---------	-----	--------------	----------

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

>A>	AA	!	LGM PHARMA	300MG; 50MG	A090956	001	Aug 23, 2011	Aug CAHN
>D>	AA	!	NEXGEN PHARMA	300MG; 50MG	A090956	001	Aug 23, 2011	Aug CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>A>	AA	!	LGM PHARMA	300MG; 50MG; 40MG	A040885	001	Nov 16, 2009	Aug CAHN
>D>	AA	!	NEXGEN PHARMA	300MG; 50MG; 40MG	A040885	001	Nov 16, 2009	Aug CAHN
	AA		TARO PHARM INDS LTD	300MG; 50MG; 40MG	A213046	001	Jul 01, 2020	Jun NEWA

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

		@	HIKMA PHARMS	325MG; 50MG; 40MG	A089718	001	Jun 12, 1995	Feb DISC
>A>	AA		LGM PHARMA	325MG; 50MG; 40MG	A209587	001	Oct 31, 2018	Aug CAHN
	AA		NESHER PHARMS	325MG; 50MG; 40MG	A211543	001	Jul 17, 2020	Jul NEWA
>D>	AA		NEXGEN PHARMA INC	325MG; 50MG; 40MG	A209587	001	Oct 31, 2018	Aug CAHN
		@	SPECGX LLC	325MG; 50MG; 40MG	A087804	001	Jan 24, 1985	May DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

>A>			LGM PHARMA	300MG; 50MG; 40MG; 30MG	A076560	002	Jul 19, 2012	Aug CAHN
>A>	AB			325MG; 50MG; 40MG; 30MG	A076560	001	Jun 10, 2004	Aug CAHN
>D>			NEXGEN PHARMA INC	300MG; 50MG; 40MG; 30MG	A076560	002	Jul 19, 2012	Aug CAHN
>D>	AB			325MG; 50MG; 40MG; 30MG	A076560	001	Jun 10, 2004	Aug CAHN
	AB		STRIDES PHARMA	325MG; 50MG; 40MG; 30MG	A204649	001	Jul 08, 2020	Jul NEWA

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ ACTAVIS LABS FL INC 300MG; 5MG
@ 300MG; 7.5MG
@ 300MG; 10MG
@ GRANULES PHARMS 325MG; 5MG
@ 325MG; 7.5MG
@ 325MG; 10MG
@ PAR PHARM 300MG; 5MG

A206470	001	Jun 02, 2016	Feb DISC
A206470	002	Jun 02, 2016	Feb DISC
A206470	003	Jun 02, 2016	Feb DISC
A211729	001	Jan 03, 2020	Jun DISC
A211729	002	Jan 03, 2020	Jun DISC
A211729	003	Jan 03, 2020	Jun DISC
A205001	001	Jul 05, 2016	May DISC

TABLET; ORAL

	HYDROCODONE BITARTRATE AND ACETAMINOPHEN					
	@	300MG; 7.5MG	A205001	002	Jul 05, 2016	May DISC
	@	300MG; 10MG	A205001	003	Jul 05, 2016	May DISC
	@ XIROMED	325MG; 5MG	A211690	001	Feb 07, 2020	Mar DISC
AA		325MG; 5MG	A211690	001	Feb 07, 2020	Feb CAHN
AA		325MG; 5MG	A211690	001	Feb 07, 2020	Jan NEWA
	@	325MG; 7.5MG	A211690	002	Feb 07, 2020	Mar DISC
AA		325MG; 7.5MG	A211690	002	Feb 07, 2020	Feb CAHN
AA		325MG; 7.5MG	A211690	002	Feb 07, 2020	Jan NEWA
	@	325MG; 10MG	A211690	003	Feb 07, 2020	Mar DISC
AA		325MG; 10MG	A211690	003	Feb 07, 2020	Feb CAHN
AA		325MG; 10MG	A211690	003	Feb 07, 2020	Jan NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

MIKART INC 300MG/5ML; 10MG/5ML

A202142 001 Nov 27, 2018 Feb CMFD

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

@ GRANULES PHARMS 325MG; 2.5MG

A211708 001 Oct 31, 2019 May DISC

@ 325MG; 5MG

A211708 002 Oct 31, 2019 May DISC

@ 325MG; 7.5MG

A211708 003 Oct 31, 2019 May DISC

@ 325MG; 10MG

A211708 004 Oct 31, 2019 May DISC

@ WATSON LABS 325MG; 5MG

A040171 001 Oct 30, 1997 Apr DISC

@ 325MG; 7.5MG

A040535 001 Sep 05, 2003 Apr DISC

@ 325MG; 10MG

A040535 002 Sep 05, 2003 Apr DISC

@ XIROMED 325MG; 5MG

A207574 001 Dec 13, 2016 Mar DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

@ APOTEX 325MG; 37.5MG

A078778 001 Apr 07, 2014 Feb DISC

>D> @ GRAVITI PHARMS 325MG; 37.5MG

A076914 001 Jul 26, 2006 Aug CAHN

@ 325MG; 37.5MG

A076914 001 Jul 26, 2006 Apr CAHN

@ MACLEODS PHARMS LTD 325MG; 37.5MG

A206885 001 May 02, 2017 May DISC

@ NOSTRUM LABS INC 325MG; 37.5MG

A078778 001 Apr 07, 2014 Apr CAHN

>A> @ RISING 325MG; 37.5MG

A076914 001 Jul 26, 2006 Aug CAHN

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

AB BRECKENRIDGE 125MG

A207503 001 Apr 30, 2020 Apr NEWA

AB 250MG

A207503 002 Apr 30, 2020 Apr NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP ! XGEN PHARMS EQ 500MG BASE/VIAL

A040784 001 Dec 10, 2008 Feb CAHN

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETIC ACID

AT SAPTALIS PHARMS 2%

A040607 001 Feb 24, 2005 Mar CAHN

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

HYDROCORTISONE AND ACETIC ACID

AT COSETTE 2%; 1%

A040609 001 Feb 06, 2006 May CAHN

>D> ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

>D> CAPSULE; ORAL

>D> SEMPREX-D

>D> +! AUXILIUM PHARMS LLC 8MG; 60MG

N019806 001 Mar 25, 1994 Aug DISC

>A> + @ 8MG; 60MG

N019806 001 Mar 25, 1994 Aug DISC

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

@ DAVA PHARMS INC 200MG

A074833 001 Apr 22, 1997 May DISC

		CREAM; TOPICAL							
		ACYCLOVIR							
AB	!	PERRIGO UK FINCO	5%	A208702	001	Feb 04, 2019	Jan	CHRS	
		ZOVIRAX							
AB	+	BAUSCH	5%	N021478	001	Dec 30, 2002	Jan	CHRS	
		OINTMENT; TOPICAL							
		ACYCLOVIR							
AB		SOLARIS PHARMA CORP	5%	A212495	001	Apr 07, 2020	Mar	NEWA	
AB		XIROMED	5%	A201501	001	Jan 29, 2020	Jan	NEWA	
		SUSPENSION; ORAL							
		ACYCLOVIR							
AB		HERITAGE PHARMS INC	200MG/5ML	A212718	001	Apr 23, 2020	Apr	NEWA	
AB		NOVITIUM PHARMA	200MG/5ML	A212252	001	Jul 10, 2020	Jul	NEWA	
		TABLET; ORAL							
		ACYCLOVIR							
AB	!	HETERO LABS LTD V	800MG	A203834	002	Oct 29, 2013	Jan	CHRS	
		ZOVIRAX							
	+	@ MYLAN	400MG	N020089	001	Apr 30, 1991	Jan	DISC	
	+	@	800MG	N020089	002	Apr 30, 1991	Jan	DISC	
		<u>ACYCLOVIR SODIUM</u>							
		INJECTABLE; INJECTION							
		ACYCLOVIR SODIUM							
AP		EXELA PHARMA	EQ 50MG BASE/ML	A207919	001	Jun 17, 2020	Jun	NEWA	
		<u>ADAPALENE</u>							
		GEL; TOPICAL							
		ADAPALENE							
AB		ALEOR DERMACEUTICALS	0.3%	A213508	001	Jun 18, 2020	Jun	NEWA	
		<u>ADENOSINE</u>							
		INJECTABLE; INJECTION							
		ADENOSINE							
	@	MYLAN LABS LTD	3MG/ML	A078640	001	Mar 21, 2014	Apr	DISC	
		<u>AIR POLYMER-TYPE A</u>							
		FOAM; INTRAUTERINE							
		EXEM FOAM KIT							
	+	@ GISKIT	10ML	N212279	001	Nov 07, 2019	Jul	CAHN	
	+	@	10ML	N212279	001	Nov 07, 2019	Jul	CAHN	
	+	@	10ML	N212279	001	Nov 07, 2019	Jun	DISC	
		<u>ALBENDAZOLE</u>							
		TABLET; ORAL							
		ALBENDAZOLE							
AB		LUPIN LTD	200MG	A211636	001	Jun 10, 2020	Jun	NEWA	
		<u>ALBUTEROL SULFATE</u>							
		AEROSOL, METERED; INHALATION							
		ALBUTEROL SULFATE							
AB1		CIPLA	EQ 0.09MG BASE/INH	A209959	001	Apr 08, 2020	Mar	NFTG	
>A> AB2		LUPIN ATLANTIS	EQ 0.09MG BASE/INH	A209954	001	Aug 24, 2020	Aug	NEWA	
AB2		PERRIGO PHARMS CO	EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020	Mar	CTEC	
AB			EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020	Feb	NFTG	
		PROAIR HFA							
AB2	+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004	Mar	CTEC	
AB	+		EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004	Feb	CFTG	
		PROVENTIL-HFA							
AB1	+	3M DRUG DELIVERY	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996	Mar	CFTG	
AB1	+	KINDEVA	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996	May	CAHN	
		SOLUTION; INHALATION							
		ALBUTEROL SULFATE							
AN		AUROBINDO PHARMA LTD	EQ 0.021% BASE	A211888	001	Apr 20, 2020	Apr	NEWA	
AN			EQ 0.042% BASE	A211888	002	Apr 20, 2020	Apr	NEWA	
	@	BAUSCH AND LOMB	EQ 0.5% BASE	A075050	001	Jun 18, 1998	Feb	DISC	
AN	!	NEPHRON	EQ 0.5% BASE	A075664	001	Jun 26, 2001	Feb	CHRS	
		SYRUP; ORAL							
		ALBUTEROL SULFATE							
	@	VISTAPHARM	EQ 2MG BASE/5ML	A077788	001	Jun 26, 2007	Jul	DISC	

TABLET;ORAL

ALBUTEROL SULFATE

	@ ARISE	EQ 2MG BASE	A210948	001	Mar 15, 2019	Jul	DISC
	@	EQ 4MG BASE	A210948	002	Mar 15, 2019	Jul	DISC
AB	AUROBINDO PHARMA LTD	EQ 2MG BASE	A213657	001	May 14, 2020	May	NEWA
AB		EQ 4MG BASE	A213657	002	May 14, 2020	May	NEWA
AB	RISING	EQ 2MG BASE	A207046	001	Jun 29, 2018	Jul	CAHN
AB		EQ 4MG BASE	A207046	002	Jun 29, 2018	Jul	CAHN

TABLET, EXTENDED RELEASE;ORAL

VOLMAX

	+ @ MURO	EQ 4MG BASE	N019604	002	Dec 23, 1992	Mar	CRLD
	+ @	EQ 8MG BASE	N019604	001	Dec 23, 1992	Mar	CRLD

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION;INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN	AUROBINDO PHARMA LTD	EQ 0.083% BASE;0.017%	A206532	001	Jul 08, 2020	Jul	NEWA
	@ WATSON LABS TEVA	EQ 0.083% BASE;0.017%	A077063	001	Dec 31, 2007	Apr	DISC

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

ALOSETRON HYDROCHLORIDE

	@ EYWA PHARMA	EQ 0.5MG BASE	A211621	001	Sep 16, 2019	Apr	DISC
	@	EQ 1MG BASE	A211621	002	Sep 16, 2019	Apr	DISC
>A> AB	MANKIND PHARMA	EQ 0.5MG BASE	A213614	001	Sep 09, 2020	Aug	NEWA
>A> AB		EQ 1MG BASE	A213614	002	Sep 09, 2020	Aug	NEWA

ALPRAZOLAM

TABLET;ORAL

ALPRAZOLAM

	@ DAVA INTL INC	0.25MG	A074174	001	Oct 19, 1993	Feb	DISC
	@	0.5MG	A074174	002	Oct 19, 1993	Feb	DISC
	@	1MG	A074174	003	Oct 19, 1993	Feb	DISC
	@	2MG	A074174	004	Oct 19, 1993	Feb	DISC
	@ OXFORD PHARMS	0.25MG	A078491	001	Sep 25, 2008	Jun	DISC
	@	0.5MG	A078491	002	Sep 25, 2008	Jun	DISC
	@	1MG	A078491	003	Sep 25, 2008	Jun	DISC
	@	2MG	A078491	004	Dec 12, 2008	Jun	DISC
	XANAX						
AB	+ UPJOHN	0.25MG	N018276	001		Apr	CAHN
AB	+	0.5MG	N018276	002		Apr	CAHN
AB	+!	1MG	N018276	003		Apr	CAHN
AB	+	2MG	N018276	004	Nov 27, 1985	Apr	CAHN

TABLET, EXTENDED RELEASE;ORAL

XANAX XR

AB	+ UPJOHN	0.5MG	N021434	001	Jan 17, 2003	Apr	CAHN
AB	+	1MG	N021434	002	Jan 17, 2003	Apr	CAHN
AB	+	2MG	N021434	003	Jan 17, 2003	Apr	CAHN
AB	+!	3MG	N021434	004	Jan 17, 2003	Apr	CAHN

ALVIMOPAN

CAPSULE;ORAL

ALVIMOPAN

	@ WATSON LABS TEVA	12MG	A208295	001	Dec 19, 2019	Jun	DISC
	ENTEREG						
	+! CUBIST PHARMS	12MG	N021775	001	May 20, 2008	Jun	CTEC

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB	! BIONPHARMA INC	100MG	A078720	001	May 29, 2008	Jun	CHRS
AB	INVATECH	100MG	A210129	001	Mar 02, 2020	Feb	NEWA
AB	RUBICON	100MG	A212044	001	May 21, 2020	May	NEWA
AB	SANDOZ	100MG	A071293	001	Feb 18, 1987	Jun	CHRS

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

AB	INVATECH	100MG	A210215	001	Mar 10, 2020	Feb	NEWA
----	----------	-------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL

OSMOLEX ER

	+ OSMOTICA PHARM	EQ 161MG BASE	N209410	004	Apr 22, 2020	Apr	NEWA
--	------------------	---------------	---------	-----	--------------	-----	------

AMIKACIN SULFATEINJECTABLE; INJECTION
AMIKACIN SULFATE

AP	TEVA PHARMS USA	EQ 250MG BASE/ML	A064045	002	Sep 28, 1993	Mar CMFD
----	-----------------	------------------	---------	-----	--------------	----------

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OILEMULSION; INTRAVENOUS
PERIKABIVEN IN PLASTIC CONTAINER

+	FRESENIUS KABI USA	2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; 124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5GM/100ML (2400ML)	N200656	003	Aug 25, 2014	Jan CHRS
---	--------------------	--	---------	-----	--------------	----------

AMINOCAPROIC ACIDSYRUP; ORAL
AMINOCAPROIC ACID

AA	TULEX PHARMS INC	1.25GM/5ML	A212494	001	Aug 11, 2020	Jul NEWA
AA	VISTAPHARM	1.25GM/5ML	A212814	001	Feb 26, 2020	Feb NEWA

AMIODARONE HYDROCHLORIDETABLET; ORAL
AMIODARONE HYDROCHLORIDE

>D>	AB	!	SANDOZ	200MG	A075315	001	Dec 23, 1998	Aug CAHN
>D>	AB			400MG	A075315	002	Jun 30, 2000	Aug CAHN
	AB		UNICHEM LABS LTD	200MG	A213446	001	Jul 21, 2020	Jul NEWA
>A>	AB	!	UPSHER SMITH LABS	200MG	A075315	001	Dec 23, 1998	Aug CAHN
>A>	AB			400MG	A075315	002	Jun 30, 2000	Aug CAHN

AMISULPRIDESOLUTION; INTRAVENOUS
BARHEMSYS

+	ACACIA	5MG/2ML (2.5MG/ML)	N209510	001	Feb 26, 2020	Feb NEWA
---	--------	--------------------	---------	-----	--------------	----------

AMITRIPTYLINE HYDROCHLORIDETABLET; ORAL
AMITRIPTYLINE HYDROCHLORIDE

AB		SANDOZ	10MG	A085968	004		Jan CMS1
AB	!		25MG	A085968	002		Jan CMS1
AB			75MG	A085968	006		Jan CMS1
AB			100MG	A085968	003		Jan CMS1
AB			150MG	A085968	005		Jan CMS1
		@ UPSHER SMITH LABS	25MG	A212654	001	Apr 07, 2020	May DISC
AB			25MG	A212654	001	Apr 07, 2020	Mar NEWA

AMLODIPINE BENZOATESUSPENSION; ORAL
KATERZIA

+	AZURITY	EQ 1MG BASE/ML	N211340	001	Jul 08, 2019	May CAHN
---	---------	----------------	---------	-----	--------------	----------

AMLODIPINE BESYLATETABLET; ORAL
AMLODIPINE BESYLATE

	@	HIKMA	EQ 2.5MG BASE	A077262	001	Jul 09, 2007	Feb DISC
	@		EQ 5MG BASE	A077262	002	Jul 09, 2007	Feb DISC
	@		EQ 10MG BASE	A077262	003	Jul 09, 2007	Feb DISC
	@	MACLEODS PHARMS LTD	EQ 5MG BASE	A201380	001	Apr 13, 2012	May DISC
	@		EQ 10MG BASE	A201380	002	Apr 13, 2012	May DISC
	@	MYLAN	EQ 2.5MG BASE	A076418	001	Oct 03, 2005	Jul DISC
	@		EQ 5MG BASE	A076418	002	Oct 03, 2005	Jul DISC
	@		EQ 10MG BASE	A076418	003	Oct 03, 2005	Jul DISC
	@	WATSON LABS	EQ 2.5MG BASE	A077671	001	Jul 19, 2007	Apr DISC
	@		EQ 5MG BASE	A077671	002	Jul 19, 2007	Apr DISC
	@		EQ 10MG BASE	A077671	003	Jul 19, 2007	Apr DISC
		NORVASC					
AB	+	UPJOHN	EQ 2.5MG BASE	N019787	001	Jul 31, 1992	Jun CAHN
AB	+		EQ 5MG BASE	N019787	002	Jul 31, 1992	Jun CAHN
AB	+		EQ 10MG BASE	N019787	003	Jul 31, 1992	Jun CAHN

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		ZYDUS PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Feb CMFD
AB			EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Feb CMFD
AB			EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Feb CMFD
AB			EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Feb CMFD
AB			EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Feb CMFD
AB			EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Feb CMFD
AB			EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Feb CMFD
AB			EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Feb CMFD
AB			EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Feb CMFD
AB			EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Feb CMFD
AB			EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Feb CMFD

CADUET

>D>	AB	+	PFIZER	EQ 2.5MG BASE;EQ 10MG BASE	N021540	009	Jul 29, 2004	Aug CAHN
	AB	+		EQ 2.5MG BASE;EQ 10MG BASE	N021540	009	Jul 29, 2004	May CAHN
>D>	AB	+		EQ 2.5MG BASE;EQ 20MG BASE	N021540	010	Jul 29, 2004	Aug CAHN
	AB	+		EQ 2.5MG BASE;EQ 20MG BASE	N021540	010	Jul 29, 2004	May CAHN
>D>	AB	+		EQ 2.5MG BASE;EQ 40MG BASE	N021540	011	Jul 29, 2004	Aug CAHN
	AB	+		EQ 2.5MG BASE;EQ 40MG BASE	N021540	011	Jul 29, 2004	May CAHN
>D>	AB	+		EQ 5MG BASE;EQ 10MG BASE	N021540	001	Jan 30, 2004	Aug CAHN
	AB	+		EQ 5MG BASE;EQ 10MG BASE	N021540	001	Jan 30, 2004	May CAHN
>D>	AB	+		EQ 5MG BASE;EQ 20MG BASE	N021540	002	Jan 30, 2004	Aug CAHN
	AB	+		EQ 5MG BASE;EQ 20MG BASE	N021540	002	Jan 30, 2004	May CAHN
>D>	AB	+		EQ 5MG BASE;EQ 40MG BASE	N021540	003	Jan 30, 2004	Aug CAHN
	AB	+		EQ 5MG BASE;EQ 40MG BASE	N021540	003	Jan 30, 2004	May CAHN
>D>	AB	+		EQ 5MG BASE;EQ 80MG BASE	N021540	004	Jan 30, 2004	Aug CAHN
	AB	+		EQ 5MG BASE;EQ 80MG BASE	N021540	004	Jan 30, 2004	May CAHN
>D>	AB	+		EQ 10MG BASE;EQ 10MG BASE	N021540	005	Jan 30, 2004	Aug CAHN
	AB	+		EQ 10MG BASE;EQ 10MG BASE	N021540	005	Jan 30, 2004	May CAHN
>D>	AB	+		EQ 10MG BASE;EQ 20MG BASE	N021540	006	Jan 30, 2004	Aug CAHN
	AB	+		EQ 10MG BASE;EQ 20MG BASE	N021540	006	Jan 30, 2004	May CAHN
>D>	AB	+		EQ 10MG BASE;EQ 40MG BASE	N021540	007	Jan 30, 2004	Aug CAHN
	AB	+		EQ 10MG BASE;EQ 40MG BASE	N021540	007	Jan 30, 2004	May CAHN
>D>	AB	+	!	EQ 10MG BASE;EQ 80MG BASE	N021540	008	Jan 30, 2004	Aug CAHN
	AB	+	!	EQ 10MG BASE;EQ 80MG BASE	N021540	008	Jan 30, 2004	May CAHN
>A>	AB	+	PHARMACIA	EQ 2.5MG BASE;EQ 10MG BASE	N021540	009	Jul 29, 2004	Aug CAHN
>A>	AB	+		EQ 2.5MG BASE;EQ 20MG BASE	N021540	010	Jul 29, 2004	Aug CAHN
>A>	AB	+		EQ 2.5MG BASE;EQ 40MG BASE	N021540	011	Jul 29, 2004	Aug CAHN
>A>	AB	+		EQ 5MG BASE;EQ 10MG BASE	N021540	001	Jan 30, 2004	Aug CAHN
>A>	AB	+		EQ 5MG BASE;EQ 20MG BASE	N021540	002	Jan 30, 2004	Aug CAHN
>A>	AB	+		EQ 5MG BASE;EQ 40MG BASE	N021540	003	Jan 30, 2004	Aug CAHN
>A>	AB	+		EQ 5MG BASE;EQ 80MG BASE	N021540	004	Jan 30, 2004	Aug CAHN
>A>	AB	+		EQ 10MG BASE;EQ 10MG BASE	N021540	005	Jan 30, 2004	Aug CAHN
>A>	AB	+		EQ 10MG BASE;EQ 20MG BASE	N021540	006	Jan 30, 2004	Aug CAHN
>A>	AB	+		EQ 10MG BASE;EQ 40MG BASE	N021540	007	Jan 30, 2004	Aug CAHN
>A>	AB	+		EQ 10MG BASE;EQ 80MG BASE	N021540	008	Jan 30, 2004	Aug CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

@	PAR PHARM	EQ 2.5MG BASE;10MG	A078381	001	Jul 29, 2010	May DISC
@		EQ 5MG BASE;10MG	A078381	002	Jul 29, 2010	May DISC
@		EQ 5MG BASE;20MG	A078381	003	Jul 29, 2010	May DISC
@		EQ 5MG BASE;40MG	A078381	005	Jul 29, 2010	May DISC
@		EQ 10MG BASE;20MG	A078381	004	Jul 29, 2010	May DISC
@		EQ 10MG BASE;40MG	A078381	006	Jul 29, 2010	May DISC

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

AB		TEVA PHARMS USA	EQ 5MG BASE;12.5MG;20MG	A202491	001	Nov 03, 2016	Jul CMFD
AB			EQ 5MG BASE;12.5MG;40MG	A202491	002	Nov 03, 2016	Jul CMFD
AB			EQ 5MG BASE;25MG;40MG	A202491	003	Nov 03, 2016	Jul CMFD
AB			EQ 10MG BASE;12.5MG;40MG	A202491	004	Nov 03, 2016	Jul CMFD
AB			EQ 10MG BASE;25MG;40MG	A202491	005	Nov 03, 2016	Jul CMFD

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA LTD	EQ 5MG BASE;12.5MG;160MG	A206180	001	Dec 19, 2017	Mar CPOT
AB		EQ 5MG BASE;25MG;160MG	A206180	002	Dec 19, 2017	Mar CPOT
AB		EQ 10MG BASE;12.5MG;160MG	A206180	003	Dec 19, 2017	Mar CPOT
AB		EQ 10MG BASE;25MG;160MG	A206180	004	Dec 19, 2017	Mar CPOT
AB		EQ 10MG BASE;25MG;320MG	A206180	005	Dec 19, 2017	Mar CPOT
AB	LUPIN LTD	EQ 5MG BASE;12.5MG;160MG	A200797	001	Jun 03, 2015	Mar CPOT
AB		EQ 5MG BASE;25MG;160MG	A200797	002	Jun 03, 2015	Mar CPOT
AB		EQ 10MG BASE;12.5MG;160MG	A200797	003	Jun 03, 2015	Mar CPOT
AB		EQ 10MG BASE;25MG;160MG	A200797	004	Jun 03, 2015	Mar CPOT
AB		EQ 10MG BASE;25MG;320MG	A200797	005	Jun 03, 2015	Mar CPOT
	@ PAR PHARM	EQ 5MG BASE;12.5MG;160MG	A201087	001	Jun 01, 2015	May DISC
AB		EQ 5MG BASE;12.5MG;160MG	A201087	001	Jun 01, 2015	Mar CPOT
	@	EQ 5MG BASE;25MG;160MG	A201087	002	Jun 01, 2015	May DISC
AB		EQ 5MG BASE;25MG;160MG	A201087	002	Jun 01, 2015	Mar CPOT
	@	EQ 10MG BASE;12.5MG;160MG	A201087	003	Jun 01, 2015	May DISC
AB		EQ 10MG BASE;12.5MG;160MG	A201087	003	Jun 01, 2015	Mar CPOT
	@	EQ 10MG BASE;25MG;160MG	A201087	004	Jun 01, 2015	May DISC
AB		EQ 10MG BASE;25MG;160MG	A201087	004	Jun 01, 2015	Mar CPOT
	@	EQ 10MG BASE;25MG;320MG	A201087	005	Jun 01, 2015	May DISC
AB		EQ 10MG BASE;25MG;320MG	A201087	005	Jun 01, 2015	Mar CPOT
	@ TEVA PHARMS	EQ 5MG BASE;12.5MG;160MG	A200435	001	Sep 25, 2012	Mar CPOT
	@	EQ 5MG BASE;25MG;160MG	A200435	002	Sep 25, 2012	Mar CPOT
	@	EQ 10MG BASE;12.5MG;160MG	A200435	005	Sep 25, 2012	Mar CPOT
	@	EQ 10MG BASE;25MG;160MG	A200435	003	Sep 25, 2012	Mar CPOT
	@	EQ 10MG BASE;25MG;320MG	A200435	004	Sep 25, 2012	Mar CPOT
	@ TORRENT	EQ 5MG BASE;12.5MG;160MG	A201593	001	Jun 03, 2015	Mar CPOT
	@	EQ 5MG BASE;25MG;160MG	A201593	002	Jun 03, 2015	Mar CPOT
	@	EQ 10MG BASE;12.5MG;160MG	A201593	003	Jun 03, 2015	Mar CPOT
	@	EQ 10MG BASE;25MG;160MG	A201593	004	Jun 03, 2015	Mar CPOT
	@	EQ 10MG BASE;25MG;320MG	A201593	005	Jun 03, 2015	Mar CPOT
	EXFORGE HCT					
AB	+ NOVARTIS	EQ 5MG BASE;12.5MG;160MG	N022314	001	Apr 30, 2009	Mar CPOT
AB	+	EQ 5MG BASE;25MG;160MG	N022314	002	Apr 30, 2009	Mar CPOT
AB	+	EQ 10MG BASE;12.5MG;160MG	N022314	003	Apr 30, 2009	Mar CPOT
AB	+	EQ 10MG BASE;25MG;160MG	N022314	004	Apr 30, 2009	Mar CPOT
AB	+!	EQ 10MG BASE;25MG;320MG	N022314	005	Apr 30, 2009	Mar CPOT

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

	@ PAR PHARM INC	EQ 5MG BASE;160MG	A090011	001	Mar 28, 2013	Jun DISC
	@	EQ 5MG BASE;320MG	A090011	003	Mar 28, 2013	Jun DISC
	@	EQ 10MG BASE;160MG	A090011	002	Mar 28, 2013	Jun DISC
	@	EQ 10MG BASE;320MG	A090011	004	Mar 28, 2013	Jun DISC

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	CARDINAL HLTH 414	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203700	001	Feb 25, 2013	May CAHN
>A> AP	UNIV WISCONSIN	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A211740	001	Sep 09, 2020	Aug NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

	@ WATSON LABS INC	EQ 12% BASE	A076829	001	Feb 07, 2006	Apr DISC
--	-------------------	-------------	---------	-----	--------------	----------

LOTION; TOPICAL

AMMONIUM LACTATE

	@ WATSON LABS INC	EQ 12% BASE	A075575	001	Jun 11, 2002	Apr DISC
--	-------------------	-------------	---------	-----	--------------	----------

AMOXAPINE

TABLET; ORAL

AMOXAPINE

	@ WATSON PHARMS TEVA	25MG	A072418	001	Aug 01, 1989	Jan CMS1
	@	50MG	A072419	001	Aug 01, 1989	Jan CMS1

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

@ DAVA PHARMS INC

250MG

A 062884 001 Feb 25, 1988 Jul DISC

@

500MG

A 062881 001 Feb 25, 1988 Jul DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN

AB HIKMA

125MG

A 205274 001 Jun 25, 2020 Jun NEWA

AB

250MG

A 205274 002 Jun 25, 2020 Jun NEWA

AB TEVA

125MG

A 064013 002 Sep 11, 1995 Jun CTEC

AB !

250MG

A 064013 001 Dec 22, 1992 Jun CTEC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AUGMENTIN ES-600

AB + NEOPHARMA

600MG/5ML;EQ 42.9MG BASE/5ML

N 050755 001 Jun 22, 2001 Jul CMFD

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB ANI PHARMS INC

1.25MG;1.25MG;1.25MG;1.25MG

A 205401 001 Jan 22, 2019 Jan CAHN

AB

2.5MG;2.5MG;2.5MG;2.5MG

A 205401 002 Jan 22, 2019 Jan CAHN

AB

3.75MG;3.75MG;3.75MG;3.75MG

A 205401 003 Jan 22, 2019 Jan CAHN

AB

5MG;5MG;5MG;5MG

A 205401 004 Jan 22, 2019 Jan CAHN

AB

6.25MG;6.25MG;6.25MG;6.25MG

A 205401 005 Jan 22, 2019 Jan CAHN

AB

7.5MG;7.5MG;7.5MG;7.5MG

A 205401 006 Jan 22, 2019 Jan CAHN

AB ELITE LABS INC

1.25MG;1.25MG;1.25MG;1.25MG

A 212037 001 Dec 11, 2019 May CAHN

AB

2.5MG;2.5MG;2.5MG;2.5MG

A 212037 002 Dec 11, 2019 May CAHN

AB

3.75MG;3.75MG;3.75MG;3.75MG

A 212037 003 Dec 11, 2019 May CAHN

AB

5MG;5MG;5MG;5MG

A 212037 004 Dec 11, 2019 May CAHN

AB

6.25MG;6.25MG;6.25MG;6.25MG

A 212037 005 Dec 11, 2019 May CAHN

AB

7.5MG;7.5MG;7.5MG;7.5MG

A 212037 006 Dec 11, 2019 May CAHN

AB MYLAN

1.25MG;1.25MG;1.25MG;1.25MG

A 211876 001 Jun 24, 2020 Jun NEWA

AB

2.5MG;2.5MG;2.5MG;2.5MG

A 211876 002 Jun 24, 2020 Jun NEWA

AB

3.75MG;3.75MG;3.75MG;3.75MG

A 211876 003 Jun 24, 2020 Jun NEWA

AB

5MG;5MG;5MG;5MG

A 211876 004 Jun 24, 2020 Jun NEWA

AB

6.25MG;6.25MG;6.25MG;6.25MG

A 211876 005 Jun 24, 2020 Jun NEWA

AB

7.5MG;7.5MG;7.5MG;7.5MG

A 211876 006 Jun 24, 2020 Jun NEWA

AB @ NESHER PHARMS

1.25MG;1.25MG;1.25MG;1.25MG

A 210080 001 Jul 17, 2019 Jan DISC

AB

2.5MG;2.5MG;2.5MG;2.5MG

A 210080 002 Jul 17, 2019 Jan DISC

AB

3.75MG;3.75MG;3.75MG;3.75MG

A 210080 003 Jul 17, 2019 Jan DISC

AB

5MG;5MG;5MG;5MG

A 210080 004 Jul 17, 2019 Jan DISC

AB

6.25MG;6.25MG;6.25MG;6.25MG

A 210080 005 Jul 17, 2019 Jan DISC

AB

7.5MG;7.5MG;7.5MG;7.5MG

A 210080 006 Jul 17, 2019 Jan DISC

AB SUN PHARM INDUSTRIES

1.25MG;1.25MG;1.25MG;1.25MG

A 211715 001 May 17, 2019 Apr CMFD

AB

2.5MG;2.5MG;2.5MG;2.5MG

A 211715 002 May 17, 2019 Apr CMFD

AB

3.75MG;3.75MG;3.75MG;3.75MG

A 211715 003 May 17, 2019 Apr CMFD

AB

5MG;5MG;5MG;5MG

A 211715 004 May 17, 2019 Apr CMFD

AB

6.25MG;6.25MG;6.25MG;6.25MG

A 211715 005 May 17, 2019 Apr CMFD

AB

7.5MG;7.5MG;7.5MG;7.5MG

A 211715 006 May 17, 2019 Apr CMFD

AB @ TEVA

1.25MG;1.25MG;1.25MG;1.25MG

A 077488 001 Apr 29, 2013 Apr DISC

AB

2.5MG;2.5MG;2.5MG;2.5MG

A 077488 002 Apr 29, 2013 Apr DISC

AB

3.75MG;3.75MG;3.75MG;3.75MG

A 077488 003 Apr 29, 2013 Apr DISC

AB

5MG;5MG;5MG;5MG

A 077488 004 Apr 29, 2013 Apr DISC

AB

6.25MG;6.25MG;6.25MG;6.25MG

A 077488 005 Apr 29, 2013 Apr DISC

AB

7.5MG;7.5MG;7.5MG;7.5MG

A 077488 006 Apr 29, 2013 Apr DISC

DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE

AB @ BARR LABS INC

1.25MG;1.25MG;1.25MG;1.25MG

A 076536 001 Feb 12, 2013 Apr DISC

AB

2.5MG;2.5MG;2.5MG;2.5MG

A 076536 002 Feb 12, 2013 Apr DISC

AB

3.75MG;3.75MG;3.75MG;3.75MG

A 076536 003 Feb 12, 2013 Apr DISC

AB

5MG;5MG;5MG;5MG

A 076536 004 Feb 12, 2013 Apr DISC

AB

6.25MG;6.25MG;6.25MG;6.25MG

A 076536 005 Feb 12, 2013 Apr DISC

AB

7.5MG;7.5MG;7.5MG;7.5MG

A 076536 006 Feb 12, 2013 Apr DISC

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB BIONPHARMA INC

1.25MG;1.25MG;1.25MG;1.25MG

A 210293 001 Apr 03, 2020 Mar NEWA

AB

1.875MG;1.875MG;1.875MG;1.875MG

A 210293 002 Apr 03, 2020 Mar NEWA

AB

2.5MG;2.5MG;2.5MG;2.5MG

A 210293 003 Apr 03, 2020 Mar NEWA

AB

3.75MG;3.75MG;3.75MG;3.75MG

A 210293 004 Apr 03, 2020 Mar NEWA

AB

5MG;5MG;5MG;5MG

A 210293 005 Apr 03, 2020 Mar NEWA

AB

7.5MG;7.5MG;7.5MG;7.5MG

A 210293 006 Apr 03, 2020 Mar NEWA

AB ELITE LABS INC

1.25MG;1.25MG;1.25MG;1.25MG

A 211352 001 Dec 07, 2018 May CAHN

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		1.875MG;1.875MG;1.875MG;1.875MG	A211352	002	Dec 07, 2018	May CAHN
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211352	003	Dec 07, 2018	May CAHN
AB		3.125MG;3.125MG;3.125MG;3.125MG	A211352	004	Dec 07, 2018	May CAHN
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211352	005	Dec 07, 2018	May CAHN
AB		5MG;5MG;5MG;5MG	A211352	006	Dec 07, 2018	May CAHN
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211352	007	Dec 07, 2018	May CAHN

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

AA	CEROVENE INC	5MG	A212582	001	Feb 04, 2020	Jan NEWA
AA		10MG	A212582	002	Feb 04, 2020	Jan NEWA
AA	HAVIX	5MG	A212901	001	May 22, 2020	May NEWA
AA		10MG	A212901	002	May 22, 2020	May NEWA
AA	MAYNE PHARMA	5MG	A213898	001	Jul 14, 2020	Jul NEWA
AA		10MG	A213898	002	Jul 14, 2020	Jul NEWA
AA	PRINSTON INC	5MG	A211861	001	Mar 11, 2020	Feb NEWA
AA		10MG	A211861	002	Mar 11, 2020	Feb NEWA
>A>	AA	RICONPHARMA LLC	A213763	001	Aug 24, 2020	Aug NEWA
>A>	AA		A213763	002	Aug 24, 2020	Aug NEWA

AMPHOTERICIN B

INJECTABLE;INJECTION

AMPHOTERICIN B

!	XGEN PHARMS	50MG/VIAL	A063206	001	Apr 29, 1992	Feb CAHN
---	-------------	-----------	---------	-----	--------------	----------

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

@	PHARM ASSOC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Jan CAHN
@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Jan CAHN

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL

AMPICILLIN TRIHYDRATE

>D>	AB	DAVA PHARMS INC	EQ 250MG BASE	A062883	001	Feb 25, 1988	Aug DISC
>A>		@	EQ 250MG BASE	A062883	001	Feb 25, 1988	Aug DISC
		@	EQ 500MG BASE	A062882	001	Feb 25, 1988	Mar DISC
>D>	AB	SANDOZ	EQ 250MG BASE	A064082	001	Aug 29, 1995	Aug CTEC
>A>			EQ 250MG BASE	A064082	001	Aug 29, 1995	Aug CTEC
		!	EQ 500MG BASE	A064082	002	Aug 29, 1995	Mar CHRS

FOR SUSPENSION;ORAL

AMPICILLIN TRIHYDRATE

@	DAVA PHARMS INC	EQ 125MG BASE/5ML	A062982	001	Feb 10, 1989	Jul DISC
@		EQ 250MG BASE/5ML	A062982	002	Feb 10, 1989	Jul DISC

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

ANAGRELIDE HYDROCHLORIDE

@	BARR	EQ 0.5MG BASE	A076530	001	Apr 18, 2005	Apr DISC
@		EQ 1MG BASE	A076530	002	Apr 18, 2005	Apr DISC

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

	@	APOTEX INC	1MG	A200654	001	May 11, 2012	Feb DISC
AB		EUGIA PHARMA	1MG	A212434	001	Jul 24, 2020	Jul NEWA
	@	MYLAN	1MG	A091051	001	Jun 28, 2010	Jan DISC

APIXABAN

TABLET;ORAL

APIXABAN

AB		ACCORD HLTHCARE	2.5MG	A210180	001	Jul 28, 2020	Jul NEWA
AB			5MG	A210180	002	Jul 28, 2020	Jul NEWA
	@	BIONPHARMA INC	2.5MG	A210152	001	Apr 08, 2020	Jul DISC
AB			2.5MG	A210152	001	Apr 08, 2020	Mar NEWA
	@		5MG	A210152	002	Apr 08, 2020	Jul DISC
AB			5MG	A210152	002	Apr 08, 2020	Mar NEWA
	@	MICRO LABS	2.5MG	A210013	001	Dec 23, 2019	Jun DISC

TABLET;ORAL

APIXABAN

@	5MG	A210013	002	Dec 23, 2019	Jun DISC
@ MYLAN	2.5MG	A210128	001	Dec 23, 2019	Jan DISC
@	5MG	A210128	002	Dec 23, 2019	Jan DISC
ELIQUIS					
+ BRISTOL MYERS SQUIBB	2.5MG	N202155	001	Dec 28, 2012	Jul CTEC
+	5MG	N202155	002	Dec 28, 2012	Jul CTEC

APOMORPHINE HYDROCHLORIDE

FILM;SUBLINGUAL

KYNMOBI

+ SUNOVION PHARMS INC	10MG	N210875	001	May 21, 2020	May NEWA
+	15MG	N210875	002	May 21, 2020	May NEWA
+	20MG	N210875	003	May 21, 2020	May NEWA
+	25MG	N210875	004	May 21, 2020	May NEWA
+	30MG	N210875	005	May 21, 2020	May NEWA

INJECTABLE;SUBCUTANEOUS

APOKYN

@ MDD US	20MG/2ML (10MG/ML)	N021264	001	Apr 20, 2004	Jul CAHN
+	30MG/3ML (10MG/ML)	N021264	002	Apr 20, 2004	Jul CAHN

ARGATROBAN

INJECTABLE;INJECTION

ARGATROBAN

AP	+	HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049	001	Jan 05, 2012	Mar CHRS
AP	+		250MG/2.5ML (100MG/ML)	N203049	001	Jan 05, 2012	Mar CRLD

INJECTABLE;INTRAVENOUS

ARGATROBAN IN 0.9% SODIUM CHLORIDE

@ TEVA PHARMS USA	250MG/250ML (1MG/ML)	N206769	001	Dec 15, 2014	Mar DISC
-------------------	----------------------	---------	-----	--------------	----------

ARTESUNATE

POWDER;INTRAVENOUS

ARTESUNATE

+	AMIVAS	110MG/VIAL	N213036	001	May 26, 2020	May NEWA
---	--------	------------	---------	-----	--------------	----------

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

SEPTOCAINE

>A>	+	DEPROCO	4%; EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	N020971	002	Mar 30, 2006	Aug CMS1
	+		4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	N020971	001	Apr 03, 2000	Feb CTEC

ASENAPINE MALEATE

TABLET;SUBLINGUAL

SAPHRIS

+	ALLERGAN	EQ 2.5MG BASE	N022117	003	Mar 12, 2015	Jan CMS1
---	----------	---------------	---------	-----	--------------	----------

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA		STRIDES PHARMA	325MG;50MG;40MG	A204195	001	Sep 22, 2016	Mar CAHN
----	--	----------------	-----------------	---------	-----	--------------	----------

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

>A>	AB	LGM PHARMA	325MG;50MG;40MG;30MG	A075231	001	Nov 30, 2001	Aug CAHN
>D>	AB	NEXGEN PHARMA INC	325MG;50MG;40MG;30MG	A075231	001	Nov 30, 2001	Aug CAHN

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENGESIC FORTE

!	GALT PHARMS	770MG;60MG;50MG	A075141	002	May 29, 1998	Jul CMFD
---	-------------	-----------------	---------	-----	--------------	----------

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

@	HERITAGE PHARMS INC	325MG;200MG	A089594	001	Mar 31, 1989	May DISC
@	NOVAST LABS	325MG;200MG	A040832	001	Jan 07, 2010	May DISC
@	SANDOZ	325MG;200MG	A040116	001	Apr 25, 1996	May DISC

ASPIRIN; METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL AND ASPIRIN

@ STEVENS J

325MG;400MG

A081145 001 Jan 31, 1995 Jul DISC

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

@ ACTAVIS LABS FL INC

325MG;4.8355MG

A090084 001 Mar 22, 2011 Jun DISC

AA

EPIC PHARMA LLC

325MG;4.8355MG

A040910 001 Jul 16, 2020 Jul NEWA

ASPIRIN; PRAVASTATIN SODIUM

TABLET;ORAL

PRAVIGARD PAC (COPACKAGED)

@ BRISTOL MYERS SQUIBB

81MG;20MG

N021387 001 Jun 24, 2003 May CPOT

@

81MG,N/A;N/A,20MG

N021387 001 Jun 24, 2003 May CDFR

@

81MG;40MG

N021387 002 Jun 24, 2003 May CPOT

@

81MG,N/A;N/A,40MG

N021387 002 Jun 24, 2003 May CDFR

@

81MG;80MG

N021387 003 Jun 24, 2003 May CPOT

@

81MG,N/A;N/A,80MG

N021387 003 Jun 24, 2003 May CDFR

@

325MG;20MG

N021387 004 Jun 24, 2003 May CPOT

@

325MG,N/A;N/A,20MG

N021387 004 Jun 24, 2003 May CDFR

@

325MG;40MG

N021387 005 Jun 24, 2003 May CPOT

@

325MG,N/A;N/A,40MG

N021387 005 Jun 24, 2003 May CDFR

@

325MG;80MG

N021387 006 Jun 24, 2003 May CPOT

@

325MG,N/A;N/A,80MG

N021387 006 Jun 24, 2003 May CDFR

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

>D> AB

AMNEAL

EQ 100MG BASE

A209717 001 Jun 01, 2020 Aug DISC

>A>

@

EQ 100MG BASE

A209717 001 Jun 01, 2020 Aug DISC

AB

EQ 100MG BASE

A209717 001 Jun 01, 2020 May NEWA

AB

EQ 150MG BASE

A209717 002 Jun 01, 2020 May NEWA

AB

EQ 200MG BASE

A209717 003 Jun 01, 2020 May NEWA

AB

EQ 300MG BASE

A209717 004 Jun 01, 2020 May NEWA

@ MYLAN

EQ 150MG BASE

A208177 001 Sep 24, 2018 Feb DISC

@

EQ 200MG BASE

A208177 002 Sep 24, 2018 Feb DISC

@

EQ 300MG BASE

A208177 003 Sep 24, 2018 Feb DISC

AB

ZYDUS PHARMS

EQ 150MG BASE

A210575 001 Jun 04, 2020 Jun NEWA

AB

EQ 200MG BASE

A210575 002 Jun 04, 2020 Jun NEWA

AB

EQ 300MG BASE

A210575 003 Jun 04, 2020 Jun NEWA

ATENOLOL

TABLET;ORAL

ATENOLOL

AB

HLTHCARE

25MG

A073026 002 May 01, 1992 Jun CMS1

AB

50MG

A073026 003 Sep 17, 1991 Jun CMS1

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

@ MYLAN

50MG;25MG

A074203 001 Oct 31, 1993 May DISC

@

100MG;25MG

A074203 002 Oct 31, 1993 May DISC

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB

LUPIN LTD

EQ 10MG BASE

A204991 001 Mar 06, 2019 Jan CMFD

AB

EQ 20MG BASE

A204991 002 Mar 06, 2019 Jan CMFD

AB

EQ 40MG BASE

A204991 003 Mar 06, 2019 Jan CMFD

AB

EQ 80MG BASE

A204991 004 Mar 06, 2019 Jan CMFD

@ PERRIGO R AND D

EQ 10MG BASE

A208478 001 Jun 23, 2020 Jul DISC

AB

EQ 10MG BASE

A208478 001 Jun 23, 2020 Jun NEWA

@

EQ 20MG BASE

A208478 002 Jun 23, 2020 Jul DISC

AB

EQ 20MG BASE

A208478 002 Jun 23, 2020 Jun NEWA

>A> AB

UMEDICA LABS PVT LTD

EQ 10MG BASE

A213853 001 Aug 19, 2020 Aug NEWA

>A> AB

EQ 20MG BASE

A213853 002 Aug 19, 2020 Aug NEWA

>A> AB

EQ 40MG BASE

A213853 003 Aug 19, 2020 Aug NEWA

>A> AB

EQ 80MG BASE

A213853 004 Aug 19, 2020 Aug NEWA

TABLET;ORAL
LIPITOR

AB	+	UPJOHN	EQ 10MG BASE	N020702	001	Dec 17, 1996	Jun CAHN
AB	+		EQ 20MG BASE	N020702	002	Dec 17, 1996	Jun CAHN
AB	+		EQ 40MG BASE	N020702	003	Dec 17, 1996	Jun CAHN
AB	+	!	EQ 80MG BASE	N020702	004	Apr 07, 2000	Jun CAHN

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

@	SCOV3	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Apr DISC
		EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Mar CAHN
@		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Apr DISC
		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Mar CAHN
@		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Apr DISC
		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Mar CAHN
@		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Apr DISC
!		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Mar CAHN

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE

>A>	+	HOSPIRA	0.25MG/5ML (0.05MG/ML)	N021146	002	Jul 09, 2001	Aug CTNA
>A>	+	@	0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001	Aug CTNA
>A>	+	!	0.5MG/5ML (0.1MG/ML)	N021146	004	Aug 17, 2017	Aug CTNA
>A>	+	!	1MG/10ML (0.1MG/ML)	N021146	003	Jul 09, 2001	Aug CTNA
>A>	+	!	1MG/10ML (0.1MG/ML)	N021146	005	Aug 17, 2017	Aug CTNA

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

>A>	+	HOSPIRA	0.25MG/5ML (0.05MG/ML)	N021146	002	Jul 09, 2001	Aug CDFR
>A>	+	@	0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001	Aug CDFR
>A>	+	!	1MG/10ML (0.1MG/ML)	N021146	003	Jul 09, 2001	Aug CDFR

ATROPINE SULFATE LIFESHIELD ABBOJECT SYRINGE

>D>	+	HOSPIRA	0.5MG/5ML (0.1MG/ML)	N021146	004	Aug 17, 2017	Aug CTNA
>D>	+	!	1MG/10ML (0.1MG/ML)	N021146	005	Aug 17, 2017	Aug CTNA

SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, ENDOTRACHEAL

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

>D>	+	HOSPIRA	0.25MG/5ML (0.05MG/ML)	N021146	002	Jul 09, 2001	Aug CDFR
>D>	+	@	0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001	Aug CDFR
>D>	+	!	1MG/10ML (0.1MG/ML)	N021146	003	Jul 09, 2001	Aug CDFR

SOLUTION/DROPS;OPHTHALMIC

ISOPTO ATROPINE

+	ALCON LABS INC	1%	N208151	001	Dec 01, 2016	Feb CRLD
!		1%	N208151	001	Dec 01, 2016	Feb CHRS

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA		LEADING PHARMA LLC	0.025MG;2.5MG	A213413	001	Feb 20, 2020	Feb NEWA
AA		MAYNE PHARMA INC	0.025MG;2.5MG	A210789	001	Jun 03, 2020	May NEWA
	@	PAR PHARM	0.025MG;2.5MG	A040357	001	May 02, 2000	May DISC

AVAPRITINIB

TABLET;ORAL

AYVAKIT

+	BLUEPRINT MEDICINES	100MG	N212608	001	Jan 09, 2020	Jan NEWA
+		200MG	N212608	002	Jan 09, 2020	Jan NEWA
+		300MG	N212608	003	Jan 09, 2020	Jan NEWA

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP		EUROHLTH INTL SARL	100MG/VIAL	A209337	001	Jun 08, 2020	Jun NEWA
----	--	--------------------	------------	---------	-----	--------------	----------

AZATHIOPRINE

TABLET;ORAL

AZATHIOPRINE

AB		ALKEM LABS LTD	25MG	A208687	001	Mar 27, 2020	Mar NEWA
AB			50MG	A208687	002	Mar 27, 2020	Mar NEWA
AB			75MG	A208687	003	Mar 27, 2020	Mar NEWA
AB			100MG	A208687	004	Mar 27, 2020	Mar NEWA
AB		RISING	50MG	A075568	001	Dec 13, 1999	May CAHN

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC									
AZELASTINE HYDROCHLORIDE									
AT		GLAND PHARMA LTD	0.05%		A210092	001	Feb 25, 2020	Feb	NEWA
SPRAY, METERED;NASAL									
AZELASTINE HYDROCHLORIDE									
AB		AUROBINDO PHARMA LTD	EQ 0.125MG BASE/SPRAY		A212289	001	May 08, 2020	Apr	NEWA

AZITHROMYCIN

FOR SUSPENSION;ORAL									
AZITHROMYCIN									
		@ TARO	EQ 200MG BASE/5ML		A211521	001	Dec 11, 2019	May	DISC
		@ TEVA PHARMS	EQ 100MG BASE/5ML		A065419	001	Jun 24, 2008	Apr	DISC
		@	EQ 200MG BASE/5ML		A065419	002	Jun 24, 2008	Apr	DISC
INJECTABLE;INJECTION									
AZITHROMYCIN									
		@ HIKMA	EQ 500MG BASE/VIAL		A065265	001	Jan 18, 2007	Mar	CAHN
		@ MYLAN LABS LTD	EQ 500MG BASE/VIAL		A204732	001	Jan 26, 2017	Mar	DISC
TABLET;ORAL									
AZITHROMYCIN									
AB		ALEMBIC PHARMS LTD	EQ 250MG BASE		A211791	001	Jan 28, 2020	Jan	NEWA
AB			EQ 500MG BASE		A211792	001	Jan 28, 2020	Jan	NEWA
AB			EQ 600MG BASE		A211793	001	Jan 27, 2020	Jan	NEWA
		@ MYLAN	EQ 600MG BASE		A065360	001	Jan 08, 2007	Jan	DISC
		@ YUNG SHIN PHARM	EQ 600MG BASE		A211068	001	May 08, 2020	Jun	DISC
AB			EQ 600MG BASE		A211068	001	May 08, 2020	Apr	NEWA

BACITRACIN

INJECTABLE;INJECTION									
BACIIM									
		@ X GEN PHARMS	50,000 UNITS/VIAL		A064153	001	May 09, 1997	Mar	DISC
BACITRACIN									
		@ AKORN	50,000 UNITS/VIAL		A206719	001	Oct 20, 2017	Mar	DISC
		@ FRESENIUS KABI USA	50,000 UNITS/VIAL		A065116	001	Dec 03, 2002	Mar	DISC
>D> AP	!	PHARMACIA AND UPJOHN	50,000 UNITS/VIAL		A060733	002		Aug	DISC
>A>		@	50,000 UNITS/VIAL		A060733	002		Aug	DISC
>D> AP		XELLIA PHARMS APS	50,000 UNITS/VIAL		A203177	001	Aug 25, 2014	Aug	CTEC
>A>	!		50,000 UNITS/VIAL		A203177	001	Aug 25, 2014	Aug	CHRS
>A>			50,000 UNITS/VIAL		A203177	001	Aug 25, 2014	Aug	CTEC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC									
LUMI-SPORYN									
AT	+	CASPER PHARMA LLC	EQ 400 UNITS/GM;EQ 3.5MG BASE/GM;EQ 10,000 UNITS/GM		N050417	001		May	CTNA

BACLOFEN

INJECTABLE;INTRATHECAL									
BACLOFEN									
		@ MAIA PHARMS INC	0.5MG/ML		A210048	001	Sep 11, 2019	Mar	DISC
		@	2MG/ML		A210048	002	Sep 11, 2019	Mar	DISC
TABLET;ORAL									
BACLOFEN									
		@ MYLAN	20MG		A077121	002	Jul 29, 2005	Jan	DISC
		@ MYLAN PHARMS INC	10MG		A090334	001	Feb 18, 2010	Apr	DISC
		@	20MG		A090334	002	Feb 18, 2010	Apr	DISC
AB		RUBICON	5MG		A209102	001	Nov 28, 2017	Apr	CTEC
AB		UNICHEM LABS LTD	10MG		A212067	001	Jul 09, 2020	Jul	NEWA
AB			20MG		A212067	002	Jul 09, 2020	Jul	NEWA
AB		ZYDUS	5MG		A211659	003	Apr 17, 2020	Apr	NEWA

BARIUM SULFATE

SUSPENSION;ORAL									
ENTERO VU 24%									
	+	BRACCO	24% (144GM/600ML)		N208143	008	May 29, 2020	Jun	NEWA

BEDAQUILINE FUMARATETABLET; ORAL
SIRTURO

+ JANSSEN THERAP EQ 20MG BASE N204384 002 May 27, 2020 May NEWA

BEMPEDOIC ACIDTABLET; ORAL
NEXLETOL

+! ESPERION THERAPS INC 180MG N211616 001 Feb 21, 2020 Feb NEWA

BEMPEDOIC ACID; EZETIMIBETABLET; ORAL
NEXLIZET

+! ESPERION THERAPS INC 180MG; 10MG N211617 001 Feb 26, 2020 Feb NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

@ MYLAN 5MG A076430 001 Feb 11, 2004 Jul DISC

@ 10MG A076430 002 Feb 11, 2004 Jul DISC

@ 20MG A076430 003 Feb 11, 2004 Jul DISC

@ 40MG A076430 004 Feb 11, 2004 Jul DISC

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ APOTEX 5MG; 6.25MG A078794 001 Aug 21, 2014 Jun DISC

@ 10MG; 12.5MG A078794 002 Aug 21, 2014 Jun DISC

@ 20MG; 12.5MG A078794 003 Aug 21, 2014 Jun DISC

@ 20MG; 25MG A078794 004 Aug 21, 2014 Jun DISC

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

SOLUTION/DROPS; OPHTHALMIC

FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE

+! BAUSCH 0.4%; 0.3% N211039 001 Mar 09, 2020 Mar NEWA

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

@ EMCURE PHARMS LTD 50MG A202061 001 Jan 27, 2012 Mar DISC

@ SPECGX LLC 50MG A040773 001 Apr 25, 2007 Apr DISC

@ TWI PHARMS 50MG A040578 001 Apr 17, 2006 Apr DISC

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPOTASTINE BESILATE

@ MYLAN 1.5% A206220 001 Mar 18, 2019 Feb DISC

BEPREVE

+! BAUSCH AND LOMB INC 1.5% N022288 001 Sep 08, 2009 Feb CTEC

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB ! GLENMARK GENERICS EQ 0.05% BASE A078930 001 Sep 23, 2008 Feb CHRS

DIPROLENE AF

+ @ MERCK SHARP DOHME EQ 0.05% BASE N019555 001 Apr 27, 1987 Feb DISC

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

@ ACTAVIS MID ATLANTIC EQ 0.05% BASE A070281 001 Jul 31, 1985 Apr DISC

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE

AB CADILA EQ 0.05% BASE A214048 001 Jul 14, 2020 Jul CAHN

AB ZYDUS PHARMS EQ 0.05% BASE A214048 001 Jul 14, 2020 Jul NEWA

SPRAY; TOPICAL

BETAMETHASONE DIPROPIONATE

@ TARO PHARMS EQ 0.05% BASE/SPRAY A211722 001 Jun 17, 2020 Jun DISC

A211722 001 Jun 17, 2020 Jun NFTG

SERNIVO

+! ENCORE DERMAT EQ 0.05% BASE/SPRAY N208079 001 Feb 05, 2016 Jun CTEC

AB +! EQ 0.05% BASE/SPRAY N208079 001 Feb 05, 2016 Jun CFTG

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

CREAM; TOPICAL

WYNZORA

+! MC2 0.064%;0.005%

N213422 001 Jul 20, 2020 Jul NEWA

SUSPENSION; TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

>A> AB TARO PHARMS 0.064%;0.005%

A213269 001 Sep 02, 2020 Aug NEWA

AB TOLMAR 0.064%;0.005%

A210765 001 May 11, 2020 Apr NFTG

TACLONEX

AB +! LEO PHARMA AS 0.064%;0.005%

N022185 001 May 09, 2008 Apr CFTG

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA ! AMNEAL PHARM 5MG

A040855 001 Nov 21, 2007 Jan CHRS

AA ! 10MG

A040855 002 Nov 21, 2007 Jan CHRS

AA ! 25MG

A040855 003 Nov 21, 2007 Jan CHRS

AA ! 50MG

A040855 004 Nov 21, 2007 Jul CHRS

@ HERITAGE PHARMA 5MG

A091256 001 May 04, 2010 Jul DISC

@ 10MG

A091256 002 May 04, 2010 Jul DISC

@ 25MG

A091256 003 May 04, 2010 Jul DISC

@ 50MG

A091256 004 May 04, 2010 Jul DISC

@ IMPAX LABS 25MG

A040721 003 Nov 01, 2006 Jan CMS1

URECHOLINE

@ ODYSSEY PHARMS 5MG

A089095 001 Dec 19, 1985 Jan DISC

@ 10MG

A088440 001 May 29, 1984 Jan DISC

@ 25MG

A088441 001 May 29, 1984 Jan DISC

@ 50MG

A089096 001 Dec 19, 1985 Jul DISC

BETRIXABAN

CAPSULE; ORAL

BEVYXXA

>D> + PORTOLA PHARMS INC 40MG

N208383 001 Jun 23, 2017 Aug DISC

>A> + @ 40MG

N208383 001 Jun 23, 2017 Aug DISC

>D> +! 80MG

N208383 002 Jun 23, 2017 Aug DISC

>A> + @ 80MG

N208383 002 Jun 23, 2017 Aug DISC

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

AB ANI PHARMS INC 75MG

A209861 001 May 08, 2018 Jan CAHN

AB HIKMA 75MG

A203663 001 Jun 16, 2020 Jun NEWA

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

@ MYLAN 50MG

A079185 001 Jul 06, 2009 Jan DISC

BIMATOPROST

IMPLANT; OPHTHALMIC

DURYSTA

+! ALLERGAN INC 10MCG

N211911 001 Mar 04, 2020 Mar NEWA

SOLUTION/DROPS; OPHTHALMIC

BIMATOPROST

>A> AT MICRO LABS 0.03%

A202505 001 Sep 08, 2020 Aug NEWA

SOLUTION/DROPS; TOPICAL

BIMATOPROST

AT ALEMBIC PHARMS LTD 0.03%

A210515 001 Jan 21, 2020 Jan NEWA

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

>D> AB CASI PHARMS INC 5MG

A075643 001 Nov 16, 2000 Aug CAHN

>D> AB 10MG

A075643 002 Nov 16, 2000 Aug CAHN

>A> AB RUBICON 5MG

A075643 001 Nov 16, 2000 Aug CAHN

>A> AB 10MG

A075643 002 Nov 16, 2000 Aug CAHN

@ TEVA PHARMS 5MG

A075644 001 Jun 26, 2001 Apr DISC

@ 10MG

A075644 002 Jun 26, 2001 Apr DISC

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB	EDENBRIDGE PHARMS	2.5MG; 6.25MG	A212678	001	Jul 09, 2020	Jul NEWA
AB		5MG; 6.25MG	A212678	002	Jul 09, 2020	Jul NEWA
AB		10MG; 6.25MG	A212678	003	Jul 09, 2020	Jul NEWA

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

BIVALIRUDIN

@ APOTEX	250MG/VIAL	A204876	001	Jul 06, 2017	Feb DISC
----------	------------	---------	-----	--------------	----------

BOSENTAN

TABLET; ORAL

BOSENTAN

AB	ALEMBIC PHARMS LTD	62.5MG	A211461	001	Jan 23, 2020	Jan NEWA
AB		125MG	A211461	002	Jan 23, 2020	Jan NEWA
	@ CIPLA	62.5MG	A210342	001	Jan 03, 2020	Jun DISC
	@	125MG	A210342	002	Jan 03, 2020	Jun DISC
	@ MYLAN	62.5MG	A205173	001	Jan 15, 2020	Jan DISC
	@	125MG	A205173	002	Jan 15, 2020	Jan DISC

BREMELANOTIDE ACETATE

SOLUTION; SUBCUTANEOUS

VYLEESI (AUTOINJECTOR)

+	PALATIN TECHNOLOGIES	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	N210557	001	Jun 21, 2019	Jul CAHN
---	----------------------	--	---------	-----	--------------	----------

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

QOLIANA

AT	+	SANDOZ INC	0.15%	N021764	001	May 22, 2006	Jun CHRS
AT	+		0.15%	N021764	001	May 22, 2006	Jun CRLD

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMFENAC SODIUM

AT2		GLAND PHARMA LTD	EQ 0.09% ACID	A211029	001	Mar 17, 2020	Mar NEWA
-----	--	------------------	---------------	---------	-----	--------------	----------

BROMOCRIPTINE MESYLATE

TABLET; ORAL

BROMOCRIPTINE MESYLATE

@ MYLAN	EQ 2.5MG BASE	A076962	001	Sep 24, 2004	Jun DISC
---------	---------------	---------	-----	--------------	----------

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA	ALKEM LABS LTD	2MG/5ML; 10MG/5ML; 30MG/5ML	A210647	001	Jul 14, 2020	Jul NEWA
AA	LANNETT CO INC	2MG/5ML; 10MG/5ML; 30MG/5ML	A213125	001	Apr 17, 2020	Apr NEWA
>A>	@ PHARM ASSOC	2MG/5ML; 10MG/5ML; 30MG/5ML	A202940	001	Jul 21, 2014	Aug CAHN
>D>	@ VINTAGE PHARMS	2MG/5ML; 10MG/5ML; 30MG/5ML	A202940	001	Jul 21, 2014	Aug CAHN
AA	WES PHARMA INC	2MG/5ML; 10MG/5ML; 30MG/5ML	A211170	001	Jun 16, 2020	Jun NEWA

BUDESONIDE

AEROSOL, FOAM; RECTAL

UCERIS

+	SALIX	2MG/ACTUATION	N205613	001	Oct 07, 2014	Feb CAHN
---	-------	---------------	---------	-----	--------------	----------

CAPSULE; ORAL

BUDESONIDE

AB	RISING	3MG	A207367	001	Apr 07, 2017	Jul CAHN
----	--------	-----	---------	-----	--------------	----------

SUSPENSION; INHALATION

BUDESONIDE

AN	LUPIN	0.5MG/2ML	A210897	001	Nov 09, 2018	Jul CAHN
----	-------	-----------	---------	-----	--------------	----------

BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION

BREZTRI AEROSPHERE

+	ASTRAZENECA AB	0.16MG/INH; 0.0048MG/INH; 0.009MG/INH	N212122	001	Jul 23, 2020	Jul NEWA
---	----------------	---------------------------------------	---------	-----	--------------	----------

BUMETANIDETABLET; ORAL
BUMETANIDE

AB	RISING	0.5MG	A212019	001	Dec 12, 2019	Jan CAHN
AB		1MG	A212019	002	Dec 12, 2019	Jan CAHN
AB		2MG	A212019	003	Dec 12, 2019	Jan CAHN

BUPIVACAINE HYDROCHLORIDE

IMPLANT; IMPLANTATION

>A> XARACOLL

>A>	+!	INNOCOLL PHARMS	100MG	N209511	001	Aug 28, 2020	Aug NEWA
-----	----	-----------------	-------	---------	-----	--------------	----------

BUPRENORPHINEFILM, EXTENDED RELEASE; TRANSDERMAL
BUPRENORPHINE

AB	AMNEAL	5MCG/HR	A211586	001	Apr 14, 2020	Mar NEWA	
AB		7.5MCG/HR	A211586	002	Apr 14, 2020	Mar NFTG	
AB		10MCG/HR	A211586	003	Apr 14, 2020	Mar NEWA	
AB		15MCG/HR	A211586	004	Apr 14, 2020	Mar NEWA	
AB		20MCG/HR	A211586	005	Apr 14, 2020	Mar NEWA	
BUTRANS							
AB	+	PURDUE PHARMA LP	7.5MCG/HR	N021306	005	Jun 30, 2014	Mar CFTG

BUPRENORPHINE HYDROCHLORIDETABLET; SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE

>D>	AB	CASI PHARMS INC	EQ 2MG BASE	A090279	001	Jun 10, 2015	Aug CAHN
>D>	AB		EQ 8MG BASE	A090279	002	Jun 10, 2015	Aug CAHN
>A>	AB	RUBICON	EQ 2MG BASE	A090279	001	Jun 10, 2015	Aug CAHN
>A>	AB		EQ 8MG BASE	A090279	002	Jun 10, 2015	Aug CAHN

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDEFILM; BUCCAL
BUNAVAIL

+	@	BDSI	EQ 2.1MG BASE; EQ 0.3MG BASE	N205637	001	Jun 06, 2014	Jun DISC
+	@		EQ 4.2MG BASE; EQ 0.7MG BASE	N205637	002	Jun 06, 2014	Jun DISC
+	@		EQ 6.3MG BASE; EQ 1MG BASE	N205637	003	Jun 06, 2014	Jun DISC

FILM; BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	MYLAN TECHNOLOGIES	EQ 2MG BASE; EQ 0.5MG BASE	A211785	001	Apr 17, 2020	Apr NEWA
AB		EQ 4MG BASE; EQ 1MG BASE	A211785	002	Apr 17, 2020	Apr NEWA

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	MAYNE PHARMA INC	EQ 2MG BASE; EQ 0.5MG BASE	A206953	001	Jul 17, 2020	Jul NEWA
AB		EQ 8MG BASE; EQ 2MG BASE	A206953	002	Jul 17, 2020	Jul NEWA
AB	RHODES PHARMS	EQ 2MG BASE; EQ 0.5MG BASE	A205601	001	Mar 30, 2020	Mar NEWA
AB		EQ 8MG BASE; EQ 2MG BASE	A205601	002	Mar 30, 2020	Mar NEWA
AB	WES PHARMA INC	EQ 2MG BASE; EQ 0.5MG BASE	A209069	001	Jul 17, 2020	Jul NEWA
AB		EQ 8MG BASE; EQ 2MG BASE	A209069	002	Jul 17, 2020	Jul NEWA

BUPROPION HYDROCHLORIDETABLET; ORAL
BUPROPION HYDROCHLORIDE

AB	CADILA PHARMS LTD	75MG	A208606	001	Jan 16, 2020	Jan NEWA
AB		100MG	A208606	002	Jan 16, 2020	Jan NEWA
AB	MICRO LABS	75MG	A207403	001	Apr 17, 2020	Apr NEWA
AB		100MG	A207403	002	Apr 17, 2020	Apr NEWA

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

@	JUBILANT GENERICS	100MG	A202774	001	Oct 11, 2013	Feb DISC
@		150MG	A202774	002	Oct 11, 2013	Feb DISC
@		150MG	A202775	001	Oct 11, 2013	Feb DISC
@		150MG	A207459	001	Jun 30, 2017	Feb DISC
@		200MG	A202774	003	Oct 11, 2013	Feb DISC
@		300MG	A207459	002	Jun 30, 2017	Feb DISC
@	WATSON LABS INC	100MG	A077455	001	Jul 19, 2010	Apr DISC
@		150MG	A077455	002	Mar 12, 2008	Apr DISC
@		200MG	A077455	003	Jul 19, 2010	Apr DISC
AB1	YICHANG HUMANWELL	100MG	A211347	001	Oct 16, 2018	Jun CMFD
AB1		150MG	A211347	002	Oct 16, 2018	Jun CMFD
AB1		200MG	A211347	003	Oct 16, 2018	Jun CMFD

TABLET, EXTENDED RELEASE;ORAL					
BUPROPION HYDROCHLORIDE					
AB3	ZHEJIANG JUTAI PHARM 150MG	A211200	002	Apr 29, 2020	Jun NEWA
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE</u>					
TABLET, EXTENDED RELEASE;ORAL					
CONTRAVE					
+	NALPROPION 90MG;8MG	N200063	001	Sep 10, 2014	Jan CAHN
<u>BUSPIRONE HYDROCHLORIDE</u>					
TABLET;ORAL					
BUSPIRONE HYDROCHLORIDE					
AB	AUROBINDO PHARMA LTD 7.5MG	A078246	005	Feb 21, 2020	Jun NEWA
AB	! MYLAN 7.5MG	A075467	002	Mar 28, 2001	Jun CHRS
AB	OXFORD PHARMS 5MG	A075388	001	May 09, 2002	Jul CMFD
AB	10MG	A075388	002	May 09, 2002	Jul CMFD
AB	15MG	A075388	003	May 09, 2002	Jul CMFD
<u>BUSULFAN</u>					
INJECTABLE;INJECTION					
BUSULFAN					
AP	MYLAN INSTITUTIONAL 6MG/ML	A208536	001	Nov 20, 2017	Apr CTNA
	@ MYLAN LABS LTD 6MG/ML	A205184	001	Jul 13, 2018	Feb DISC
<u>BUTABARBITAL SODIUM</u>					
TABLET;ORAL					
BUTISOL SODIUM					
+	@ MYLAN SPECIALITY LP 30MG	N000793	004		May DISC
<u>CABERGOLINE</u>					
TABLET;ORAL					
CABERGOLINE					
	@ MYLAN 0.5MG	A202947	001	Dec 02, 2013	Jan DISC
<u>CALCITRIOL</u>					
CAPSULE;ORAL					
CALCITRIOL					
AB	SUN PHARM 0.25MCG	A204556	001	Feb 21, 2019	Mar CMFD
AB	0.5MCG	A204556	002	Feb 21, 2019	Mar CMFD
INJECTABLE;INJECTION					
CALCITRIOL					
AP	! AKORN 0.001MG/ML	A078066	001	Jan 29, 2008	Jan CTEC
AP	GLAND PHARMA LTD 0.001MG/ML	A211030	001	Feb 03, 2020	Jan NEWA
<u>CALCIUM ACETATE</u>					
CAPSULE;ORAL					
CALCIUM ACETATE					
	@ LOTUS PHARM CO LTD 667MG	A203298	001	Jul 26, 2016	Jan DISC
<u>CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE</u>					
SOLUTION;INTRAPERITONEAL					
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
>D> AT	FRESENIUS MEDCL 25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	001	Nov 30, 1984	Aug CRLD
>A> AT	! 25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	001	Nov 30, 1984	Aug CHRS
>A> AT	+ 25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	001	Nov 30, 1984	Aug CRLD
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER					
>D> AT	FRESENIUS MEDCL 25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018883	004	Nov 30, 1984	Aug CRLD
>A> AT	! 25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018883	004	Nov 30, 1984	Aug CHRS
>A> AT	+ 25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018883	004	Nov 30, 1984	Aug CRLD
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER					
>D> AT	FRESENIUS MEDCL 18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020171	001	Aug 19, 1992	Aug CRLD
>A> AT	! 18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020171	001	Aug 19, 1992	Aug CHRS
>A> AT	+ 18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020171	001	Aug 19, 1992	Aug CRLD

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

>D>	AT	FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	002	Nov 30, 1984	Aug CRLD
>A>	AT	+	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	002	Nov 30, 1984	Aug CHRS
>A>	AT	+	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	002	Nov 30, 1984	Aug CRLD
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER							
>D>	AT	FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018883	005	Nov 30, 1984	Aug CRLD
>A>	AT	+	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018883	005	Nov 30, 1984	Aug CHRS
>A>	AT	+	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018883	005	Nov 30, 1984	Aug CRLD
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER							
>D>	AT	FRESENIUS MEDCL	18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020171	002	Aug 19, 1992	Aug CRLD
>A>	AT	+	18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020171	002	Aug 19, 1992	Aug CHRS
>A>	AT	+	18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020171	002	Aug 19, 1992	Aug CRLD
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER							
>D>	AT	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	003	Nov 30, 1984	Aug CRLD
>A>	AT	+	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	003	Nov 30, 1984	Aug CHRS
>A>	AT	+	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	003	Nov 30, 1984	Aug CRLD
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER							
>D>	AT	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018883	006	Nov 30, 1984	Aug CRLD
>A>	AT	+	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018883	006	Nov 30, 1984	Aug CHRS
>A>	AT	+	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018883	006	Nov 30, 1984	Aug CRLD
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER							
>D>	AT	FRESENIUS MEDCL	18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020171	003	Aug 19, 1992	Aug CRLD
>A>	AT	+	18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020171	003	Aug 19, 1992	Aug CHRS
>A>	AT	+	18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020171	003	Aug 19, 1992	Aug CRLD

CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE

SOLUTION;ORAL

XYWAV

>A>	+	JAZZ	0.234GM/ML;0.096GM/ML;0.13GM/ML;0.04GM/ML	N212690	001	Jul 21, 2020	Aug CPOT
>D>	+		0.234GM/ML;0.096GM/ML;0.13GM/ML;0.04GM/ML	N212690	001	Jul 21, 2020	Aug CPOT
	+		0.234GM/ML;0.096GM/ML;0.13GM/ML;0.04GM/ML	N212690	001	Jul 21, 2020	Jul NEWA

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB		RELANCE LIFE	150MG	A211724	001	Apr 27, 2020	Apr NEWA
AB			500MG	A211724	002	Apr 27, 2020	Apr NEWA

CAPMATINIB HYDROCHLORIDE

TABLET;ORAL

TABRECTA

+	NOVARTIS PHARM	EQ 150MG BASE	N213591	001	May 06, 2020	May NEWA
+		EQ 200MG BASE	N213591	002	May 06, 2020	May NEWA

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

@	SETON PHARMS	12.5MG	A212223	001	Oct 30, 2019	May DISC
@		25MG	A212223	002	Oct 30, 2019	May DISC
@		50MG	A212223	003	Oct 30, 2019	May DISC
@		100MG	A212223	004	Oct 30, 2019	May DISC
@	TEVA	12.5MG	A074322	001	Feb 13, 1996	Apr DISC
@		25MG	A074322	002	Feb 13, 1996	Apr DISC
@		50MG	A074322	003	Feb 13, 1996	Apr DISC
@		100MG	A074322	004	Feb 13, 1996	Apr DISC

TABLET; ORAL

CAPTOPRIL

@ WATSON LABS

12.5MG

A074386 001 May 23, 1996 Apr DISC

@

25MG

A074386 002 May 23, 1996 Apr DISC

@

50MG

A074386 003 May 23, 1996 Apr DISC

@

100MG

A074386 004 May 23, 1996 Apr DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB NOSTRUM LABS INC

100MG

A076697 001 May 20, 2011 May CMFD

AB

200MG

A076697 002 May 20, 2011 May CMFD

AB

300MG

A076697 003 May 20, 2011 May CMFD

TABLET; ORAL

CARBAMAZEPINE

AB TORRENT PHARMS

100MG

A077272 001 Dec 07, 2005 Mar CTEC

AB

UMEDICA LABS PVT LTD

100MG

A207798 001 Apr 15, 2020 Mar NEWA

AB

200MG

A207798 002 Apr 15, 2020 Mar NEWA

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

>D> AB TARO PHARM INDS

100MG

A075687 001 Oct 24, 2000 Aug CHRS

>A> AB

!

100MG

A075687 001 Oct 24, 2000 Aug CHRS

>D>

TEGRETOL

>D> AB +! NOVARTIS

100MG

N018281 001 Aug DISC

>A>

+

@

100MG

N018281 001 Aug DISC

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB UNIQUE PHARM

100MG

A211623 001 Apr 24, 2020 Apr NEWA

AB

200MG

A211623 002 Apr 24, 2020 Apr NEWA

AB

400MG

A211623 003 Apr 24, 2020 Apr NEWA

CARBIDOPA

TABLET; ORAL

CARBIDOPA

AB ANI PHARMS INC

25MG

A203261 001 Mar 10, 2014 Jan CAHN

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB MYLAN

12.5MG; 200MG; 50MG

A203424 001 Aug 13, 2020 Jul NEWA

AB

18.75MG; 200MG; 75MG

A203424 002 Aug 13, 2020 Jul NEWA

AB

25MG; 200MG; 100MG

A203424 003 Aug 13, 2020 Jul NEWA

AB

31.25MG; 200MG; 125MG

A203424 004 Aug 13, 2020 Jul NEWA

AB

37.5MG; 200MG; 150MG

A203424 005 Aug 13, 2020 Jul NEWA

AB

50MG; 200MG; 200MG

A203424 006 Aug 13, 2020 Jul NEWA

STALEVO 125

AB + ORION PHARMA

31.25MG; 200MG; 125MG

N021485 006 Aug 29, 2008 Jul CTEC

STALEVO 200

AB +! ORION PHARMA

50MG; 200MG; 200MG

N021485 004 Aug 02, 2007 Jul CTEC

STALEVO 50

AB +! ORION PHARMA

12.5MG; 200MG; 50MG

N021485 001 Jun 11, 2003 Jul CTEC

STALEVO 75

AB + ORION PHARMA

18.75MG; 200MG; 75MG

N021485 005 Aug 29, 2008 Jul CTEC

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

SINEMET CR

+ @ MERCK SHARP DOHME

25MG; 100MG

N019856 002 Dec 24, 1992 Jan DISC

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP EUGIA PHARMA

600MG/60ML (10MG/ML)

A205487 004 Aug 03, 2020 Jul NEWA

INJECTABLE; INTRAVENOUS

CARBOPLATIN

! ACCORD HLTHCARE

1GM/100ML (10MG/ML)

A206775 005 Apr 06, 2020 Jul NEWA

@ PLIVA LACHEMA

50MG/5ML (10MG/ML)

A078631 001 Dec 02, 2008 Apr DISC

@

150MG/15ML (10MG/ML)

A078631 002 Dec 02, 2008 Apr DISC

@

450MG/45ML (10MG/ML)

A078631 003 Dec 02, 2008 Apr DISC

@

600MG/60ML (10MG/ML)

A078631 004 Dec 02, 2008 Apr DISC

@ TEVA PHARMS USA

50MG/5ML (10MG/ML)

A077139 001 Sep 21, 2005 May DISC

@

150MG/15ML (10MG/ML)

A077139 002 Sep 21, 2005 May DISC

INJECTABLE; INTRAVENOUS
CARBOPLATIN

@	450MG/45ML (10MG/ML)	A077139	003	Sep 21, 2005	May DISC
@	600MG/60ML (10MG/ML)	A077139	004	Sep 21, 2005	May DISC

CARFILZOMIBPOWDER; INTRAVENOUS
CARFILZOMIB

AP	APOTEX	30MG/VIAL	A211185	001	Mar 20, 2020	Mar NFTG
AP		60MG/VIAL	A209425	001	Mar 16, 2020	Mar NEWA
	KYPROLIS					
AP	+ ONYX THERAP	30MG/VIAL	N202714	002	Jun 03, 2016	Mar CFTG

CARGLUMIC ACID

>D>	TABLET; ORAL					
>D>	CARBAGLU					
>D>	+! RECORDATI RARE	200MG	N022562	001	Mar 18, 2010	Aug CDFR
>A>	TABLET, FOR SUSPENSION; ORAL					
>A>	CARBAGLU					
>A>	+! RECORDATI RARE	200MG	N022562	001	Mar 18, 2010	Aug CDFR

CARISOPRODOLTABLET; ORAL
CARISOPRODOL

	@ HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996	Feb DISC
AA	OXFORD PHARMS	350MG	A040188	001	Mar 07, 1997	Apr CMFD

CEDAZURIDINE; DECITABINETABLET; ORAL
INQOVI

+!	OTSUKA	100MG; 35MG	N212576	001	Jul 07, 2020	Jul NEWA
----	--------	-------------	---------	-----	--------------	----------

CEFEPIME HYDROCHLORIDEINJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

AP	ASTRAL	EQ 1GM BASE/VIAL	A212721	001	Jul 21, 2020	Jul NEWA
AP		EQ 2GM BASE/VIAL	A212721	002	Jul 21, 2020	Jul NEWA

CEFIXIMEFOR SUSPENSION; ORAL
SUPRAX

@	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Jan DISC
---	--------------	-----------	---------	-----	--------------	----------

TABLET; ORAL
SUPRAX

@	LUPIN PHARMS	400MG	A065130	001	Feb 12, 2004	Jan DISC
---	--------------	-------	---------	-----	--------------	----------

CEFOXITIN SODIUMINJECTABLE; INJECTION
MEFOXIN IN PLASTIC CONTAINER

@	MYLAN INSTITUTIONAL	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993	Mar DISC
@		EQ 40MG BASE/ML	A063182	002	Jan 25, 1993	Mar DISC

CEFPROZILFOR SUSPENSION; ORAL
CEFPROZIL

@	TEVA PHARMS	125MG/5ML	A065236	001	Dec 08, 2005	Apr DISC
@		250MG/5ML	A065236	002	Dec 08, 2005	Apr DISC

CELECOXIBCAPSULE; ORAL
CELECOXIB

AB	NANJING	200MG	A213598	001	May 13, 2020	Apr NEWA
>D>	@ QINGDAO BAHEAL PHARM	50MG	A208856	001	Aug 07, 2019	Aug CMFD
>A>	AB	50MG	A208856	001	Aug 07, 2019	Aug CMFD
	@	50MG	A208856	001	Aug 07, 2019	May DISC
>D>	@	100MG	A208856	002	Aug 07, 2019	Aug CMFD
>A>	AB	100MG	A208856	002	Aug 07, 2019	Aug CMFD
	@	100MG	A208856	002	Aug 07, 2019	May DISC
>D>	@	200MG	A208856	003	Aug 07, 2019	Aug CMFD
>A>	AB	200MG	A208856	003	Aug 07, 2019	Aug CMFD
	@	200MG	A208856	003	Aug 07, 2019	May DISC
>D>	@	400MG	A208856	004	Aug 07, 2019	Aug CMFD

CAPSULE;ORAL									
CELECOXIB									
>A>	AB	400MG	A208856	004	Aug 07, 2019	Aug	CMFD		
	@	400MG	A208856	004	Aug 07, 2019	May	DISC		
	AB	TIANJIN TIANYAO	50MG	A207872	001	Feb 25, 2020	Feb	NEWA	
	AB		100MG	A207872	002	Feb 25, 2020	Feb	NEWA	
	AB		200MG	A207872	003	Feb 25, 2020	Feb	NEWA	
	AB		400MG	A207872	004	Feb 25, 2020	Feb	NEWA	
	AB	UMEDICA LABS PVT LTD	50MG	A210628	001	Nov 27, 2019	Jan	CDFR	
	AB		100MG	A210628	002	Nov 27, 2019	Jan	CDFR	
	AB		200MG	A210628	003	Nov 27, 2019	Jan	CDFR	
	AB		400MG	A210628	004	Nov 27, 2019	Jan	CDFR	
SOLUTION;ORAL									
ELYXYB									
	+!	DR REDDYS	25MG/ML	N212157	001	May 05, 2020	Jun	CAHN	
	+!		25MG/ML	N212157	001	May 05, 2020	May	NEWA	
<u>CENOBAMATE</u>									
TABLET;ORAL									
XCOPRI									
	+	SK LIFE	12.5MG	N212839	001	Mar 10, 2020	Mar	NEWA	
	+		25MG	N212839	002	Mar 10, 2020	Mar	NEWA	
	+		50MG	N212839	003	Mar 10, 2020	Mar	NEWA	
	+		100MG	N212839	004	Mar 10, 2020	Mar	NEWA	
	+		150MG	N212839	005	Mar 10, 2020	Mar	NEWA	
	+!		200MG	N212839	006	Mar 10, 2020	Mar	NEWA	
<u>CHENODIOL</u>									
TABLET;ORAL									
CHENODIOL									
>A>	!	LGM PHARMA	250MG	A091019	001	Oct 22, 2009	Aug	CAHN	
>D>	!	NEXGEN PHARMA	250MG	A091019	001	Oct 22, 2009	Aug	CAHN	
<u>CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE</u>									
CAPSULE;ORAL									
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE									
	AB	MISEMER	5MG;2.5MG	A210579	001	Jul 29, 2020	Jul	NEWA	
	AB	SUNRISE PHARM INC	5MG;2.5MG	A211421	001	Jul 07, 2020	Jul	NFTG	
LIBRAX									
	AB	+! BAUSCH	5MG;2.5MG	N012750	001		Jul	CFTG	
		+!	5MG;2.5MG	N012750	001		Jun	CAHN	
<u>CHLOROQUINE PHOSPHATE</u>									
TABLET;ORAL									
ARALEN									
	+	@ SANOFI AVENTIS US	500MG	N006002	001		Apr	CPOT	
CHLOROQUINE PHOSPHATE									
	@	HIKMA PHARMS	EQ 150MG BASE	A083082	001		Feb	DISC	
	@		250MG	A083082	001		Apr	CPOT	
AA			500MG	A083082	002	Sep 17, 1999	Apr	CPOT	
	@	IMPAX LABS	250MG	A080880	001		Apr	CPOT	
	@		500MG	A040516	001	Aug 29, 2003	Apr	CPOT	
AA		IPCA LABS LTD	250MG	A090610	001	Dec 03, 2009	Apr	CPOT	
AA			500MG	A090249	001	Dec 03, 2009	Apr	CPOT	
	@	MD PHARM	250MG	A087228	001		Apr	CPOT	
AA	!	NATCO PHARMA LTD	EQ 150MG BASE	A091621	001	Jan 21, 2011	Feb	CHRS	
AA	!		250MG	A091621	001	Jan 21, 2011	Apr	CPOT	
AA	!		500MG	A090612	001	Jan 21, 2011	Apr	CPOT	
	@	PUREPAC PHARM	250MG	A080886	001		Apr	CPOT	
	@	TEVA	250MG	A087504	001	Jan 13, 1982	Apr	CPOT	
	@	WATSON LABS	250MG	A087979	001	Dec 21, 1982	Apr	CPOT	
	@		500MG	A088030	001	Dec 21, 1982	Apr	CPOT	
<u>CHLORPROMAZINE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
CHLORPROMAZINE HYDROCHLORIDE									
	AP	AUROBINDO PHARMA LTD	25MG/ML	A211816	001	Jul 07, 2020	Jul	NEWA	
	AP	! WEST-WARD PHARMS INT	25MG/ML	A083329	001		Jul	CTEC	
TABLET;ORAL									
CHLORPROMAZINE HYDROCHLORIDE									
>A>	AB	MAYNE PHARMA	10MG	A213590	001	Aug 31, 2020	Aug	NEWA	
>A>	AB		25MG	A213590	002	Aug 31, 2020	Aug	NEWA	

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

>A>	AB		50MG	A213590	003	Aug 31, 2020	Aug NEWA
>A>	AB		100MG	A213590	004	Aug 31, 2020	Aug NEWA
>A>	AB		200MG	A213590	005	Aug 31, 2020	Aug NEWA
	AB	ZYDUS	10MG	A213368	001	Jan 17, 2020	Jan NEWA
	AB		25MG	A213368	002	Jan 17, 2020	Jan NEWA
	AB		50MG	A213368	003	Jan 17, 2020	Jan NEWA
	AB		100MG	A213368	004	Jan 17, 2020	Jan NEWA
	AB		200MG	A213368	005	Jan 17, 2020	Jan NEWA

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

	AB	ALKEM LABS LTD	25MG	A213412	001	Feb 11, 2020	Jan NEWA
	AB		50MG	A213412	002	Feb 11, 2020	Jan NEWA
>D>	AB	ARISE	25MG	A210742	001	Oct 12, 2018	Aug CAHN
>D>	AB		50MG	A210742	002	Oct 12, 2018	Aug CAHN
>A>	AB	DR REDDYS	25MG	A210742	001	Oct 12, 2018	Aug CAHN
>A>	AB		50MG	A210742	002	Oct 12, 2018	Aug CAHN
	AB	VISTAPHARM	25MG	A211063	001	Feb 26, 2019	Feb CAHN
	AB		50MG	A211063	002	Feb 26, 2019	Feb CAHN

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

>A>	AA	AUROBINDO PHARMA LTD	500MG	A089853	001	May 04, 1988	Aug CAHN
>D>	AA	AUROLIFE PHARMA LLC	500MG	A089853	001	May 04, 1988	Aug CAHN
	AA		500MG	A089853	001	May 04, 1988	Jun CMFD
	AB	GLENMARK PHARMS LTD	375MG	A212185	001	May 26, 2020	May NEWA
	AB		750MG	A212185	002	May 26, 2020	May NEWA
	AB	MAYNE PHARMA	375MG	A211849	001	Jul 21, 2020	Jul NEWA
	AA		500MG	A211849	002	Jul 21, 2020	Jul NEWA
	AB		750MG	A211849	003	Jul 21, 2020	Jul NEWA
	AB	TEVA PHARMS USA INC	375MG	A212898	001	Jun 17, 2020	Jun NEWA
	AB		750MG	A212898	002	Jun 17, 2020	Jun NEWA

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

	AB	AJANTA PHARMA LTD	EQ 4GM RESIN/PACKET	A211119	001	Apr 06, 2020	Mar NEWA
	AB		EQ 4GM RESIN/SCOOPFUL	A211119	002	Apr 06, 2020	Mar NEWA
		LOCHOLEST					
	@	ALLIED	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996	Feb CAHN
	@		EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996	Feb CAHN
	@	INVATECH	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996	Jan CAHN
	@		EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996	Jan CAHN
		LOCHOLEST LIGHT					
	@	ALLIED	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996	Feb CAHN
	@		EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996	Feb CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

FENOFIBRIC ACID

	AB	MICRO LABS	EQ 45MG FENOFIBRIC ACID	A213450	001	Jun 16, 2020	Jun NEWA
	AB		EQ 135MG FENOFIBRIC ACID	A213450	002	Jun 16, 2020	Jun NEWA
	AB	TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Mar CMFD
	AB		EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Mar CMFD

CILOSTAZOL

TABLET;ORAL

CILOSTAZOL

>A>	AB	CHARTWELL RX	50MG	A077831	002	Sep 24, 2012	Aug CMS1
-----	----	--------------	------	---------	-----	--------------	----------

CIMETIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CIMETIDINE HYDROCHLORIDE

	@	DAVA PHARMS INC	EQ 300MG BASE/2ML	A074428	001	Apr 25, 1996	May DISC
--	---	-----------------	-------------------	---------	-----	--------------	----------

CINACALCET HYDROCHLORIDE

TABLET; ORAL

CINACALCET HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 30MG BASE	A211892	001	May 15, 2020	May NEWA
AB		EQ 60MG BASE	A211892	002	May 15, 2020	May NEWA
AB		EQ 90MG BASE	A211892	003	May 15, 2020	May NEWA
AB	ACME LABS	EQ 30MG BASE	A213325	001	May 18, 2020	May NEWA
AB		EQ 60MG BASE	A213325	002	May 18, 2020	May NEWA
AB		EQ 90MG BASE	A213325	003	May 18, 2020	May NEWA
	@ LUPIN LTD	EQ 30MG BASE	A210548	001	Jun 28, 2019	Jan DISC
	@	EQ 60MG BASE	A210548	002	Jun 28, 2019	Jan DISC
	@	EQ 90MG BASE	A210548	003	Jun 28, 2019	Jan DISC

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS; OTIC

CIPRODEX

AB	+! NOVARTIS	0.3%; 0.1%	N021537	001	Jul 18, 2003	Jul CFTG
	CIPROFLOXACIN AND DEXAMETHASONE					
AB	DR REDDYS LABS LTD	0.3%; 0.1%	A205548	001	Aug 10, 2020	Jul NFTG

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP	AUROBINDO PHARMA LTD	EQ 2MG BASE/ML	A209144	001	May 08, 2020	Apr NEWA
AP	HOSPIRA INC	EQ 2MG BASE/ML	A203238	001	Mar 30, 2018	Jan CMFD
AP	PIRAMAL HLTHCARE UK	EQ 2MG BASE/ML	A212190	001	May 04, 2020	Apr NEWA
>A> AP	ZYDUS PHARMS	EQ 2MG BASE/ML	A213527	001	Aug 31, 2020	Aug NEWA

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

@	JUBILANT GENERICS	EQ 10MG BASE
@		EQ 20MG BASE
@		EQ 40MG BASE

A205407	001	Dec 23, 2015	Mar DISC
A205407	002	Dec 23, 2015	Mar DISC
A205407	003	Dec 23, 2015	Mar DISC

CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE

GEL; VAGINAL

PHEXXI

+!	EVOFEM INC	1%; 1.8%; 0.4%	N208352	001	May 22, 2020	May NEWA
----	------------	----------------	---------	-----	--------------	----------

>A> CLASCOTERONE

>A> CREAM; TOPICAL

>A> WINLEVI

>A>	+!	CASSIOPEA SPA	1%	N213433	001	Aug 26, 2020	Aug NEWA
-----	----	---------------	----	---------	-----	--------------	----------

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

!	GENUS	EQ 0.5MG BASE/5ML	A073399	001	Jun 30, 1994	Jul CAHN
---	-------	-------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM; TOPICAL

CLINDAMYCIN PHOSPHATE

	@	TARO PHARM INDS LTD	1%	A210004	001	Mar 11, 2020	May DISC
AT			1%	A210004	001	Mar 11, 2020	Feb NEWA

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE

AB	SOLARIS PHARMA CORP	EQ 1% BASE	A211872	001	Jul 29, 2020	Jul NEWA
----	---------------------	------------	---------	-----	--------------	----------

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

@	ALVOGEN INC	EQ 150MG BASE/ML	A062801	001	Jul 24, 1987	Jul DISC
---	-------------	------------------	---------	-----	--------------	----------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

@	G AND W LABS INC	EQ 1% BASE	A062811	001	Sep 01, 1988	Jul DISC
@	VINTAGE PHARMS	EQ 1% BASE	A203343	001	May 29, 2015	Jun DISC

CLOBAZAMSUSPENSION; ORAL
CLOBAZAM

AB	HETERO LABS LTD III	2.5MG/ML	A209796	001	Feb 24, 2020	Feb NEWA
AB	LANNETT CO INC	2.5MG/ML	A213110	001	Apr 24, 2020	Apr NEWA
	@ TEVA PHARMS USA	2.5MG/ML	A211032	001	Jan 31, 2020	Apr DISC
AB		2.5MG/ML	A211032	001	Jan 31, 2020	Jan NEWA

TABLET; ORAL
CLOBAZAM

AB	APOTEX	10MG	A209853	001	Jun 09, 2020	Jun NEWA
AB		20MG	A209853	002	Jun 09, 2020	Jun NEWA

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

AB1	ALEOR DERMACEUTICALS	0.05%	A213291	001	Jan 27, 2020	Jan NEWA
>A> AB1	ENCUBE	0.05%	A212982	001	Aug 28, 2020	Aug NEWA

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	ANI PHARMS INC	0.05%	A075733	001	Aug 22, 2001	Jun CAHN
AB2	INGENUS PHARMS LLC	0.05%	A075733	001	Aug 22, 2001	May CAHN

LOTION; TOPICAL

IMPEKLO

+!	MYLAN	0.05%	N213691	001	May 19, 2020	Jun CAHN
+!	MYLAN LABS INC	0.05%	N213691	001	May 19, 2020	May NEWA

SHAMPOO; TOPICAL

CLOBETASOL PROPIONATE

AB	ALEOR DERMACEUTICALS	0.05%	A213290	001	May 18, 2020	May NEWA
----	----------------------	-------	---------	-----	--------------	----------

SPRAY; TOPICAL

CLOBETASOL PROPIONATE

@	ALEOR DERMACEUTICALS	0.05%	A211191	001	Oct 02, 2019	Jan DISC
---	----------------------	-------	---------	-----	--------------	----------

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

CLOCORTOLONE PIVALATE

AB	TARO	0.1%	A206370	001	Apr 21, 2020	Apr NFTG
----	------	------	---------	-----	--------------	----------

CLODERM

AB	+! EPI HLTH	0.1%	N017765	001		Apr CFTG
----	-------------	------	---------	-----	--	----------

CLOMIPHENE CITRATE

TABLET; ORAL

MILOPHENE

@	GRANATA BIO	50MG	A072196	001	Dec 20, 1988	Jul CAHN
---	-------------	------	---------	-----	--------------	----------

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB	LEADING PHARMA LLC	25MG	A211364	001	Feb 07, 2020	Jan NEWA
AB		50MG	A211364	002	Feb 07, 2020	Jan NEWA
AB		75MG	A211364	003	Feb 07, 2020	Jan NEWA
AB	MANKIND PHARMA	25MG	A211767	001	Apr 08, 2019	Jan CMFD
AB		50MG	A211767	002	Apr 08, 2019	Jan CMFD
AB		75MG	A211767	003	Apr 08, 2019	Jan CMFD
AB	MICRO LABS	25MG	A213219	001	Jun 22, 2020	Jun NEWA
AB		50MG	A213219	002	Jun 22, 2020	Jun NEWA
AB		75MG	A213219	003	Jun 22, 2020	Jun NEWA
	@ TEVA	25MG	A074958	001	Aug 26, 1997	Feb DISC
	@	50MG	A074958	002	Aug 26, 1997	Feb DISC
	@	75MG	A074958	003	Aug 26, 1997	Feb DISC
AB	TULEX PHARMS INC	25MG	A210653	001	Apr 03, 2020	Mar NEWA
AB		50MG	A210653	002	Apr 03, 2020	Mar NEWA
AB		75MG	A210653	003	Apr 03, 2020	Mar NEWA
AB	UNIQUE PHARM LABS	25MG	A212285	001	Aug 07, 2020	Jul NEWA
AB		50MG	A212285	002	Aug 07, 2020	Jul NEWA
AB		75MG	A212285	003	Aug 07, 2020	Jul NEWA
AB	VGYAAN	25MG	A213221	001	Jun 22, 2020	Jun NEWA
AB		50MG	A213221	002	Jun 22, 2020	Jun NEWA
AB		75MG	A213221	003	Jun 22, 2020	Jun NEWA

CLONAZEPAMTABLET; ORAL
CLONAZEPAM

@ MYLAN	0.5MG	A075150	001	Oct 05, 1998	May DISC
@	1MG	A075150	002	Oct 05, 1998	Jun DISC
@	2MG	A075150	003	Oct 05, 1998	May DISC

CLONIDINE HYDROCHLORIDEINJECTABLE; INJECTION
CLONIDINE HYDROCHLORIDE

AP	XGEN PHARMS	1MG/10ML (0.1MG/ML)	A203167	001	Oct 29, 2013	Feb CAHN
AP		5MG/10ML (0.5MG/ML)	A203167	002	Oct 29, 2013	Feb CAHN

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

@ AUROBINDO PHARMA LTD	0.1MG	A070886	002	Aug 31, 1988	May CAHN
@	0.2MG	A070886	001	Aug 31, 1988	May CAHN
@	0.3MG	A070886	003	Aug 31, 1988	May CAHN

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE HYDROCHLORIDE

AB1	UPSHER SMITH LABS	0.1MG	A211433	001	Oct 12, 2018	Feb CMFD
-----	-------------------	-------	---------	-----	--------------	----------

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	! APOTEX INC	EQ 300MG BASE	A076274	002	Mar 04, 2014	May CHRS
	@ CELLTRION	EQ 75MG BASE	A202266	001	Aug 14, 2012	Jun DISC
	@	EQ 300MG BASE	A202266	002	Nov 20, 2012	Jun DISC
AB	POLYGEN PHARMS	EQ 75MG BASE	A213351	001	Jul 17, 2020	Jul NEWA
AB		EQ 300MG BASE	A213351	002	Jul 17, 2020	Jul NEWA
	PLAVIX					
AB	+ SANOFI AVENTIS US	EQ 300MG BASE	N020839	002	Sep 20, 2007	May CHRS

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC	3.75MG	A072112	002	Aug 26, 1988	Feb CMS1
@	7.5MG	A072112	003	Aug 26, 1988	Feb CMS1

COCAINE HYDROCHLORIDE

SOLUTION; NASAL

NUMBRINO

CODY LABS INC	4%	N209575	001	Jan 10, 2020	Jan NEWA
---------------	----	---------	-----	--------------	----------

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA	PHARM ASSOC	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A040660	001	Dec 07, 2006	Jun CAHN
	PROMETH VC W/ CODEINE					
AA	! NOSTRUM LABS INC	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A088764	001	Oct 31, 1984	Jun CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE WITH CODEINE

@ PHARM ASSOC	10MG/5ML; 6.25MG/5ML	A040650	001	Jan 31, 2006	Jun CAHN
@ VINTAGE	10MG/5ML; 6.25MG/5ML	A040650	001	Jan 31, 2006	Apr DISC

COLCHICINE

TABLET; ORAL

COLCHICINE

AB	AMNEAL PHARMS	0.6MG	A204711	001	Sep 28, 2016	Jan CMFD
AB	GRANULES PHARMS	0.6MG	A210425	001	Feb 05, 2020	Jan NEWA
	ZYDUS PHARMS	0.3MG	A211519	002	Nov 14, 2019	Jul NEWA
AB		0.6MG	A211519	001	Feb 19, 2019	Jul CMFD

COLESEVELAM HYDROCHLORIDEBAR, CHEWABLE; ORAL
WELCHOL

+ @ DAIICHI SANKYO INC	3.75GM	N210895	001	Apr 03, 2019	Jun DISC
------------------------	--------	---------	-----	--------------	----------

FOR SUSPENSION;ORAL

COLESEVELAM HYDROCHLORIDE

>D>		GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018	Aug CTEC
>A>	AB		1.875GM/PACKET	A202190	001	Jul 16, 2018	Aug CTEC
>A>	AB	WATSON LABS INC	1.875GM/PACKET	A202178	001	Sep 01, 2020	Aug NEWA
>A>	AB		3.75GM/PACKET	A202178	002	Sep 01, 2020	Aug NEWA

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

	AB	INVAGEN PHARMS	625MG	A212602	001	Apr 20, 2020	Apr NEWA
>A>	AB	WATSON LABS INC	625MG	A200830	001	Sep 02, 2020	Aug NEWA
	AB	ZHEJIANG JINGXIN	625MG	A209946	001	Jul 15, 2020	Jul NEWA

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

>D>	AP	EMCURE PHARMS LTD	EQ 150MG BASE/VIAL	A202359	001	Sep 28, 2012	Aug DISC
>A>		@	EQ 150MG BASE/VIAL	A202359	001	Sep 28, 2012	Aug DISC
	AP	XGEN PHARMS	EQ 150MG BASE/VIAL	A064216	001	Feb 26, 1999	Feb CAHN

CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE

SOLUTION;INTRAVENOUS

TRALEMENT

	+	!	AM REGENT	EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML	N209376	001	Jul 02, 2020	Jul NEWA
--	---	---	-----------	---	---------	-----	--------------	----------

CYANOCOBALAMIN

SPRAY, METERED;NASAL

CYANOCOBALAMIN

>A>									
>A>	AB	PERRIGO UK FINCO	0.5MG/SPRAY	A212458	001	Sep 09, 2020	Aug NFTG		
		NASCOBAL							
>D>		+	!	ENDO PHARMS INC	0.5MG/SPRAY	N021642	001	Jan 31, 2005	Aug CFTG
>A>	AB	+	!		0.5MG/SPRAY	N021642	001	Jan 31, 2005	Aug CFTG

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

	AB	MYLAN PHARMS INC	10MG	A073144	001	May 30, 1991	Jun CHRS	
	AB	!	RUBICON	10MG	A208170	003	May 31, 2017	Jun CHRS
	AB	UNICHEM LABS LTD	5MG	A213324	001	Jul 06, 2020	Jul NEWA	
	AB		7.5MG	A213324	002	Jul 06, 2020	Jul NEWA	
	AB		10MG	A213324	003	Jul 05, 2020	Jul NEWA	

CYCLOPHOSPHAMIDE

CAPSULE;ORAL

CYCLOPHOSPHAMIDE

	AB	ANI PHARMS INC	25MG	A207014	001	Mar 19, 2018	Jan CAHN
	AB		50MG	A207014	002	Mar 19, 2018	Jan CAHN

SOLUTION;INTRAVENOUS

CYCLOPHOSPHAMIDE

	+	!	INGENUS PHARMS LLC	500MG/2.5ML (200MG/ML)	N212501	001	Jul 30, 2020	Jul NEWA
	+	!		1GM/5ML (200MG/ML)	N212501	002	Jul 30, 2020	Jul NEWA

TABLET;ORAL

CYTOXAN

>D>		+	@	BAXTER HLTHCARE	25MG	N012141	002		Aug CMFD
>A>		+			25MG	N012141	002		Aug CMFD
>D>		+	@		50MG	N012141	001		Aug CMFD
>A>		+	!		50MG	N012141	001		Aug CMFD

CYCLOSPORINE

INJECTABLE;INJECTION

CYCLOSPORINE

>D>	AP	AM REGENT	50MG/ML	A065151	001	Oct 07, 2003	Aug CAHN
>A>	AP	PADDOCK LABS LLC	50MG/ML	A065151	001	Oct 07, 2003	Aug CAHN

CYPROHEPTADINE HYDROCHLORIDE

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

	AA	APPCO	4MG	A206553	001	Nov 29, 2016	Mar CAHN
		@	PAR PHARM	4MG	A087129	001	May DISC

CYSTEAMINE BITARTRATE

GRANULE; ORAL

PROCYSBI

+	HORIZON PHARMA USA	EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020	Feb NEWA
+	!	EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020	Feb NEWA

GRANULE, DELAYED RELEASE; ORAL

PROCYSBI

+	HORIZON PHARMA USA	EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020	Jul CDFR
+	!	EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020	Jul CDFR

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

>A> CYSTADROPS

>A>	+	!	RECORDATI RARE	EQ 0.37% BASE	N211302	001	Aug 19, 2020	Aug NEWA
-----	---	---	----------------	---------------	---------	-----	--------------	----------

CYSTEINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

NOURESS

+	@	AVADEL LEGACY	500MG/10ML (50MG/ML)	N212535	001	Dec 13, 2019	May CRLD
	@		500MG/10ML (50MG/ML)	N212535	001	Dec 13, 2019	May DISC
+	@	EXELA PHARMA	500MG/10ML (50MG/ML)	N212535	001	Dec 13, 2019	Jul CAHN

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP		HONG KONG	20MG/ML	A206189	001	Jun 26, 2020	Jun NEWA
----	--	-----------	---------	---------	-----	--------------	----------

DABIGATRAN ETEXILATE MESYLATE

CAPSULE; ORAL

DABIGATRAN ETEXILATE MESYLATE

AB		ALKEM LABS LTD	EQ 75MG BASE	A208040	001	Mar 11, 2020	Feb NFTG
AB			EQ 150MG BASE	A208040	002	Mar 11, 2020	Feb NFTG
AB		HETERO LABS LTD III	EQ 75MG BASE	A207961	001	May 06, 2020	Apr NEWA
AB			EQ 150MG BASE	A207961	002	May 06, 2020	Apr NEWA

PRADAXA

AB	+	BOEHRINGER INGELHEIM	EQ 75MG BASE	N022512	001	Oct 19, 2010	Feb CFTG
AB	+	!	EQ 150MG BASE	N022512	002	Oct 19, 2010	Feb CFTG

DACTINOMYCIN

INJECTABLE; INJECTION

DACTINOMYCIN

AP		XGEN PHARMS	0.5MG/VIAL	A203999	001	May 20, 2019	Feb CAHN
----	--	-------------	------------	---------	-----	--------------	----------

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

DALFAMPRIDINE

	@	MYLAN	10MG	A206858	001	Jul 06, 2020	Jul DISC
AB			10MG	A206858	001	Jul 06, 2020	Jul NEWA

DANTROLENE SODIUM

INJECTABLE; INJECTION

REVONTO

AP		USWM	20MG/VIAL	A078378	001	Jul 24, 2007	Jun CAHN
----	--	------	-----------	---------	-----	--------------	----------

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

QTERNMET XR

>D>							
>D>	+	ASTRAZENECA AB	2.5MG;1GM;EQ 2.5MG BASE	N210874	001	May 02, 2019	Aug DISC
>A>	+	@	2.5MG;1GM;EQ 2.5MG BASE	N210874	001	May 02, 2019	Aug DISC
>D>	+		5MG;1GM;EQ 2.5MG BASE	N210874	002	May 02, 2019	Aug DISC
>A>	+	@	5MG;1GM;EQ 2.5MG BASE	N210874	002	May 02, 2019	Aug DISC
>D>	+		5MG;1GM;EQ 5MG BASE	N210874	003	May 02, 2019	Aug DISC
>A>	+	@	5MG;1GM;EQ 5MG BASE	N210874	003	May 02, 2019	Aug DISC
>D>	+	!	10MG;1GM;EQ 5MG BASE	N210874	004	May 02, 2019	Aug DISC
>A>	+	@	10MG;1GM;EQ 5MG BASE	N210874	004	May 02, 2019	Aug DISC

DAPSONEGEL; TOPICAL
ACZONE

AB	+!	ALMIRALL	7.5%	N207154	001	Feb 24, 2016	Jun CTEC
AB		TARO PHARMS	7.5%	A210191	001	Jun 26, 2019	Feb NEWA

DAPTOMYCINPOWDER; IV (INFUSION)
DAPTOMYCIN

>A>	AP	BE PHARMS	350MG/VIAL	A213425	001	Aug 20, 2020	Aug NEWA
>A>	AP	DR REDDYS	350MG/VIAL	A211403	001	Aug 31, 2020	Aug NEWA

DARIFENACIN HYDROBROMIDETABLET, EXTENDED RELEASE; ORAL
DARIFENACIN HYDROBROMIDE

@	ALAN LABS INC	EQ 7.5MG BASE	A209571	002	Oct 22, 2019	Apr DISC
@		EQ 15MG BASE	A209571	001	Oct 22, 2019	Apr DISC
@	ANCHEN PHARMS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	Feb DISC
@		EQ 15MG BASE	A091190	002	Mar 13, 2015	Feb DISC

DEFERASIROXGRANULE; ORAL
DEFERASIROX

AB		ALKEM LABS LTD	90MG	A213374	001	Jul 14, 2020	Jul NFTG
AB			180MG	A213374	002	Jul 14, 2020	Jul NFTG
AB			360MG	A213374	003	Jul 14, 2020	Jul NFTG
AB	+	JADENU SPRINKLE					
AB	+	NOVARTIS	90MG	N207968	001	May 18, 2017	Jul CFTG
AB	+		180MG	N207968	002	May 18, 2017	Jul CFTG
AB	+		360MG	N207968	003	May 18, 2017	Jul CFTG

TABLET; ORAL
DEFERASIROX

AB		ALEMBIC PHARMS LTD	180MG	A211824	003	Jun 15, 2020	Jun NEWA
AB		ALKEM LABS LTD	90MG	A210555	001	Mar 30, 2020	Mar NEWA
AB			180MG	A210555	003	Jul 02, 2020	Jul NEWA
AB			360MG	A210555	002	Mar 30, 2020	Mar NEWA
AB		AMNEAL	90MG	A210727	001	Dec 27, 2019	Feb CAHN
AB			180MG	A210727	003	Jun 15, 2020	Jun NEWA
AB			360MG	A210727	002	Dec 27, 2019	Feb CAHN
AB		CIPLA	90MG	A211852	001	Feb 11, 2020	Jan NEWA
AB			180MG	A211852	003	Jun 15, 2020	Jun NEWA
AB			360MG	A211852	002	Feb 11, 2020	Jan NEWA
AB		MSN	180MG	A210945	003	Jun 16, 2020	Jun NEWA
AB		PIRAMAL HLTHCARE UK	180MG	A212995	003	Jun 15, 2020	Jun NEWA
AB		SUN PHARM	180MG	A211641	003	Jun 15, 2020	Jun NEWA
AB		TEVA PHARMS USA	180MG	A209223	003	Apr 24, 2020	Apr NEWA
AB		ZYDUS PHARMS	180MG	A211383	003	Jun 15, 2020	Jun NEWA

TABLET, FOR SUSPENSION; ORAL
DEFERASIROX

AB		ZYDUS PHARMS	125MG	A208882	001	May 05, 2020	Apr NEWA
AB			250MG	A208882	002	May 05, 2020	Apr NEWA
AB			500MG	A208882	003	May 05, 2020	Apr NEWA

DEFERIPRONESOLUTION; ORAL
FERRIPROX

+	CHIESI	80MG/ML	N208030	002	Apr 20, 2018	Mar CAHN
+	+	100MG/ML	N208030	001	Sep 09, 2015	Mar CAHN

TABLET; ORAL
DEFERIPRONE

>D>		@ TARO PHARM INDS LTD	500MG	A208800	001	Feb 08, 2019	Aug CMFD
>A>	AB		500MG	A208800	001	Feb 08, 2019	Aug CMFD

FERRIPROX

+	CHIESI	500MG	N021825	001	Oct 14, 2011	Mar CAHN
+		1GM	N021825	002	Jul 25, 2019	Mar CAHN
+	+	1GM	N212269	001	May 19, 2020	May NEWA

DEFEROXAMINE MESYLATEINJECTABLE; INJECTION
DEFEROXAMINE MESYLATE

AP	!	HOSPIRA	2GM/VIAL	A076019	002	Mar 17, 2004	Jul CHRS
		DESFERAL					
	+	@ NOVARTIS	2GM/VIAL	N016267	002	May 25, 2000	Jul DISC

DELAVIRDINE MESYLATETABLET; ORAL
RESCRIPTOR

	+	@ VIIIV HLTHCARE	200MG	N020705	002	Jul 14, 1999	Mar DISC
--	---	------------------	-------	---------	-----	--------------	----------

DESIPRAMINE HYDROCHLORIDETABLET; ORAL
DESIPRAMINE HYDROCHLORIDE

>D>	AB		ANI PHARMS INC	10MG	A205153	001	Oct 28, 2016	Aug DISC
>A>		@		10MG	A205153	001	Oct 28, 2016	Aug DISC
>D>	AB			25MG	A205153	002	Oct 28, 2016	Aug DISC
>A>		@		25MG	A205153	002	Oct 28, 2016	Aug DISC
>D>	AB			50MG	A205153	003	Oct 28, 2016	Aug DISC
>A>		@		50MG	A205153	003	Oct 28, 2016	Aug DISC
>D>	AB			75MG	A205153	004	Oct 28, 2016	Aug DISC
>A>		@		75MG	A205153	004	Oct 28, 2016	Aug DISC
>D>	AB			100MG	A205153	005	Oct 28, 2016	Aug DISC
>A>		@		100MG	A205153	005	Oct 28, 2016	Aug DISC
>D>	AB			150MG	A205153	006	Oct 28, 2016	Aug DISC
>A>		@		150MG	A205153	006	Oct 28, 2016	Aug DISC

DESMOPRESSIN ACETATEINJECTABLE; INJECTION
DESMOPRESSIN ACETATE

AP		UBI	0.004MG/ML	A210218	001	Feb 14, 2020	Feb NEWA
----	--	-----	------------	---------	-----	--------------	----------

TABLET; ORAL
DESMOPRESSIN ACETATE

>D>	AB		IMPAX LABS INC	0.1MG	A077122	001	Jan 25, 2006	Aug DISC
>A>		@		0.1MG	A077122	001	Jan 25, 2006	Aug DISC
>D>	AB			0.2MG	A077122	002	Jan 25, 2006	Aug DISC
>A>		@		0.2MG	A077122	002	Jan 25, 2006	Aug DISC
		@ MYLAN		0.1MG	A200653	001	Jun 27, 2014	Jul DISC
		@		0.2MG	A200653	002	Jun 27, 2014	Jul DISC

DESOGESTREL; ETHINYL ESTRADIOLTABLET; ORAL-28
DESOGESTREL AND ETHINYL ESTRADIOL

AB		NAARI PTE LTD	0.15MG,N/A;0.02MG,0.01MG	A209170	001	Jun 05, 2017	Jun CAHN
		@	0.15MG;0.03MG	A207067	001	Sep 13, 2018	Jun CAHN
		EMOQUETTE					
		@ VINTAGE PHARMS LLC	0.15MG;0.03MG	A076675	001	Feb 25, 2011	Apr DISC
		SIMLIYA					
AB		AUROBINDO PHARMA LTD	0.15MG,N/A;0.02MG,0.01MG	A206853	001	Mar 22, 2017	Mar CTNA

DESONIDEGEL; TOPICAL
DESONATE

AB	+	!	LEO PHARMA AS	0.05%	N021844	001	Oct 20, 2006	Apr CFTG
----	---	---	---------------	-------	---------	-----	--------------	----------

DESONIDE

>A>	AB		CINTEX SVCS	0.05%	A202470	001	May 11, 2020	Aug CAHN
>D>	AB		TERESINA	0.05%	A202470	001	May 11, 2020	Aug CAHN
	AB			0.05%	A202470	001	May 11, 2020	Apr NFTG

LOTION; TOPICAL

DESONIDE

>A>	AB		ALEOR DERMACEUTICALS	0.05%	A213632	001	Aug 24, 2020	Aug NEWA
-----	----	--	----------------------	-------	---------	-----	--------------	----------

DESOXIMETASONECREAM; TOPICAL
DESOXIMETASONE

AB		CADILA	0.25%	A205620	001	Sep 28, 2018	Mar CMFD
AB		COSETTE	0.25%	A209595	001	Mar 04, 2020	Feb NEWA

OINTMENT;TOPICAL
DESOXIMETASONE

>A>	AB	CADILA	0.25%	A205206	001	Sep 19, 2017	Aug CAHN
>D>	AB	ZYDUS PHARMS	0.25%	A205206	001	Sep 19, 2017	Aug CAHN

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
DESVENLAFAXINE SUCCINATE

>D>	AB	CASI PHARMS INC	EQ 50MG BASE	A204028	001	Jun 29, 2015	Aug CAHN
>D>	AB		EQ 100MG BASE	A204028	002	Jun 29, 2015	Aug CAHN
		@ MYLAN	EQ 50MG BASE	A204095	001	Jun 29, 2015	Feb DISC
>A>	AB	RUBICON	EQ 50MG BASE	A204028	001	Jun 29, 2015	Aug CAHN
>A>	AB		EQ 100MG BASE	A204028	002	Jun 29, 2015	Aug CAHN
	AB	YICHANG HUMANWELL	EQ 50MG BASE	A210014	001	Oct 01, 2018	Jun CMFD
	AB		EQ 100MG BASE	A210014	002	Oct 01, 2018	Jun CMFD

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

AP		AUROBINDO PHARMA LTD	EQ 10MG PHOSPHATE/ML	A210966	001	Jun 05, 2020	Jun NEWA
----	--	----------------------	----------------------	---------	-----	--------------	----------

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC
TOBRADEX ST

+	!	EYEVANCE	0.05%;0.3%	N050818	001	Feb 13, 2009	Feb CAHN
---	---	----------	------------	---------	-----	--------------	----------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION
DEXMEDETOMIDINE HYDROCHLORIDE

AP		AMNEAL PHARMS CO	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A207551	001	May 20, 2020	May NEWA
AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A207551	002	May 20, 2020	May NEWA
AP		GLAND PHARMA LTD	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A209307	001	Jun 03, 2020	May NEWA
AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A209307	002	Jun 03, 2020	May NEWA
AP		HIKMA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A206407	001	Jan 30, 2020	Jan NEWA
AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A206407	002	Jan 30, 2020	Jan NEWA
AP		JIANGSU HENGRUI MED	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	A209065	002	Jun 12, 2020	Jun NEWA
AP			EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A209065	001	Sep 19, 2017	Jun CTNA
AP			EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A209065	001	Sep 19, 2017	Jan CTNA
AP			EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A209065	003	Jun 12, 2020	Jun NEWA
AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A209065	004	Jun 12, 2020	Jun NEWA
>A>	AP	MYLAN LABS LTD	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A212571	001	Aug 27, 2020	Aug NEWA
>A>	AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A212571	002	Aug 27, 2020	Aug NEWA
		PRECEDEX					
+	!	HOSPIRA	EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	N021038	005	Jan 31, 2020	Jun NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDE

>A>	AB	GRANULES PHARMS	5MG	A213813	001	Sep 09, 2020	Aug NEWA
>A>	AB		10MG	A213813	002	Sep 09, 2020	Aug NEWA
>A>	AB		15MG	A213813	003	Sep 09, 2020	Aug NEWA
>A>	AB		20MG	A213813	004	Sep 09, 2020	Aug NEWA
>A>	AB		25MG	A213813	005	Sep 09, 2020	Aug NEWA
>A>	AB		30MG	A213813	006	Sep 09, 2020	Aug NEWA
>A>	AB		35MG	A213813	007	Sep 09, 2020	Aug NEWA
>A>	AB		40MG	A213813	008	Sep 09, 2020	Aug NEWA

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		BIONPHARMA INC	5MG	A209754	001	Mar 24, 2020	Mar NEWA
AB			10MG	A209754	002	Mar 24, 2020	Mar NEWA

DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE;ORAL
DEXTROAMPHETAMINE SULFATE

>D>	@ PII	5MG	A205077	001	Jun 21, 2019	Aug CAHN
	@	5MG	A205077	001	Jun 21, 2019	Jan DISC
>D>	@	10MG	A205077	002	Jun 21, 2019	Aug CAHN
	@	10MG	A205077	002	Jun 21, 2019	Jan DISC
>D>	@	15MG	A205077	003	Jun 21, 2019	Aug CAHN
	@	15MG	A205077	003	Jun 21, 2019	Jan DISC
>A>	@ STRIDES PHARMA	5MG	A205077	001	Jun 21, 2019	Aug CAHN
>A>	@	10MG	A205077	002	Jun 21, 2019	Aug CAHN
>A>	@	15MG	A205077	003	Jun 21, 2019	Aug CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDESYRUP;ORAL
PROMETHAZINE DM

AA	! SLATE	15MG/5ML;6.25MG/5ML	A040649	001	Feb 14, 2006	Mar CMFD
	@	15MG/5ML;6.25MG/5ML	A040649	001	Feb 14, 2006	Feb CAHN
		PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE				
AA	AMNEAL PHARMS	15MG/5ML;6.25MG/5ML	A090575	001	Feb 08, 2011	Mar CMFD
	@ HI TECH PHARMA	15MG/5ML;6.25MG/5ML	A040027	001	Jul 31, 1996	Mar DISC

DEXTROSE; SODIUM CHLORIDEINJECTABLE;INJECTION
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	@ FRESenius KABI USA	2.5GM/100ML;450MG/100ML	A211190	001	Dec 20, 2019	Jun DISC
		DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
>A> AP	FRESenius KABI USA	5GM/100ML;300MG/100ML	A211194	001	Aug 26, 2020	Aug NFTG
>D>	+! ICU MEDICAL INC	5GM/100ML;300MG/100ML	N017799	001		Aug CFTG
>A> AP	+!	5GM/100ML;300MG/100ML	N017799	001		Aug CFTG

DIAZEPAMSPRAY;NASAL
VALTOCO

+	NEURELIS INC	5MG/SPRAY	N211635	001	Jan 10, 2020	Jan NEWA
+		7.5MG/SPRAY	N211635	002	Jan 10, 2020	Jan NEWA
+!		10MG/SPRAY	N211635	003	Jan 10, 2020	Jan NEWA

DIAZOXIDESUSPENSION;ORAL
DIAZOXIDE

AB	NOVITIUM PHARMA	50MG/ML	A210799	001	Jul 08, 2020	Jul NEWA
----	-----------------	---------	---------	-----	--------------	----------

DICLOFENAC EPOLAMINESYSTEM;TOPICAL
FLECTOR

+!	INST BIOCHEM	1.3%	N021234	001	Jan 31, 2007	Feb CDFR
	LICART					
+!	IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018	Apr CHRS
+		1.3%	N206976	001	Dec 19, 2018	Apr CMFD

DICLOFENAC POTASSIUMCAPSULE;ORAL
DICLOFENAC POTASSIUM

	@ STRIDES PHARMA	25MG	A210078	001	Dec 03, 2019	Jun DISC
--	------------------	------	---------	-----	--------------	----------

TABLET;ORAL
CATAFLAM

	+ @ NOVARTIS	50MG	N020142	002	Nov 24, 1993	Jan CRLD
		DICLOFENAC POTASSIUM				
>D> AB	CASI PHARMS INC	50MG	A075229	001	Nov 20, 1998	Aug CAHN
>A> AB	RUBICON	50MG	A075229	001	Nov 20, 1998	Aug CAHN

DICLOFENAC SODIUMGEL;TOPICAL
DICLOFENAC SODIUM

>D> AB	AMNEAL PHARMS	1%	A208077	001	Mar 18, 2016	Aug CMS1
>D> AB	ENCUBE	1%	A210986	001	Jan 27, 2020	Aug CMS1
	AB	1%	A210986	001	Jan 27, 2020	Jan NEWA
>D> AB	MYLAN	1%	A204306	001	May 06, 2019	Aug CMS1

SOLUTION/DROPS;OPHTHALMIC

DICLOFENAC SODIUM

@ RUBICON 0.1%

A 077600 001 Nov 13, 2008 Jul CAHN

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM

@ MICRO LABS USA 50MG

A 074986 001 Feb 26, 1999 Mar CAHN

@ 75MG

A 074986 002 Feb 26, 1999 Mar CAHN

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

ARTHROTEC

>D> AB + GD SEARLE LLC 50MG;0.2MG

N 020607 001 Dec 24, 1997 Aug CAHN

>D> AB +! 75MG;0.2MG

N 020607 002 Dec 24, 1997 Aug CAHN

>A> AB + PFIZER 50MG;0.2MG

N 020607 001 Dec 24, 1997 Aug CAHN

>A> AB +! 75MG;0.2MG

N 020607 002 Dec 24, 1997 Aug CAHN

DICLOFENAC SODIUM AND MISOPROSTOL

AB YUNG SHIN PHARM 50MG;0.2MG

A 205143 001 Feb 19, 2020 Feb NEWA

AB 75MG;0.2MG

A 205143 002 Feb 19, 2020 Feb NEWA

DICYCLOMINE HYDROCHLORIDE

SYRUP;ORAL

DICYCLOMINE HYDROCHLORIDE

AA ! GENERICS 10MG/5ML

A 040169 001 Mar 24, 2005 May CTEC

AA HIKMA 10MG/5ML

A 212286 001 May 22, 2020 May NEWA

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL

DIDANOSINE

AUROBINDO PHARMA 125MG

A 090094 001 Sep 24, 2008 Jun CTEC

200MG

A 090094 002 Sep 24, 2008 Jun CTEC

250MG

A 090094 003 Sep 24, 2008 Jun CTEC

! 400MG

A 090094 004 Sep 24, 2008 Jun CHRS

400MG

A 090094 004 Sep 24, 2008 Jun CTEC

VIDEX EC

+ @ BRISTOL MYERS SQUIBB 125MG

N 021183 001 Oct 31, 2000 Jun DISC

+ @ 200MG

N 021183 002 Oct 31, 2000 Jun DISC

+ @ 250MG

N 021183 003 Oct 31, 2000 Jun DISC

+ @ 400MG

N 021183 004 Oct 31, 2000 Jun DISC

FOR SOLUTION;ORAL

VIDEX

+ @ BRISTOL-MYERS SQUIBB 10MG/ML

N 020156 001 Oct 09, 1991 Jun DISC

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

TENUATE

+ @ NOSTRUM LABS INC 25MG

N 011722 002 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

TENUATE DOSPAN

+ @ NOSTRUM LABS INC 75MG

N 012546 001 Mar CAHN

DIHYDROERGOTAMINE MESYLATE

SPRAY, METERED;NASAL

DIHYDROERGOTAMINE MESYLATE

AB CIPLA 0.5MG/SPRAY

A 212907 001 May 20, 2020 May NEWA

AB CUSTOPHARM INC 0.5MG/SPRAY

A 211393 001 Feb 28, 2020 Feb NFTG

MIGRANAL

AB +! BAUSCH 0.5MG/SPRAY

N 020148 001 Dec 08, 1997 Feb CFTG

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB2 ACCORD HLTHCARE 120MG

A 206997 001 Apr 28, 2020 Apr NEWA

AB2 180MG

A 206997 002 Apr 28, 2020 Apr NEWA

AB2 240MG

A 206997 003 Apr 28, 2020 Apr NEWA

AB2 APOTEX 120MG

A 074943 003 Dec 19, 2000 Apr CTEC

DILTIZAC

@ APOTEX 120MG

A 076395 001 Feb 01, 2006 Apr DISC

@ 180MG

A 076395 002 Feb 01, 2006 Apr DISC

@ 240MG

A 076395 003 Feb 01, 2006 Apr DISC

@ 300MG

A 076395 004 Feb 01, 2006 Apr DISC

@ 360MG

A 076395 005 Feb 01, 2006 Apr DISC

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

>A> DIMETHYL FUMARATE

>A> AB	MYLAN	120MG	A210531	001	Aug 17, 2020	Aug NFTG
>A> AB		240MG	A210531	002	Aug 17, 2020	Aug NFTG
	TECFIDERA					
>D>	+	BIOMGEN IDEC INC	120MG	N204063	001	Mar 27, 2013
>A> AB	+		120MG	N204063	001	Mar 27, 2013
>D>	+		240MG	N204063	002	Mar 27, 2013
>A> AB	+		240MG	N204063	002	Mar 27, 2013

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

NORPACE

AB	+	PFIZER	EQ 100MG BASE	N017447	001		Jul CAHN
AB	+		EQ 150MG BASE	N017447	002		Jul CAHN

CAPSULE, EXTENDED RELEASE;ORAL

NORPACE CR

	+	PFIZER	EQ 100MG BASE	N018655	001	Jul 20, 1982	Jul CAHN
	+		EQ 150MG BASE	N018655	002	Jul 20, 1982	Jul CAHN

DISULFIRAM

TABLET;ORAL

DISULFIRAM

	@	HIKMA	250MG	A202652	001	Feb 05, 2014	Feb DISC
	@		500MG	A202652	002	Feb 05, 2014	Feb DISC

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

DIVALPROEX SODIUM

AB		AJANTA PHARMA LTD	EQ 125MG VALPROIC ACID	A213181	001	Mar 02, 2020	Feb NEWA
	@	MYLAN	EQ 125MG VALPROIC ACID	A090407	001	Mar 28, 2011	Jan DISC

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

	@	MYLAN	EQ 125MG VALPROIC ACID	A090062	001	Mar 17, 2009	Jan DISC
	@		EQ 250MG VALPROIC ACID	A090062	002	Mar 17, 2009	Jan DISC
	@		EQ 500MG VALPROIC ACID	A090062	003	Mar 17, 2009	Jan DISC

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

>D> AB		IMPAX LABS	EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009	Aug DISC
>A>	@		EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009	Aug DISC
>D> AB			EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009	Aug DISC
>A>	@		EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009	Aug DISC

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

AP		SHILPA MEDICARE LTD	20MG/ML (20MG/ML)	A210327	001	May 16, 2019	Jan CMFD
AP			80MG/4ML (20MG/ML)	A210327	002	May 16, 2019	Jan CMFD
AP			160MG/8ML (20MG/ML)	A210327	003	May 16, 2019	Jan CMFD

DOFETILIDE

CAPSULE;ORAL

DOFETILIDE

AB		ACCORD HLTHCARE	0.125MG	A213338	001	Jun 19, 2020	Jun NEWA
AB			0.25MG	A213338	002	Jun 19, 2020	Jun NEWA
AB			0.5MG	A213338	003	Jun 19, 2020	Jun NEWA
AB		MSN	0.125MG	A213220	001	Jan 29, 2020	Jan NEWA
AB			0.25MG	A213220	002	Jan 29, 2020	Jan NEWA
AB			0.5MG	A213220	003	Jan 29, 2020	Jan NEWA

DOLUTEGRAVIR SODIUM

TABLET, FOR SUSPENSION;ORAL

TIVICAY PD

	+	VIIV HLTHCARE	EQ 5MG BASE	N213983	001	Jun 12, 2020	Jun NEWA
--	---	---------------	-------------	---------	-----	--------------	----------

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

>D>	AB	GRAVITI PHARMS	5MG	A202114	001	Jul 05, 2013	Aug CAHN
	AB		5MG	A202114	001	Jul 05, 2013	Apr CAHN
>D>	AB		10MG	A202114	002	Jul 05, 2013	Aug CAHN
	AB		10MG	A202114	002	Jul 05, 2013	Apr CAHN
		@ HERITAGE PHARMA	5MG	A077344	001	May 31, 2011	Jul DISC
		@	10MG	A077344	002	May 31, 2011	Jul DISC
		@ MYLAN PHARMS INC	5MG	A090521	001	May 31, 2011	Mar DISC
		@	10MG	A090521	002	May 31, 2011	Mar DISC
>A>	AB	RISING	5MG	A202114	001	Jul 05, 2013	Aug CAHN
>A>	AB		10MG	A202114	002	Jul 05, 2013	Aug CAHN

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

>A>	@	INDOCO	EQ 2% BASE	A202053	001	Sep 11, 2014	Aug CAHN
>D>	@	WATSON LABS INC	EQ 2% BASE	A202053	001	Sep 11, 2014	Aug CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

>A>	@	INDOCO	EQ 2% BASE; EQ 0.5% BASE	A202054	001	Sep 03, 2014	Aug CAHN
AT		MICRO LABS	EQ 2.0% BASE; EQ 0.5% BASE	A204777	001	May 28, 2020	May NEWA
>D>	@	WATSON LABS INC	EQ 2% BASE; EQ 0.5% BASE	A202054	001	Sep 03, 2014	Aug CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

CARDURA

AB	+	UPJOHN	EQ 1MG BASE	N019668	001	Nov 02, 1990	Jun CAHN
AB	+		EQ 2MG BASE	N019668	002	Nov 02, 1990	Jun CAHN
AB	+		EQ 4MG BASE	N019668	003	Nov 02, 1990	Jun CAHN
AB	+		EQ 8MG BASE	N019668	004	Nov 02, 1990	Jun CAHN

DOXAZOSIN MESYLATE

	@	ANI PHARMS INC	EQ 1MG BASE	A075432	001	Oct 18, 2000	Jan DISC
	@		EQ 2MG BASE	A075432	002	Oct 18, 2000	Jan DISC
	@		EQ 4MG BASE	A075432	003	Oct 18, 2000	Jan DISC
	@		EQ 8MG BASE	A075432	004	Oct 18, 2000	Jan DISC
	@	DAVA PHARMS INC	EQ 1MG BASE	A076161	001	Jun 10, 2004	Jul DISC
	@		EQ 2MG BASE	A076161	002	Jun 10, 2004	Jul DISC
	@		EQ 4MG BASE	A076161	003	Jun 10, 2004	Jul DISC
	@		EQ 8MG BASE	A076161	004	Jun 10, 2004	Jul DISC

TABLET, EXTENDED RELEASE; ORAL

CARDURA XL

+	UPJOHN	EQ 4MG BASE	N021269	001	Feb 22, 2005	Jun CAHN
+	!	EQ 8MG BASE	N021269	002	Feb 22, 2005	Jun CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

AB		CONTRACT PHARMACAL	EQ 10MG BASE	A213474	001	Jul 28, 2020	Jul NEWA
AB			EQ 25MG BASE	A213474	002	Jul 28, 2020	Jul NEWA
AB			EQ 50MG BASE	A213474	003	Jul 28, 2020	Jul NEWA
AB			EQ 75MG BASE	A213474	004	Jul 28, 2020	Jul NEWA
AB			EQ 100MG BASE	A213474	005	Jul 28, 2020	Jul NEWA
AB		LANNETT CO INC	EQ 10MG BASE	A212997	001	Jul 24, 2020	Jul NEWA
AB			EQ 25MG BASE	A212997	002	Jul 24, 2020	Jul NEWA
AB			EQ 50MG BASE	A212997	003	Jul 24, 2020	Jul NEWA
AB			EQ 75MG BASE	A212997	004	Jul 24, 2020	Jul NEWA
AB			EQ 100MG BASE	A212997	005	Jul 24, 2020	Jul NEWA
AB		TARO PHARM INDS LTD	EQ 10MG BASE	A213063	001	Jul 01, 2020	Jun NEWA
AB			EQ 25MG BASE	A213063	002	Jul 01, 2020	Jun NEWA
AB			EQ 50MG BASE	A213063	003	Jul 01, 2020	Jun NEWA
AB			EQ 75MG BASE	A213063	004	Jul 01, 2020	Jun NEWA
AB			EQ 100MG BASE	A213063	005	Jul 01, 2020	Jun NEWA
>A>	AB	UPSHER SMITH LABS	EQ 10MG BASE	A210268	001	Sep 04, 2020	Aug NEWA
>A>	AB		EQ 25MG BASE	A210268	002	Sep 04, 2020	Aug NEWA
>A>	AB		EQ 50MG BASE	A210268	003	Sep 04, 2020	Aug NEWA
>A>	AB		EQ 75MG BASE	A210268	004	Sep 04, 2020	Aug NEWA
>A>	AB		EQ 100MG BASE	A210268	005	Sep 04, 2020	Aug NEWA

CONCENTRATE;ORAL							
DOXEPIN HYDROCHLORIDE							
AA	!	LANNETT CO INC	EQ 10MG BASE/ML	A074721	001	Dec 29, 1998	May CHRS
	@	TEVA PHARMS	EQ 10MG BASE/ML	A071609	001	Nov 09, 1987	May DISC
TABLET;ORAL							
DOXEPIN HYDROCHLORIDE							
AB		PAR PHARM INC	EQ 3MG BASE	A202510	001	Jul 24, 2020	Jul NEWA
AB			EQ 6MG BASE	A202510	002	Jul 24, 2020	Jul NEWA
<u>DOXERCALCIFEROL</u>							
INJECTABLE;INJECTION							
DOXERCALCIFEROL							
AP		MEITHEAL	4MCG/2ML (2MCG/ML)	A211670	001	Feb 07, 2020	Feb CAHN
AP		NANJING KING-FRIEND	4MCG/2ML (2MCG/ML)	A211670	001	Feb 07, 2020	Jan NEWA
<u>DOXYCYCLINE</u>							
CAPSULE;ORAL							
DOXYCYCLINE							
	@	MYLAN PHARMS INC	EQ 150MG BASE	A202778	001	Jun 08, 2012	Jan DISC
MONODOX							
	+	@ CHARTWELL RX	EQ 50MG BASE	N050641	002	Feb 10, 1992	Jul CAHN
	+	@	EQ 75MG BASE	N050641	003	Oct 18, 2006	Jul CAHN
	+	@	EQ 100MG BASE	N050641	001	Dec 29, 1989	Jul CAHN
<u>DOXYCYCLINE HYCLATE</u>							
CAPSULE;ORAL							
DOXYCYCLINE HYCLATE							
AB		ZHEJIANG YONGTAI	EQ 50MG BASE	A212610	001	Mar 31, 2020	Mar NEWA
AB			EQ 100MG BASE	A212610	002	Mar 31, 2020	Mar NEWA
SYSTEM, EXTENDED RELEASE;PERIODONTAL							
ATRIDOX							
	+	! DEN-MAT	50MG	N050751	001	Sep 03, 1998	Jul CAHN
TABLET;ORAL							
DOXYCYCLINE HYCLATE							
AB		AJANTA PHARMA LTD	EQ 75MG BASE	A211584	001	Jun 01, 2020	May NEWA
AB			EQ 150MG BASE	A211584	002	Jun 01, 2020	May NEWA
AB		ALEMBIC PHARMS LTD	EQ 20MG BASE	A210537	001	Mar 03, 2020	Feb NEWA
AB			EQ 75MG BASE	A211744	001	Jun 30, 2020	Jun NEWA
AB			EQ 100MG BASE	A210536	001	May 14, 2020	May NEWA
AB			EQ 150MG BASE	A211744	002	Jun 30, 2020	Jun NEWA
AB	!	CARIBE HOLDINGS	EQ 100MG BASE	A062269	002	Nov 08, 1982	Jul CHRS
	@	HERITAGE PHARMA	EQ 20MG BASE	A065163	001	May 13, 2005	Jul DISC
AB		HIKMA INTL PHARMS	EQ 100MG BASE	A065095	001	Jul 02, 2003	Jul CHRS
AB		OAKLOCK LLC	EQ 100MG BASE	A210664	001	Mar 16, 2020	Mar NEWA
TABLET, DELAYED RELEASE;ORAL							
DORYX							
	+	@ MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Jul DISC
	+		EQ 80MG BASE	N050795	004	Apr 11, 2013	Mar CMFD
DOXYCYCLINE HYCLATE							
AB		PRINSTON INC	EQ 50MG BASE	A207494	003	Feb 19, 2019	Feb NEWA
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE</u>							
TABLET, DELAYED RELEASE;ORAL							
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE							
AB		MYLAN PHARMS INC	10MG;10MG	A207825	001	Jul 06, 2020	Jul NEWA
<u>DRONABINOL</u>							
CAPSULE;ORAL							
DRONABINOL							
AB		ASCENT PHARMS INC	2.5MG	A207421	001	Feb 07, 2020	Jan NEWA
AB			5MG	A207421	002	Feb 07, 2020	Jan NEWA
AB			10MG	A207421	003	Feb 07, 2020	Jan NEWA
MARINOL							
AB	+	ALKEM LABS LTD	2.5MG	N018651	001	May 31, 1985	Jan CAHN
AB	+	!	5MG	N018651	002	May 31, 1985	Jan CAHN
AB	+		10MG	N018651	003	May 31, 1985	Jan CAHN
SOLUTION;ORAL							
SYNDROS							
	+	! BENUVIA	5MG/ML	N205525	001	Mar 23, 2017	Feb CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL		DROSPIRENONE AND ETHINYL ESTRADIOL			
AB	ALLIED	3MG;0.02MG	A203291	001	Jul 18, 2017 Jan CAHN
TABLET; ORAL-28		DROSPIRENONE AND ETHINYL ESTRADIOL			
	@ APOTEX	3MG;0.03MG	A205876	001	Sep 21, 2016 Jul DISC
AB	HETERO LABS LTD	3MG;0.03MG	A213034	001	Jan 24, 2020 Jan NEWA
AB	NAARI PTE LTD	3MG;0.03MG	A207245	001	Nov 22, 2016 Jun CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL		DULOXETINE HYDROCHLORIDE			
	@ QINGDAO BAHEAL PHARM	EQ 20MG BASE	A210599	001	Apr 17, 2019 May DISC
	@	EQ 30MG BASE	A210599	002	Apr 17, 2019 May DISC
	@	EQ 60MG BASE	A210599	003	Apr 17, 2019 May DISC
	@ YAOPHARMA CO LTD	EQ 20MG BASE	A207219	001	Aug 16, 2019 Mar DISC
	@	EQ 30MG BASE	A207219	002	Aug 16, 2019 Mar DISC
	@	EQ 60MG BASE	A207219	003	Aug 16, 2019 Mar DISC

DUTASTERIDE

CAPSULE; ORAL		DUTASTERIDE			
AB	ACELLA	0.5MG	A206373	001	Mar 17, 2016 Jul CAHN
	@ ACTAVIS LABS FL INC	0.5MG	A202808	001	Nov 20, 2015 Jan DISC
	@ APOTEX INC	0.5MG	A204292	001	Nov 24, 2015 Feb DISC
AB	AUROBINDO PHARMA LTD	0.5MG	A202660	001	Nov 20, 2015 May CAHN
	@ HIKMA	0.5MG	A202204	001	Nov 23, 2015 Feb DISC
	@ STRIDES PHARMA	0.5MG	A208227	001	Jun 22, 2018 Mar CAHN

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL		EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE			
>D>	@ TEVA PHARMS USA	600MG;200MG;300MG	A091215	001	Nov 09, 2018 Aug CMFD
>A>	AB	600MG;200MG;300MG	A091215	001	Nov 09, 2018 Aug CMFD

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL		EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE			
AB	LAURUS LABS LTD	400MG;300MG;300MG	A213038	001	May 14, 2020 May NFTG
AB		600MG;300MG;300MG	A212786	001	May 14, 2020 May NFTG
SYMFI					
AB	+! MYLAN LABS LTD	600MG;300MG;300MG	N022142	001	Mar 22, 2018 May CFTG
SYMFI LO					
AB	+! MYLAN	400MG;300MG;300MG	N208255	001	Feb 05, 2018 May CFTG

ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM

CAPSULE; ORAL		ORIAHNN (COPACKAGED)			
	+! ABBVIE INC	EQ 300MG BASE, 1MG, 0.5MG; EQ 300MG BASE	N213388	001	May 29, 2020 May NEWA

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL		ELETRIPTAN HYDROBROMIDE			
>D>	AB	YUNG SHIN PHARM	EQ 20MG BASE	A209680	001 Jul 13, 2020 Aug DISC
>A>		@	EQ 20MG BASE	A209680	001 Jul 13, 2020 Aug DISC
	AB		EQ 20MG BASE	A209680	001 Jul 13, 2020 Jul NEWA
>D>	AB		EQ 40MG BASE	A209680	002 Jul 13, 2020 Aug DISC
>A>		@	EQ 40MG BASE	A209680	002 Jul 13, 2020 Aug DISC
	AB		EQ 40MG BASE	A209680	002 Jul 13, 2020 Jul NEWA
RELPAK					
AB	+ UPJOHN	EQ 20MG BASE	N021016	001	Dec 26, 2002 Jul CAHN
AB	+!	EQ 40MG BASE	N021016	002	Dec 26, 2002 Jul CAHN

EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL		TRIJARDY XR			
	+ BOEHRINGER INGELHEIM	5MG;2.5MG;1GM	N212614	001	Jan 27, 2020 Jan NEWA
	+	10MG;5MG;1GM	N212614	002	Jan 27, 2020 Jan NEWA
	+	12.5MG;2.5MG;1GM	N212614	003	Jan 27, 2020 Jan NEWA

TABLET, EXTENDED RELEASE;ORAL
TRIJARDY XR

+! 25MG; 5MG; 1GM N212614 004 Jan 27, 2020 Jan NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

>D> @ AMNEAL PHARMS CO 200MG; 300MG A209721 004 Aug 22, 2018 Aug CMFD
>A> AB 200MG; 300MG A209721 004 Aug 22, 2018 Aug CMFD
@ MYLAN 200MG; 300MG A206436 001 Apr 09, 2018 Feb DISC
AB ZYDUS PHARMS 200MG; 300MG A212689 001 Feb 28, 2020 Feb NEWA

ENALAPRIL MALEATE

SOLUTION;ORAL

EPANED

+! AZURITY 1MG/ML N208686 001 Sep 20, 2016 May CAHN

ENTECAVIR

TABLET;ORAL

ENTECAVIR

@ MYLAN 0.5MG A206226 001 Mar 26, 2019 Jan DISC
@ 1MG A206226 002 Mar 26, 2019 Jan DISC
AB PHARMADAX INC 0.5MG A212106 001 Aug 10, 2020 Jul NEWA
AB 1MG A212106 002 Aug 10, 2020 Jul NEWA
AB SUNSHINE 0.5MG A211978 001 May 20, 2020 May NEWA
AB 1MG A211978 002 May 20, 2020 May NEWA
@ YAOPHARMA CO LTD 0.5MG A212201 001 Nov 04, 2019 Apr DISC
@ 1MG A212201 002 Nov 04, 2019 Apr DISC

ENZALUTAMIDE

>A> TABLET;ORAL

>A> XTANDI

>A> + ASTELLAS 40MG N213674 001 Aug 04, 2020 Aug NEWA

>A> +! 80MG N213674 002 Aug 04, 2020 Aug NEWA

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

AKOVAZ

AP +! EXELA PHARMA 50MG/ML (50MG/ML) N208289 001 Apr 29, 2016 Jul CAHN

EMERPHED

+! NEXUS PHARMS 50MG/10ML (5MG/ML) N213407 001 Apr 17, 2020 Apr NEWA

EPHEDRINE SULFATE

>D> AP ANDERSEN 50MG/ML (50MG/ML) A209646 001 Aug 04, 2020 Aug CAHN

AP 50MG/ML (50MG/ML) A209646 001 Aug 04, 2020 Jul NEWA

>A> AP FRESENIUS KABI USA 50MG/ML (50MG/ML) A209646 001 Aug 04, 2020 Aug CAHN

EPINEPHRINE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

ADRENALIN

AP +! PAR STERILE PRODUCTS EQ 30MG BASE/30ML (EQ 1MG BASE/ML) N204640 001 Dec 18, 2013 Apr CFTG

EPINEPHRINE

AP INTL MEDICATION SYS EQ 30MG BASE/30ML (EQ 1MG BASE/ML) A211880 001 Apr 24, 2020 Apr NFTG

EPLERENONE

TABLET;ORAL

EPLERENONE

AB COREPHARMA 25MG A078482 001 Jul 30, 2008 Feb CAHN

AB 50MG A078482 002 Jul 30, 2008 Feb CAHN

AB PIRAMAL HLTHCARE UK 25MG A212765 001 Aug 10, 2020 Jul NEWA

AB 50MG A212765 002 Aug 10, 2020 Jul NEWA

EPROSARTAN MESYLATE

TABLET;ORAL

EPROSARTAN MESYLATE

@ MYLAN PHARMS INC EQ 400MG BASE A202012 001 Nov 16, 2011 Apr DISC

@ EQ 600MG BASE A202012 002 Nov 16, 2011 Apr DISC

EPTIFIBATIDE

INJECTABLE; INJECTION
EPTIFIBATIDE

AP	HYBIO	2MG/ML	A207864	001	Mar 20, 2020	Mar NEWA
AP		75MG/100ML	A207864	002	Mar 20, 2020	Mar NEWA

ERAVACYCLINE DIHYDROCHLORIDE

POWDER; INTRAVENOUS
XERAVA

+	TETRAPHASE PHARMS	EQ 100MG BASE/VIAL	N211109	002	Jun 03, 2020	Jun NEWA
---	-------------------	--------------------	---------	-----	--------------	----------

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL
ERLOTINIB HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 25MG BASE	A211083	001	Jul 02, 2020	Jul NEWA
AB		EQ 100MG BASE	A211083	002	Jul 02, 2020	Jul NEWA
AB		EQ 150MG BASE	A211083	003	Jul 02, 2020	Jul NEWA
AB	ZYDUS PHARMS	EQ 25MG BASE	A213065	001	Apr 16, 2020	Apr NEWA
AB		EQ 100MG BASE	A213065	002	Apr 16, 2020	Apr NEWA
AB		EQ 150MG BASE	A213065	003	Apr 16, 2020	Apr NEWA

ERYTHROMYCIN

TABLET; ORAL
ERYTHROMYCIN

AB	TORRENT	250MG	A212015	001	Jul 06, 2020	Jul NEWA
AB		500MG	A212015	002	Jul 06, 2020	Jul NEWA

ESCITALOPRAM OXALATE

SOLUTION; ORAL
ESCITALOPRAM OXALATE

AA	ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	Jan CAHN
AA	! HETERO LABS LTD III	EQ 5MG BASE/5ML	A202221	001	Jun 12, 2012	Apr CHRS
	LEXAPRO					
	+ @ ALLERGAN	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Apr DISC

TABLET; ORAL

ESCITALOPRAM OXALATE

>D>	AB	GRAVITI PHARMS	EQ 5MG BASE	A078777	001	Sep 11, 2012	Aug CAHN
>D>	AB		EQ 10MG BASE	A078777	002	Sep 11, 2012	Aug CAHN
>D>	AB		EQ 20MG BASE	A078777	003	Sep 11, 2012	Aug CAHN
		@ MACLEODS PHARMS LTD	EQ 5MG BASE	A202210	001	Sep 11, 2012	May DISC
		@	EQ 10MG BASE	A202210	002	Sep 11, 2012	May DISC
		@	EQ 20MG BASE	A202210	003	Sep 11, 2012	May DISC
>A>	AB	RISING	EQ 5MG BASE	A078777	001	Sep 11, 2012	Aug CAHN
>A>	AB		EQ 10MG BASE	A078777	002	Sep 11, 2012	Aug CAHN
>A>	AB		EQ 20MG BASE	A078777	003	Sep 11, 2012	Aug CAHN

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL
ESOMEPRAZOLE MAGNESIUM

AB	HETERO LABS LTD III	EQ 20MG BASE	A211977	001	Jun 02, 2020	May NEWA
AB		EQ 40MG BASE	A211977	002	Jun 02, 2020	May NEWA

FOR SUSPENSION, DELAYED RELEASE; ORAL
ESOMEPRAZOLE MAGNESIUM

AB	CIPLA	EQ 10MG BASE/PACKET	A211752	001	Mar 23, 2020	Mar NFTG
AB		EQ 20MG BASE/PACKET	A211751	001	Mar 23, 2020	Mar NFTG
AB		EQ 40MG BASE/PACKET	A211751	002	Mar 23, 2020	Mar NFTG

NEXIUM

AB	+ ASTRAZENECA PHARMS	EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008	Mar CFTG
AB	+	EQ 20MG BASE/PACKET	N021957	001	Oct 20, 2006	Mar CFTG
AB	+	EQ 40MG BASE/PACKET	N021957	002	Oct 20, 2006	Mar CFTG

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

AB	DR REDDYS LABS LTD	EQ 20MG BASE; 375MG	A204206	001	Feb 18, 2020	Feb NEWA
AB		EQ 20MG BASE; 500MG	A204206	002	Feb 18, 2020	Feb NEWA
	VIMOVO					
AB	+ HORIZON	EQ 20MG BASE; 375MG	N022511	002	Apr 30, 2010	Feb CTEC
AB	+	EQ 20MG BASE; 500MG	N022511	001	Apr 30, 2010	Feb CTEC

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP	GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A203349	001	Apr 01, 2020	Mar NEWA
AP		EQ 40MG BASE/VIAL	A203349	002	Apr 01, 2020	Mar NEWA

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL
ESOMEPRAZOLE STRONTIUM

	+ @ BELCHER	24.65MG	N202342	001	Aug 06, 2013	Mar CAHN
	+ @	49.3MG	N202342	002	Aug 06, 2013	Mar CAHN

ESTAZOLAM

TABLET;ORAL
ESTAZOLAM

>D>	AB	NOVITIUM PHARMA	1MG	A074826	001	Jul 03, 1997	Aug CAHN
	AB		1MG	A074826	001	Jul 03, 1997	Jul CAHN
>D>	AB		2MG	A074826	002	Jul 03, 1997	Aug CAHN
	AB		2MG	A074826	002	Jul 03, 1997	Jul CAHN
>A>	AB	PAR PHARM	1MG	A074826	001	Jul 03, 1997	Aug CAHN
>A>	AB		2MG	A074826	002	Jul 03, 1997	Aug CAHN

ESTRADIOL VALERATE

INJECTABLE;INJECTION
DELESTROGEN

AO	+!	PAR STERILE PRODUCTS	10MG/ML	N009402	002		Apr CTEC
		ESTRADIOL VALERATE					
AO		HIKMA	10MG/ML	A203723	001	Apr 21, 2020	Apr NEWA
AO			20MG/ML	A203723	002	Apr 21, 2020	Apr NEWA
AO			40MG/ML	A203723	003	Apr 21, 2020	Apr NEWA

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL
ESTRADIOL AND NORETHINDRONE ACETATE

	@ NAARI PTE LTD	1MG;0.5MG	A210233	001	Feb 28, 2018	Jun CAHN
	@ TEVA PHARMS USA	0.5MG;0.1MG	A200747	001	Mar 08, 2012	Jan DISC

ESTROPIPATE

TABLET;ORAL
ESTROPIPATE

	@ MYLAN	0.75MG	A040359	001	Aug 26, 1999	Jan DISC
	@	1.5MG	A040359	002	Aug 26, 1999	Jan DISC

ESZOPICLONE

TABLET;ORAL
ESZOPICLONE

	@ HIKMA	1MG	A091153	001	Apr 15, 2014	Feb DISC
	@	2MG	A091153	002	Apr 15, 2014	Feb DISC
	@	3MG	A091153	003	Apr 15, 2014	Feb DISC

ETHACRYNATE SODIUM

INJECTABLE;INJECTION
ETHACRYNATE SODIUM

AP	VPI PHARMS INC	EQ 50MG BASE/VIAL	A208663	001	Jun 09, 2020	Jun NEWA
----	----------------	-------------------	---------	-----	--------------	----------

ETHACRYNIC ACID

TABLET;ORAL
ETHACRYNIC ACID

AB	UPSHER SMITH LABS	25MG	A212417	001	Feb 19, 2020	Feb NEWA
----	-------------------	------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET;ORAL-28
NORQUEST FE

	@ PFIZER	0.035MG;75MG;1MG	N018926	001	Jul 18, 1986	Jul CAHN
--	----------	------------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; LEVONORGESTREL

SYSTEM;TRANSDERMAL

TWIRLA

+! AGILE 0.03MG/24HR;0.12MG/24HR N204017 001 Feb 14, 2020 Feb NEWA

TABLET;ORAL

BALCOLTRA

+! AVION PHARMS 0.02MG;0.1MG N208612 001 Jan 09, 2018 Jan CHRS

+ 0.02MG;0.1MG N208612 001 Jan 09, 2018 Jan CRLD

TABLET;ORAL-28

ELIFEMME

@ XIROMED 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG A202507 001 Dec 04, 2015 Mar DISC

LEVONORGESTREL AND ETHINYL ESTRADIOL

>A> AB ACCORD HLTHCARE 0.02MG;0.1MG A207065 001 Aug 17, 2020 Aug NEWA

@ MYLAN LABS LTD 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG A202970 001 Mar 23, 2018 Feb DISC

ORSYTHIA

@ VINTAGE PHARMS LLC 0.02MG;0.1MG A077099 001 May 11, 2011 Jun DISC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

>D> BREVICON 28-DAY

>D> AB ALLERGAN 0.035MG;0.5MG N017743 001 Aug DISC

>A> @ 0.035MG;0.5MG N017743 001 Aug DISC

DASETTA 7/7/7

>D> AB NOVAST LABS LTD 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG A090946 001 Dec 22, 2011 Aug CHRS

>A> AB ! 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG A090946 001 Dec 22, 2011 Aug CHRS

NORETHINDRONE AND ETHINYL ESTRADIOL

AB NAARI PTE LTD 0.035MG;1MG A206864 001 Apr 28, 2017 Jun CAHN

>D> ORTHO-NOVUM 7/7/7-28

>D> AB +! JANSSEN PHARMS 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG N018985 002 Apr 04, 1984 Aug DISC

>A> + @ 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG N018985 002 Apr 04, 1984 Aug DISC

TABLET, CHEWABLE;ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB NAARI PTE LTD 0.035MG;0.4MG A207066 001 Mar 29, 2017 Jun CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

LOESTRIN 24 FE

AB + TEVA BRANDED PHARM 0.02MG;1MG N021871 001 Feb 17, 2006 Jan CAHN

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

@ MYLAN LABS LTD 0.02MG;1MG A202742 001 Oct 30, 2014 Jun DISC

TABLET;ORAL-21

GILDESS 1.5/30

@ VINTAGE PHARMS LLC 0.03MG;1.5MG A077075 002 Jul 24, 2012 Jun DISC

LOESTRIN 21 1.5/30

AB + TEVA BRANDED PHARM 0.03MG;1.5MG N017875 001 Jan CAHN

LOESTRIN 21 1/20

AB + TEVA BRANDED PHARM 0.02MG;1MG N017876 001 Jan CAHN

LOESTRIN FE 1.5/30

AB +! TEVA BRANDED PHARM 0.03MG;1.5MG N017355 001 Jan CAHN

TABLET;ORAL-28

CHABELINA FE

AB NOVAST LABS 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG A202962 001 Apr 15, 2020 Mar NEWA

GILDESS FE 1.5/30

@ VINTAGE PHARMS LLC 0.03MG;1.5MG A077075 001 Apr 28, 2005 Jun DISC

LOESTRIN FE 1/20

AB + TEVA BRANDED PHARM 0.02MG;1MG N017354 001 Jan CAHN

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

@ MYLAN LABS LTD 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG A205069 001 Jun 22, 2018 Feb DISC

TABLET, CHEWABLE;ORAL

FINZALA

AB @ TEVA PHARMS USA INC 0.02MG;1MG A210087 001 Apr 07, 2020 Jul DISC

0.02MG;1MG A210087 001 Apr 07, 2020 Mar NEWA

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

>D>	AB	GLENMARK GENERICS	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG	A200494	001	Jun 17, 2011	Aug CHRS
>A>	AB	!	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG	A200494	001	Jun 17, 2011	Aug CHRS
	AB	!	GLENMARK PHARMS	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG	A204057	001	Feb 23, 2016
							Jul CHRS
>D>		ORTHO TRI-CYCLEN					
>D>	AB	+!	JANSSEN PHARMS	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG	N019697	001	Jul 03, 1992
							Aug DISC
>A>		+ @		0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG	N019697	001	Jul 03, 1992
							Aug DISC
		ORTHO TRI-CYCLEN LO					
		+ @	JANSSEN PHARMS	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG	N021241	001	Aug 22, 2002
							Jul DISC
		TRI-PREVIFEM					
		@	VINTAGE PHARMS LLC	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG	A076335	001	Mar 26, 2004
							Jun DISC

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

AB		PURACAP PHARM LLC	250MG	A210654	001	Mar 16, 2020	Mar NEWA
----	--	-------------------	-------	---------	-----	--------------	----------

ETODOLAC

TABLET; ORAL

ETODOLAC

@ TEVA

400MG

A075009 001 Nov 26, 1997 Feb DISC

@

500MG

A075009 002 Dec 28, 1999 Feb DISC

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

@ MYLAN LABS LTD

2MG/ML

A078289 001 Jan 02, 2009 Feb DISC

EVEROLIMUS

TABLET; ORAL

EVEROLIMUS

AB		HIKMA	2.5MG	A207486	001	Jun 08, 2020	Jun NEWA
AB			5MG	A207486	002	Jun 08, 2020	Jun NEWA
AB			7.5MG	A207486	003	Jun 08, 2020	Jun NEWA
AB		MYLAN	2.5MG	A212936	001	Jun 08, 2020	Jun NEWA
AB			5MG	A212936	002	Jun 08, 2020	Jun NEWA
AB			7.5MG	A212936	003	Jun 08, 2020	Jun NEWA
AB			10MG	A212936	004	Jun 08, 2020	Jun NEWA
AB		TEVA PHARMS USA	2.5MG	A210050	001	Dec 09, 2019	Jun CMFD
		@	2.5MG	A210050	001	Dec 09, 2019	Jun DISC
AB			5MG	A210050	002	Dec 09, 2019	Jun CMFD
		@	5MG	A210050	002	Dec 09, 2019	Jun DISC
AB			7.5MG	A210050	003	Dec 09, 2019	Jun CMFD
		@	7.5MG	A210050	003	Dec 09, 2019	Jun DISC
		@	10MG	A210050	004	Dec 09, 2019	Jun DISC
		ZORTRESS					
AB		+ NOVARTIS	0.75MG	N021560	003	Apr 20, 2010	Jul CHRS
		+!	1MG	N021560	004	Aug 10, 2018	Jul CHRS

EXEMESTANE

TABLET; ORAL

EXEMESTANE

@ MAYNE PHARMA INC

25MG

A208764 001 Aug 08, 2019 Jan DISC

AB		QILU	25MG	A213547	001	Apr 13, 2020	Mar NEWA
----	--	------	------	---------	-----	--------------	----------

EZETIMIBE

TABLET; ORAL

EZETIMIBE

@ MYLAN

10MG

A201790 001 Apr 26, 2019 Feb DISC

@ TEVA PHARMS USA

10MG

A078724 001 Jun 12, 2017 Mar DISC

FAMOTIDINETABLET; ORAL
FAMOTIDINE

AB	!	AUROBINDO PHARMA LTD	40MG	A206530	002	Dec 22, 2015	Jan CHRS
	@	MYLAN	20MG	A075704	001	Apr 16, 2001	Feb DISC
	@	TEVA	20MG	A075311	001	Apr 16, 2001	Mar DISC
	@		40MG	A075311	002	Apr 16, 2001	Mar DISC
		PEPCID					
	+	@ VALEANT PHARMS NORTH	20MG	N019462	001	Oct 15, 1986	Jan DISC
	+	@	40MG	N019462	002	Oct 15, 1986	Jan DISC

FEBUXOSTATTABLET; ORAL
FEBUXOSTAT

AB		SUNSHINE	40MG	A213069	001	Jun 02, 2020	May NEWA
AB			80MG	A213069	002	Jun 02, 2020	May NEWA

FENFLURAMINE HYDROCHLORIDESOLUTION; ORAL
FINTEPLA

+	!	ZOGENIX INC	EQ 2.2MG BASE/ML	N212102	001	Jun 25, 2020	Jun NEWA
---	---	-------------	------------------	---------	-----	--------------	----------

FENOFIBRATECAPSULE; ORAL
FENOFIBRATE (MICRONIZED)

AB		ANI PHARMS INC	67MG	A209504	001	Apr 30, 2018	Jan CAHN
AB			134MG	A209504	002	Apr 30, 2018	Jan CAHN
AB			200MG	A209504	003	Apr 30, 2018	Jan CAHN
	@	MYLAN PHARMS INC	43MG	A202579	001	Jan 10, 2013	Mar DISC
	@		130MG	A202579	002	Jan 10, 2013	Mar DISC

TABLET; ORAL
FENOFIBRATE

AB		ALEMBIC PHARMS LTD	54MG	A213252	001	Jan 17, 2020	Jan NEWA
AB			160MG	A213252	002	Jan 17, 2020	Jan NEWA
>D>	AB	APPCO	54MG	A210670	001	Sep 06, 2019	Aug CAHN
	AB		54MG	A210670	001	Sep 06, 2019	Jan CAHN
>D>	AB		160MG	A210670	002	Sep 06, 2019	Aug CAHN
	AB		160MG	A210670	002	Sep 06, 2019	Jan CAHN
>A>	AB	DR REDDYS	54MG	A210670	001	Sep 06, 2019	Aug CAHN
>A>	AB		160MG	A210670	002	Sep 06, 2019	Aug CAHN
	AB	GRAVITI PHARMS	48MG	A211122	001	Mar 18, 2020	Mar NEWA
	AB		54MG	A210606	001	Aug 17, 2018	Jan CMFD
	AB		145MG	A211122	002	Mar 18, 2020	Mar NEWA
	AB		160MG	A210606	002	Aug 17, 2018	Jan CMFD
	AB	MANKIND PHARMA	54MG	A213864	001	Jun 12, 2020	Jun NEWA
	AB		160MG	A213864	002	Jun 12, 2020	Jun NEWA

FENOFIBRIC ACIDTABLET; ORAL
FIBRICOR

+	@	ATHENA	35MG	N022418	001	Aug 14, 2009	Jul DISC
---	---	--------	------	---------	-----	--------------	----------

FENTANYLFILM, EXTENDED RELEASE; TRANSDERMAL
FENTANYL-37

AB		SPECGX LLC	37.5MCG/HR	A077154	006	Jan 14, 2020	Jul NEWA
		FENTANYL-62					
AB		MYLAN TECHNOLOGIES	62.5MCG/HR	A076258	007	Dec 29, 2014	Jul CTEC
AB		SPECGX LLC	62.5MCG/HR	A077154	007	Jan 14, 2020	Jul NEWA
		FENTANYL-87					
AB		MYLAN TECHNOLOGIES	87.5MCG/HR	A076258	008	Dec 29, 2014	Jul CTEC

FENTANYL CITRATEINJECTABLE; INJECTION
FENTANYL CITRATE

>A>	AP	FRESENIUS KABI USA	EQ 0.05MG BASE/ML	A212086	001	Sep 01, 2020	Aug NEWA		
		FENTANYL CITRATE PRESERVATIVE FREE							
	AP	+	!	HIKMA	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb CAHN

FERRIC DERISOMALTOSESOLUTION; INTRAVENOUS
MONOFERRIC

+ @	PHARMACOSMOS AS	100MG/ML (100MG/ML)	N208171	001	Jan 16, 2020	Jun DISC
+	!	100MG/ML (100MG/ML)	N208171	001	Jan 16, 2020	Jan NEWA
+ @		500MG/5ML (100MG/ML)	N208171	002	Jan 16, 2020	Jun DISC
+	!	500MG/5ML (100MG/ML)	N208171	002	Jan 16, 2020	Jan NEWA
+	!	1GM/10ML (100MG/ML)	N208171	003	Jan 16, 2020	Jan NEWA

FERRIC PYROPHOSPHATE CITRATESOLUTION; INTRAVENOUS
TRIFERIC AVNU

+	!	ROCKWELL MEDICAL INC	6.75MG IRON/4.5ML (1.5MG IRON/ML)	N212860	001	Mar 27, 2020	Mar NEWA
---	---	----------------------	-----------------------------------	---------	-----	--------------	----------

FESOTERODINE FUMARATETABLET, EXTENDED RELEASE; ORAL
FESOTERODINE FUMARATE

@	DR REDDYS LABS LTD	4MG	A204975	001	Aug 13, 2019	Feb DISC
@		8MG	A204975	002	Aug 13, 2019	Feb DISC

FEXOFENADINE HYDROCHLORIDETABLET; ORAL
FEXOFENADINE HYDROCHLORIDE

@	BARR	30MG	A076191	001	Aug 31, 2005	Mar DISC
@		60MG	A076191	002	Aug 31, 2005	Mar DISC
@		180MG	A076191	003	Aug 31, 2005	Mar DISC

FIDAXOMICINFOR SUSPENSION; ORAL
DIFICID

+	!	CUBIST PHARMS LLC	40MG/ML	N213138	001	Jan 24, 2020	Jan NEWA
---	---	-------------------	---------	---------	-----	--------------	----------

FINASTERIDETABLET; ORAL
FINASTERIDE

@	TEVA	1MG	A076905	001	Nov 05, 2013	Mar DISC
---	------	-----	---------	-----	--------------	----------

FINGOLIMOD HYDROCHLORIDECAPSULE; ORAL
FINGOLIMOD HYDROCHLORIDE

@	BIOCON LTD	EQ 0.5MG BASE	A207979	001	Dec 04, 2019	Jun DISC
AB	GLENMARK PHARMS LTD	EQ 0.5MG BASE	A207985	001	Jun 18, 2020	Jun NEWA
AB	HETERO LABS LTD V	EQ 0.5MG BASE	A207933	001	May 18, 2020	May NEWA
AB	STRIDES PHARMA	EQ 0.5MG BASE	A207971	001	Jun 29, 2020	Jun NEWA
AB	TEVA PHARMS USA	EQ 0.5MG BASE	A208008	001	Jul 02, 2020	Jul NEWA

FLORTAUCIPIR F-18SOLUTION; INTRAVENOUS
TAUVID

+	!	AVID RADIOPHARMS INC	30ML (8.1-51mCi/ML)	N212123	001	May 28, 2020	May NEWA
+	!		50ML (8.1-51mCi/ML)	N212123	002	May 28, 2020	May NEWA

FLUCONAZOLEFOR SUSPENSION; ORAL
FLUCONAZOLE

@	HIKMA	50MG/5ML	A076246	001	Jul 29, 2004	Feb DISC
@		200MG/5ML	A076246	002	Jul 29, 2004	Feb DISC

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

@	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764	001	Jan 30, 2012	Mar DISC
@		400MG/200ML (2MG/ML)	A078764	002	Jan 30, 2012	Mar DISC
@	HOSPIRA	200MG/100ML (2MG/ML)	A076304	001	Jul 29, 2004	Mar DISC
@		400MG/200ML (2MG/ML)	A076304	002	Jul 29, 2004	Mar DISC
@	WOODWARD	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	Mar DISC
@		400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	Mar DISC

TABLET; ORAL

FLUCONAZOLE

AB	ANI PHARMS INC	50MG	A078423	001	Mar 07, 2011	Jul CAHN
AB		100MG	A078423	002	Mar 07, 2011	Jul CAHN
AB		150MG	A078423	003	Mar 07, 2011	Jul CAHN
AB		200MG	A078423	004	Mar 07, 2011	Jul CAHN

TABLET;ORAL
FLUCONAZOLE

@ MYLAN	50MG	A076351	001	Jul 29, 2004	Jan DISC
@	100MG	A076351	002	Jul 29, 2004	Jan DISC
@	150MG	A076351	003	Jul 29, 2004	Jan DISC
@	200MG	A076351	004	Jul 29, 2004	Jan DISC
@ TEVA	50MG	A074681	001	Jul 29, 2004	Mar DISC
@	100MG	A074681	002	Jul 29, 2004	Mar DISC
@	150MG	A074681	003	Jul 29, 2004	Mar DISC
@	200MG	A074681	004	Jul 29, 2004	Mar DISC

FLUCYTOSINE

CAPSULE;ORAL
FLUCYTOSINE

AB AUROBINDO PHARMA LTD	250MG	A213665	001	May 01, 2020	Apr NEWA
AB	500MG	A213665	002	May 01, 2020	Apr NEWA
AB STRIDES PHARMA	250MG	A212632	001	Apr 17, 2020	Apr NEWA
AB	500MG	A212632	002	Apr 17, 2020	Apr NEWA

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS
FLUDEOXYGLUCOSE F18

AP @ UNIV TX SW MEDCTR	20-200mCi/ML	A210265	001	Feb 06, 2020	May DISC
	20-200mCi/ML	A210265	001	Feb 06, 2020	Jan NEWA

FLUNISOLIDE

SPRAY, METERED;NASAL
FLUNISOLIDE

! APOTEX 0.029MG/SPRAY
0.029MG/SPRAY

A077436 001 Aug 09, 2007 Mar CHRS
A077436 001 Aug 09, 2007 Mar CMFD

NASALIDE

>D> @ IVAX RES 0.025MG/SPRAY
>A> + @ 0.025MG/SPRAY

N018148 001 Aug CRLD
N018148 001 Aug CRLD

FLUOCINOLONE ACETONIDE

OIL;TOPICAL
FLUOCINOLONE ACETONIDE

>A> AT AMNEAL 0.01%
>A> AT 0.01%
>D> AT IDENTI PHARMS INC 0.01%
>D> AT 0.01%

A201759 001 Oct 17, 2011 Aug CAHN
A201764 001 Oct 17, 2011 Aug CAHN
A201759 001 Oct 17, 2011 Aug CAHN
A201764 001 Oct 17, 2011 Aug CAHN

OIL/DROPS;OTIC

FLUOCINOLONE ACETONIDE

>A> AT AMNEAL 0.01%
>D> AT IDENTI PHARMS INC 0.01%

A091306 001 Oct 17, 2011 Aug CAHN
A091306 001 Oct 17, 2011 Aug CAHN

FLUOCINONIDE

CREAM;TOPICAL
FLUOCINONIDE

AB1 AMNEAL 0.05%
AB CADILA 0.1%
AB ZYDUS PHARMS 0.1%

A210554 001 Aug 21, 2018 Apr CMFD
A208989 001 Feb 10, 2020 Feb CAHN
A208989 001 Feb 10, 2020 Jan NEWA

SOLUTION;TOPICAL
FLUOCINONIDE

@ TEVA 0.05%

A072511 001 Feb 07, 1989 Mar DISC

>D> FLUORODOPA F-18

SOLUTION;INTRAVENOUS
FLUORODOPA F18

>D> +! FEINSTEIN 0.42-8.33mCi/ML
>A> + @ 0.42-8.33mCi/ML

N200655 001 Oct 10, 2019 Aug DISC
N200655 001 Oct 10, 2019 Aug DISC

FLUOROESTRADIOL F-18

SOLUTION;INTRAVENOUS
CERIANNA

+! ZIONEXA 50ML (4-100mCi/ML)

N212155 001 May 20, 2020 May NEWA

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

@ INGENUS PHARMS LLC 500MG/10ML (50MG/ML)
 @ 500MG/10ML (50MG/ML)
 @ 1GM/20ML (50MG/ML)
 @ 2.5GM/50ML (50MG/ML)

A209219 001 Dec 12, 2019 Apr DISC
 A209271 001 Dec 11, 2019 Apr DISC
 A209219 002 Dec 12, 2019 Apr DISC
 A209271 002 Dec 11, 2019 Apr DISC

SOLUTION; TOPICAL

EFUDEX

>D> EFUDEX
 >D> AT +! BAUSCH 5% N016831 002 Aug DISC
 >A> + @ 5% N016831 002 Aug DISC
 FLUOROURACIL
 >D> AT ! TARO 5% A076526 002 Nov 05, 2003 Aug CTEC
 >A> ! 5% A076526 002 Nov 05, 2003 Aug CTEC
 AT ! 5% A076526 002 Nov 05, 2003 Mar CHRS

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

>A> AB1 ACCORD HLTHCARE EQ 10MG BASE A202729 001 Aug 27, 2020 Aug NEWA
 >A> AB1 EQ 20MG BASE A202729 002 Aug 27, 2020 Aug NEWA
 >A> AB EQ 40MG BASE A202729 003 Aug 27, 2020 Aug NEWA
 @ BARR EQ 10MG BASE A074803 002 Jan 30, 2002 Mar DISC
 @ EQ 20MG BASE A074803 001 Aug 02, 2001 Mar DISC
 @ SPECGX LLC EQ 10MG BASE A075658 001 Jan 29, 2002 May DISC
 @ EQ 20MG BASE A075658 002 Jan 29, 2002 May DISC

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

AA AUROBINDO PHARMA LTD EQ 20MG BASE/5ML A079209 001 Mar 20, 2009 Mar CMFD
 @ SPECGX LLC EQ 20MG BASE/5ML A075920 001 Jan 29, 2002 May DISC

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

AB AUROBINDO PHARMA LTD EQ 10MG BASE A213286 001 Apr 08, 2020 Mar NEWA
 AB EQ 20MG BASE A213286 002 Apr 08, 2020 Mar NEWA
 AB EQ 60MG BASE A213265 001 Jun 10, 2020 Jun NEWA
 SARAFEM
 + @ APIL EQ 15MG BASE N021860 002 May 19, 2006 Jul DISC
 + EQ 15MG BASE N021860 002 May 19, 2006 Apr CTEC
 SELFEMRA
 @ TEVA PHARMS USA EQ 10MG BASE A200151 001 Feb 03, 2014 Apr DISC
 @ EQ 15MG BASE A200151 002 Feb 03, 2014 Apr DISC
 @ EQ 20MG BASE A200151 003 Feb 03, 2014 Apr DISC

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

AB AMNEAL 1MG A213647 001 Jul 09, 2020 Jul NEWA
 AB 2.5MG A213647 002 Jul 09, 2020 Jul NEWA
 AB 5MG A213647 003 Jul 09, 2020 Jul NEWA
 AB 10MG A213647 004 Jul 09, 2020 Jul NEWA
 >D> @ MYLAN 1MG A089804 002 Aug 12, 1988 Aug CMFD
 >A> AB 1MG A089804 002 Aug 12, 1988 Aug CMFD
 @ 1MG A089804 002 Aug 12, 1988 Jul DISC
 @ SANDOZ 1MG A089586 002 Oct 16, 1987 Mar DISC
 @ 2.5MG A089586 003 Oct 16, 1987 Mar DISC
 @ 5MG A089586 004 Oct 16, 1987 Mar DISC
 @ 10MG A089586 001 Oct 16, 1987 Mar DISC

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

>D> +! ALMIRALL 0.025% N012806 003 Aug DISC
 >A> + @ 0.025% N012806 003 Aug DISC

FLUTICASONE PROPIONATE

POWDER; INHALATION

ARMONAIR DIGIHALER

+ TEVA PHARM 0.055MG/INH N208798 004 Feb 20, 2020 Mar NEWA
 + 0.113MG/INH N208798 005 Feb 20, 2020 Mar NEWA
 +! 0.232MG/INH N208798 006 Feb 20, 2020 Mar NEWA

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL						
FLUVOXAMINE MALEATE						
AB	BIONPHARMA INC	150MG	A212182	001	May 11, 2020	Apr NEWA
TABLET;ORAL						
FLUVOXAMINE MALEATE						
	@ TEVA	25MG	A075893	001	Sep 10, 2002	Mar DISC
	@	50MG	A075893	002	Sep 10, 2002	Mar DISC
	@	100MG	A075893	003	Sep 10, 2002	Mar DISC

FOLIC ACID

INJECTABLE;INJECTION						
FOLIC ACID						
AP	X-GEN PHARMS INC	5MG/ML	A202522	001	Nov 06, 2019	Jan CAHN
AP	XGEN PHARMS	5MG/ML	A202522	001	Nov 06, 2019	Feb CAHN
TABLET;ORAL						
FOLIC ACID						
	@ VINTAGE	1MG	A040756	001	Jun 04, 2010	Jun DISC

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS									
FOSAPREPITANT DIMEGLUMINE									
>A>	AP	ACCORD HLTHCARE	EQ	150MG	BASE/VIAL	A204025	001	Aug 26, 2020	Aug NEWA
>A>	AP	NAVINTA LLC	EQ	150MG	BASE/VIAL	A212957	002	Aug 20, 2020	Aug NEWA
>A>	AP	QILU	EQ	150MG	BASE/VIAL	A213106	001	Sep 08, 2020	Aug NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL							
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE							
AB	!	AUROBINDO PHARMA	20MG;12.5MG	A079245	002	Jul 09, 2009	Apr CHRS
	@	EMCURE PHARMS LTD	10MG;12.5MG	A079025	001	Sep 17, 2010	Apr DISC
	@		20MG;12.5MG	A079025	002	Sep 17, 2010	Apr DISC

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

POWDER;INTRAVENOUS						
AKYNZEO						
+!	HELSINN HLTHCARE	EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL	N210493	001	Apr 19, 2018	May CMS1
SOLUTION;INTRAVENOUS						
AKYNZEO						
+!	HELSINN HLTHCARE	EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)	N210493	002	May 27, 2020	May NEWA

FOSTEMSAVIR TROMETHAMINE

TABLET, EXTENDED RELEASE;ORAL						
RUKOBIA						
+!	VIIIV HLTHCARE	EQ 600MG BASE	N212950	001	Jul 02, 2020	Jul NEWA

FULVESTRANT

INJECTABLE;INTRAMUSCULAR						
FULVESTRANT						
AO	CHIA TAI TIANQING	50MG/ML	A211422	001	Feb 07, 2020	Jan NEWA
AO	DR REDDYS	50MG/ML	A209246	001	Aug 07, 2020	Jul NEWA

FUROSEMIDE

INJECTABLE;INJECTION						
FUROSEMIDE						
AP	GLAND PHARMA LTD	10MG/ML	A213902	001	Jul 01, 2020	Jun NEWA
TABLET;ORAL						
FUROSEMIDE						
	@ AVET	20MG	N018413	001	Nov 30, 1983	Jan DISC
	@	40MG	N018413	002	Nov 30, 1983	Jan DISC

GABAPENTIN

CAPSULE;ORAL							
GABAPENTIN							
AB	CSPC OUYI	100MG	A075477	001	Mar 23, 2005	Jan	CMFD
AB		300MG	A075477	002	Mar 23, 2005	Jan	CMFD
AB		400MG	A075477	003	Mar 23, 2005	Jan	CMFD
	@ JIANGSU HENGRUI MED	100MG	A091008	001	Oct 26, 2017	May	DISC

CAPSULE;ORAL									
GABAPENTIN									
	@	300MG	A091008	002	Oct 26, 2017	May	DISC		
	@	400MG	A091008	003	Oct 26, 2017	May	DISC		
	@ TEVA PHARMS	100MG	A075435	001	Oct 08, 2004	Mar	DISC		
	@	300MG	A075435	002	Oct 08, 2004	Mar	DISC		
	@	400MG	A075435	003	Oct 08, 2004	Mar	DISC		
>A>	AB	ZHEJIANG YONGTAI	100MG	A213603	001	Aug 17, 2020	Aug	NEWA	
>A>	AB		300MG	A213603	002	Aug 17, 2020	Aug	NEWA	
>A>	AB		400MG	A213603	003	Aug 17, 2020	Aug	NEWA	
NEURONTIN									
AB	+ UPJOHN	100MG	N020235	001	Dec 30, 1993	Jun	CAHN		
AB	+	300MG	N020235	002	Dec 30, 1993	Jun	CAHN		
AB	+!	400MG	N020235	003	Dec 30, 1993	Jun	CAHN		
SOLUTION;ORAL									
GABAPENTIN									
	@ VISTAPHARM	250MG/5ML	A211330	001	Dec 03, 2019	May	DISC		
NEURONTIN									
AA	+! UPJOHN	250MG/5ML	N021129	001	Mar 02, 2000	Jun	CAHN		
TABLET;ORAL									
GABAPENTIN									
	@ MYLAN PHARMS INC	600MG	A090335	001	Jun 01, 2010	Mar	DISC		
	@	800MG	A090335	002	Jun 01, 2010	Mar	DISC		
	@ TEVA PHARMS USA	600MG	A205807	001	Mar 10, 2017	Mar	DISC		
	@	800MG	A205807	002	Mar 10, 2017	Mar	DISC		
GRALISE									
BX	+! ALMATICA	300MG	N022544	001	Jan 28, 2011	Jan	CAHN		
BX	+!	600MG	N022544	002	Jan 28, 2011	Jan	CAHN		
NEURONTIN									
AB	+ UPJOHN	600MG	N020882	001	Oct 09, 1998	Jun	CAHN		
AB	+!	800MG	N020882	002	Oct 09, 1998	Jun	CAHN		
<u>GALANTAMINE HYDROBROMIDE</u>									
TABLET;ORAL									
GALANTAMINE HYDROBROMIDE									
	@ HIKMA	EQ 4MG BASE	A077608	001	Feb 11, 2009	Feb	DISC		
	@	EQ 8MG BASE	A077608	002	Feb 11, 2009	Feb	DISC		
	@	EQ 12MG BASE	A077608	003	Feb 11, 2009	Feb	DISC		
<u>GEMCITABINE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
GEMCITABINE HYDROCHLORIDE									
	@ APOTEX	200MG/5.26ML (38MG/ML)	A206776	001	May 23, 2017	Feb	DISC		
	@	1GM/26.3ML (38MG/ML)	A206776	002	May 23, 2017	Feb	DISC		
	@	2GM/52.6ML (38MG/ML)	A206776	003	May 23, 2017	Feb	DISC		
>D>	AP	EMCURE PHARMS LTD	EQ 200MG BASE/VIAL	A202063	001	Sep 11, 2012	Aug	DISC	
>A>	@		EQ 200MG BASE/VIAL	A202063	001	Sep 11, 2012	Aug	DISC	
>D>	AP		EQ 1GM BASE/VIAL	A202063	002	Sep 11, 2012	Aug	DISC	
>A>	@		EQ 1GM BASE/VIAL	A202063	002	Sep 11, 2012	Aug	DISC	
	@ MYLAN LABS LTD	EQ 200MG BASE/VIAL	A200145	001	Jul 25, 2011	Jul	DISC		
	@	EQ 1GM BASE/VIAL	A200145	002	Jul 25, 2011	May	DISC		
	@	EQ 2GM BASE/VIAL	A200145	003	Jul 25, 2011	Mar	DISC		
AP	SHILPA MEDICARE LTD	EQ 200MG BASE/VIAL	A207575	001	Feb 22, 2019	Jan	CMFD		
AP		EQ 1GM BASE/VIAL	A207575	002	Feb 22, 2019	Jan	CMFD		
	@ TEVA PHARMS	EQ 200MG BASE/VIAL	A077983	002	Jan 25, 2011	Mar	DISC		
	@	EQ 1GM BASE/VIAL	A077983	001	Jan 25, 2011	Mar	DISC		
<u>GEMFIBROZIL</u>									
TABLET;ORAL									
GEMFIBROZIL									
AB	CADILA	600MG	A204189	001	Aug 28, 2018	Feb	CAHN		
	@ TEVA	600MG	A074256	001	Oct 31, 1993	Feb	DISC		
<u>GLIMEPIRIDE</u>									
TABLET;ORAL									
GLIMEPIRIDE									
	@ MYLAN	1MG	A077624	001	Nov 28, 2005	Apr	DISC		
	@	2MG	A077624	002	Nov 28, 2005	Apr	DISC		
	@	4MG	A077624	003	Nov 28, 2005	Apr	DISC		

GLYBURIDETABLET; ORAL
GLYBURIDE

AB1	ORIENT PHARMA CO LTD	1.25MG	A206483	001	Feb 22, 2019	May CMFD
AB1		2.5MG	A206483	002	Feb 22, 2019	May CMFD
AB1		5MG	A206483	003	Feb 22, 2019	May CMFD
	GLYBURIDE (MICRONIZED)					
	@ MYLAN	1.5MG	A074792	001	Jun 26, 1998	Jan DISC
	@	3MG	A074792	002	Jun 26, 1998	Jan DISC
	@	6MG	A074792	003	Aug 17, 1999	Jan DISC

GLYCOPYRROLATEINJECTABLE; INJECTION
GLYCOPYRROLATE

AP	ACCORD HLTHCARE	0.2MG/ML	A213238	001	Jul 08, 2020	Jul NEWA
AP	RICONPHARMA LLC	0.2MG/ML	A210083	001	Feb 21, 2020	Feb NEWA

POWDER; INHALATION
SEEBRI

+	@ NOVARTIS	15.6MCG/INH	N207923	001	Oct 29, 2015	Mar CAHN
+	@ SUNOVION PHARMS INC	15.6MCG/INH	N207923	001	Oct 29, 2015	Mar DISC

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

GLYRX-PF

	EXELA PHARMA	1MG/5ML (0.2MG/ML)	N210997	003	Apr 09, 2020	Apr NEWA
--	--------------	--------------------	---------	-----	--------------	----------

TABLET; ORAL

GLYCOPYRROLATE

>A>	LGM PHARMA	1.5MG	A091522	001	Mar 12, 2012	Aug CAHN
>D>	NEXGEN PHARMA	1.5MG	A091522	001	Mar 12, 2012	Aug CAHN

GLYCOPYRROLATE; INDACATEROL MALEATEPOWDER; INHALATION
UTIBRON

+	@ NOVARTIS	15.6MCG/INH; 27.5MCG/INH	N207930	001	Oct 29, 2015	Mar CAHN
+	@ SUNOVION PHARMS INC	15.6MCG/INH; 27.5MCG/INH	N207930	001	Oct 29, 2015	Mar DISC

GRANISETRON HYDROCHLORIDEINJECTABLE; INJECTION
GRANISETRON HYDROCHLORIDE

	@ MYLAN LABS LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A203454	001	Apr 04, 2017	Apr DISC
	@	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A203454	002	Apr 04, 2017	Apr DISC
	@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A203453	001	Jan 31, 2017	Mar DISC
AP	PUNISKA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262	001	Dec 31, 2007	May CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258	001	Jun 30, 2008	May CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258	002	Jun 30, 2008	May CAHN
	@ YUNG SHIN PHARM	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A202647	001	Mar 06, 2020	Apr DISC
AP		EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A202647	001	Mar 06, 2020	Feb NEWA
>D> AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A202648	001	Jun 29, 2020	Aug DISC
>A>	@	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A202648	001	Jun 29, 2020	Aug DISC
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A202648	001	Jun 29, 2020	Jun NEWA
>D> AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A202648	002	Jun 29, 2020	Aug DISC
>A>	@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A202648	002	Jun 29, 2020	Aug DISC
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A202648	002	Jun 29, 2020	Jun NEWA

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

	@ MYLAN	EQ 1MG BASE	A078725	001	Jan 30, 2008	Jan DISC
--	---------	-------------	---------	-----	--------------	----------

GRISEOFULVIN, MICROSIZESUSPENSION; ORAL
GRISEOFULVIN

AB	COSETTE	125MG/5ML	A065438	001	Oct 08, 2010	May CAHN
----	---------	-----------	---------	-----	--------------	----------

GRISEOFULVIN, ULTRAMICROSIZETABLET; ORAL
GRIS-PEG

>A> AB	+	BAUSCH	125MG	N050475	001	Aug CAHN
>A> AB	+		250MG	N050475	002	Aug CAHN
>D> AB	+	VALEANT PHARMS INC	125MG	N050475	001	Aug CAHN
>D> AB	+		250MG	N050475	002	Aug CAHN
AB	+		250MG	N050475	002	Jul CHRS

TABLET;ORAL

GRISEOFULVIN, ULTRAMICROSIZE					
AB	! MOUNTAIN	250MG	A204371	002	Jan 09, 2014 Jul CHRS

HALCINONIDE

SOLUTION;TOPICAL

HALOG

!	SUN PHARM INDS INC	0.1%	N017823	001	Mar CMFD
---	--------------------	------	---------	-----	----------

HALOBETASOL PROPIONATE

LOTION;TOPICAL

HALOBETASOL PROPIONATE

	@ PERRIGO ISRAEL	0.05%	A211464	001	Jun 03, 2020 Jun DISC
AB		0.05%	A211464	001	Jun 03, 2020 May NFTG
ULTRAVATE					
	+! SUN PHARM INDUSTRIES	0.05%	N208183	001	Nov 06, 2015 Jun CTEC
AB	+!	0.05%	N208183	001	Nov 06, 2015 May CFTG

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

AB	UPSHER SMITH LABS	0.5MG	A211061	001	Jan 08, 2020 Jun CAHN
AB		1MG	A211061	002	Jan 08, 2020 Jun CAHN
AB		2MG	A211061	003	Jan 08, 2020 Jun CAHN
AB		5MG	A211061	004	Jan 08, 2020 Jun CAHN
AB		10MG	A211061	005	Jan 08, 2020 Jun CAHN
AB		20MG	A211061	006	Jan 08, 2020 Jun CAHN

HALOPERIDOL LACTATE

INJECTABLE;INJECTION

HALOPERIDOL

>D>	@ FRESENIUS KABI USA	EQ 5MG BASE/ML	A210356	001	Jul 01, 2019 Aug CMFD
>A> AP		EQ 5MG BASE/ML	A210356	001	Jul 01, 2019 Aug CMFD
	@ TEVA PHARMS USA	EQ 5MG BASE/ML	A076035	001	Aug 29, 2001 Mar DISC

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

AP	GLAND PHARMA LTD	1,000 UNITS/ML	A205323	002	Nov 18, 2019 Apr NEWA
AP	NANJING KING-FRIEND	5,000 UNITS/ML	A212061	001	Jul 15, 2020 Jul NEWA
AP		20,000 UNITS/ML	A211004	001	Feb 24, 2020 Feb NEWA
	+ @ PFIZER	10,000 UNITS/ML	N201370	003	Jul 21, 2011 Jun DISC
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	FRESENIUS KABI USA	200 UNITS/100ML	A212441	001	Jul 24, 2020 Jul NEWA
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	2,000 UNITS/1000ML	N018609	004	Apr 23, 2020 Apr NEWA
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	FRESENIUS KABI USA	200 UNITS/100ML	A212441	002	Jul 24, 2020 Jul NEWA
HEPARIN SODIUM PRESERVATIVE FREE					
AP	+! FRESENIUS KABI USA	10,000 UNITS/ML	N017029	019	Nov 22, 2010 Mar CTEC
AP	NANJING KING-FRIEND	10,000 UNITS/ML	A212060	001	Apr 02, 2020 Mar NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

	@ NOSTRUM LABS INC	1.5MG/5ML;5MG/5ML	A210663	001	Jun 11, 2019 Apr CAHN
--	--------------------	-------------------	---------	-----	-----------------------

TABLET;ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AA	! NOVEL LABS INC	1.5MG;5MG	A091528	001	Apr 20, 2011 Jan CHRS
TUSSIGON					
	@ KING PHARMS	1.5MG;5MG	A088508	001	Jul 30, 1985 Jan DISC

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDRALAZINE HYDROCHLORIDE

AP	XGEN PHARMS	20MG/ML	A203110	001	Jun 29, 2015 Feb CAHN
TABLET;ORAL					
HYDRALAZINE HYDROCHLORIDE					
	@ STRIDES PHARMA	10MG	A200770	004	Jun 25, 2019 Jan DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

@ IVAX SUB TEVA PHARMS 12.5MG

A077005 001 Jul 13, 2005 Mar DISC

TABLET; ORAL

HYDROCHLOROTHIAZIDE

@ MYLAN PHARMS INC 25MG

A040735 002 Jan 23, 2007 Jan DISC

@ 50MG

A040735 003 Jan 23, 2007 Jan DISC

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

@ COREPHARMA 12.5MG; 10MG

A076674 001 Oct 05, 2004 Feb CAHN

@ 12.5MG; 20MG

A076674 002 Oct 05, 2004 Feb CAHN

@ 25MG; 20MG

A076674 003 Oct 05, 2004 Feb CAHN

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ HERITAGE PHARMS INC 12.5MG; 7.5MG

A202150 001 Mar 07, 2014 Apr DISC

@ 12.5MG; 15MG

A202150 002 Mar 07, 2014 Apr DISC

@ 25MG; 15MG

A202150 003 Mar 07, 2014 Apr DISC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB ACCORD HLTHCARE 12.5MG; 20MG

A209281 001 Feb 07, 2019 Jul CMFD

AB 12.5MG; 40MG

A209281 002 Feb 07, 2019 Jul CMFD

AB 25MG; 40MG

A209281 003 Feb 07, 2019 Jul CMFD

AB UMEDICA LABS PVT LTD 12.5MG; 20MG

A208847 001 Sep 17, 2019 May CMFD

@ 12.5MG; 20MG

A208847 001 Sep 17, 2019 Mar DISC

AB 12.5MG; 40MG

A208847 003 Sep 17, 2019 May CMFD

@ 12.5MG; 40MG

A208847 003 Sep 17, 2019 Mar DISC

AB 25MG; 40MG

A208847 002 Sep 17, 2019 May CMFD

@ 25MG; 40MG

A208847 002 Sep 17, 2019 Mar DISC

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

ALDACTAZIDE

AB + PFIZER 25MG; 25MG

N012616 004 Dec 30, 1982 Jul CAHN

+! 50MG; 50MG

N012616 005 Dec 30, 1982 Jul CAHN

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

@ MACLEODS PHARMS LTD 12.5MG; 40MG

A204169 001 Nov 02, 2015 May DISC

@ 12.5MG; 80MG

A204169 002 Nov 02, 2015 May DISC

@ 25MG; 80MG

A204169 003 Nov 02, 2015 May DISC

@ MYLAN 12.5MG; 40MG

A091648 001 Feb 25, 2014 Apr DISC

@ 12.5MG; 80MG

A091648 002 Feb 25, 2014 Apr DISC

@ 25MG; 80MG

A091648 003 Feb 25, 2014 Apr DISC

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB CADILA 25MG; 37.5MG

A208358 001 Feb 11, 2019 Feb CAHN

@ DURAMED PHARMS BARR 25MG; 37.5MG

A075052 001 Jun 18, 1999 Mar DISC

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

@ PLIVA 25MG; 37.5MG

A074026 001 Apr 26, 1996 Mar DISC

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

HYDROCODONE BITARTRATE

AB ALVOGEN 10MG

A206986 001 Jan 21, 2020 Jan NFTG

AB 15MG

A206986 002 Jan 21, 2020 Jan NFTG

AB 20MG

A206986 003 Jan 21, 2020 Jan NFTG

AB 30MG

A206986 004 Jan 21, 2020 Jan NFTG

AB 40MG

A206986 005 Jan 21, 2020 Jan NFTG

AB 50MG

A206986 006 Jan 21, 2020 Jan NFTG

CAPSULE, EXTENDED RELEASE;ORAL
ZOHYDRO ER

AB	+	!	PERSION	10MG	N202880	001	Oct 25, 2013	Jan	CFTG
AB	+			15MG	N202880	002	Oct 25, 2013	Jan	CFTG
AB	+			20MG	N202880	003	Oct 25, 2013	Jan	CFTG
AB	+			30MG	N202880	004	Oct 25, 2013	Jan	CFTG
AB	+			40MG	N202880	005	Oct 25, 2013	Jan	CFTG
AB	+			50MG	N202880	006	Oct 25, 2013	Jan	CFTG

HYDROCORTISONE

ENEMA;RECTAL

HYDROCORTISONE

@ TEVA PHARMS 100MG/60ML

A074171 001 May 27, 1994 Mar DISC

LOTION;TOPICAL

HYDROCORTISONE

@ FOUGERA PHARMS 2.5%

A040351 001 Jul 25, 2000 Apr DISC

STIE-CORT

AT ! PERRIGO CO 2.5%

A089074 001 Nov 26, 1985 Apr CHRS

OINTMENT;TOPICAL

HYDROCORTISONE

@ ACTAVIS MID ATLANTIC 1%

A087796 001 Oct 13, 1982 Mar DISC

TABLET;ORAL

HYDROCORTISONE

AB STRIDES PHARMA 5MG

A207029 001 Apr 27, 2017 Feb CAHN

AB 10MG

A207029 002 Apr 27, 2017 Feb CAHN

AB 20MG

A207029 003 Apr 27, 2017 Feb CAHN

>D> AB VINTAGE 5MG

A040761 001 Jul 16, 2007 Aug DISC

>A> @ 5MG

A040761 001 Jul 16, 2007 Aug DISC

>D> AB 10MG

A040761 002 Jul 16, 2007 Aug DISC

>A> @ 10MG

A040761 002 Jul 16, 2007 Aug DISC

>D> AB 20MG

A040761 003 Jul 16, 2007 Aug DISC

>A> @ 20MG

A040761 003 Jul 16, 2007 Aug DISC

>A> HYDROCORTISONE ACETATE

>A> CREAM;TOPICAL

>A> CARMOL HC

>A> @ FOUGERA PHARMS 1%

A080505 001 Aug CAIN

HYDROCORTISONE ACETATE

@ IMPERIUM 2.5%

A040259 001 Jul 29, 1999 Jun CAHN

>A> U-CORT

>A> TARO 1%

A089472 001 Jun 13, 1988 Aug CAIN

>D> HYDROCORTISONE ACETATE; UREA

>D> CREAM;TOPICAL

>D> CARMOL HC

>D> @ FOUGERA PHARMS 1%;10%

A080505 001 Aug CAIN

>D> U-CORT

>D> TARO 1%;10%

A089472 001 Jun 13, 1988 Aug CAIN

HYDROCORTISONE VALERATE

OINTMENT;TOPICAL

HYDROCORTISONE VALERATE

AB COSETTE 0.2%

A211764 001 Mar 04, 2020 Feb NEWA

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

DILAUDID

+! FRESENIUS KABI USA 0.2MG/ML

N019034 006 Jan 16, 2020 Jan NEWA

HYDROMORPHONE HYDROCHLORIDE

@ BARR 10MG/ML

A076444 001 Apr 25, 2003 Mar DISC

SOLUTION;ORAL

HYDROMORPHONE HYDROCHLORIDE

AA LANNETT CO INC 5MG/5ML

A207108 001 Apr 22, 2020 Apr NEWA

TABLET;ORAL

HYDROMORPHONE HYDROCHLORIDE

AB NOSTRUM LABS INC 8MG

A076723 001 Oct 18, 2005 Feb CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB	ACCORD HLTHCARE	200MG	A213342	001	Apr 07, 2020	Mar NEWA
AB	HAVIX	200MG	A212902	001	May 14, 2020	May NEWA
AB	LAURUS LABS LTD	200MG	A210959	001	Jan 15, 2019	Mar CMFD
AB	LUPIN LTD	200MG	A210543	001	Jul 06, 2018	Mar CMFD

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

HYDROXYPROGESTERONE CAPROATE

	@ AM REGENT	1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Feb DISC
AP1		1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Jan CMS1

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

AB	LEADING PHARMA LLC	500MG	A213438	001	Apr 08, 2020	Mar NEWA
----	--------------------	-------	---------	-----	--------------	----------

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

	@ VINTAGE PHARMS	10MG/5ML	A040391	001	Apr 10, 2002	May DISC
--	------------------	----------	---------	-----	--------------	----------

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

	@ AUROBINDO PHARMA LTD	10MG	A087871	002	Dec 20, 1982	May CAHN
	@	25MG	A087871	003	Dec 20, 1982	May CAHN
	@	50MG	A087871	001	Dec 20, 1982	May CAHN
>D> AB	NUVO PHARM	10MG	A207120	001	Mar 29, 2017	Aug CMS1
>A> AB		10MG	A207120	001	Mar 29, 2017	Aug CMS1
>D> AB		50MG	A207122	001	Mar 29, 2017	Aug CMS1
>A> AB		50MG	A207122	001	Mar 29, 2017	Aug CMS1

HYDROXYZINE PAMOATE

CAPSULE; ORAL

VISTARIL

AB	+	PFIZER	EQ 25MG HYDROCHLORIDE	N011459	002	Jul CMFD
AB	+		EQ 50MG HYDROCHLORIDE	N011459	004	Jul CMFD

IBUPROFEN

TABLET; ORAL

IBUPROFEN

AB	AUROBINDO PHARMA LTD	400MG	A213794	001	May 08, 2020	Apr NEWA
AB		600MG	A213794	002	May 08, 2020	Apr NEWA
AB		800MG	A213794	003	May 08, 2020	Apr NEWA

IBUPROFEN LYISINE

INJECTABLE; INTRAVENOUS

IBUPROFEN LYISINE

AP	XGEN PHARMS	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016	Feb CAHN
----	-------------	------------------------------------	---------	-----	--------------	----------

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

COMBUNOX

	+ @ FOREST LABS	400MG; 5MG	N021378	001	Nov 26, 2004	Apr CRLD
	OXYCODONE HYDROCHLORIDE AND IBUPROFEN					
	ACTAVIS ELIZABETH	400MG; 5MG	A078769	001	Jan 04, 2008	Apr CTEC
	@ BARR LABS INC	400MG; 5MG	A078316	001	Nov 29, 2007	Apr DISC

ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS

ICATIBANT ACETATE

AP	CIPLA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A212446	001	Jul 13, 2020	Jul NEWA
AP	FRESENIUS KABI USA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A208317	001	Jun 18, 2020	Jun NEWA
AP	JIANGSU HANSO PHARM	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A211021	001	Mar 09, 2020	Feb NEWA
>A> AP	SLAYBACK PHARMA LLC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A211501	001	Sep 01, 2020	Aug NEWA

ICOSAPENT ETHYL

CAPSULE;ORAL

ICOSAPENT ETHYL

AB	DR REDDYS	1GM	A209499	001	Aug 07, 2020	Jul NEWA
AB	HIKMA	1GM	A209457	001	May 21, 2020	May NFTG
VASCEPA						
AB	+! AMARIN PHARMS	1GM	N202057	001	Jul 26, 2012	May CFTG

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

AB	EUGIA PHARMA	EQ 100MG BASE	A212773	001	Jul 23, 2020	Jul NEWA
AB		EQ 400MG BASE	A212773	002	Jul 23, 2020	Jul NEWA
AB	ZYDUS PHARMS	EQ 100MG BASE	A210658	001	Apr 08, 2020	Mar NEWA
AB		EQ 400MG BASE	A210658	002	Apr 08, 2020	Mar NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL

IMIPRAMINE HYDROCHLORIDE

AB	OXFORD PHARMS	10MG	A040751	003	Feb 28, 2008	Apr CMFD
AB		25MG	A040751	002	Feb 28, 2008	Apr CMFD
AB		50MG	A040751	001	Feb 28, 2008	Apr CMFD

INDACATEROL MALEATE

POWDER;INHALATION

ARCAPTA NEOHALER

	+ @ NOVARTIS	EQ 75MCG BASE	N022383	001	Jul 01, 2011	Mar CAHN
	+ @ SUNOVION PHARMS INC	EQ 75MCG BASE	N022383	001	Jul 01, 2011	Mar DISC

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

AB	ANI PHARMS INC	1.25MG	A075201	001	Dec 04, 1998	Jan CAHN
AB		2.5MG	A075201	002	Dec 04, 1998	Jan CAHN

INDINAVIR SULFATE

CAPSULE;ORAL

CRIXIVAN

	+ @ MERCK SHARP DOHME	EQ 200MG BASE	N020685	003	Mar 13, 1996	Mar DISC
>D>	+!	EQ 400MG BASE	N020685	001	Mar 13, 1996	Aug DISC
>A>	+ @	EQ 400MG BASE	N020685	001	Mar 13, 1996	Aug DISC

INDOMETHACIN

CAPSULE;ORAL

INDOMETHACIN

	@ HERITAGE	25MG	N018851	001	May 18, 1984	Jul DISC
AB		25MG	N018851	001	May 18, 1984	Jan CAHN
	@	50MG	N018851	002	May 18, 1984	Jul DISC
AB		50MG	N018851	002	May 18, 1984	Jan CAHN
	@ HERITAGE PHARMA	25MG	A070719	001	Feb 12, 1986	Apr DISC
	@	50MG	A070756	001	Feb 12, 1986	Mar DISC

CAPSULE, EXTENDED RELEASE;ORAL

INDOMETHACIN

	@ MYLAN	75MG	A202139	001	Mar 20, 2014	May DISC
SUPPOSITORY;RECTAL						
INDOMETHACIN						
!	COSETTE	50MG	A073314	001	Aug 31, 1992	Jul CAHN

INGENOL MEBUTATE

GEL;TOPICAL

INGENOL MEBUTATE

	@ PERRIGO UK FINCO	0.015%	A209018	001	Jan 07, 2019	Jun DISC
	@	0.05%	A209019	001	Jan 09, 2019	Jun DISC
PICATO						
	+! LEO LABS	0.015%	N202833	001	Jan 23, 2012	Jun CTEC
	+!	0.05%	N202833	002	Jan 23, 2012	Jun CTEC

IPRATROPIUM BROMIDE

	SOLUTION; INHALATION						
	IPRATROPIUM BROMIDE						
	@ WATSON LABS	0.02%	A076291	001	May 09, 2005	Apr	DISC
	SPRAY, METERED; NASAL						
	IPRATROPIUM BROMIDE						
AB	APOTEX INC	0.021MG/SPRAY	A076156	001	Apr 18, 2003	Jan	CMFD

IRBESARTAN

	TABLET; ORAL						
	IRBESARTAN						
	@ HIKMA	75MG	A090201	001	Oct 15, 2012	Feb	DISC
	@	150MG	A090201	002	Oct 15, 2012	Feb	DISC
	@	300MG	A090201	003	Oct 15, 2012	Feb	DISC

IRINOTECAN HYDROCHLORIDE

	INJECTABLE; INJECTION						
	IRINOTECAN HYDROCHLORIDE						
	@ CIPLA LTD	40MG/2ML (20MG/ML)	A077219	001	Feb 20, 2008	Apr	DISC
	@	100MG/5ML (20MG/ML)	A077219	002	Feb 20, 2008	Apr	DISC
	@ PLIVA LACHEMA	40MG/2ML (20MG/ML)	A078122	001	Oct 31, 2008	Apr	DISC
	@	100MG/5ML (20MG/ML)	A078122	002	Oct 31, 2008	Apr	DISC

ISOSORBIDE MONONITRATE

	TABLET, EXTENDED RELEASE; ORAL						
	ISOSORBIDE MONONITRATE						
	@ HIKMA INTL PHARMS	30MG	A076813	002	Mar 30, 2006	Feb	DISC
	@	60MG	A076813	001	Jan 07, 2005	Feb	DISC

ISOTRETINOIN

	CAPSULE; ORAL						
	ABSORICA LD						
	+ @ SUN PHARM	20MG	N211913	003	Nov 05, 2019	Jun	DISC
	+ @	28MG	N211913	005	Nov 05, 2019	Jun	DISC

ITRACONAZOLE

	CAPSULE; ORAL						
	ITRACONAZOLE						
>D> AB	PII	100MG	A206410	001	Jul 02, 2019	Aug	CAHN
>A> AB	STRIDES PHARMA	100MG	A206410	001	Jul 02, 2019	Aug	CAHN
	SOLUTION; ORAL						
	ITRACONAZOLE						
>A> AA	ANNORA PHARMA	10MG/ML	A212239	001	Sep 01, 2020	Aug	NEWA
	@ APOTEX	10MG/ML	A208481	001	Aug 02, 2019	Feb	DISC

IVERMECTIN

	CREAM; TOPICAL						
	IVERMECTIN						
	@ PERRIGO UK FINCO	1%	A210225	001	Apr 13, 2020	Jul	DISC
AB		1%	A210225	001	Apr 13, 2020	Mar	NEWA
	LOTION; TOPICAL						
	IVERMECTIN						
AB	TARO	0.5%	A210720	001	May 06, 2020	Apr	NFTG
	SKLICE						
AB	+! ARBOR PHARMS LLC	0.5%	N202736	001	Feb 07, 2012	Apr	CFTG

KETOCONAZOLE

	TABLET; ORAL						
	KETOCONAZOLE						
AB	HAVIX	200MG	A075912	001	Jan 10, 2002	Apr	CMFD

KETOROLAC TROMETHAMINE

	INJECTABLE; INJECTION						
	KETOROLAC TROMETHAMINE						
>A> AP	NEPHRON	30MG/ML	A211445	001	Aug 20, 2020	Aug	NEWA
	TABLET; ORAL						
	KETOROLAC TROMETHAMINE						
AB	MYLAN	10MG	A074761	001	May 16, 1997	Feb	CHRS
	@ PLIVA	10MG	A075284	001	Jun 23, 1999	Apr	DISC
AB	! TEVA	10MG	A074754	001	May 16, 1997	Feb	CHRS

LABETALOL HYDROCHLORIDEINJECTABLE; INJECTION
NORMODYNE

+ @ SCHERING 5MG/ML

N018686 001 Aug 01, 1984 Jan CRLD

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB HERITAGE PHARMA 100MG

A074787 001 Aug 03, 1998 Feb CMFD

AB 200MG

A074787 002 Aug 03, 1998 Feb CMFD

>D> LACTITOL

>D> FOR SOLUTION; ORAL

>D> PIZENSY

>D> +! BRAINTREE LABS 10GM

N211281 001 Feb 12, 2020 Aug DISC

>A> + @ 10GM

N211281 001 Feb 12, 2020 Aug DISC

+! 10GM

N211281 001 Feb 12, 2020 Feb NEWA

+ 10GM/PACKET

N211281 001 Feb 12, 2020 Feb NEWA

LACTULOSE

SOLUTION; ORAL, RECTAL

ENULOSE

@ ACTAVIS MID ATLANTIC 10GM/15ML

A071548 001 Aug 15, 1988 Jul DISC

LACTULOSE

AA ! FRESENIUS KABI 10GM/15ML

A090502 001 Jan 25, 2012 Jul CHRS

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TEMIXYS

+! CELLTRION 300MG; 300MG

N211284 001 Nov 16, 2018 May CHRS

+ 300MG; 300MG

N211284 001 Nov 16, 2018 May CRLD

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

@ MYLAN LABS LTD 150MG; 300MG

A079079 001 Aug 12, 2019 Apr CAHN

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

>D> AB CIPLA 25MG

A077783 001 Nov 01, 2010 Aug DISC

>A> @ 25MG

A077783 001 Nov 01, 2010 Aug DISC

>D> AB 100MG

A077783 002 Nov 01, 2010 Aug DISC

>A> @ 100MG

A077783 002 Nov 01, 2010 Aug DISC

>D> AB 150MG

A077783 003 Nov 01, 2010 Aug DISC

>A> @ 150MG

A077783 003 Nov 01, 2010 Aug DISC

>D> AB 200MG

A077783 004 Nov 01, 2010 Aug DISC

>A> @ 200MG

A077783 004 Nov 01, 2010 Aug DISC

@ MYLAN 25MG

A077420 001 Jan 27, 2009 Mar DISC

@ 100MG

A077420 002 Jan 27, 2009 Mar DISC

@ 150MG

A077420 003 Jan 27, 2009 Mar DISC

@ 200MG

A077420 004 Jan 27, 2009 Mar DISC

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

AB DR REDDYS LABS LTD 250MG

A202383 006 Sep 06, 2018 Mar NEWA

AB ZYDUS PHARMS 25MG

A207763 001 Apr 01, 2020 Mar NEWA

AB 50MG

A207763 002 Apr 01, 2020 Mar NEWA

AB 100MG

A207763 003 Apr 01, 2020 Mar NEWA

AB 200MG

A207763 004 Apr 01, 2020 Mar NEWA

AB 250MG

A207763 005 Apr 01, 2020 Mar NEWA

AB 300MG

A207763 006 Apr 01, 2020 Mar NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

AB HETERO LABS LTD III 15MG

A203083 001 May 18, 2020 May NEWA

AB 30MG

A203083 002 May 18, 2020 May NEWA

LANTHANUM CARBONATE

		POWDER; ORAL							
		FOSRENOL							
	+	TAKEDA PHARMS USA	EQ 750MG BASE	N204734	001	Sep 24, 2014	Jul	CAHN	
	+	!	EQ 1GM BASE	N204734	002	Sep 24, 2014	Jul	CAHN	
		TABLET, CHEWABLE; ORAL							
		FOSRENOL							
	@	TAKEDA PHARMS USA	EQ 250MG BASE	N021468	001	Oct 26, 2004	Jul	CAHN	
AB	+		EQ 500MG BASE	N021468	002	Oct 26, 2004	Jul	CAHN	
AB	+		EQ 750MG BASE	N021468	003	Nov 23, 2005	Jul	CAHN	
AB	+	!	EQ 1GM BASE	N021468	004	Nov 23, 2005	Jul	CAHN	

LASMIDITAN SUCCINATE

		TABLET; ORAL							
		REYVOW							
	+	ELI LILLY AND CO	50MG	N211280	001	Jan 31, 2020	Jan	NEWA	
	+	!	100MG	N211280	002	Jan 31, 2020	Jan	NEWA	

LATANOPROST

		SOLUTION/DROPS; OPHTHALMIC							
		LATANOPROST							
	@	AUROBINDO PHARMA LTD	0.005%	A206519	001	Sep 03, 2019	Mar	DISC	
		XALATAN							
AT	+	!	UPJOHN	N020597	001	Jun 05, 1996	Jun	CAHN	

LEFLUNOMIDE

		TABLET; ORAL							
		LEFLUNOMIDE							
	@	BARR	10MG	A077083	001	Sep 13, 2005	Apr	DISC	
	@		20MG	A077083	002	Sep 13, 2005	Apr	DISC	
>D>	@	FOSUN PHARMA	10MG	A077087	001	Sep 13, 2005	Aug	CMFD	
>A> AB			10MG	A077087	001	Sep 13, 2005	Aug	CMFD	
>D>	@		20MG	A077087	002	Sep 13, 2005	Aug	CMFD	
>A> AB			20MG	A077087	002	Sep 13, 2005	Aug	CMFD	
AB		LUPIN LTD	10MG	A211863	001	Feb 04, 2020	Jan	NEWA	
AB			20MG	A211863	002	Feb 04, 2020	Jan	NEWA	
	@	TEVA PHARMS	10MG	A077084	001	Sep 13, 2005	Apr	DISC	
	@		20MG	A077084	002	Sep 13, 2005	Apr	DISC	

LEMBOREXANT

		TABLET; ORAL							
		DAYVIGO							
	+	EISAI INC	5MG	N212028	001	Apr 07, 2020	Apr	NEWA	
	+	!	10MG	N212028	002	Apr 07, 2020	Apr	NEWA	

LETROZOLE

		TABLET; ORAL							
		LETROZOLE							
	@	JIANGSU HENGRUI MED	2.5MG	A202716	001	May 16, 2013	May	DISC	
	@	VINTAGE PHARMS LLC	2.5MG	A090789	001	Jun 03, 2011	Jul	DISC	

LEUCOVORIN CALCIUM

		TABLET; ORAL							
		LEUCOVORIN CALCIUM							
AB		EPIC PHARMA LLC	EQ 5MG BASE	A074544	001	Aug 28, 1997	Mar	CMFD	
AB			EQ 25MG BASE	A074544	002	Aug 28, 1997	Mar	CMFD	
AB		HIKMA	EQ 10MG BASE	A072734	001	Feb 22, 1993	Jul	CTEC	
AB			EQ 15MG BASE	A072735	001	Feb 22, 1993	Jul	CTEC	
AB		RICONPHARMA LLC	EQ 5MG BASE	A211132	001	Jul 30, 2020	Jul	NEWA	
AB			EQ 10MG BASE	A211132	002	Jul 30, 2020	Jul	NEWA	
AB			EQ 15MG BASE	A211132	003	Jul 30, 2020	Jul	NEWA	
AB			EQ 25MG BASE	A211132	004	Jul 30, 2020	Jul	NEWA	

LEUPROLIDE ACETATE

		INJECTABLE; INJECTION							
		LUPRON DEPOT-PED KIT							
	+	@ ABBVIE ENDOCRINE INC	3.75MG/VIAL, 7.5MG/VIAL	N020263	003	Apr 16, 1993	May	CTNA	
	+	@	7.5MG/VIAL, 7.5MG/VIAL	N020263	004	Apr 16, 1993	May	CTNA	
	+	!	7.5MG/VIAL	N020263	002	Apr 16, 1993	May	CTNA	
	+	!	11.25MG/VIAL	N020263	005	Jan 21, 1994	May	CTNA	
	+	!	11.25MG/VIAL	N020263	007	Aug 15, 2011	May	CTNA	

INJECTABLE;INJECTION							
LUPRON DEPOT-PED KIT							
+	!	15MG/VIAL	N020263	006	Jan 21, 1994	May	CTNA
+	!	30MG/VIAL	N020263	008	Aug 15, 2011	May	CTNA
INJECTABLE;SUBCUTANEOUS							
ELIGARD KIT							
+	!	TOLMAR THERAP 7.5MG/VIAL	N021343	001	Jan 23, 2002	May	CTNA
+	!	22.5MG/VIAL	N021379	001	Jul 24, 2002	May	CTNA
+	!	30MG/VIAL	N021488	001	Feb 13, 2003	May	CTNA
+	!	45MG/VIAL	N021731	001	Dec 14, 2004	May	CTNA
POWDER;INTRAMUSCULAR							
LUPRON DEPOT-PED KIT							
+	@	ABBVIE ENDOCRINE INC 3.75MG, 7.5MG	N020263	003	Apr 16, 1993	May	CPOT
+	@	3.75MG/VIAL, 7.5MG/VIAL	N020263	003	Apr 16, 1993	May	CDFR
+	!	7.5MG	N020263	002	Apr 16, 1993	May	CPOT
+	!	7.5MG/VIAL	N020263	002	Apr 16, 1993	May	CDFR
+	@	7.5MG, 7.5MG	N020263	004	Apr 16, 1993	May	CPOT
+	@	7.5MG/VIAL, 7.5MG/VIAL	N020263	004	Apr 16, 1993	May	CDFR
+	!	11.25MG	N020263	005	Jan 21, 1994	May	CPOT
+	!	11.25MG/VIAL	N020263	005	Jan 21, 1994	May	CDFR
+	!	11.25MG	N020263	007	Aug 15, 2011	May	CPOT
+	!	11.25MG/VIAL	N020263	007	Aug 15, 2011	May	CDFR
+	!	15MG	N020263	006	Jan 21, 1994	May	CPOT
+	!	15MG/VIAL	N020263	006	Jan 21, 1994	May	CDFR
+	!	30MG	N020263	008	Aug 15, 2011	May	CPOT
+	!	30MG/VIAL	N020263	008	Aug 15, 2011	May	CDFR
POWDER;SUBCUTANEOUS							
ELIGARD KIT							
+	!	TOLMAR THERAP 7.5MG	N021343	001	Jan 23, 2002	May	CPOT
+	!	7.5MG/VIAL	N021343	001	Jan 23, 2002	May	CDFR
+	!	22.5MG	N021379	001	Jul 24, 2002	May	CPOT
+	!	22.5MG/VIAL	N021379	001	Jul 24, 2002	May	CDFR
+	!	30MG	N021488	001	Feb 13, 2003	May	CPOT
+	!	30MG/VIAL	N021488	001	Feb 13, 2003	May	CDFR
+	!	45MG	N021731	001	Dec 14, 2004	May	CPOT
+	!	45MG/VIAL	N021731	001	Dec 14, 2004	May	CDFR
FENSOLVI KIT							
+	!	TOLMAR 45MG	N213150	001	May 01, 2020	May	NEWA
<u>LEVAMLODIPINE MALEATE</u>							
TABLET;ORAL							
CONJUPRI							
+	@	CSPC OUYI EQ 1.25MG BASE	N212895	001	Dec 19, 2019	May	DISC
<u>LEVETIRACETAM</u>							
INJECTABLE;INTRAVENOUS							
LEVETIRACETAM							
AP	@	FRESENIUS KABI USA 500MG/5ML (100MG/ML)	A090813	001	May 26, 2010	Jul	DISC
		XGEN PHARMS 500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Feb	CAHN
LEVETIRACETAM IN SODIUM CHLORIDE							
AP		NEXUS PHARMS 500MG/100ML (5MG/ML)	A213532	001	Jul 06, 2020	Jul	NEWA
AP		1000MG/100ML (10MG/ML)	A213532	002	Jul 06, 2020	Jul	NEWA
AP		1500MG/100ML (15MG/ML)	A213532	003	Jul 06, 2020	Jul	NEWA
SOLUTION;ORAL							
LEVETIRACETAM							
AA		ACI HEALTHCARE LTD 100MG/ML	A078582	001	Jan 15, 2009	Jun	CMFD
TABLET;ORAL							
LEVETIRACETAM							
AB	@	TEVA PHARMS 250MG	A078101	001	Jan 15, 2009	Apr	DISC
	@	500MG	A078101	002	Jan 15, 2009	Apr	DISC
	@	750MG	A078101	003	Jan 15, 2009	Apr	DISC
	@	1GM	A078101	004	Jan 15, 2009	Apr	DISC
AB		VIWIT PHARM 250MG	A078869	001	Mar 13, 2009	Mar	CAHN
AB		250MG	A078869	001	Mar 13, 2009	Mar	CAHN
AB		500MG	A078869	002	Mar 13, 2009	Mar	CAHN
AB		500MG	A078869	002	Mar 13, 2009	Mar	CAHN
AB		750MG	A078869	003	Mar 13, 2009	Mar	CAHN
AB		750MG	A078869	003	Mar 13, 2009	Mar	CAHN
AB		1GM	A078869	004	Mar 13, 2009	Mar	CAHN
AB		1GM	A078869	004	Mar 13, 2009	Mar	CAHN
AB		VKT PHARMA 250MG	A090767	001	Jul 28, 2010	Jul	CAHN
AB		500MG	A090767	002	Jul 28, 2010	Jul	CAHN

TABLET;ORAL

LEVETIRACETAM						
AB		750MG	A090767	003	Jul 28, 2010	Jul CAHN
AB		1GM	A090767	004	Jul 28, 2010	Jul CAHN
AB	ZHEJIANG JINGXIN	250MG	A091491	001	Dec 14, 2010	Jun CAHN
AB		500MG	A091491	002	Dec 14, 2010	Jun CAHN
AB		750MG	A091491	003	Dec 14, 2010	Jun CAHN
AB		1GM	A091491	004	Dec 14, 2010	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM						
	@ ACTAVIS ELIZABETH	500MG	A091557	001	Sep 12, 2011	Apr DISC
	@	750MG	A091557	002	Sep 12, 2011	Apr DISC
AB	OVERSEAS	750MG	A212688	001	Jun 11, 2020	Jun NEWA
	@ TEVA PHARMS	500MG	A091430	001	Sep 12, 2011	Apr DISC
	@	750MG	A091430	002	Sep 12, 2011	Apr DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE						
	@ APOTEX	2.5MG/5ML	A202915	001	Aug 21, 2014	Feb DISC

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE						
	@ APOTEX	5MG	A203027	001	Feb 13, 2015	Feb DISC

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN						
AP	GLAND PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)	A205540	001	Apr 22, 2020	Apr NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A205540	002	Apr 22, 2020	Apr NEWA

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN						
	@ RUBICON	0.5%	A078282	001	Dec 20, 2010	Jul CAHN

LEVOLEUCOVORIN CALCIUM

POWDER;INTRAVENOUS

LEVOLEUCOVORIN CALCIUM						
>D> AP	AMNEAL	EQ 50MG BASE/VIAL	A207547	001	Feb 13, 2017	Aug DISC
>A>	@	EQ 50MG BASE/VIAL	A207547	001	Feb 13, 2017	Aug DISC

SOLUTION;INTRAVENOUS

LEVOLEUCOVORIN CALCIUM						
AP	! INGENUS PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210623	001	May 03, 2018	Apr CHRS
AP	!	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210623	002	May 03, 2018	Apr CHRS
	@ SANDOZ INC	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Apr DISC

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE						
AB	NOVITIUM PHARMA	2MG	A213479	001	Jul 01, 2020	Jun NEWA

LEVOTHYROXINE SODIUM

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM						
AP	DR REDDYS	100MCG/VIAL	A208837	001	Mar 27, 2020	Mar NEWA

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

THYRO-TABS						
AB2, +	ALVOGEN	0.3MG	N021116	009	Oct 24, 2002	Jan CHRS
AB4						

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE						
>A>	@ GENEYORK PHARMS	5%	A212486	001	Oct 17, 2019	Aug CAHN
AT	MACLEODS PHARMS LTD	5%	A211697	001	Mar 16, 2020	Mar NEWA
>D>	@ SUNGEN PHARMA	5%	A212486	001	Oct 17, 2019	Aug CAHN
	@	5%	A212486	001	Oct 17, 2019	Mar DISC
AT		5%	A212486	001	Oct 17, 2019	Mar CPOT

OINTMENT; TOPICAL							
LIDOCAINE							
		@ TEVA PHARMS USA	5%	A210256	001	Jan 16, 2018	Apr DISC
PATCH; TOPICAL							
LIDOCAINE							
>A>	AB	AMNEAL	5%	A206463	001	Aug 24, 2020	Aug NEWA
	AB	RHODES PHARMS	5%	A209190	001	Apr 30, 2020	Apr NEWA
<u>LIDOCAINE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
LIDOCAINE HYDROCHLORIDE							
	AP	HUONS	1%	A212821	001	May 07, 2020	Apr NEWA
	AP	WEST-WARD PHARMS INT	1%	A080407	001		Mar CMFD
	AP		2%	A080407	002		Mar CMFD
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE							
	AP	WEST-WARD PHARMS INT	1%	A084625	001		Mar CMFD
	AP		2%	A084625	002		Mar CMFD
SOLUTION; ORAL							
LIDOCAINE HYDROCHLORIDE							
>D>	AT	HI TECH PHARMA	2%	A040014	001	Jul 10, 1995	Aug CHRS
>A>	AT	!	2%	A040014	001	Jul 10, 1995	Aug CHRS
LIDOCAINE HYDROCHLORIDE VISCOUS							
>D>	AT	! LANNETT CO INC	2%	A040708	001	Feb 27, 2007	Aug DISC
>A>		@	2%	A040708	001	Feb 27, 2007	Aug DISC
SOLUTION; TOPICAL							
LIDOCAINE HYDROCHLORIDE							
	AT	WOCKHARDT BIO AG	4%	A087881	001	Nov 18, 1982	Jun CMFD
<u>LINCOMYCIN HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
LINCOMYCIN							
	AP	XGEN PHARMS	EQ 300MG BASE/ML	A201746	001	Jun 04, 2015	Feb CAHN
<u>LINEZOLID</u>							
TABLET; ORAL							
LINEZOLID							
		@ GATE PHARMS	600MG	A091210	001	Feb 05, 2016	Apr DISC
		@ TEVA PHARMS USA	600MG	A078061	001	May 18, 2015	May DISC
<u>LIOTHYRONINE SODIUM</u>							
INJECTABLE; INJECTION							
LIOTHYRONINE SODIUM							
	AP	XGEN PHARMS	EQ 0.01MG BASE/ML	A076923	001	Aug 17, 2005	Feb CAHN
TABLET; ORAL							
LIOTHYRONINE SODIUM							
	AB	SUN PHARM	EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Jan CMFD
	AB		EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Jan CMFD
	AB		EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Jan CMFD
	AB	TEVA PHARMS USA	EQ 0.005MG BASE	A211510	001	Oct 26, 2018	Jul CMFD
	AB		EQ 0.025MG BASE	A211510	002	Oct 26, 2018	Jul CMFD
	AB		EQ 0.05MG BASE	A211510	003	Oct 26, 2018	Jul CMFD
<u>LISDEXAMFETAMINE DIMESYLATE</u>							
CAPSULE; ORAL							
VYVANSE							
	+	TAKEDA PHARMS USA	10MG	N021977	007	Oct 30, 2014	Jul CAHN
	+		20MG	N021977	004	Dec 10, 2007	Jul CAHN
	+		30MG	N021977	001	Feb 23, 2007	Jul CAHN
	+		40MG	N021977	005	Dec 10, 2007	Jul CAHN
	+		50MG	N021977	002	Feb 23, 2007	Jul CAHN
	+		60MG	N021977	006	Dec 10, 2007	Jul CAHN
	+	!	70MG	N021977	003	Feb 23, 2007	Jul CAHN
TABLET, CHEWABLE; ORAL							
VYVANSE							
	+	TAKEDA PHARMS USA	10MG	N208510	001	Jan 28, 2017	Jul CAHN
	+		20MG	N208510	002	Jan 28, 2017	Jul CAHN
	+		30MG	N208510	003	Jan 28, 2017	Jul CAHN
	+		40MG	N208510	004	Jan 28, 2017	Jul CAHN
	+		50MG	N208510	005	Jan 28, 2017	Jul CAHN
	+	!	60MG	N208510	006	Jan 28, 2017	Jul CAHN

LISINOPRIL

SOLUTION;ORAL							
QBRELIS							
+	!	AZURITY	1MG/ML	N208401	001	Jul 29, 2016	May CAHN
TABLET;ORAL							
LISINOPRIL							
	@	ASCENT PHARMS INC	2.5MG	A075903	001	Jul 01, 2002	Jul CAHN
	@		5MG	A075903	002	Jul 01, 2002	Jul CAHN
	@		10MG	A075903	003	Jul 01, 2002	Jul CAHN
	@		20MG	A075903	004	Jul 01, 2002	Jul CAHN
	@		30MG	A075903	005	Jul 01, 2002	Jul CAHN
	@		40MG	A075903	006	Jul 01, 2002	Jul CAHN
AB		COREPHARMA	2.5MG	A076102	001	Sep 30, 2002	Feb CAHN
AB			5MG	A076102	002	Sep 30, 2002	Feb CAHN
AB			10MG	A076102	003	Sep 30, 2002	Feb CAHN
AB			20MG	A076102	004	Sep 30, 2002	Feb CAHN
AB			30MG	A076102	005	Sep 30, 2002	Feb CAHN
AB			40MG	A076102	006	Sep 30, 2002	Feb CAHN

LITHIUM CARBONATE

CAPSULE;ORAL							
LITHIUM CARBONATE							
AB	+	HIKMA	150MG	N017812	002	Jan 28, 1987	Jan CAHN
AB	+		300MG	N017812	001		Jan CAHN
AB	+	!	600MG	N017812	003	Jan 28, 1987	Jan CAHN
	@	MYLAN	150MG	A076243	002	Feb 24, 2003	Jan DISC
	@		300MG	A076243	001	Jun 27, 2002	Jan DISC

LITHIUM CITRATE

SYRUP;ORAL							
LITHIUM CITRATE							
AA	+	!	HIKMA	EQ 300MG CARBONATE/5ML	N018421	001	Jan CAHN

LOFEXIDINE HYDROCHLORIDE

TABLET;ORAL							
LUCEMYRA							
+	!	USWM	EQ 0.18MG BASE	N209229	001	May 16, 2018	Jun CAHN

LOMITAPIDE MESYLATE

CAPSULE;ORAL							
JUXTAPID							
+		AMRYT	EQ 5MG BASE	N203858	001	Dec 21, 2012	May CAHN
+			EQ 10MG BASE	N203858	002	Dec 21, 2012	May CAHN
+			EQ 20MG BASE	N203858	003	Dec 21, 2012	May CAHN
+			EQ 30MG BASE	N203858	004	Apr 23, 2015	May CAHN

LORAZEPAM

TABLET;ORAL							
LORAZEPAM							
	@	MYLAN	0.5MG	A077657	001	Mar 16, 2006	Mar DISC
	@		1MG	A077657	002	Mar 16, 2006	Mar DISC
	@		2MG	A077657	003	Mar 16, 2006	Mar DISC

LORCASERIN HYDROCHLORIDE

TABLET;ORAL							
BELVIQ							
+	@	EISAI INC	10MG	N022529	001	Jun 27, 2012	Feb DISC
TABLET, EXTENDED RELEASE;ORAL							
BELVIQ XR							
+	@	EISAI INC	20MG	N208524	001	Jul 15, 2016	Feb DISC

LOSARTAN POTASSIUM

TABLET;ORAL							
LOSARTAN POTASSIUM							
	@	HIKMA	25MG	A077459	001	Oct 06, 2010	Feb DISC
	@		50MG	A077459	002	Oct 06, 2010	Feb DISC
	@		100MG	A077459	003	Oct 06, 2010	Feb DISC

LOVASTATINTABLET; ORAL
LOVASTATIN

AB	COREPHARMA	10MG	A077748	001	Feb 28, 2007	Feb CAHN
AB		20MG	A077748	002	Feb 28, 2007	Feb CAHN
AB		40MG	A077748	003	Feb 28, 2007	Feb CAHN

LURBINECTEDINPOWDER; INTRAVENOUS
ZEPZELCA

+!	JAZZ	4MG/VIAL	N213702	001	Jun 15, 2020	Jun NEWA
----	------	----------	---------	-----	--------------	----------

MAFENIDE ACETATECREAM; TOPICAL
SULFAMYLOX

+!	RISING	EQ 85MG BASE/GM	N016763	001		May CAHN
----	--------	-----------------	---------	-----	--	----------

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE CORP	1GM/100ML	A211965	001	Aug 11, 2020	Jul NEWA
	MAGNESIUM SULFATE IN PLASTIC CONTAINER					
AP	BAXTER HLTHCARE CORP	2GM/50ML (40MG/ML)	A211966	001	Jun 01, 2020	May NEWA
AP		4GM/50ML (80MG/ML)	A211966	002	Jun 01, 2020	May NEWA
AP		4GM/100ML (40MG/ML)	A211966	003	Jun 01, 2020	May NEWA
AP	GLAND PHARMA LTD	2GM/50ML (40MG/ML)	A213917	001	Jul 10, 2020	Jul NEWA
AP		4GM/100ML (40MG/ML)	A213917	002	Jul 10, 2020	Jul NEWA

MAZINDOLTABLET; ORAL
SANOREX

+	@ NOVARTIS	1MG	N017247	001		Jan CAHN
+	@	2MG	N017247	002		Jan CAHN

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

MECAMYLAMINE HYDROCHLORIDE

>A>	!	LGM PHARMA	2.5MG	A204054	001	Mar 19, 2013	Aug CAHN
>D>	!	NEXGEN PHARMA	2.5MG	A204054	001	Mar 19, 2013	Aug CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

>A>	AA	ANNORA PHARMA	25MG	A087128	001		Aug CAHN
>D>	AA	AUREX	25MG	A087128	001		Aug CAHN
	AA	INDICUS PHARMA	50MG	A205136	003	Feb 22, 2019	Jun CTEC
		@ MYLAN PHARMS INC	12.5MG	A202640	001	Sep 17, 2012	Jan DISC
		@	25MG	A202640	002	Sep 17, 2012	Jan DISC
	AA	ZYDUS	12.5MG	A213957	001	Jun 23, 2020	Jun NEWA
	AA		25MG	A213957	002	Jun 23, 2020	Jun NEWA

MEFENAMIC ACIDCAPSULE; ORAL
PONSTEL

AB	+!	AVION PHARMS	250MG	N015034	003		Jul CAHN
----	----	--------------	-------	---------	-----	--	----------

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

!	BARR	250MG	A076392	001	Dec 29, 2003	Feb CTEC
@	HIKMA	250MG	A076523	001	Oct 01, 2004	Feb DISC

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

	@	HIKMA	40MG/ML	A075997	001	Feb 15, 2002	Feb DISC
AB	!	PAR PHARM	40MG/ML	A075671	001	Jul 25, 2001	Feb CHRS
	@	TEVA PHARMS	40MG/ML	A075681	001	May 05, 2003	Apr DISC

MELOXICAM

CAPSULE; ORAL							
MELOXICAM							
AB	LUPIN LTD	5MG	A209487	001	Jun 01, 2020	May	NFTG
AB		10MG	A209487	002	Jun 01, 2020	May	NFTG
VIVLODEX							
AB	+ ZYLA	5MG	N207233	001	Oct 22, 2015	May	CFTG
AB	+!	10MG	N207233	002	Oct 22, 2015	May	CFTG
SOLUTION; INTRAVENOUS							
ANJESO							
	+! BAUDAX	30MG/ML (30MG/ML)	N210583	001	Feb 20, 2020	Feb	NEWA
TABLET, ORALLY DISINTEGRATING; ORAL							
QMIIZ ODT							
	+ @ TERSERA THERAPS LLC	7.5MG	N211210	001	Oct 19, 2018	Apr	DISC
	+ @	15MG	N211210	002	Oct 19, 2018	Apr	DISC

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION							
MELPHALAN HYDROCHLORIDE							
	@ ALVOGEN INC	EQ 50MG BASE/VIAL	A204817	001	May 17, 2019	May	DISC
AP	BPI LABS LLC	EQ 50MG BASE/VIAL	A209197	001	May 08, 2020	Apr	NEWA
AP	INGENUS PHARMS LLC	EQ 50MG BASE/VIAL	A210947	001	Feb 18, 2020	Feb	NEWA
	@ PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A204773	001	Aug 22, 2016	Feb	DISC
	@ TWI PHARMS	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Jan	DISC
	@ USWM	EQ 50MG BASE/VIAL	A207032	001	May 03, 2019	Jun	CAHN
POWDER; INTRAVENOUS							
EVOMELA							
	+! ACROTECH	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Mar	CTEC
AP	+!	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Feb	CFTG
MELPHALAN HYDROCHLORIDE							
	@ ACTAVIS LLC	EQ 50MG BASE/VIAL	A209323	001	Mar 06, 2020	Mar	DISC
AP		EQ 50MG BASE/VIAL	A209323	001	Mar 06, 2020	Feb	NFTG

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL							
MEMANTINE HYDROCHLORIDE							
AB	ANI PHARMS INC	7MG	A205365	001	Feb 28, 2020	Feb	NEWA
AB		14MG	A205365	002	Feb 28, 2020	Feb	NEWA
AB		21MG	A205365	003	Feb 28, 2020	Feb	NEWA
AB		28MG	A205365	004	Feb 28, 2020	Feb	NEWA
SOLUTION; ORAL							
MEMANTINE HYDROCHLORIDE							
>A> AA	MEDLEY PHARMS	2MG/ML	A210319	001	Aug 31, 2020	Aug	NEWA
TABLET; ORAL							
MEMANTINE HYDROCHLORIDE							
	@ CHARTWELL	5MG	A090244	001	Jul 11, 2018	Mar	CAHN
	@	10MG	A090244	002	Jul 11, 2018	Mar	CAHN
AB	HIKMA	5MG	A208173	001	Feb 28, 2020	Feb	NEWA
AB		10MG	A208173	002	Feb 28, 2020	Feb	NEWA
AB	NINGBO	5MG	A212947	001	Apr 03, 2020	Apr	CAHN
AB		5MG	A212947	001	Apr 03, 2020	Mar	NEWA
AB		10MG	A212947	002	Apr 03, 2020	Apr	CAHN
AB		10MG	A212947	002	Apr 03, 2020	Mar	NEWA
	@ TEVA PHARMS	5MG	A090052	001	Oct 25, 2011	Apr	DISC
	@	10MG	A090052	002	Oct 25, 2011	Apr	DISC

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL							
MEPERIDINE HYDROCHLORIDE							
AA	! EPIC PHARMA	50MG	A040331	001	May 28, 1999	Feb	CHRS
AA	!	100MG	A040331	002	May 28, 1999	Feb	CHRS
	@ HIKMA	50MG	A040110	001	Mar 12, 1997	Feb	DISC
	@	100MG	A040110	002	Mar 12, 1997	Feb	DISC

MEPROBAMATE

TABLET; ORAL							
MEPROBAMATE							
>A>	@ ACELLA	400MG	A084153	001		Aug	CAHN
>D>	@ IVC INDS	400MG	A084153	001		Aug	CAHN

MESALAMINESUPPOSITORY;RECTAL
MESALAMINE

>A>	AB	ACTAVIS MID ATLANTIC	1GM	A205654	001	Aug 14, 2020	Aug NEWA
	AB	ANNORA PHARMA	1GM	A213377	001	Mar 19, 2020	Mar NEWA
	AB	ZYDUS PHARMS	1GM	A208953	001	Feb 12, 2020	Jan NEWA

METAXALONETABLET;ORAL
METAXALONE

	AB	MOUNTAIN	400MG	A040486	001	Feb 27, 2015	Mar CTEC
	AB	RISING	800MG	A208774	001	Sep 24, 2018	Jul CAHN
	AB	SCIEGEN PHARMS INC	400MG	A207466	002	Mar 13, 2020	Mar NEWA

METFORMIN HYDROCHLORIDESOLUTION;ORAL
METFORMIN HYDROCHLORIDE

	AB	SAPTALIS PHARMS	500MG/5ML	A211309	001	Mar 03, 2020	Feb NFTG
		RIOMET					
	AB	+! RANBAXY	500MG/5ML	N021591	001	Sep 11, 2003	Feb CFTG
		+!	500MG/5ML	N021591	001	Sep 11, 2003	Jan CAHN

TABLET;ORAL

METFORMIN HYDROCHLORIDE

		@ HERITAGE PHARMA	500MG	A075978	001	Jan 25, 2002	Mar DISC
		@	850MG	A075978	002	Jan 25, 2002	Mar DISC
		@	1GM	A075978	003	Nov 05, 2002	Mar DISC
		@ MACLEODS PHARMS LTD	500MG	A205330	001	Oct 31, 2017	May DISC
		@	850MG	A205330	002	Oct 31, 2017	May DISC
		@	1GM	A205330	003	Oct 31, 2017	May DISC
		@ MYLAN	500MG	A075976	001	Jan 24, 2002	Jan DISC
		@	850MG	A075976	002	Jan 24, 2002	Jan DISC
		@	1GM	A075976	003	Jan 24, 2002	Jan DISC

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

	AB2	AJANTA PHARMA LTD	500MG	A213651	001	Apr 09, 2020	Mar NEWA
	AB2		1GM	A213651	002	Apr 09, 2020	Mar NEWA
		@ APOTEX	750MG	A076706	002	Dec 29, 2005	May DISC
		@ BARR	750MG	A076863	001	Oct 14, 2004	Apr DISC
		@ MACLEODS PHARMS LTD	500MG	A206955	001	Dec 07, 2016	May DISC
		@	750MG	A206955	002	Dec 07, 2016	May DISC
	AB1	YICHANG HUMANWELL	500MG	A211052	001	Sep 24, 2018	Jun CMFD
	AB		750MG	A211052	002	Sep 24, 2018	Jun CMFD

METHADONE HYDROCHLORIDECONCENTRATE;ORAL
METHADONE HYDROCHLORIDE

	AA	SPECGX LLC	10MG/ML	A207368	001	Aug 22, 2019	May CAHN
--	----	------------	---------	---------	-----	--------------	----------

SOLUTION;ORAL

METHADONE HYDROCHLORIDE

	AA	SPECGX LLC	5MG/5ML	A207537	001	Oct 02, 2019	May CAHN
	AA		10MG/5ML	A207537	002	Oct 01, 2019	May CAHN

TABLET;ORAL

DOLOPHINE HYDROCHLORIDE

		+ @ HIKMA	5MG	N006134	002		Jun DISC
		+ @	10MG	N006134	010		Jun DISC

METHADONE HYDROCHLORIDE

	AA	NOSTRUM LABS INC	5MG	A210484	001	Aug 02, 2018	Mar CAHN
	AA		5MG	A210484	001	Aug 02, 2018	Mar CAHN
	AA		10MG	A210484	002	Aug 02, 2018	Mar CAHN
	AA		10MG	A210484	002	Aug 02, 2018	Mar CAHN
	AA	ROXANE	5MG	A088108	001	Mar 08, 1983	May CMFD
	AA		10MG	A088109	001	Mar 08, 1983	May CMFD
	AA	! SPECGX LLC	5MG	A040517	001	Apr 27, 2004	Jun CHRS
	AA	!	10MG	A040517	002	Apr 27, 2004	Jun CHRS
	AA	VISTAPHARM	10MG	A204166	001	Mar 16, 2020	Mar NEWA
		METHADOSE					
		@ SPECGX LLC	5MG	A040050	001	Apr 15, 1993	May DISC
		@	10MG	A040050	002	Apr 15, 1993	May DISC

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

@ BAUSCH

25MG

A207438 001 Oct 05, 2018 Jul CAHN

@

50MG

A207438 002 Oct 05, 2018 Jul CAHN

METHENAMINE HIPPURATE

TABLET; ORAL

METHENAMINE HIPPURATE

@ IMPAX LABS INC

1GM

A076411 001 Jun 20, 2003 Jul DISC

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA

AUROBINDO PHARMA LTD

750MG

A213967 001 Aug 12, 2020 Jul NEWA

@ HIKMA INTL PHARMS

500MG

A085159 001 Feb DISC

@

750MG

A085123 001 Feb DISC

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

+ @ PAR STERILE PRODUCTS

2.5GM/VIAL

N011559 002 Jul DISC

METHOTREXATE

SOLUTION; INTRAVENOUS

METHOTREXATE

>A>

+! ACCORD HLTHCARE

5GM/50ML (100MG/ML)

N214121 001 Aug 24, 2020 Aug NEWA

SOLUTION; SUBCUTANEOUS

>D>

REDITREX

>D>

CUMBERLAND PHARMS

7.5MG/0.3ML (7.5MG/0.3ML)

N210737 001 Nov 27, 2019 Aug DISC

>A>

@

7.5MG/0.3ML (7.5MG/0.3ML)

N210737 001 Nov 27, 2019 Aug DISC

>D>

@

10MG/0.4ML (10MG/0.4ML)

N210737 002 Nov 27, 2019 Aug DISC

>A>

@

10MG/0.4ML (10MG/0.4ML)

N210737 002 Nov 27, 2019 Aug DISC

>D>

@

12.5MG/0.5ML (12.5MG/0.5ML)

N210737 003 Nov 27, 2019 Aug DISC

>A>

@

12.5MG/0.5ML (12.5MG/0.5ML)

N210737 003 Nov 27, 2019 Aug DISC

>D>

@

15MG/0.6ML (15MG/0.6ML)

N210737 004 Nov 27, 2019 Aug DISC

>A>

@

15MG/0.6ML (15MG/0.6ML)

N210737 004 Nov 27, 2019 Aug DISC

>D>

@

17.5MG/0.7ML (17.5MG/0.7ML)

N210737 005 Nov 27, 2019 Aug DISC

>A>

@

17.5MG/0.7ML (17.5MG/0.7ML)

N210737 005 Nov 27, 2019 Aug DISC

>D>

@

20MG/0.8ML (20MG/0.8ML)

N210737 006 Nov 27, 2019 Aug DISC

>A>

@

20MG/0.8ML (20MG/0.8ML)

N210737 006 Nov 27, 2019 Aug DISC

>D>

@

22.5MG/ML (22.5MG/ML)

N210737 007 Nov 27, 2019 Aug DISC

>A>

@

22.5MG/ML (22.5MG/ML)

N210737 007 Nov 27, 2019 Aug DISC

>D>

@

25MG/1ML (25MG/1ML)

N210737 008 Nov 27, 2019 Aug DISC

>A>

@

25MG/1ML (25MG/1ML)

N210737 008 Nov 27, 2019 Aug DISC

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

@ MYLAN LABS LTD

EQ 50MG BASE/2ML (EQ 25MG BASE/ML)

A201529 001 Mar 29, 2012 Jan DISC

@

EQ 100MG BASE/4ML (EQ 25MG
BASE/ML)

A201529 002 Mar 29, 2012 Jan DISC

@

EQ 200MG BASE/8ML (EQ 25MG
BASE/ML)

A201529 003 Mar 29, 2012 Jan DISC

PHARMACHEMIE BV

EQ 100MG BASE/4ML (EQ 25MG
BASE/ML)

A040843 003 Feb 27, 2012 Jan CTEC

SOLUTION; ORAL

XATMEP

+! AZURITY

EQ 2MG BASE/ML

N208400 001 Apr 25, 2017 May CAHN

+! EQ 2.5MG BASE/ML

N208400 001 Apr 25, 2017 Jul CPOT

TABLET; ORAL

METHOTREXATE SODIUM

AB

ACCORD HLTHCARE

EQ 2.5MG BASE

A213343 001 Jan 24, 2020 Jan NEWA

+ @ DAVA PHARMS INC

EQ 2.5MG BASE

N008085 002 Mar DISC

AB

EUGIA PHARMA

EQ 2.5MG BASE

A210454 001 Jan 30, 2020 Jan NEWA

AB

!

HIKMA

EQ 2.5MG BASE

A040054 001 Aug 01, 1994 Mar CHRS

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

AA	BAYSHORE PHARMS LLC	2.5MG	A200602	001	Sep 24, 2012	Apr CTEC
AA	!	5MG	A200602	002	Sep 24, 2012	Apr CTEC
AA	BRECKENRIDGE PHARM	2.5MG	A040642	001	Dec 06, 2011	Apr CMFD
AA		5MG	A040642	002	Dec 06, 2011	Apr CMFD

METHYLDOPA

TABLET; ORAL

METHYLDOPA

@	HERITAGE PHARMA	250MG	A070098	001	Feb 20, 1986	Apr DISC
@		500MG	A070343	001	Feb 20, 1986	Apr DISC
@	WATSON LABS	500MG	A070625	001	Jun 06, 1986	Apr DISC

METHYLENE BLUE

SOLUTION; INTRAVENOUS

PROVAYBLUE

+	PROVEPHARM SAS	10MG/2ML (5MG/ML)	N204630	002	Jul 18, 2019	Jun NEWA
---	----------------	-------------------	---------	-----	--------------	----------

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHYLERGONOVINE MALEATE

AB	TULEX PHARMS INC	0.2MG	A212233	001	May 01, 2020	Apr NEWA
----	------------------	-------	---------	-----	--------------	----------

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL

COTEMPLA XR-ODT

+	NEOS THERAPS INC	8.6MG	N205489	001	Jun 19, 2017	Jul CTEC
AB	+	8.6MG	N205489	001	Jun 19, 2017	Jun CFTG
+		17.3MG	N205489	002	Jun 19, 2017	Jul CTEC
AB	+	17.3MG	N205489	002	Jun 19, 2017	Jun CFTG
+		25.9MG	N205489	003	Jun 19, 2017	Jul CTEC
AB	+	25.9MG	N205489	003	Jun 19, 2017	Jun CFTG
+		25.9MG	N205489	003	Jun 19, 2017	Jun CHRS

METHYLPHENIDATE

@	ACTAVIS ELIZABETH	8.6MG	A210924	001	Jun 19, 2020	Jul DISC
AB		8.6MG	A210924	001	Jun 19, 2020	Jun NFTG
@		17.3MG	A210924	002	Jun 19, 2020	Jul DISC
AB		17.3MG	A210924	002	Jun 19, 2020	Jun NFTG
@		25.9MG	A210924	003	Jun 19, 2020	Jul DISC
AB		25.9MG	A210924	003	Jun 19, 2020	Jun NFTG

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

@	BARR LABS INC	10MG	A079031	004	Oct 15, 2014	Apr DISC
@		20MG	A079031	001	Jul 13, 2012	Apr DISC
@		30MG	A079031	002	Jul 13, 2012	Apr DISC
@		40MG	A079031	003	Jul 13, 2012	Apr DISC

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	ALKEM LABS LTD	5MG/5ML	A211647	001	Mar 30, 2020	Mar NEWA
AA		10MG/5ML	A211647	002	Mar 30, 2020	Mar NEWA
AA	ANDA REPOSITORY	5MG/5ML	A210764	001	Apr 10, 2020	Jul CAHN
AA		10MG/5ML	A210764	002	Apr 10, 2020	Jul CAHN
AA	PATRIN PHARMA INC	5MG/5ML	A210764	001	Apr 10, 2020	Mar NEWA
AA		10MG/5ML	A210764	002	Apr 10, 2020	Mar NEWA
AA	QUAGEN	5MG/5ML	A213567	001	Jun 04, 2020	Jun NEWA
AA		10MG/5ML	A213567	002	Jun 04, 2020	Jun NEWA

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>D>	AB	BRECKENRIDGE	5MG	A207587	001	Mar 03, 2017	Aug CAHN
>D>	AB		10MG	A207587	002	Mar 03, 2017	Aug CAHN
>D>	AB		20MG	A207587	003	Mar 03, 2017	Aug CAHN
>A>	AB	NOSTRUM LABS INC	5MG	A207587	001	Mar 03, 2017	Aug CAHN
>A>	AB		10MG	A207587	002	Mar 03, 2017	Aug CAHN
>A>	AB		20MG	A207587	003	Mar 03, 2017	Aug CAHN
	AB	PRINSTON INC	5MG	A212697	001	Jul 23, 2020	Jul NEWA
	AB		10MG	A212697	002	Jul 23, 2020	Jul NEWA
	AB		20MG	A212697	003	Jul 23, 2020	Jul NEWA

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@ WATSON LABS	5MG	A040220	001	Aug 29, 1997	Apr	DISC
@	10MG	A040220	002	Aug 29, 1997	Apr	DISC
@	20MG	A040220	003	Aug 29, 1997	Apr	DISC

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	ACTAVIS LABS FL	18MG	A076772	001	Mar 22, 2018	Jul	CMFD
	@	18MG	A076772	001	Mar 22, 2018	Mar	DISC
AB		27MG	A076772	002	Mar 22, 2018	Jul	CMFD
	@	27MG	A076772	002	Mar 22, 2018	Mar	DISC
AB		36MG	A076772	003	Mar 22, 2018	Jul	CMFD
	@	36MG	A076772	003	Mar 22, 2018	Mar	DISC
AB		54MG	A076655	001	Mar 21, 2018	Jul	CMFD
	@	54MG	A076655	001	Mar 21, 2018	Mar	DISC
>D> AB	ANI PHARMS INC	18MG	A208607	001	Jul 14, 2017	Aug	DISC
>A>	@	18MG	A208607	001	Jul 14, 2017	Aug	DISC
>D> AB		27MG	A208607	002	Jul 14, 2017	Aug	DISC
>A>	@	27MG	A208607	002	Jul 14, 2017	Aug	DISC
>D> AB		36MG	A208607	003	Jul 14, 2017	Aug	DISC
>A>	@	36MG	A208607	003	Jul 14, 2017	Aug	DISC
>D> AB		54MG	A208607	004	Jul 14, 2017	Aug	DISC
>A>	@	54MG	A208607	004	Jul 14, 2017	Aug	DISC
AB	DR REDDYS	18MG	A213473	001	Jul 29, 2020	Jul	NEWA
AB		27MG	A213473	002	Jul 29, 2020	Jul	NEWA
AB		36MG	A213473	003	Jul 29, 2020	Jul	NEWA
AB		54MG	A213473	004	Jul 29, 2020	Jul	NEWA
>A> AB	SUN PHARM INDS INC	18MG	A205135	001	Aug 19, 2020	Aug	NEWA
>A> AB		27MG	A205135	002	Aug 19, 2020	Aug	NEWA
>A> AB		36MG	A205135	003	Aug 19, 2020	Aug	NEWA
>A> AB		54MG	A205135	004	Aug 19, 2020	Aug	NEWA

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

@ DURAMED PHARMS BARR	4MG	A088497	001	Feb 21, 1984	Mar	DISC
-----------------------	-----	---------	-----	--------------	-----	------

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

AB	AMNEAL	40MG/ML	A210043	001	May 20, 2019	Jul	CMFD
AB		80MG/ML	A210043	002	May 20, 2019	Jul	CMFD

METOCLOPRAMIDE HYDROCHLORIDE

SPRAY, METERED;NASAL

GIMOTI

+!	EVOKE PHARMA INC	EQ 15MG BASE/SPRAY	N209388	001	Jun 19, 2020	Jun	NEWA
----	------------------	--------------------	---------	-----	--------------	-----	------

METOLAZONE

TABLET;ORAL

METOLAZONE

@ ANI PHARMS INC	2.5MG	A075543	001	Jan 06, 2004	May	CMS1
@	5MG	A075543	002	Mar 01, 2004	May	CMS1

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

@	ACTAVIS ELIZABETH	EQ 25MG TARTRATE	A204161	001	Nov 25, 2016	Mar	DISC
@		EQ 50MG TARTRATE	A204161	002	Nov 25, 2016	Mar	DISC
@		EQ 100MG TARTRATE	A204161	003	Nov 25, 2016	Mar	DISC
@		EQ 200MG TARTRATE	A204161	004	Nov 25, 2016	Mar	DISC
@	ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A076862	002	Aug 03, 2009	Jan	DISC
@		EQ 100MG TARTRATE	A077298	001	Apr 15, 2010	Jan	DISC
@		EQ 200MG TARTRATE	A077298	002	Apr 15, 2010	Jan	DISC
AB	PHARMADAX INC	EQ 25MG TARTRATE	A203028	001	Mar 31, 2020	Mar	NEWA
AB		EQ 50MG TARTRATE	A203028	002	Mar 31, 2020	Mar	NEWA
AB		EQ 100MG TARTRATE	A203699	001	Mar 30, 2020	Mar	NEWA
AB		EQ 200MG TARTRATE	A203699	002	Mar 30, 2020	Mar	NEWA

METOPROLOL TARTRATE

TABLET; ORAL

		METOPROLOL TARTRATE					
		@ HERITAGE PHARMA	50MG	A074141	001	Jan 31, 1995	Feb DISC
		@	100MG	A074141	002	Jan 31, 1995	Feb DISC
AB		YOUNGTECH PHARMS INC	25MG	A208955	001	Feb 05, 2020	Jan NEWA
AB			50MG	A208955	002	Feb 05, 2020	Jan NEWA
AB			100MG	A208955	003	Feb 05, 2020	Jan NEWA

METRONIDAZOLE

CAPSULE; ORAL

FLAGYL

>D>	AB	+!	GD SEARLE LLC	375MG	N020334	001	May 03, 1995	Aug CAHN
>A>	AB	+!	PFIZER	375MG	N020334	001	May 03, 1995	Aug CAHN

INJECTABLE; INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

AP		GLAND PHARMA LTD	500MG/100ML	A212435	001	Aug 03, 2020	Jul NEWA
		@ MYLAN LABS LTD	500MG/100ML	A205531	001	May 09, 2017	Jun DISC

TABLET; ORAL

FLAGYL

>D>	AB	+	GD SEARLE LLC	250MG	N012623	001		Aug CAHN
>D>	AB	+!		500MG	N012623	003		Aug CAHN
>A>	AB	+	PFIZER	250MG	N012623	001		Aug CAHN
>A>	AB	+!		500MG	N012623	003		Aug CAHN

TABLET, EXTENDED RELEASE; ORAL

FLAGYL ER

>D>		+	@ GD SEARLE LLC	750MG	N020868	001	Nov 26, 1997	Aug CAHN
>A>		+	@ PFIZER	750MG	N020868	001	Nov 26, 1997	Aug CAHN

METYROSINE

CAPSULE; ORAL

DEMSEER

AB		+!	BAUSCH	250MG	N017871	001		Jul CFTG
----	--	----	--------	-------	---------	-----	--	----------

METYROSINE

AB			AMNEAL	250MG	A213734	001	Jul 24, 2020	Jul NFTG
----	--	--	--------	-------	---------	-----	--------------	----------

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

AB			ANI PHARMS INC	150MG	A074450	001	May 16, 1996	Jun CMFD
AB				200MG	A074450	002	May 16, 1996	Jun CMFD
AB				250MG	A074450	003	May 16, 1996	Jun CMFD
AB			CROSSMEDIKA SA	150MG	A213500	001	Jul 22, 2020	Jul NEWA
AB				200MG	A213500	002	Jul 22, 2020	Jul NEWA
AB				250MG	A213500	003	Jul 22, 2020	Jul NEWA
AB			TEVA	150MG	A074377	001	May 16, 1995	Jun CTEC
AB				200MG	A074377	002	May 16, 1995	Jun CTEC
AB		!		250MG	A074377	003	May 16, 1995	Jun CTEC

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

@ MYLAN ASI

@

EQ 1MG BASE/ML

EQ 5MG BASE/ML

A090315	001	Nov 29, 2010	Jan DISC
A090315	002	Nov 29, 2010	Jan DISC

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

AB			AUROBINDO PHARMA LTD	2.5MG	A212774	001	Aug 10, 2020	Jul NEWA
AB				5MG	A212774	002	Aug 10, 2020	Jul NEWA
AB				10MG	A212774	003	Aug 10, 2020	Jul NEWA
>A>	AB		ZYDUS	2.5MG	A213055	001	Sep 01, 2020	Aug NEWA
>A>	AB			5MG	A213055	002	Sep 01, 2020	Aug NEWA
>A>	AB			10MG	A213055	003	Sep 01, 2020	Aug NEWA

MIFEPRISTONE

TABLET; ORAL

KORLYM

AB		+!	CORCEPT THERAP	300MG	N202107	001	Feb 17, 2012	Jul CFTG
----	--	----	----------------	-------	---------	-----	--------------	----------

TABLET;ORAL							
MIFEPRISTONE							
AB	TEVA PHARMS USA INC	300MG	A211436	001	Aug 03, 2020	Jul	NFTG
<u>MIGLUSTAT</u>							
CAPSULE;ORAL							
MIGLUSTAT							
AB	EDENBRIDGE PHARMS	100MG	A209821	001	Aug 06, 2020	Jul	NEWA
<u>MILRINONE LACTATE</u>							
INJECTABLE;INJECTION							
MILRINONE LACTATE							
AP	MEITHEAL	EQ 1MG BASE/ML	A211671	001	Mar 24, 2020	Apr	CAHN
AP	NANJING KING-FRIEND	EQ 1MG BASE/ML	A211671	001	Mar 24, 2020	Mar	NEWA
MILRINONE LACTATE IN DEXTROSE 5%							
>A> AP	AUROBINDO PHARMA LTD	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A209666	001	Sep 03, 2020	Aug	NEWA
>A> AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A209666	002	Sep 03, 2020	Aug	NEWA
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	GLAND PHARMA LTD	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A213585	001	Jul 16, 2020	Jul	NEWA
AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A213585	002	Jul 16, 2020	Jul	NEWA
<u>MINOCYCLINE HYDROCHLORIDE</u>							
AEROSOL, FOAM;TOPICAL							
ZILXI							
+	FOAMIX	EQ 1.5% BASE	N213690	001	May 28, 2020	May	NEWA
CAPSULE, EXTENDED RELEASE;ORAL							
XIMINO							
	JOURNEY	EQ 45MG BASE	N201922	001	Jul 11, 2012	Feb	CAHN
@		EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Feb	CAHN
		EQ 90MG BASE	N201922	003	Jul 11, 2012	Feb	CAHN
@		EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Feb	CAHN
		EQ 135MG BASE	N201922	005	Jul 11, 2012	Feb	CAHN
TABLET;ORAL							
MINOCYCLINE HYDROCHLORIDE							
AB	AUROBINDO PHARMA LTD	EQ 50MG BASE	A213662	001	May 01, 2020	Apr	NEWA
AB		EQ 75MG BASE	A213662	002	May 01, 2020	Apr	NEWA
AB		EQ 100MG BASE	A213662	003	May 01, 2020	Apr	NEWA
<u>MIRABEGRON</u>							
TABLET, EXTENDED RELEASE;ORAL							
MIRABEGRON							
@	SAWAI USA	25MG	A209446	001	Dec 27, 2019	Jan	DISC
MYRBETRIQ							
+	APGDI	25MG	N202611	001	Jun 28, 2012	Jan	CTEC
<u>MIRTAZAPINE</u>							
TABLET, ORALLY DISINTEGRATING;ORAL							
MIRTAZAPINE							
@	IMPAX LABS INC	15MG	A076901	001	Jun 28, 2005	Jul	DISC
@		30MG	A076901	002	Jun 28, 2005	Jul	DISC
@		45MG	A076901	003	Jun 28, 2005	Jul	DISC
<u>MISOPROSTOL</u>							
TABLET;ORAL							
CYTOTECH							
>D> AB	+ GD SEARLE LLC	0.1MG	N019268	003	Sep 21, 1990	Aug	CAHN
>D> AB	+	0.2MG	N019268	001	Dec 27, 1988	Aug	CAHN
>A> AB	+ PFIZER	0.1MG	N019268	003	Sep 21, 1990	Aug	CAHN
>A> AB	+	0.2MG	N019268	001	Dec 27, 1988	Aug	CAHN
<u>MITOMYCIN</u>							
POWDER;PYELOALYCEAL							
JELMYTO							
+	UROGEN PHARMA	40MG/VIAL	N211728	001	Apr 15, 2020	Apr	NEWA

MOMETASONE FUROATE

SPRAY, METERED;NASAL
MOMETASONE FUROATE

AB	AMNEAL PHARMS	0.05MG/SPRAY	A207989	001	Apr 03, 2017	Mar CPOT
AB	APOTEX INC	0.05MG/SPRAY	A091161	001	Mar 22, 2016	Mar CPOT
	NASONEX					
AB	+! MERCK SHARP DOHME	0.05MG/SPRAY	N020762	001	Oct 01, 1997	Mar CPOT

MONOMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL
BAFIERTAM

+!	BANNER LIFE SCIENCES	95MG	N210296	001	Apr 28, 2020	Apr NEWA
----	----------------------	------	---------	-----	--------------	----------

MONTELUKAST SODIUM

GRANULE;ORAL

AB	AUROBINDO PHARMA LTD	EQ 4MG BASE/PACKET	A213471	001	Feb 18, 2020	Feb NEWA
----	----------------------	--------------------	---------	-----	--------------	----------

TABLET;ORAL

MONTELUKAST SODIUM

@	HIKMA	EQ 10MG BASE	A090655	001	Aug 03, 2012	Feb DISC
---	-------	--------------	---------	-----	--------------	----------

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

>A>	AB	AMNEAL PHARMS	EQ 4MG BASE	A205107	001	Sep 04, 2020	Aug NEWA
>A>	AB		EQ 5MG BASE	A205107	002	Sep 04, 2020	Aug NEWA
	@	JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015	Jan DISC
	@		EQ 5MG BASE	A203795	002	Feb 27, 2015	Jan DISC

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL
KADIAN

+	ALLERGAN	70MG	N020616	010	Jul 09, 2012	Apr CTEC
---	----------	------	---------	-----	--------------	----------

MORPHINE SULFATE

@	TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014	Apr DISC
@		30MG	A202718	002	Dec 29, 2014	Apr DISC
@		40MG	A202718	007	Jun 03, 2015	Apr DISC
@		50MG	A202718	003	Dec 29, 2014	Apr DISC
@		60MG	A202718	004	Dec 29, 2014	Apr DISC
@		70MG	A202718	008	Jun 03, 2015	Apr DISC
@		80MG	A202718	005	Dec 29, 2014	Apr DISC
@		100MG	A202718	006	Dec 29, 2014	Apr DISC

INJECTABLE;INJECTION
DURAMORPH PF

AP	+! HIKMA	0.5MG/ML	N018565	001	Sep 18, 1984	Feb CAHN
AP	+!	1MG/ML	N018565	002	Sep 18, 1984	Feb CAHN
	INFUMORPH					
AP	+! HIKMA	10MG/ML	N018565	003	Jul 19, 1991	Feb CAHN
AP	+!	25MG/ML	N018565	004	Jul 19, 1991	Feb CAHN

MORPHINE SULFATE

AP	HIKMA	4MG/ML	A205758	001	May 21, 2015	Feb CAHN
AP		8MG/ML	A205758	002	May 21, 2015	Feb CAHN
AP		10MG/ML	A205758	003	May 21, 2015	Feb CAHN
	@	HOSPIRA	A071850	001	May 11, 1988	May DISC
	+ @	ICU MEDICAL INC	N019916	001	Oct 30, 1992	May DISC

SOLUTION;INTRAMUSCULAR

MORPHINE SULFATE (AUTOINJECTOR)

+!	MERIDIAN MEDCL TECHN	10MG/0.7ML (10MG/0.7ML)	N019999	001	Jul 12, 1990	Jun CPOT
+!		15MG/ML	N019999	001	Jul 12, 1990	Jun CTNA
+!		15MG/ML	N019999	001	Jul 12, 1990	Jun CDFR

TABLET, EXTENDED RELEASE;ORAL

MORPHABOND ER

>D>	+	DAIICHI SANKYO INC	15MG	N206544	001	Oct 02, 2015	Aug DISC
>A>	+	@	15MG	N206544	001	Oct 02, 2015	Aug DISC
>D>	+		30MG	N206544	002	Oct 02, 2015	Aug DISC
>A>	+	@	30MG	N206544	002	Oct 02, 2015	Aug DISC
>D>	+		60MG	N206544	003	Oct 02, 2015	Aug DISC
>A>	+	@	60MG	N206544	003	Oct 02, 2015	Aug DISC
>D>	+	!	100MG	N206544	004	Oct 02, 2015	Aug DISC
>A>	+	@	100MG	N206544	004	Oct 02, 2015	Aug DISC

MORPHINE SULFATE

@	NESHER PHARMS	15MG	A076733	001	May 19, 2004	Mar DISC
@		100MG	A077855	001	Sep 27, 2007	Mar DISC

TABLET, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

@ 200MG A077855 002 Sep 27, 2007 Mar DISC

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
MOXIFLOXACIN HYDROCHLORIDE

AT1 GLAND PHARMA LTD EQ 0.5% BASE A208778 001 Mar 30, 2020 Mar NEWA
AT1 MYLAN EQ 0.5% BASE A206447 001 Mar 30, 2020 Mar NEWA

TABLET;ORAL
AVELOX

+ @ BAYER HLTHCARE EQ 400MG BASE N021085 001 Dec 10, 1999 Apr DISC
MOXIFLOXACIN HYDROCHLORIDE
AB ! DR REDDYS LABS LTD EQ 400MG BASE A076938 001 Mar 04, 2014 Apr CHRS

MUPIROCIN CALCIUM

CREAM;TOPICAL
MUPIROCIN

AB ! GLENMARK PHARMS INC EQ 2% BASE A201587 001 Jan 24, 2013 Apr CTEC
AB TARO EQ 2% BASE A207116 001 Apr 27, 2020 Apr NEWA

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL
MYCOPHENOLATE MOFETIL

@ VINTAGE PHARMS LLC 250MG A090111 001 Dec 22, 2009 Jun DISC

TABLET;ORAL
MYCOPHENOLATE MOFETIL

AB CONCORD BIOTECH LTD 500MG A212087 001 Jul 31, 2020 Jul NEWA

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL
MYCOPHENOLIC ACID

@ TEVA PHARMS USA 180MG A202720 001 Oct 30, 2014 Mar DISC
@ 360MG A202720 002 Oct 30, 2014 Mar DISC

NABILONE

CAPSULE;ORAL
CESAMET

+! BAUSCH 1MG N018677 001 Dec 26, 1985 Mar CAHN

NABUMETONE

TABLET;ORAL
NABUMETONE

AB ! INVAGEN PHARMS 750MG A078671 002 Mar 07, 2008 Jul CHRS
>A> AB LGM PHARMA 500MG A203166 001 Aug 30, 2019 Aug CAHN
>A> AB 750MG A203166 002 Aug 30, 2019 Aug CAHN
>A> 1GM A203166 003 Aug 30, 2019 Aug CAHN
>D> AB NEXGEN PHARMA INC 500MG A203166 001 Aug 30, 2019 Aug CAHN
>D> AB 750MG A203166 002 Aug 30, 2019 Aug CAHN
>D> 1GM A203166 003 Aug 30, 2019 Aug CAHN

NADOLOL

TABLET;ORAL
CORCARD

AB + USWM 20MG N018063 005 Oct 28, 1986 Jun CAHN
AB + 40MG N018063 001 Jun CAHN
AB +! 80MG N018063 002 Jun CAHN
@ 120MG N018063 003 Jun CAHN
@ 160MG N018063 004 Jun CAHN

NADOLOL

@ VGYAAN 20MG A212856 001 Sep 13, 2019 Mar DISC
@ 40MG A212856 002 Sep 13, 2019 Mar DISC
@ 80MG A212856 003 Sep 13, 2019 Mar DISC

NAFARELIN ACETATE

SPRAY, METERED;NASAL
SYNAREL

+! PFIZER EQ 0.2MG BASE/SPRAY N019886 001 Feb 13, 1990 Jul CAHN

NAFCILLIN SODIUM

INJECTABLE; INJECTION						
NAFCILLIN SODIUM						
	@ FRESenius	EQ 1GM BASE/VIAL	A206682	001	Dec 10, 2019	Jul DISC
	@	EQ 2GM BASE/VIAL	A206682	002	Dec 10, 2019	Jul DISC
AP		EQ 10GM BASE/VIAL	A206761	001	Jun 02, 2020	May NEWA

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION						
NALBUPHINE HYDROCHLORIDE						
	@ MYLAN LABS LTD	10MG/ML	A206506	001	Feb 06, 2019	Feb DISC
	@	10MG/ML	A207595	001	Jan 11, 2019	Feb DISC
	@	20MG/ML	A206506	002	Feb 06, 2019	Feb DISC
	@	20MG/ML	A207595	002	Jan 11, 2019	Feb DISC

NALOXEGOL OXALATE

TABLET; ORAL						
MOVANTIK						
	+ REDHILL	EQ 12.5MG BASE	N204760	001	Sep 16, 2014	Jul CAHN
	+!	EQ 25MG BASE	N204760	002	Sep 16, 2014	Jul CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION						
NALOXONE HYDROCHLORIDE						
AP	DR REDDYS	1MG/ML	A213209	001	Mar 16, 2020	Mar NEWA
AP	! INTL MEDICATION	1MG/ML	A072076	001	Mar 24, 1988	Mar CTEC
	@ PAR STERILE PRODUCTS	0.4MG/ML	A211286	001	Jan 17, 2020	Jul DISC
AP		0.4MG/ML	A211286	001	Jan 17, 2020	Jan NEWA

NALTREXONE HYDROCHLORIDE

TABLET; ORAL						
NALTREXONE HYDROCHLORIDE						
>D> AB	APOTEX	50MG	A207905	001	Jul 21, 2017	Aug CAHN
>A> AB	CHARTWELL	50MG	A207905	001	Jul 21, 2017	Aug CAHN

NAPROXEN

SUSPENSION; ORAL						
NAPROXEN						
AB	AMNEAL	25MG/ML	A212705	001	Jul 31, 2020	Jul NEWA
TABLET; ORAL						
NAPROXEN						
	@ MYLAN	250MG	A074121	001	Dec 21, 1993	Jan DISC
	@	375MG	A074121	002	Dec 21, 1993	Jan DISC
	@	500MG	A074121	003	Dec 21, 1993	Jan DISC
AB	SCIEGEN PHARMS INC	250MG	A212517	001	Feb 21, 2020	Feb NEWA
AB		375MG	A212517	002	Feb 21, 2020	Feb NEWA
AB		500MG	A212517	003	Feb 21, 2020	Feb NEWA
TABLET, DELAYED RELEASE; ORAL						
NAPROXEN						
	@ PLIVA	375MG	A075337	001	May 26, 1999	Mar DISC
	@	500MG	A075337	002	May 26, 1999	Mar DISC

NAPROXEN SODIUM

TABLET; ORAL						
NAPROXEN SODIUM						
	@ TEVA	EQ 250MG BASE	A074198	001	Dec 21, 1993	Mar DISC
	@	EQ 500MG BASE	A074198	002	Dec 21, 1993	Mar DISC

NATEGLINIDE

TABLET; ORAL						
NATEGLINIDE						
	@ ALVOGEN	60MG	A205055	001	Dec 11, 2015	Mar DISC
	@	120MG	A205055	002	Dec 11, 2015	Mar DISC

NEOMYCIN SULFATE

TABLET; ORAL						
NEOMYCIN SULFATE						
	@ BRECKENRIDGE	500MG	A065468	001	Mar 29, 2010	Apr DISC
	@ NOSTRUM LABS INC	500MG	A065468	001	Mar 29, 2010	Jul CAHN
AA	XGEN PHARMS	500MG	A065220	001	Jul 28, 2006	Feb CAHN

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

AT	WATSON LABS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A062664	001	Apr 08, 1986	Mar	CMFD
AT	XGEN PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A065106	001	Jan 31, 2006	Feb	CAHN
AT		EQ 40MG BASE/ML; 200,000 UNITS/ML	A065108	001	Jan 31, 2006	Feb	CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

AP	+!	EXELA PHARMA	5MG/10ML (0.5MG/ML)	N204078	001	May 31, 2013	Jul	CAHN
AP	+!		10MG/10ML (1MG/ML)	N204078	002	May 31, 2013	Jul	CAHN

NEOSTIGMINE METHYLSULFATE

>D>		FRESENIUS KABI USA	3MG/3ML (1MG/ML)	N203629	003	Sep 18, 2018	Aug	CRLD
>A>	+		3MG/3ML (1MG/ML)	N203629	003	Sep 18, 2018	Aug	CHRS
>A>	+		3MG/3ML (1MG/ML)	N203629	003	Sep 18, 2018	Aug	CRLD
>D>			5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015	Aug	CRLD
>A>	+		5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015	Aug	CHRS
>A>	+		5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015	Aug	CRLD
>D>			10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015	Aug	CRLD
>A>	+		10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015	Aug	CHRS
>A>	+		10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015	Aug	CRLD

NETARSUDIL MESYLATE

SOLUTION/DROPS; OPHTHALMIC

RHOPRESSA

+!	AERIE PHARMS INC	EQ 0.02% BASE	N208254	001	Dec 18, 2017	Feb	CAIN
----	------------------	---------------	---------	-----	--------------	-----	------

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

@	MYLAN	500MG	A203742	001	Feb 22, 2019	Jan	DISC
@		750MG	A203742	002	Feb 22, 2019	Jan	DISC
@		1GM	A203742	003	Feb 22, 2019	Jan	DISC

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

>D>	AB	EPIC PHARMA	20MG	A074928	001	Mar 19, 1998	Aug	CTEC
>A>			20MG	A074928	001	Mar 19, 1998	Aug	CTEC
>D>	AB		30MG	A074928	002	Mar 19, 1998	Aug	CTEC
>A>	!		30MG	A074928	002	Mar 19, 1998	Aug	CHRS
>A>			30MG	A074928	002	Mar 19, 1998	Aug	CTEC
>D>	AB	MYLAN	20MG	A074642	001	Jul 18, 1996	Aug	DISC
>A>	@		20MG	A074642	001	Jul 18, 1996	Aug	DISC
>D>	AB	!	30MG	A074642	002	Jul 18, 1996	Aug	DISC
>A>	@		30MG	A074642	002	Jul 18, 1996	Aug	DISC

INJECTABLE; INJECTION

NICARDIPINE HYDROCHLORIDE

		AM REGENT	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	May	CMFD
>D>		EXELA PHARMA SCIENCE	25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008	Aug	CRLD
>A>	+		25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008	Aug	CHRS
>A>	+		25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008	Aug	CRLD

INJECTABLE; INTRAVENOUS

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

>D>		EXELA PHARMA SCIENCE	20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016	Aug	CRLD
>A>	+		20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016	Aug	CHRS
>A>	+		20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016	Aug	CRLD
			20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016	May	CMFD
>D>			40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016	Aug	CRLD
>A>	+		40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016	Aug	CHRS
>A>	+		40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016	Aug	CRLD
			40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016	May	CMFD

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

AB	ACELLA	10MG	A072781	001	Jul 30, 1993	Jul	CAHN
----	--------	------	---------	-----	--------------	-----	------

<u>NIFURTIMOX</u>									
>A>	TABLET;ORAL								
>A>	LAMPIT								
>A>	+	BAYER HEALTHCARE	30MG	N213464	001	Aug 06, 2020	Aug	NEWA	
>A>	+	!	120MG	N213464	002	Aug 06, 2020	Aug	NEWA	
<u>NIMODIPINE</u>									
SOLUTION;ORAL									
NYMALIZE									
	+	@ ARBOR PHARMS LLC	3MG/ML	N203340	001	May 10, 2013	Apr	DISC	
	+	!	3MG/ML	N203340	001	May 10, 2013	Apr	CPOT	
	+	!	6MG/ML	N203340	002	Apr 08, 2020	Apr	NEWA	
<u>NIRAPARIB TOSYLATE</u>									
CAPSULE;ORAL									
ZEJULA									
	+	!	GLAXOSMITHKLINE	EQ 100MG BASE	N208447	001	Mar 27, 2017	Jan	CAHN
<u>NITROGLYCERIN</u>									
FILM, EXTENDED RELEASE;TRANSDERMAL									
NITRO-DUR									
BX	+	!	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	Mar	CTEC
BX	+	!		0.2MG/HR	N020145	002	Apr 04, 1995	Mar	CTEC
BX	+	!		0.4MG/HR	N020145	004	Apr 04, 1995	Mar	CTEC
BX	+	!		0.6MG/HR	N020145	005	Apr 04, 1995	Mar	CTEC
TABLET;SUBLINGUAL									
NITROGLYCERIN									
			@ ACTAVIS LABS FL INC	0.3MG	A203693	001	Oct 16, 2017	Mar	DISC
			@	0.4MG	A203693	002	Oct 16, 2017	Mar	DISC
			@	0.6MG	A203693	003	Oct 16, 2017	Mar	DISC
NITROSTAT									
AB	+		UPJOHN	0.3MG	N021134	001	May 01, 2000	Jul	CAHN
AB	+			0.4MG	N021134	002	May 01, 2000	Jul	CAHN
AB	+	!		0.6MG	N021134	003	May 01, 2000	Jul	CAHN
<u>NIZATIDINE</u>									
CAPSULE;ORAL									
NIZATIDINE									
			@ MYLAN PHARMS INC	150MG	A075806	001	Jul 05, 2002	May	DISC
			@	300MG	A075806	002	Jul 05, 2002	May	DISC
AB	!		WATSON LABS	300MG	A075616	002	Jul 09, 2002	May	CHRS
<u>NORETHINDRONE</u>									
TABLET;ORAL-28									
NOR-QD									
AB1	+	!	TEVA BRANDED PHARM	0.35MG	N017060	001		Jan	CAHN
NORETHINDRONE									
AB1			NAARI PTE LTD	0.35MG	A206807	001	Dec 13, 2016	Jun	CAHN
<u>NUSINERSEN SODIUM</u>									
SOLUTION;INTRATHECAL									
SPINRAZA									
	+	!	BIOGEN IDEC	EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML)	N209531	001	Dec 23, 2016	Jun	CPOT
<u>NYSTATIN</u>									
CREAM;TOPICAL									
NYSTATIN									
			@ VINTAGE	100,000 UNITS/GM	A065315	001	May 31, 2006	Jul	DISC
POWDER;TOPICAL									
NYSTATIN									
AT			XGEN PHARMS	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Feb	CAHN
SUSPENSION;ORAL									
NYSTATIN									
AA			SOCORRO	100,000 UNITS/ML	A062832	001	Dec 27, 1991	May	CMFD

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL							
NYSTATIN AND TRIAMCINOLONE ACETONIDE							
AT	TORRENT	100,000 UNITS/GM;0.1%	A213142	001	Jul 14, 2020	Jul	NEWA
OINTMENT; TOPICAL							
NYSTATIN AND TRIAMCINOLONE ACETONIDE							
AT	CADILA	100,000 UNITS/GM;0.1%	A207764	001	Nov 08, 2018	Jun	CAHN
	@ VITRUVIAS THERAP	100,000 UNITS/GM;0.1%	A207316	001	Nov 18, 2019	May	CPOT
	@	100000 UNITS/GM;0.1%	A207316	001	Nov 18, 2019	May	DISC
AT	ZYDUS PHARMS	100,000 UNITS/GM;0.1%	A207764	001	Nov 08, 2018	Mar	CMFD

OCTREOTIDE ACETATE

CAPSULE, DELAYED RELEASE; ORAL
MYCAPSSA

+! CHIASSMA EQ 20MG BASE

N208232 001 Jun 26, 2020 Jun NEWA

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

@ HERITAGE PHARMS INC EQ 0.05MG BASE/ML

A204669 001 Dec 27, 2018 Feb DISC

@ EQ 0.1MG BASE/ML

A204669 002 Dec 27, 2018 Feb DISC

@ EQ 0.5MG BASE/ML

A204669 003 Dec 27, 2018 Feb DISC

SANDOSTATIN

+ @ NOVARTIS EQ 0.2MG BASE/ML

N019667 004 Jun 12, 1991 May DISC

+ @ EQ 1MG BASE/ML

N019667 005 Jun 12, 1991 May DISC

SOLUTION; SUBCUTANEOUS

BYNFEZIA PEN

+! SUN PHARM EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)

N213224 001 Jan 28, 2020 Jan NEWA

OLANZAPINE

TABLET; ORAL
OLANZAPINE

AB	INDOCO	2.5MG	A206155	001	Jul 31, 2020	Jul	NEWA
AB		5MG	A206155	002	Jul 31, 2020	Jul	NEWA
AB		7.5MG	A206155	003	Jul 31, 2020	Jul	NEWA
AB		10MG	A206155	004	Jul 31, 2020	Jul	NEWA
AB		15MG	A206155	005	Jul 31, 2020	Jul	NEWA
AB		20MG	A206155	006	Jul 31, 2020	Jul	NEWA
	@ IVAX PHARMS INC	20MG	A077301	001	Apr 29, 2015	Mar	DISC
	@ JIANGSU HANSON PHARM	2.5MG	A209399	001	Sep 24, 2018	May	DISC
	@	5MG	A209399	002	Sep 24, 2018	May	DISC
	@	10MG	A209399	003	Sep 24, 2018	May	DISC
	@ TEVA PHARMS	2.5MG	A076000	001	Oct 24, 2011	Jan	DISC
	@	5MG	A076000	002	Oct 24, 2011	Jan	DISC
	@	7.5MG	A076000	003	Oct 24, 2011	Jan	DISC
	@	10MG	A076000	004	Oct 24, 2011	Jan	DISC
	@	15MG	A076000	005	Oct 24, 2011	Jan	DISC

OLMESARTAN MEDOXOMIL

TABLET; ORAL
OLMESARTAN MEDOXOMIL

AB	INVENTIA	5MG	A208659	001	May 18, 2020	May	NEWA
AB		20MG	A208659	002	May 18, 2020	May	NEWA
AB		40MG	A208659	003	May 18, 2020	May	NEWA
	@ JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Feb	DISC
	@	20MG	A205482	002	Apr 24, 2017	Feb	DISC
	@	40MG	A205482	003	Apr 24, 2017	Feb	DISC
AB	SANDOZ INC	5MG	A090237	001	Apr 13, 2020	Mar	NEWA
AB		20MG	A090237	002	Apr 13, 2020	Mar	NEWA
AB		40MG	A090237	003	Apr 13, 2020	Mar	NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

>D> AT	APOTEX	EQ 0.1% BASE	A078350	001	Dec 07, 2015	Aug	CMS1
>D> AT	AUROBINDO PHARMA LTD	EQ 0.1% BASE	A204812	001	Dec 18, 2015	Aug	CMS1
>D> AT		EQ 0.2% BASE	A209995	001	Apr 04, 2019	Aug	CMS1
	@ CIPLA	EQ 0.1% BASE	A206046	001	Jul 26, 2017	Mar	DISC
	@	EQ 0.2% BASE	A206087	001	Dec 05, 2017	Mar	DISC
	@ WATSON LABS INC	EQ 0.7% BASE	A208637	001	Feb 19, 2020	Mar	DISC
AT		EQ 0.7% BASE	A208637	001	Feb 19, 2020	Feb	NFTG

SOLUTION/DROPS;OPHTHALMIC
PATADAY ONCE DAILY RELIEF

	AT	+	NOVARTIS	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Mar CTEC
	AT	+		EQ 0.7% BASE	N206276	001	Jan 30, 2015	Feb CFTG

SPRAY, METERED;NASAL
OLOPATADINE HYDROCHLORIDE

>A>	AB		AKORN INC	0.665MG/SPRAY	A213757	001	Aug 19, 2020	Aug NEWA
	AB		AMNEAL	0.665MG/SPRAY	A210901	001	Jan 28, 2020	Jan NEWA

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS

	AB		CSPC NBP PHARM CO	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211979	001	May 12, 2020	Apr NEWA
>A>	AB		GLW	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A212504	001	Aug 19, 2020	Aug NEWA
	AB		PURACAP PHARM LLC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210093	001	Jun 15, 2020	Jun NEWA
	AB		SOFGEN PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211355	001	Jul 10, 2019	Feb CMFD

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

		@	MYLAN	10MG	A205070	001	Jun 29, 2018	Feb DISC
		@		20MG	A075876	002	May 29, 2003	Jan DISC
		@		20MG	A205070	002	Jun 29, 2018	Feb DISC
		@		40MG	A205070	003	Jun 29, 2018	Feb DISC
		@	TEVA PHARMS USA	40MG	A204661	002	Jun 13, 2017	May DISC

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

	AB		GUARDIAN DRUG	20MG;1.1GM	A212587	001	Apr 30, 2020	Apr NEWA
	AB			40MG;1.1GM	A212587	002	Apr 30, 2020	Apr NEWA

ONDANSETRON

FILM;ORAL
ZUPLLENZ

		+	FORTOVIA	4MG	N022524	001	Jul 02, 2010	May CAHN
		+		8MG	N022524	002	Jul 02, 2010	May CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

		@	BARR	4MG	A076693	001	Jun 25, 2007	Mar DISC
		@		8MG	A076693	002	Jun 25, 2007	Mar DISC
		@	TEVA	4MG	A076810	001	Jun 25, 2007	Mar DISC
		@		8MG	A076810	002	Jun 25, 2007	Mar DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

	AP	!	EMCURE PHARMS	EQ 2MG BASE/ML	A090424	001	Apr 16, 2010	May DISC
	AP	!	GLAND PHARMA LTD	EQ 2MG BASE/ML	A090648	001	Jun 15, 2012	Jun CHRS
	AP	!	QILU	EQ 2MG BASE/ML	A203711	001	Sep 08, 2014	Mar CHRS

TABLET;ORAL

		@	MYLAN	EQ 4MG BASE	A076930	001	Jun 25, 2007	Jan DISC
		@		EQ 8MG BASE	A076930	002	Jun 25, 2007	Jan DISC
		@	PLIVA HRVATSKA DOO	EQ 4MG BASE	A077112	001	Jun 25, 2007	Mar DISC
		@		EQ 8MG BASE	A077112	002	Jun 25, 2007	Mar DISC
		@		EQ 24MG BASE	A077112	003	Jun 25, 2007	Mar DISC

OPICAPONE

CAPSULE;ORAL
ONGENTYS

		+	NEUROCRINE	25MG	N212489	001	Apr 24, 2020	Apr NEWA
		+		50MG	N212489	002	Apr 24, 2020	Apr NEWA

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB	MSN	EQ 30MG BASE	A212544	001	May 20, 2020	May NEWA
AB		EQ 45MG BASE	A212544	002	May 20, 2020	May NEWA
AB		EQ 75MG BASE	A212544	003	May 20, 2020	May NEWA
AB	SUNSHINE	EQ 30MG BASE	A212739	001	Mar 04, 2020	Feb NEWA
AB		EQ 45MG BASE	A212739	002	Mar 04, 2020	Feb NEWA
AB		EQ 75MG BASE	A212739	003	Mar 04, 2020	Feb NEWA

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB	AJANTA PHARMA LTD	EQ 6MG BASE/ML	A212784	001	May 27, 2020	May NEWA
----	-------------------	----------------	---------	-----	--------------	----------

OSILODROSTAT PHOSPHATE

TABLET;ORAL

ISTURISA

+	RECORDATI RARE	EQ 1MG BASE	N212801	001	Mar 06, 2020	Mar NEWA
+		EQ 5MG BASE	N212801	002	Mar 06, 2020	Mar NEWA
+	!	EQ 10MG BASE	N212801	003	Mar 06, 2020	Mar NEWA

OXACILLIN SODIUM

INJECTABLE;INJECTION

OXACILLIN SODIUM

AP	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A206198	001	Jul 20, 2020	Jul NEWA
AP		EQ 2GM BASE/VIAL	A206198	002	Jul 20, 2020	Jul NEWA
AP		EQ 10GM BASE/VIAL	A206199	001	Jul 27, 2020	Jul NEWA

OXALIPLATIN

INJECTABLE;INTRAVENOUS

OXALIPLATIN

>D>	AP	ACCORD HLTHCARE	200MG/40ML (5MG/ML)	A207474	003	Mar 21, 2017	Aug DISC
>A>	@		200MG/40ML (5MG/ML)	A207474	003	Mar 21, 2017	Aug DISC
>D>	AP	FRESENIUS KABI USA	200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017	Aug DISC
>A>	@		200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017	Aug DISC
>D>	AP	GLAND PHARMA LTD	200MG/40ML (5MG/ML)	A207325	003	Oct 18, 2017	Aug DISC
>A>	@		200MG/40ML (5MG/ML)	A207325	003	Oct 18, 2017	Aug DISC
>D>	AP	! QILU	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Aug DISC
>A>	!		200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Aug CMFD
>A>	@		200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Aug DISC

OXAPROZIN

TABLET;ORAL

DAYPRO

AB	+! PFIZER	600MG	N018841	004	Oct 29, 1992	Jul CAHN
	OXAPROZIN					
AB	CHARTWELL	600MG	A075987	001	Sep 02, 2004	Mar CAHN
	@ IVAX SUB TEVA PHARMS	600MG	A075846	001	May 13, 2002	Mar DISC

OXAPROZIN POTASSIUM

TABLET;ORAL

DAYPRO ALTA

@ PFIZER

600MG

N020776	001	Oct 17, 2002	Jul CAHN
---------	-----	--------------	----------

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

AB	FRONTIDA BIOPHARM	10MG	A071026	002	Aug 10, 1987	Mar CMFD
AB		15MG	A071026	003	Aug 10, 1987	Mar CMFD
AB		30MG	A071026	001	Aug 10, 1987	Mar CMFD

OXCARBAZEPINE

TABLET;ORAL

OXCARBAZEPINE

@ HIKMA

150MG

A077795	001	Oct 09, 2007	Feb DISC
---------	-----	--------------	----------

@

300MG

A077795	002	Oct 09, 2007	Feb DISC
---------	-----	--------------	----------

@

600MG

A077795	003	Oct 09, 2007	Feb DISC
---------	-----	--------------	----------

OXYBUTYNIN CHLORIDE

TABLET; ORAL

OXYBUTYNIN CHLORIDE

>D>	AB	ARISE	5MG	A209025	001	Dec 21, 2017	Aug CAHN
	AB	LEADING PHARMA LLC	5MG	A212798	001	Apr 06, 2020	Mar NEWA
>A>	AB	RISING	5MG	A209025	001	Dec 21, 2017	Aug CAHN

TABLET, EXTENDED RELEASE; ORAL

OXYBUTYNIN CHLORIDE

	@	IMPAX PHARMS	5MG	A076745	002	May 09, 2007	Jul DISC
	@		10MG	A076745	003	May 09, 2007	Jul DISC
	@		15MG	A076745	001	Nov 09, 2006	Jul DISC
	@	MYLAN PHARMS INC	10MG	A076644	001	Nov 09, 2006	Jan DISC
	@		15MG	A076644	002	May 10, 2007	Jan DISC

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

	@	ANI PHARMS INC	100MG/5ML	A203447	001	Aug 30, 2017	Jan DISC
AA		AUROLIFE PHARMA LLC	5MG/5ML	A212429	001	Jan 27, 2020	Jan NEWA
AA			100MG/5ML	A212429	002	Jan 27, 2020	Jan NEWA
	@	HIKMA	100MG/5ML	A203208	001	Jul 12, 2013	Feb DISC
AA		RHODES PHARMS	100MG/5ML	A205853	001	Apr 29, 2020	Apr NEWA

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

	@	NESHER PHARMS	5MG	A077290	001	Dec 08, 2005	Mar DISC
	@		10MG	A077290	002	Dec 08, 2005	Mar DISC
	@		15MG	A077290	003	Dec 08, 2005	Mar DISC
	@		20MG	A077290	004	Dec 08, 2005	Mar DISC
	@		30MG	A077290	005	Dec 08, 2005	Mar DISC

ROXYBOND

	@	OHEMO LIFE	5MG	N209777	001	Apr 20, 2017	May CAHN
	@		15MG	N209777	002	Apr 20, 2017	May CAHN
	@		30MG	N209777	003	Apr 20, 2017	May CAHN

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

UPNEEQ

+	!	RVL PHARMS	0.1%	N212520	001	Jul 08, 2020	Jul NEWA
---	---	------------	------	---------	-----	--------------	----------

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OXYMORPHONE HYDROCHLORIDE

	@	ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013	Mar DISC
	@		7.5MG	A079046	001	Dec 13, 2010	Mar DISC
	@		10MG	A079046	004	Jul 11, 2013	Mar DISC
	@		15MG	A079046	002	Dec 13, 2010	Mar DISC
	@		20MG	A079046	005	Jul 11, 2013	Mar DISC
	@		30MG	A079046	006	Jul 11, 2013	Mar DISC
	@		40MG	A079046	007	Jul 11, 2013	Mar DISC
	@	SPECGX LLC	5MG	A202946	001	Jun 27, 2014	May DISC
	@		7.5MG	A202946	002	Jun 27, 2014	May DISC
	@		10MG	A202946	003	Jun 27, 2014	May DISC
	@		15MG	A202946	004	Jun 27, 2014	May DISC
	@		20MG	A202946	005	Jun 27, 2014	May DISC
	@		30MG	A202946	006	Jun 27, 2014	May DISC
	@		40MG	A202946	007	Jun 27, 2014	May DISC

OZANIMOD HYDROCHLORIDE

CAPSULE; ORAL

ZEPOSIA

+		CELGENE INTL	0.23MG	N209899	001	Mar 25, 2020	Mar NEWA
+			0.46MG	N209899	002	Mar 25, 2020	Mar NEWA
+	!		0.92MG	N209899	003	Mar 25, 2020	Mar NEWA

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

>A>	AP	MSN	6MG/ML	A213434	001	Aug 24, 2020	Aug NEWA
-----	----	-----	--------	---------	-----	--------------	----------

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS
PALONOSETRON HYDROCHLORIDE

AP	INGENUS PHARMS LLC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	May NEWA
----	--------------------	--	---------	-----	--------------	----------

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION
PAMIDRONATE DISODIUM

@	TEVA PHARMS USA	30MG/10ML (3MG/ML)	A076153	001	Mar 27, 2002	Mar DISC
@		90MG/10ML (9MG/ML)	A076153	002	Mar 27, 2002	Mar DISC

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

AB	SUN PHARM	EQ 40MG BASE	A213725	001	Jun 30, 2020	Jun NFTG
	PROTONIX					
AB	+! WYETH PHARMS	EQ 40MG BASE	N022020	001	Nov 14, 2007	Jun CFTG
	TABLET, DELAYED RELEASE;ORAL					
	PANTOPRAZOLE SODIUM					
	@ MACLEODS PHARMS LTD	EQ 20MG BASE	A200821	001	Feb 16, 2012	May DISC
	@	EQ 40MG BASE	A200821	002	Feb 16, 2012	May DISC
	@ TEVA	EQ 20MG BASE	A077056	001	Aug 02, 2007	May DISC
	@	EQ 40MG BASE	A077056	002	Aug 02, 2007	May DISC

PAROXETINE HYDROCHLORIDE

TABLET;ORAL
PAROXETINE HYDROCHLORIDE

@	JUBILANT GENERICS	EQ 10MG BASE	A205528	001	Nov 27, 2015	Jan DISC
@		EQ 20MG BASE	A205528	002	Nov 27, 2015	Jan DISC
@		EQ 30MG BASE	A205528	003	Nov 27, 2015	Jan DISC
@		EQ 40MG BASE	A205528	004	Nov 27, 2015	Jan DISC

PASIREOTIDE DIASPARTATE

SOLUTION;SUBCUTANEOUS
SIGNIFOR

+	RECORDATI RARE	EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	N200677	001	Dec 14, 2012	Feb CAHN
+		EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	N200677	002	Dec 14, 2012	Feb CAHN
+	!	EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	N200677	003	Dec 14, 2012	Feb CAHN

PASIREOTIDE PAMOATE

FOR SUSPENSION;INTRAMUSCULAR
SIGNIFOR LAR KIT

+	RECORDATI RARE	EQ 10MG BASE/VIAL	N203255	004	Jun 29, 2018	Feb CAHN
+		EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014	Feb CAHN
+		EQ 30MG BASE/VIAL	N203255	005	Jun 29, 2018	Feb CAHN
+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014	Feb CAHN
+	!	EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014	Feb CAHN

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL
VOTRIENT

+	@ NOVARTIS	EQ 400MG BASE	N022465	002	Oct 19, 2009	Jan CRLD
---	------------	---------------	---------	-----	--------------	----------

>D> PEGAPTANIB SODIUM

>D> INJECTABLE;INTRAVITREAL
>D> MACUGEN

>D>	+	VALEANT PHARMS LLC	EQ 0.3MG ACID/0.09ML	N021756	001	Dec 17, 2004	Aug DISC
>A>	+	@	EQ 0.3MG ACID/0.09ML	N021756	001	Dec 17, 2004	Aug DISC

PEMETREXED

SOLUTION;INTRAVENOUS
PEMETREXED

>A>	+	ACTAVIS LLC	100MG/4ML (25MG/ML)	N208419	001	Aug 21, 2020	Aug NEWA
>A>	+	!	500MG/20ML (25MG/ML)	N208419	002	Aug 21, 2020	Aug NEWA
>A>	+	!	1GM/40ML (25MG/ML)	N208419	003	Aug 21, 2020	Aug NEWA
		PEMFEXY					
	+	EAGLE PHARMS	500MG/20ML (25MG/ML)	N209472	001	Feb 08, 2020	Feb NEWA

PEMIGATINIB

TABLET; ORAL

PEMAZYRE

+	INCYTE CORP	4.5MG	N213736	001	Apr 17, 2020	Apr	NEWA
+		9MG	N213736	002	Apr 17, 2020	Apr	NEWA
+	!	13.5MG	N213736	003	Apr 17, 2020	Apr	NEWA

PENICILLAMINE

CAPSULE; ORAL

PENICILLAMINE

AB	ANI PHARMS INC	250MG	A209921	001	May 07, 2019	Jan	CAHN
AB	APOTEX	250MG	A213310	001	Apr 28, 2020	Apr	NEWA
AB	DR REDDYS	250MG	A211867	001	Aug 04, 2020	Jul	NEWA

TABLET; ORAL

PENICILLAMINE

>D>	AB	TEVA PHARMS USA	250MG	A211497	001	Feb 13, 2020	Aug	DISC
>A>		@	250MG	A211497	001	Feb 13, 2020	Aug	DISC
	AB		250MG	A211497	001	Feb 13, 2020	Feb	NEWA

PERMETHRIN

CREAM; TOPICAL

ELIMITE

+	@ MYLAN	5%	N019855	001	Aug 25, 1989	Feb	DISC
---	---------	----	---------	-----	--------------	-----	------

PERMETHRIN

AB	!	PERRIGO ISRAEL	5%	A076369	001	Apr 21, 2003	Feb	CHRS
----	---	----------------	----	---------	-----	--------------	-----	------

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

AB	ZYDUS PHARMS	2MG	A205232	001	Apr 06, 2020	Mar	NEWA
AB		4MG	A205232	002	Apr 06, 2020	Mar	NEWA
AB		8MG	A205232	003	Apr 06, 2020	Mar	NEWA
AB		16MG	A205232	004	Apr 06, 2020	Mar	NEWA

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

AA	NOSTRUM LABS INC	35MG	A203600	001	Dec 27, 2017	Mar	CAHN
AA		35MG	A203600	001	Dec 27, 2017	Mar	CAHN

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

AB	+	CONCORDIA	10MG	N008708	001		Jun	CMFD
----	---	-----------	------	---------	-----	--	-----	------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

@	BARR	15MG	A090591	001	Mar 18, 2010	Mar	DISC
@		30MG	A090591	002	Mar 18, 2010	Mar	DISC

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

@	BARR	37.5MG	A090470	001	Aug 31, 2009	Mar	DISC
---	------	--------	---------	-----	--------------	-----	------

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

AP1	ACCORD HLTHCARE	10MG/ML (10MG/ML)	A213237	001	Jul 01, 2020	Jun	NEWA
AP1		50MG/5ML (10MG/ML)	A213237	002	Jul 01, 2020	Jun	NEWA
AP1		100MG/10ML (10MG/ML)	A213237	003	Jul 01, 2020	Jun	NEWA
AP1	APOLLO	10MG/ML (10MG/ML)	A211081	001	Jul 17, 2020	Jul	NEWA
AP1		50MG/5ML (10MG/ML)	A211081	002	Jul 17, 2020	Jul	NEWA
AP1		100MG/10ML (10MG/ML)	A211081	003	Jul 17, 2020	Jul	NEWA
AP1	CAPLIN	10MG/ML (10MG/ML)	A213318	001	Jun 11, 2020	Jun	NEWA
AP1		50MG/5ML (10MG/ML)	A213318	002	Jun 11, 2020	Jun	NEWA
AP1		100MG/10ML (10MG/ML)	A213318	003	Jun 11, 2020	Jun	NEWA
AP1	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A211920	001	Jun 05, 2020	Jun	NEWA
AP1		100MG/10ML (10MG/ML)	A211920	002	Jun 05, 2020	Jun	NEWA
AP1	RICONPHARMA LLC	10MG/ML (10MG/ML)	A209967	001	Jan 16, 2020	Jan	NEWA
AP1		50MG/5ML (10MG/ML)	A209967	002	Jan 16, 2020	Jan	NEWA
AP1		100MG/10ML (10MG/ML)	A209967	003	Jan 16, 2020	Jan	NEWA

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

AP1		SAGENT PHARMS INC	10MG/ML (10MG/ML)	A209967	001	Jan 16, 2020	Jun CAHN
AP1			50MG/5ML (10MG/ML)	A209967	002	Jan 16, 2020	Jun CAHN
AP1			100MG/10ML (10MG/ML)	A209967	003	Jan 16, 2020	Jun CAHN
VAZCULEP							
AP1	+	EXELA PHARMA	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jul CAHN
AP1	+		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jul CAHN
AP1	+		100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jul CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA	!	PHARM ASSOC	5MG/5ML;6.25MG/5ML	A040654	001	Dec 07, 2006	Jun CAHN
----	---	-------------	--------------------	---------	-----	--------------	----------

PHENYTOIN

SUSPENSION;ORAL

DILANTIN-125

AB	+	UPJOHN	125MG/5ML	N008762	001		Jul CAHN
		DILANTIN-30					
	@	UPJOHN	30MG/5ML	N008762	002		Jul CAHN

TABLET, CHEWABLE;ORAL

DILANTIN

>A>	AB	!	PHARMACIA	50MG	A084427	001	Aug CAHN
>D>	AB	!	UPJOHN	50MG	A084427	001	Aug CAHN
	AB	!		50MG	A084427	001	Jul CAHN

PHENYTOIN SODIUM

CAPSULE;ORAL

DILANTIN

	!	UPJOHN	30MG EXTENDED	A084349	001		Jul CAHN
AB	!		100MG EXTENDED	A084349	002		Jul CAHN
EXTENDED PHENYTOIN SODIUM							
	@	LUPIN LTD	100MG EXTENDED	A211633	001	Sep 30, 2019	Apr DISC

PILOCARPINE HYDROCHLORIDE

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	5MG	A212377	001	Aug 13, 2019	Mar CMFD
	@		5MG	A212377	001	Aug 13, 2019	Feb DISC
AB			7.5MG	A212377	002	Aug 13, 2019	Mar CMFD
	@		7.5MG	A212377	002	Aug 13, 2019	Feb DISC

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

	@	MYLAN PHARMS INC	EQ 15MG BASE	A076801	001	Aug 17, 2012	Jan DISC
	@		EQ 30MG BASE	A076801	002	Aug 17, 2012	Jan DISC
	@		EQ 45MG BASE	A076801	003	Aug 17, 2012	Jan DISC
AB		NOSTRUM LABS INC	EQ 15MG BASE	A078472	001	Feb 13, 2013	Jul CAHN
AB			EQ 30MG BASE	A078472	002	Feb 13, 2013	Jul CAHN
AB			EQ 45MG BASE	A078472	003	Feb 13, 2013	Jul CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP		ASTRAL	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A212287	001	Jul 29, 2019	Apr CMFD
AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A212287	002	Jul 29, 2019	Apr CMFD
AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A212287	003	Jul 29, 2019	Apr CMFD

PIROXICAM

CAPSULE;ORAL

PIROXICAM

AB		STRIDES PHARMA	10MG	A206136	001	Jun 20, 2017	Mar CAHN
AB			20MG	A206136	002	Jun 20, 2017	Mar CAHN

PODOFILOXSOLUTION;TOPICAL
CONDYLOX

AT	+	TEVA BRANDED PHARM	0.5%	N019795	001	Dec 13, 1990	Jan CAHN
----	---	--------------------	------	---------	-----	--------------	----------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

AA		NOSTRUM LABS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A202060	001	Mar 08, 2017	Jul CAHN
----	--	------------------	--	---------	-----	--------------	----------

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

AEROSPORIN

@ GLAXOSMITHKLINE

POLYMYXIN B SULFATE

EQ 500,000 UNITS BASE/VIAL

A062036 001

Jan CMS1

>D>	AP	MYLAN ASI	EQ 500,000 UNITS BASE/VIAL	A090110	001	Jun 29, 2011	Aug DISC
-----	----	-----------	----------------------------	---------	-----	--------------	----------

>A>		@	EQ 500,000 UNITS BASE/VIAL	A090110	001	Jun 29, 2011	Aug DISC
-----	--	---	----------------------------	---------	-----	--------------	----------

AP		XGEN PHARMS	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Feb CAHN
----	--	-------------	----------------------------	---------	-----	--------------	----------

POSACONAZOLE

SUSPENSION;ORAL

NOXAFIL

AB	+	SCHERING	40MG/ML	N022003	001	Sep 15, 2006	May CFTG
----	---	----------	---------	---------	-----	--------------	----------

POSACONAZOLE

AB		HIKMA	40MG/ML	A208773	001	May 15, 2020	May NFTG
----	--	-------	---------	---------	-----	--------------	----------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MICRO-K

+ @ NESHER PHARMS

8MEQ

N018238 001

May DISC

MICRO-K 10

+ @ NESHER PHARMS

10MEQ

N018238 002

May 14, 1984

May DISC

POTASSIUM CHLORIDE

AB		STRIDES PHARMA	8MEQ	A205549	001	Dec 08, 2015	Mar CAHN
----	--	----------------	------	---------	-----	--------------	----------

AB			10MEQ	A205549	002	Dec 08, 2015	Mar CAHN
----	--	--	-------	---------	-----	--------------	----------

FOR SUSPENSION, EXTENDED RELEASE;ORAL

MICRO-K LS

+ @ KV PHARM

20MEQ/PACKET

N019561 003

Aug 26, 1988

Feb CRLD

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 10MEQ

>A>	AP	FRESENIUS KABI USA	14.9MG/ML	A211087	001	Sep 09, 2020	Aug NEWA
-----	----	--------------------	-----------	---------	-----	--------------	----------

>A>	AP		746MG/100ML	A211087	002	Sep 09, 2020	Aug NEWA
-----	----	--	-------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 20MEQ

>A>	AP	FRESENIUS KABI USA	29.8MG/ML	A211087	003	Sep 09, 2020	Aug NEWA
-----	----	--------------------	-----------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 40MEQ

>A>	AP	FRESENIUS KABI USA	2.98GM/100ML	A211087	004	Sep 09, 2020	Aug NEWA
-----	----	--------------------	--------------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB1		AMNEAL	10MEQ	A212861	001	May 08, 2020	Apr NEWA
-----	--	--------	-------	---------	-----	--------------	----------

>D>	AB1		15MEQ	A212861	002	May 08, 2020	Aug DISC
-----	-----	--	-------	---------	-----	--------------	----------

>A>		@	15MEQ	A212861	002	May 08, 2020	Aug DISC
-----	--	---	-------	---------	-----	--------------	----------

AB1			15MEQ	A212861	002	May 08, 2020	Apr NEWA
-----	--	--	-------	---------	-----	--------------	----------

AB1			20MEQ	A212861	003	May 08, 2020	Apr NEWA
-----	--	--	-------	---------	-----	--------------	----------

>A>	AB1	CENTAUR PHARMS PVT	10MEQ	A213588	001	Aug 21, 2020	Aug NEWA
-----	-----	--------------------	-------	---------	-----	--------------	----------

>A>	AB1		20MEQ	A213588	002	Aug 21, 2020	Aug NEWA
-----	-----	--	-------	---------	-----	--------------	----------

AB2		GRANULES PHARMS	8MEQ	A211797	001	Mar 04, 2020	Feb NEWA
-----	--	-----------------	------	---------	-----	--------------	----------

AB2			10MEQ	A211797	002	Mar 04, 2020	Feb NEWA
-----	--	--	-------	---------	-----	--------------	----------

>D>		@ PII	10MEQ	A206630	001	Mar 29, 2019	Aug CAHN
-----	--	-------	-------	---------	-----	--------------	----------

>D>		@	15MEQ	A206630	002	Mar 29, 2019	Aug CAHN
-----	--	---	-------	---------	-----	--------------	----------

>D>		@	20MEQ	A206630	003	Mar 29, 2019	Aug CAHN
-----	--	---	-------	---------	-----	--------------	----------

		@ STRIDES PHARMA	8MEQ	A206881	001	Jan 22, 2019	Feb CAHN
--	--	------------------	------	---------	-----	--------------	----------

>A>		@	10MEQ	A206630	001	Mar 29, 2019	Aug CAHN
-----	--	---	-------	---------	-----	--------------	----------

		@	10MEQ	A206881	002	Jan 22, 2019	Feb CAHN
--	--	---	-------	---------	-----	--------------	----------

		@	10MEQ	A210097	001	Jun 17, 2019	Feb CAHN
--	--	---	-------	---------	-----	--------------	----------

>A>		@	15MEQ	A206630	002	Mar 29, 2019	Aug CAHN
-----	--	---	-------	---------	-----	--------------	----------

>A>		@	20MEQ	A206630	003	Mar 29, 2019	Aug CAHN
-----	--	---	-------	---------	-----	--------------	----------

		@	20MEQ	A210098	001	Apr 26, 2019	Feb CAHN
--	--	---	-------	---------	-----	--------------	----------

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CITRATE

AB	BIONPHARMA INC	10MEQ	A212799	001	Jun 29, 2020	Jun	NEWA
AB		15MEQ	A212799	002	Jun 29, 2020	Jun	NEWA
AB	RISING	5MEQ	A077440	001	Jun 09, 2006	Apr	CAHN
AB		10MEQ	A077440	002	Jun 09, 2006	Apr	CAHN

PRALIDOXIME CHLORIDE

INJECTABLE;INJECTION
PRALIDOXIME CHLORIDE (AUTOINJECTOR)
+! MERIDIAN MEDCL TECHN 300MG/ML
SOLUTION;INTRAMUSCULAR
PRALIDOXIME CHLORIDE (AUTOINJECTOR)

+!	MERIDIAN MEDCL TECHN	300MG/ML	N018986	001	Apr 26, 1983	Jun	CTNA
+!		600MG/2ML (300MG/ML)	N018986	001	Apr 26, 1983	Jun	CDFR
			N018986	001	Apr 26, 1983	Jun	CPOT

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

>D>	AB	GRAVITI PHARMS	0.25MG	A211088	001	Oct 03, 2018	Aug	CAHN
	AB		0.25MG	A211088	001	Oct 03, 2018	May	CAHN
>D>	AB		0.5MG	A211088	002	Oct 03, 2018	Aug	CAHN
	AB		0.5MG	A211088	002	Oct 03, 2018	May	CAHN
>D>	AB		0.75MG	A211088	003	Oct 03, 2018	Aug	CAHN
	AB		0.75MG	A211088	003	Oct 03, 2018	May	CAHN
>D>	AB		1MG	A211088	004	Oct 03, 2018	Aug	CAHN
	AB		1MG	A211088	004	Oct 03, 2018	May	CAHN
>D>	AB		1.5MG	A211088	005	Oct 03, 2018	Aug	CAHN
	AB		1.5MG	A211088	005	Oct 03, 2018	May	CAHN
	@	HERITAGE PHARMA	0.125MG	A077724	001	Feb 19, 2008	Apr	DISC
	@		0.25MG	A077724	002	Feb 19, 2008	Apr	DISC
	@		0.5MG	A077724	003	Feb 19, 2008	Apr	DISC
	@		1MG	A077724	004	Feb 19, 2008	Apr	DISC
	@		1.5MG	A077724	005	Feb 19, 2008	Apr	DISC
	@	MACLEODS PHARMS LTD	0.125MG	A202164	001	Sep 20, 2012	Jun	DISC
	@		0.25MG	A202164	002	Sep 20, 2012	Jun	DISC
	@		0.5MG	A202164	003	Sep 20, 2012	Jun	DISC
	@		1MG	A202164	004	Sep 20, 2012	Jun	DISC
	@		1.5MG	A202164	005	Sep 20, 2012	Jun	DISC
	@	MYLAN	0.125MG	A077854	001	Oct 08, 2010	Jan	DISC
	@		0.25MG	A077854	002	Oct 08, 2010	Jan	DISC
	@		0.5MG	A077854	003	Oct 08, 2010	Jan	DISC
	@		0.75MG	A090764	001	Apr 09, 2010	Jan	DISC
	@		1MG	A077854	004	Oct 08, 2010	Jan	DISC
	@		1.5MG	A077854	005	Oct 08, 2010	Jan	DISC
>A>	AB	RISING	0.25MG	A211088	001	Oct 03, 2018	Aug	CAHN
>A>	AB		0.5MG	A211088	002	Oct 03, 2018	Aug	CAHN
>A>	AB		0.75MG	A211088	003	Oct 03, 2018	Aug	CAHN
>A>	AB		1MG	A211088	004	Oct 03, 2018	Aug	CAHN
>A>	AB		1.5MG	A211088	005	Oct 03, 2018	Aug	CAHN
	AB	ZENNOVA	0.125MG	A090151	001	Apr 30, 2012	Feb	CAHN
	AB		0.25MG	A090151	002	Apr 30, 2012	Feb	CAHN
	AB		0.5MG	A090151	003	Apr 30, 2012	Feb	CAHN
	AB		0.75MG	A090151	006	Apr 30, 2012	Feb	CAHN
	AB		1MG	A090151	004	Apr 30, 2012	Feb	CAHN
	AB		1.5MG	A090151	005	Apr 30, 2012	Feb	CAHN

PRASTERONE

INSERT;VAGINAL
INTRAROSA

+!	MILLICENT	6.5MG	N208470	001	Nov 16, 2016	Jun	CAHN
----	-----------	-------	---------	-----	--------------	-----	------

PRASUGREL HYDROCHLORIDE

TABLET;ORAL
PRASUGREL

AB	DR REDDYS LABS LTD	EQ 5MG BASE	A205926	001	Jul 07, 2020	Jul	NEWA
AB		EQ 10MG BASE	A205926	002	Jul 07, 2020	Jul	NEWA

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

AB	APPCO	10MG	A209869	001	Apr 13, 2018	Jul CAHN
AB		20MG	A209869	002	Apr 13, 2018	Jul CAHN
AB		40MG	A209869	003	Apr 13, 2018	Jul CAHN
AB		80MG	A209869	004	Apr 13, 2018	Jul CAHN

PREDNICARBATE

CREAM; TOPICAL

DERMATOP E EMOLLIENT

+	@ VALEANT BERMUDA	0.1%	N020279	001	Oct 29, 1993	Apr DISC
---	-------------------	------	---------	-----	--------------	----------

PREDNICARBATE

@	FOUGERA PHARMS	0.1%	A077287	001	Sep 19, 2006	Apr DISC
---	----------------	------	---------	-----	--------------	----------

OINTMENT; TOPICAL

DERMATOP

+	@ VALEANT PHARMS NORTH	0.1%	N019568	001	Sep 23, 1991	Feb DISC
---	------------------------	------	---------	-----	--------------	----------

PREDNICARBATE

!	FOUGERA PHARMS	0.1%	A077236	001	Mar 09, 2007	Feb CTEC
AB	!	0.1%	A077236	001	Mar 09, 2007	Feb CHRS

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

OMNIPRED

AB	+	NOVARTIS	1%	N017469	001	Jan CHRS
AB	+		1%	N017469	001	Jan CRLD

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

PHARM ASSOC	EQ 30MG BASE/5ML	A204962	001	Mar 11, 2020	Feb NEWA
@ VINTAGE	EQ 15MG BASE/5ML	A079010	001	May 26, 2009	Jun DISC

PREDNISONE

TABLET; ORAL

PREDNISONE

>D>	AB	AMNEAL	1MG	A213385	001	Jun 16, 2020	Aug DISC
>A>		@	1MG	A213385	001	Jun 16, 2020	Aug DISC
	AB		1MG	A213385	001	Jun 16, 2020	Jun NEWA
>D>	AB		5MG	A213385	002	Jun 16, 2020	Aug DISC
>A>		@	5MG	A213385	002	Jun 16, 2020	Aug DISC
	AB		5MG	A213385	002	Jun 16, 2020	Jun NEWA
>D>	AB		10MG	A213386	001	Jun 24, 2020	Aug DISC
>A>		@	10MG	A213386	001	Jun 24, 2020	Aug DISC
	AB		10MG	A213386	001	Jun 24, 2020	Jun NEWA
>D>	AB		20MG	A213386	002	Jun 24, 2020	Aug DISC
>A>		@	20MG	A213386	002	Jun 24, 2020	Aug DISC
	AB		20MG	A213386	002	Jun 24, 2020	Jun NEWA
>A>	AB	STRIDES PHARMA	1MG	A210785	001	Sep 02, 2020	Aug NEWA

TABLET, DELAYED RELEASE; ORAL

PREDNISONE

@	ACTAVIS LABS FL INC	1MG	A204867	001	Apr 25, 2017	Apr DISC
@		2MG	A204867	002	Apr 25, 2017	Apr DISC
@		5MG	A204867	003	Apr 25, 2017	Apr DISC

RAYOS

+	HORIZON PHARMA USA	1MG	N202020	001	Jul 26, 2012	Apr CTEC
+		2MG	N202020	002	Jul 26, 2012	Apr CTEC
+	!	5MG	N202020	003	Jul 26, 2012	Apr CTEC

PREGABALIN

CAPSULE; ORAL

LYRICA

AB	+	PFIZER	25MG	N021446	001	Dec 30, 2004	Jun CAHN
AB	+		50MG	N021446	002	Dec 30, 2004	Jun CAHN
AB	+		75MG	N021446	003	Dec 30, 2004	Jun CAHN
AB	+		100MG	N021446	004	Dec 30, 2004	Jun CAHN
AB	+		150MG	N021446	005	Dec 30, 2004	Jun CAHN
AB	+		200MG	N021446	006	Dec 30, 2004	Jun CAHN
AB	+		225MG	N021446	007	Dec 30, 2004	Jun CAHN
AB	+	!	300MG	N021446	008	Dec 30, 2004	Jun CAHN

CAPSULE;ORAL
PREGABALIN

AB	ACTAVIS ELIZABETH	25MG	A091025	001	Jul 09, 2020	Jul NEWA
AB		50MG	A091025	002	Jul 09, 2020	Jul NEWA
AB		75MG	A091025	003	Jul 09, 2020	Jul NEWA
AB		100MG	A091025	004	Jul 09, 2020	Jul NEWA
AB		150MG	A091025	005	Jul 09, 2020	Jul NEWA
AB		200MG	A091025	006	Jul 09, 2020	Jul NEWA
AB		225MG	A091025	007	Jul 09, 2020	Jul NEWA
AB		300MG	A091025	008	Jul 09, 2020	Jul NEWA
AB	CELLTRION	50MG	A212865	001	Mar 20, 2020	Mar NEWA
AB		75MG	A212865	002	Mar 20, 2020	Mar NEWA
AB		100MG	A212865	003	Mar 20, 2020	Mar NEWA
AB		150MG	A212865	004	Mar 20, 2020	Mar NEWA
AB	HIKAL	25MG	A213423	001	Mar 23, 2020	Mar NEWA
AB		50MG	A213423	002	Mar 23, 2020	Mar NEWA
AB		75MG	A213423	003	Mar 23, 2020	Mar NEWA
AB		100MG	A213423	004	Mar 23, 2020	Mar NEWA
AB		150MG	A213423	005	Mar 23, 2020	Mar NEWA
AB		200MG	A213423	006	Mar 23, 2020	Mar NEWA
AB		225MG	A213423	007	Mar 23, 2020	Mar NEWA
AB		300MG	A213423	008	Mar 23, 2020	Mar NEWA
	@ MYLAN	25MG	A091228	001	Sep 20, 2019	Feb DISC
	@	50MG	A091228	002	Sep 20, 2019	Feb DISC
	@	75MG	A091228	003	Sep 20, 2019	Feb DISC
	@	100MG	A091228	004	Sep 20, 2019	Feb DISC
	@	150MG	A091228	005	Sep 20, 2019	Feb DISC
	@	200MG	A091228	006	Sep 20, 2019	Feb DISC
	@	225MG	A091228	007	Sep 20, 2019	Feb DISC
	@	300MG	A091228	008	Sep 20, 2019	Feb DISC

SOLUTION;ORAL
LYRICA

AA	+! PFIZER	20MG/ML	N022488	001	Jan 04, 2010	Jun CAHN
	TABLET, EXTENDED RELEASE;ORAL					
	LYRICA CR					
	+ PFIZER	82.5MG	N209501	001	Oct 11, 2017	Jun CAHN
	+	165MG	N209501	002	Oct 11, 2017	Jun CAHN
	+!	330MG	N209501	003	Oct 11, 2017	Jun CAHN

PRIMIDONESUSPENSION;ORAL
MYSOLINE

>D>	@ NURO PHARMA	250MG/5ML	N010401	001		Aug CRLD
>A>	+ @	250MG/5ML	N010401	001		Aug CRLD

PROCHLORPERAZINE MALEATETABLET;ORAL
COMPAZINE

	+ @ GLAXOSMITHKLINE	EQ 5MG BASE	N010571	001		Mar CRLD
	+ @	EQ 10MG BASE	N010571	002		Mar CRLD
	+ @	EQ 25MG BASE	N010571	003		Mar CRLD
	PROCHLORPERAZINE MALEATE					
	@ SANDOZ	EQ 5MG BASE	A040101	001	Jul 19, 1996	Mar DISC
	@	EQ 10MG BASE	A040101	002	Jul 19, 1996	Mar DISC
	PROCOMP					
AB	! JUBILANT CADISTA	EQ 10MG BASE	A040268	002	Feb 27, 1998	Mar CHRS

PROGESTERONESYSTEM;VAGINAL
MILPROSA

	+! FERRING PHARMS INC	1.78GM	N201110	001	Apr 29, 2020	Apr NEWA
--	-----------------------	--------	---------	-----	--------------	----------

PROMETHAZINE HYDROCHLORIDEINJECTABLE;INJECTION
PROMETHAZINE HYDROCHLORIDE

AP	XGEN PHARMS	25MG/ML	A040737	001	Apr 24, 2008	Feb CAHN
AP		50MG/ML	A040737	002	Apr 24, 2008	Feb CAHN

SUPPOSITORY;RECTAL
PROMETHAZINE HYDROCHLORIDE

	@ WATSON LABS INC	12.5MG	A040479	001	Jun 24, 2003	Mar DISC
	@	25MG	A040479	002	Jun 24, 2003	Mar DISC

SYRUP;ORAL					
PROMETHAZINE HYDROCHLORIDE					
	@ PHARM ASSOC	6.25MG/5ML	A040643	001	Apr 26, 2006 Jun CAHN
	@ VINTAGE	6.25MG/5ML	A040643	001	Apr 26, 2006 Jun DISC
<u>PROPAFENONE HYDROCHLORIDE</u>					
CAPSULE, EXTENDED RELEASE;ORAL					
PROPAFENONE HYDROCHLORIDE					
AB	TWI PHARMS	225MG	A212928	001	Jun 18, 2020 Jun NEWA
AB		325MG	A212928	002	Jun 18, 2020 Jun NEWA
AB		425MG	A212928	003	Jun 18, 2020 Jun NEWA
AB	UPSHER SMITH LABS	225MG	A212744	001	Jun 25, 2020 Jun NEWA
AB		325MG	A212744	002	Jun 25, 2020 Jun NEWA
AB		425MG	A212744	003	Jun 25, 2020 Jun NEWA
<u>PROPOFOL</u>					
INJECTABLE;INJECTION					
PROPOFOL					
AB	WEST-WARD PHARMS INT	10MG/ML	A074848	001	Apr 19, 2005 Jul CMFD
<u>PROPRANOLOL HYDROCHLORIDE</u>					
TABLET;ORAL					
PROPRANOLOL HYDROCHLORIDE					
	@ IMPAX LABS INC	10MG	A071972	001	Apr 06, 1988 Jul DISC
	@	20MG	A071972	002	Apr 06, 1988 Jul DISC
	@	40MG	A071972	003	Apr 06, 1988 Jul DISC
<u>PYRAZINAMIDE</u>					
TABLET;ORAL					
PYRAZINAMIDE					
AB	! AKORN	500MG	A081319	001	Jun 30, 1992 Jul CTEC
	!	500MG	A081319	001	Jun 30, 1992 Feb CHRS
		500MG	A081319	001	Jun 30, 1992 Feb CTEC
	@ DAVA PHARMS INC	500MG	A080157	001	Feb DISC
AB	MACLEODS PHARMS LTD	500MG	A212541	001	Jul 27, 2020 Jul NEWA
	@ NOVITIUM PHARMA	500MG	A080157	001	Jul CAHN
<u>PYRIMETHAMINE</u>					
TABLET;ORAL					
DARAPRIM					
AB	+! VYERA PHARMS LLC	25MG	N008578	001	Feb CFTG
PYRIMETHAMINE					
AB	CEROVENE INC	25MG	A207127	001	Feb 28, 2020 Feb NFTG
<u>QUETIAPINE FUMARATE</u>					
TABLET;ORAL					
QUETIAPINE FUMARATE					
AB	ZENNOVA	EQ 25MG BASE	A090960	001	Mar 27, 2012 Feb CAHN
AB		EQ 50MG BASE	A090960	002	Mar 27, 2012 Feb CAHN
AB		EQ 100MG BASE	A090960	003	Mar 27, 2012 Feb CAHN
AB		EQ 200MG BASE	A090960	004	Mar 27, 2012 Feb CAHN
AB		EQ 300MG BASE	A090960	005	Mar 27, 2012 Feb CAHN
AB		EQ 400MG BASE	A090960	006	Mar 27, 2012 Feb CAHN
<u>QUINAPRIL HYDROCHLORIDE</u>					
TABLET;ORAL					
QUINAPRIL HYDROCHLORIDE					
	@ MYLAN	EQ 5MG BASE	A076694	001	Dec 23, 2004 Mar DISC
	@	EQ 10MG BASE	A076694	002	Dec 23, 2004 Mar DISC
	@	EQ 20MG BASE	A076694	003	Dec 23, 2004 Mar DISC
	@	EQ 40MG BASE	A076694	004	Dec 23, 2004 Mar DISC
<u>QUINIDINE SULFATE</u>					
TABLET;ORAL					
QUINIDINE SULFATE					
!	SANDOZ	200MG	A088072	002	May CHRS
		200MG	A088072	002	May CTEC
!		300MG	A088072	001	Sep 26, 1983 Apr CHRS
		300MG	A088072	001	Sep 26, 1983 Apr CTEC
	@ WATSON LABS	200MG	A083288	001	Apr DISC
	@	300MG	A085583	001	Apr DISC

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

RALOXIFENE HYDROCHLORIDE

>A>	AB	CADILA PHARMS LTD	60MG	A211324	001	Aug 18, 2020	Aug NEWA
-----	----	-------------------	------	---------	-----	--------------	----------

RAMELTEON

TABLET;ORAL

RAMELTEON

>A>	AB	GRANULES PHARMS	8MG	A213186	001	Aug 21, 2020	Aug NEWA
	AB	I3 PHARMS	8MG	A212650	001	Apr 10, 2020	Mar NEWA

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

@	TEVA PHARMS	1.25MG	A077470	001	Jun 18, 2008	Mar DISC
@		2.5MG	A077470	002	Jun 18, 2008	Mar DISC
@		5MG	A077470	003	Jun 18, 2008	Mar DISC
@		10MG	A077470	004	Jun 18, 2008	Mar DISC

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

@	AJANTA PHARMA LTD	EQ 150MG BASE	A209859	001	Sep 27, 2018	Jun DISC
@		EQ 300MG BASE	A209859	002	Sep 27, 2018	Jun DISC
@	APPCO	EQ 150MG BASE	A211893	001	Apr 05, 2019	May DISC
@		EQ 300MG BASE	A211893	002	Apr 05, 2019	May DISC

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

	@	AMNEAL PHARMS	EQ 15MG BASE/ML	A078312	001	Sep 02, 2008	Apr DISC
	@	HI TECH PHARMA	EQ 15MG BASE/ML	A091078	001	Mar 22, 2011	May DISC
AA		NOSTRUM LABS INC	EQ 15MG BASE/ML	A078684	001	Aug 27, 2009	Jul CAHN
	@	TARO	EQ 15MG BASE/ML	A077476	001	Jun 13, 2011	May DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

	@	AMNEAL PHARMS NY	EQ 150MG BASE	A077824	001	Oct 13, 2006	Jan DISC
	@		EQ 300MG BASE	A077824	002	Oct 13, 2006	Jan DISC
	@	HERITAGE PHARMA	EQ 150MG BASE	A075165	001	Sep 30, 1998	Apr DISC
	@		EQ 300MG BASE	A075165	002	Sep 30, 1998	Apr DISC
	@	STRIDES PHARMA	EQ 150MG BASE	A205512	001	Aug 22, 2016	Apr DISC
	@		EQ 150MG BASE	A210010	001	Aug 01, 2018	Jan DISC
	@		EQ 300MG BASE	A205512	002	Aug 22, 2016	Apr DISC
AB	!		EQ 300MG BASE	A205512	002	Aug 22, 2016	Jan CHRS
	@		EQ 300MG BASE	A210010	002	Aug 01, 2018	Jan DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

AB		ANI PHARMS INC	500MG	A210482	001	Oct 29, 2019	Jan CAHN
AB			1GM	A210482	002	Oct 29, 2019	Jan CAHN
	@	CIPLA	500MG	A211291	001	May 28, 2019	Jul DISC
	@		1GM	A211291	002	May 28, 2019	Jul DISC
AB		MANKIND PHARMA	500MG	A212284	001	Feb 12, 2020	Jan NEWA
AB			1GM	A212284	002	Feb 12, 2020	Jan NEWA
AB		MICRO LABS	500MG	A211745	001	Feb 27, 2020	Feb NEWA
AB			1GM	A211745	002	Feb 27, 2020	Feb NEWA
AB		SUNGEN PHARMA	500MG	A212781	001	Mar 23, 2020	Mar NEWA
AB			1GM	A212781	002	Mar 23, 2020	Mar NEWA
AB		SUNSHINE	500MG	A211865	001	Mar 23, 2020	Mar NEWA
AB			1GM	A211865	002	Mar 23, 2020	Mar NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

@	WATSON LABS INC	EQ 0.5MG BASE	A201823	001	Jul 01, 2013	Mar DISC
@		EQ 1MG BASE	A201823	002	Jul 01, 2013	Mar DISC

REMIMAZOLAM BESYLATEPOWDER; INTRAVENOUS
BYFAVO

+!	ACACIA	EQ 20MG BASE/VIAL	N212295	001	Jul 02, 2020	Jul CAHN
+!	COSMO	EQ 20MG BASE/VIAL	N212295	001	Jul 02, 2020	Jul NEWA

REPAGLINIDETABLET; ORAL
REPAGLINIDE

@	ACTAVIS TOTOWA	0.5MG	A090008	001	Jan 22, 2014	Mar DISC
@		1MG	A090008	002	Jan 22, 2014	Mar DISC
@		2MG	A090008	003	Jan 22, 2014	Mar DISC

RIBAVIRINCAPSULE; ORAL
RIBAVIRIN

@	TEVA	200MG	A076277	001	Oct 04, 2004	Mar DISC
---	------	-------	---------	-----	--------------	----------

TABLET; ORAL
RIBAVIRIN

@	BEXIMCO PHARMS USA	200MG	A202546	001	Aug 12, 2014	Feb DISC
@		400MG	A202546	002	Aug 12, 2014	Feb DISC
@		500MG	A202546	003	Aug 12, 2014	Feb DISC
@		600MG	A202546	004	Aug 12, 2014	Feb DISC
@	ZYDUS PHARMS USA	400MG	A077094	002	Mar 16, 2007	Feb DISC
@		500MG	A077094	004	Apr 18, 2008	Feb DISC
@		600MG	A077094	003	Mar 16, 2007	Feb DISC

RIFAMPININJECTABLE; INJECTION
RIFAMPIN

@	EMCURE PHARMS LTD	600MG/VIAL	A204101	001	Aug 18, 2014	May DISC
---	-------------------	------------	---------	-----	--------------	----------

RILUZOLETABLET; ORAL
RILUZOLE

AB	KENTON	50MG	A206045	001	Dec 09, 2019	Mar CAHN
----	--------	------	---------	-----	--------------	----------

RIMEGEPANT SULFATETABLET, ORALLY DISINTEGRATING; ORAL
NURTEC ODT

+!	BIOHAVEN PHARM	EQ 75MG BASE	N212728	001	Feb 27, 2020	Feb NEWA
----	----------------	--------------	---------	-----	--------------	----------

RIPRETINIBTABLET; ORAL
QINLOCK

+!	DECIPHERA PHARMS	50MG	N213973	001	May 15, 2020	May NEWA
----	------------------	------	---------	-----	--------------	----------

>A> RISDIPLAMFOR SOLUTION; ORAL
EVRYSDI

>A>	+!	GENENTECH INC	0.75MG/ML	N213535	001	Aug 07, 2020	Aug NEWA
-----	----	---------------	-----------	---------	-----	--------------	----------

RISPERIDONETABLET; ORAL
RISPERIDONE

@	MYLAN	0.25MG	A076288	001	Sep 15, 2008	Jun DISC
---	-------	--------	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERIDONE

@	ACTAVIS LABS FL INC	0.5MG	A076996	001	Apr 19, 2011	Mar DISC
@		1MG	A076996	002	Apr 19, 2011	Mar DISC
@		2MG	A076996	003	Apr 19, 2011	Mar DISC
@		3MG	A076996	004	Apr 19, 2011	Mar DISC
@		4MG	A076996	005	Apr 19, 2011	Mar DISC
@	HERITAGE PHARMA	0.5MG	A076908	001	Mar 12, 2012	Apr DISC
@		1MG	A076908	002	Mar 12, 2012	Apr DISC
@		2MG	A076908	003	Mar 12, 2012	Apr DISC

RITODRINE HYDROCHLORIDEINJECTABLE; INJECTION
YUTOPAR

@ ASTRAZENECA	15MG/ML	N018580	002	Sep 27, 1984	Jan CMS1
---------------	---------	---------	-----	--------------	----------

RIVASTIGMINE TARTRATECAPSULE; ORAL
RIVASTIGMINE TARTRATE

@ APOTEX INC	EQ 1.5MG BASE	A091072	001	May 16, 2013	May DISC
@	EQ 3MG BASE	A091072	002	May 16, 2013	May DISC
@	EQ 4.5MG BASE	A091072	003	May 16, 2013	May DISC
@	EQ 6MG BASE	A091072	004	May 16, 2013	May DISC

RIZATRIPTAN BENZOATETABLET, ORALLY DISINTEGRATING; ORAL
RIZATRIPTAN BENZOATE

@ MYLAN PHARMS INC	EQ 5MG BASE	A078173	001	Dec 31, 2012	Feb DISC
@	EQ 10MG BASE	A078173	002	Dec 31, 2012	Feb DISC

ROCURONIUM BROMIDEINJECTABLE; INJECTION
ROCURONIUM BROMIDE

@ TEVA PHARMS	50MG/5ML (10MG/ML)	A078717	001	Nov 26, 2008	Mar DISC
@	100MG/10ML (10MG/ML)	A078717	002	Nov 26, 2008	Mar DISC

ROFLUMILASTTABLET; ORAL
ROFLUMILAST

AB @ MICRO LABS	500MCG	A208180	001	Mar 22, 2019	Jun DISC
STRIDES PHARMA	500MCG	A208247	001	Mar 30, 2020	Mar NEWA

ROMIDEPSINSOLUTION; INTRAVENOUS
ROMIDEPSIN

+ TEVA PHARMS USA INC	10MG/2ML (5MG/ML)	N208574	001	Mar 13, 2020	Mar NEWA
+!	27.5MG/5.5ML (5MG/ML)	N208574	002	Mar 13, 2020	Mar NEWA

ROPINIROLE HYDROCHLORIDETABLET; ORAL
ROPINIROLE HYDROCHLORIDE

@ HIKMA	EQ 0.25MG BASE	A077852	001	May 05, 2008	Feb DISC
@	EQ 0.5MG BASE	A077852	002	May 05, 2008	Feb DISC
@	EQ 1MG BASE	A077852	003	May 05, 2008	Feb DISC
@	EQ 2MG BASE	A077852	004	May 05, 2008	Feb DISC
@	EQ 3MG BASE	A077852	005	May 05, 2008	Feb DISC
@	EQ 4MG BASE	A077852	006	May 05, 2008	Feb DISC
@	EQ 5MG BASE	A077852	007	May 19, 2008	Feb DISC

TABLET, EXTENDED RELEASE; ORAL
REQUIP XL

+ @ GLAXOSMITHKLINE LLC	EQ 8MG BASE	N022008	004	Jun 13, 2008	Mar DISC
ROPINIROLE HYDROCHLORIDE					
@ WATSON LABS INC	EQ 2MG BASE	A200431	001	Jun 06, 2012	Mar DISC
@	EQ 4MG BASE	A200431	002	Jun 06, 2012	Mar DISC
@	EQ 6MG BASE	A200431	003	Jun 06, 2012	Mar DISC
@	EQ 8MG BASE	A200431	004	Jun 06, 2012	Mar DISC
@	EQ 12MG BASE	A200431	005	Jun 06, 2012	Mar DISC

ROPIVACAINE HYDROCHLORIDESOLUTION; INJECTION
ROPIVACAINE HYDROCHLORIDE

AP	CAPLIN	40MG/20ML (2MG/ML)	A212808	001	Apr 09, 2020	Mar NEWA
AP		100MG/20ML (5MG/ML)	A212808	002	Apr 09, 2020	Mar NEWA
AP		150MG/30ML (5MG/ML)	A212808	003	Apr 09, 2020	Mar NEWA
AP		200MG/20ML (10MG/ML)	A212808	004	Apr 09, 2020	Mar NEWA
AP	HIKMA	40MG/20ML (2MG/ML)	A214074	001	Jul 20, 2020	Jul NEWA
AP		150MG/30ML (5MG/ML)	A214074	002	Jul 20, 2020	Jul NEWA
AP		150MG/20ML (7.5MG/ML)	A214074	003	Jul 20, 2020	Jul NEWA
AP		200MG/20ML (10MG/ML)	A214074	004	Jul 20, 2020	Jul NEWA

ROSUVASTATIN CALCIUM

CAPSULE;ORAL

>D> EZALLOR

>D>	+	SUN PHARMA GLOBAL	EQ 5MG BASE	N208647	001	Dec 18, 2018	Aug CTNA
>D>	+		EQ 10MG BASE	N208647	002	Dec 18, 2018	Aug CTNA
>D>	+		EQ 20MG BASE	N208647	003	Dec 18, 2018	Aug CTNA
>D>	+		EQ 40MG BASE	N208647	004	Dec 18, 2018	Aug CTNA

>A> EZALLOR SPRINKLE

>A>	+	SUN PHARMA GLOBAL	EQ 5MG BASE	N208647	001	Dec 18, 2018	Aug CTNA
>A>	+		EQ 10MG BASE	N208647	002	Dec 18, 2018	Aug CTNA
>A>	+		EQ 20MG BASE	N208647	003	Dec 18, 2018	Aug CTNA
>A>	+		EQ 40MG BASE	N208647	004	Dec 18, 2018	Aug CTNA

TABLET;ORAL

ROSUVASTATIN CALCIUM

	@	APOTEX INC	5MG	A079145	001	Jul 19, 2016	Jun DISC
	@		10MG	A079145	002	Jul 19, 2016	Jun DISC
	@		20MG	A079145	003	Jul 19, 2016	Jun DISC
	@		40MG	A079145	004	Jul 19, 2016	Jun DISC
AB		RENATA	5MG	A207062	001	Oct 31, 2016	Jul CAHN
AB			10MG	A207062	002	Oct 31, 2016	Jul CAHN
AB			20MG	A207062	003	Oct 31, 2016	Jul CAHN
AB			40MG	A207062	004	Oct 31, 2016	Jul CAHN
AB		SUNSHINE	5MG	A210667	001	Apr 01, 2020	Mar NEWA
AB			10MG	A210667	002	Apr 01, 2020	Mar NEWA
AB			20MG	A210667	003	Apr 01, 2020	Mar NEWA
AB			40MG	A210667	004	Apr 01, 2020	Mar NEWA
	@	ZHEJIANG YONGTAI	5MG	A212059	001	Nov 04, 2019	Apr DISC
	@		10MG	A212059	002	Nov 04, 2019	Apr DISC
	@		20MG	A212059	003	Nov 04, 2019	Apr DISC
	@		40MG	A212059	004	Nov 04, 2019	Apr DISC

SAFINAMIDE MESYLATE

TABLET;ORAL

XADAGO

+	MDD US	50MG	N207145	001	Mar 21, 2017	Jul CAHN
+		100MG	N207145	002	Mar 21, 2017	Jul CAHN

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL

KUVAN

>D>	+	BIOMARIN PHARM	500MG/PACKET	N205065	002	Oct 27, 2015	Aug CTEC
>A> AB	+		500MG/PACKET	N205065	002	Oct 27, 2015	Aug CTEC
		SAPROPTERIN DIHYDROCHLORIDE					
>D>	@	PAR PHARM INC	500MG/PACKET	A210027	001	Aug 20, 2019	Aug CMFD
>A> AB			500MG/PACKET	A210027	001	Aug 20, 2019	Aug CMFD

TABLET;ORAL

KUVAN

>D>	+	BIOMARIN PHARM	100MG	N022181	001	Dec 13, 2007	Aug CTEC
>A> AB	+		100MG	N022181	001	Dec 13, 2007	Aug CTEC
		SAPROPTERIN DIHYDROCHLORIDE					
>D>	@	PAR PHARM INC	100MG	A207200	001	May 10, 2019	Aug CMFD
>A> AB			100MG	A207200	001	May 10, 2019	Aug CMFD

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL

SELEGILINE HYDROCHLORIDE

@ DAVA PHARMS INC 5MG

A075352 001 Nov 30, 1998 Feb DISC

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

@ I3 PHARMS 5MG

A074672 001 Apr 01, 1997 Jul CAHN

@ MLV 5MG

A074672 001 Apr 01, 1997 Mar CAHN

SELEXIPAG

TABLET;ORAL

UPTRAVI

+	ACTELION PHARMS LTD	0.4MG	N207947	002	Dec 21, 2015	Jan CHRS
+		1.6MG	N207947	008	Dec 21, 2015	Jan CHRS

SELPERCATINIBCAPSULE;ORAL
RETEVMO

+	LOXO ONCOLOGY INC	40MG	N213246	001	May 08, 2020	May NEWA
+	!	80MG	N213246	002	May 08, 2020	May NEWA

SELUMETINIB SULFATECAPSULE;ORAL
KOSELUGO

+	ASTRAZENECA PHARMS	EQ 10MG BASE	N213756	001	Apr 10, 2020	Apr NEWA
+	!	EQ 25MG BASE	N213756	002	Apr 10, 2020	Apr NEWA

SEMAGLUTIDESOLUTION;SUBCUTANEOUS
OZEMPIC

+	!	NOVO	4MG/3ML (1.34MG/ML)	N209637	002	Apr 09, 2019	Jan NEWA
---	---	------	---------------------	---------	-----	--------------	----------

SERTRALINE HYDROCHLORIDECONCENTRATE;ORAL
ZOLOFT

AA	+	!	UPJOHN	EQ 20MG BASE/ML	N020990	001	Dec 07, 1999	Jun CAHN
----	---	---	--------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

			@	SUN PHARM INDS LTD	EQ 25MG BASE	A077977	001	Feb 06, 2007	Jul DISC
			@		EQ 50MG BASE	A077977	002	Feb 06, 2007	Jul DISC
			@		EQ 100MG BASE	A077977	003	Feb 06, 2007	Jul DISC
			@		EQ 150MG BASE	A077977	004	Feb 06, 2007	Jul DISC
			@		EQ 200MG BASE	A077977	005	Feb 06, 2007	Jul DISC
AB				VIWIT PHARM	EQ 25MG BASE	A076882	001	Feb 06, 2007	Mar CAHN
AB					EQ 25MG BASE	A076882	001	Feb 06, 2007	Mar CAHN
AB					EQ 50MG BASE	A076882	002	Feb 06, 2007	Mar CAHN
AB					EQ 50MG BASE	A076882	002	Feb 06, 2007	Mar CAHN
AB					EQ 100MG BASE	A076882	003	Feb 06, 2007	Mar CAHN
AB					EQ 100MG BASE	A076882	003	Feb 06, 2007	Mar CAHN
				ZOLOFT					
AB	+			UPJOHN	EQ 25MG BASE	N019839	005	Mar 06, 1996	Jun CAHN
AB	+				EQ 50MG BASE	N019839	001	Dec 30, 1991	Jun CAHN
AB	+	!			EQ 100MG BASE	N019839	002	Dec 30, 1991	Jun CAHN
			@		EQ 150MG BASE	N019839	003	Dec 30, 1991	Jun CAHN
			@		EQ 200MG BASE	N019839	004	Dec 30, 1991	Jun CAHN

SEVELAMER CARBONATE

TABLET;ORAL

SEVELAMER CARBONATE

AB				ANXIN	800MG	A212970	001	Apr 09, 2020	Mar NEWA
			@	IMPAX LABS INC	800MG	A090975	001	Oct 23, 2017	Jul DISC
>D>	AB			MYLAN	800MG	A201069	001	Aug 05, 2020	Aug DISC
>A>			@		800MG	A201069	001	Aug 05, 2020	Aug DISC
AB					800MG	A201069	001	Aug 05, 2020	Jul NEWA
AB				ZYDUS PHARMS	800MG	A207759	001	Aug 11, 2020	Jul NEWA

SILDENAFIL CITRATEFOR SUSPENSION;ORAL
REVATIO

AB	+	!	UPJOHN	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	Jun CAHN
----	---	---	--------	-----------------	---------	-----	--------------	----------

SILDENAFIL CITRATE

AB				APTAPHARMA INC	EQ 10MG BASE/ML	A213041	001	Aug 06, 2020	Jul NEWA
AB				TEVA PHARMS USA	EQ 10MG BASE/ML	A211534	001	May 29, 2020	May NEWA

SOLUTION;INTRAVENOUS
REVATIO

AP	+	!	UPJOHN	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Jun CAHN
----	---	---	--------	--	---------	-----	--------------	----------

TABLET;ORAL
REVATIO

AB	+	!	UPJOHN	EQ 20MG BASE	N021845	001	Jun 03, 2005	Jun CAHN
----	---	---	--------	--------------	---------	-----	--------------	----------

SILDENAFIL CITRATE

AB				APPCO	EQ 25MG BASE	A207178	001	Mar 02, 2020	Apr CPOT
AB					25MG	A207178	001	Mar 02, 2020	Feb NEWA
AB					EQ 50MG BASE	A207178	002	Mar 02, 2020	Apr CPOT
AB					50MG	A207178	002	Mar 02, 2020	Feb NEWA
AB					EQ 100MG BASE	A207178	003	Mar 02, 2020	Apr CPOT

TABLET;ORAL
SILDENAFIL CITRATE

AB		100MG	A207178	003	Mar 02, 2020	Feb NEWA
	@ PERRIGO R AND D	EQ 25MG BASE	A205791	001	Apr 23, 2020	Jul DISC
AB		EQ 25MG BASE	A205791	001	Apr 23, 2020	Apr NEWA
	@	EQ 50MG BASE	A205791	002	Apr 23, 2020	Jul DISC
AB		EQ 50MG BASE	A205791	002	Apr 23, 2020	Apr NEWA
AB	REYOUNG	EQ 25MG BASE	A208494	001	Jun 12, 2020	Jun NEWA
AB		EQ 50MG BASE	A208494	002	Jun 12, 2020	Jun NEWA
AB		EQ 100MG BASE	A208494	003	Jun 12, 2020	Jun NEWA
AB	SUNSHINE	EQ 25MG BASE	A213032	001	Jun 11, 2020	Jun NEWA
AB		EQ 50MG BASE	A213032	002	Jun 11, 2020	Jun NEWA
AB		EQ 100MG BASE	A213032	003	Jun 11, 2020	Jun NEWA
>A>	AB	UMEDICA LABS PVT LTD	A209302	001	Aug 25, 2020	Aug NEWA
>A>	AB	EQ 100MG BASE	A209302	002	Aug 25, 2020	Aug NEWA
VIAGRA						
AB	+ UPJOHN	EQ 25MG BASE	N020895	001	Mar 27, 1998	Jun CAHN
AB	+	EQ 50MG BASE	N020895	002	Mar 27, 1998	Jun CAHN
AB	+	EQ 100MG BASE	N020895	003	Mar 27, 1998	Jun CAHN

SILODOSIN

CAPSULE;ORAL
SILODOSIN

AB	HETERO LABS LTD V	4MG	A204793	001	Feb 14, 2020	Feb NEWA
AB		8MG	A204793	002	Feb 14, 2020	Feb NEWA

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;INTRAVENOUS
AMMONUL

AP	+! BAUSCH	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Jun CAHN
----	-----------	-----------------------------	---------	-----	--------------	----------

SODIUM BICARBONATE

INJECTABLE;INJECTION
SODIUM BICARBONATE

AP	! EXELA PHARMA	0.5MEQ/ML	A211091	001	Jun 20, 2019	Jul CHRS
AP	!	0.9MEQ/ML	A211091	002	Jun 20, 2019	Jul CHRS
AP	!	1MEQ/ML	A211091	003	Jun 20, 2019	Jul CHRS
	@ HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09, 2005	Jul DISC
	@	1MEQ/ML	A077394	002	Nov 09, 2005	Jul DISC
AP	HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017	Jul CMFD

SODIUM CHLORIDE

INJECTABLE;INJECTION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

>D>	AP	BAXTER HLTHCARE	450MG/100ML	N018016	001	Aug CRLD
>A>	AP	+!	450MG/100ML	N018016	001	Aug CHRS
>A>	AP	+	450MG/100ML	N018016	001	Aug CRLD

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
NEPHRON

AP		9MG/ML	A211968	001	Apr 23, 2020	Apr NEWA
----	--	--------	---------	-----	--------------	----------

SOLUTION;INTRAVENOUS
SODIUM CHLORIDE 14.6%

	+	HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984	Jul CTNA	
	+		2.5MEQ/ML	N018897	001	Jul 20, 1984	Jul CDFR	
	+	@	50MEQ/20ML (2.5MEQ/ML)	N018897	001	Jul 20, 1984	Jul DISC	
	+		50MEQ/20ML (2.5MEQ/ML)	N018897	001	Jul 20, 1984	Jul CPOT	
	+	!	100MEQ/40ML (2.5MEQ/ML)	N018897	002	Jul 20, 1984	Jul NEWA	
		SODIUM CHLORIDE 23.4%						
	+	!	HOSPIRA	400MEQ/100ML (4MEQ/ML)	N018897	003	Jun 18, 2020	Jul NEWA

SODIUM IODIDE I-123

CAPSULE;ORAL
SODIUM IODIDE I 123

AA	CURIUM	100uCi	A071909	001	Feb 28, 1989	Feb CAHN
AA		200uCi	A071910	001	Feb 28, 1989	Feb CAHN

SODIUM IODIDE I-131

SOLUTION;ORAL
HICON

AA	+!	JUBILANT DRAXIMAGE	250-1000mCi	N021305	007	Dec 05, 2011	Jan CFTG
		SODIUM IODIDE I 131					
AA		INTL ISOTOPES	250-1000mCi	A209166	001	Feb 05, 2020	Jan NFTG

SODIUM LACTATE

INJECTABLE;INJECTION
SODIUM LACTATE IN PLASTIC CONTAINER
+ @ HOSPIRA 5MEQ/ML

N018947 001 Sep 05, 1984 Jun DISC

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION
SODIUM NITROPRUSSIDE
@ AMPHASTAR PHARMS INC 25MG/ML
>A> AP HAINAN POLY PHARM 25MG/ML

A209832 001 Dec 18, 2017 Jul DISC
A214199 001 Aug 25, 2020 Aug NEWA

SODIUM OXYBATE

SOLUTION;ORAL
SODIUM OXYBATE
AA HIKMA 0.5GM/ML
XYREM
AA +! JAZZ PHARMS 0.5GM/ML

A202090 001 Jan 17, 2017 Jul CPOT
N021196 001 Jul 17, 2002 Jul CPOT

SODIUM PHENYLBUTYRATE

TABLET;ORAL
SODIUM PHENYLBUTYRATE
@ ALVOGEN 500MG

A090910 001 Nov 18, 2011 Jan DISC

SODIUM POLYSTYRENE SULFONATE

SUSPENSION;ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
@ HIKMA 15GM/60ML

A089049 001 Nov 17, 1986 Feb DISC

SOFOSBUVIR; VELPATASVIR

TABLET;ORAL
EPCLUSA
+ GILEAD SCIENCES INC 200MG;50MG

N208341 002 Mar 19, 2020 Mar NEWA

SOLIFENACIN SUCCINATE

SUSPENSION;ORAL
VESICARE LS
+! ASTELLAS 1MG/ML
TABLET;ORAL
SOLIFENACIN SUCCINATE

N209529 001 May 26, 2020 May NEWA

>D>	AB	GRAVITI PHARMS	5MG	A211423	001	Dec 11, 2019	Aug CAHN
	AB		5MG	A211423	001	Dec 11, 2019	May CAHN
>D>	AB		10MG	A211423	002	Dec 11, 2019	Aug CAHN
	AB		10MG	A211423	002	Dec 11, 2019	May CAHN
>A>	AB	RISING	5MG	A211423	001	Dec 11, 2019	Aug CAHN
>A>	AB		10MG	A211423	002	Dec 11, 2019	Aug CAHN
	AB	SUNSHINE	5MG	A213346	001	Apr 13, 2020	Mar NEWA
	AB		10MG	A213346	002	Apr 13, 2020	Mar NEWA

SOLRIAMFETOL HYDROCHLORIDE

TABLET;ORAL
SUNOSI
+ JAZZ EQ 75MG BASE
+ 75MG
+! EQ 150MG BASE
+ EQ 150MG BASE
+ 150MG

N211230 001 Jun 17, 2019 Jan CPOT
N211230 001 Jun 17, 2019 Jan CAIN
N211230 002 Jun 17, 2019 Apr CHRS
N211230 002 Jun 17, 2019 Jan CPOT
N211230 002 Jun 17, 2019 Jan CAIN

SPIRONOLACTONE

TABLET;ORAL
ALDACTONE
AB + PFIZER 25MG
AB + 50MG
AB +! 100MG

N012151 009 Dec 30, 1983 Jul CAHN
N012151 008 Dec 30, 1982 Jul CAHN
N012151 010 Dec 30, 1983 Jul CAHN

STREPTOMYCIN SULFATE

INJECTABLE;INJECTION
STREPTOMYCIN SULFATE
! XGEN PHARMS EQ 1GM BASE/VIAL

A064210 001 Jun 30, 1998 Feb CAHN

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
QUELICIN PRESERVATIVE FREE

	+ @	HOSPIRA	50MG/ML		N008845	002			Apr	CRLD
	+ @		100MG/ML		N008845	004			Apr	CRLD
		SUCCINYLCHOLINE CHLORIDE								
AP		ACCORD HLTHCARE	20MG/ML		A213705	001	May 20, 2020		May	NEWA
AP		AMPHASTAR PHARMS INC	20MG/ML		A213432	001	Jun 08, 2020		Jun	NEWA
AP		ASPIRO	20MG/ML		A213810	001	May 04, 2020		Apr	NEWA
AP		GLAND PHARMA LTD	20MG/ML		A214246	001	Jun 16, 2020		Jun	NEWA
AP		HIKMA	20MG/ML		A213229	001	Jun 12, 2020		Jun	NEWA
AP		INDOCO	20MG/ML		A214308	001	May 22, 2020		May	NEWA
AP		NIVAGEN PHARMS INC	20MG/ML		A211625	001	May 19, 2020		May	NEWA
		SUCOSTRIN								
	+ @	APOTHECON	20MG/ML		N008847	001			Apr	CRLD
	+ @		100MG/ML		N008847	003			Apr	CRLD

SUCRALFATE

TABLET; ORAL
SUCRALFATE

AB		NOSTRUM LABS INC	1GM		A074415	001	Jun 08, 1998		May	CMFD
----	--	------------------	-----	--	---------	-----	--------------	--	-----	------

SULFACETAMIDE SODIUM

LOTION; TOPICAL
KLARON

AB	+!	BAUSCH	10%		N019931	001	Dec 23, 1996		Mar	CAHN
----	----	--------	-----	--	---------	-----	--------------	--	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP		TEVA PHARMS USA	80MG/ML; 16MG/ML		A073303	001	Oct 31, 1991		Mar	CMFD
----	--	-----------------	------------------	--	---------	-----	--------------	--	-----	------

SULFASALAZINE

TABLET; ORAL
SULFASALAZINE

>A>	AB	NUVO PHARMS INC	500MG		A040349	001	Jan 11, 2002		Aug	CAHN
>D>	AB	VINTAGE PHARMS	500MG		A040349	001	Jan 11, 2002		Aug	CAHN
		TABLET, DELAYED RELEASE; ORAL								
		SULFASALAZINE								
>A>	AB	NUVO PHARMS INC	500MG		A075339	001	Jan 11, 2002		Aug	CAHN
>D>	AB	VINTAGE PHARMS	500MG		A075339	001	Jan 11, 2002		Aug	CAHN

SUMATRIPTAN SUCCINATE

TABLET; ORAL
SUMATRIPTAN SUCCINATE

AB		COREPHARMA	EQ 25MG BASE		A200263	001	Jun 19, 2012		Feb	CAHN
AB			EQ 50MG BASE		A200263	002	Jun 19, 2012		Feb	CAHN
AB			EQ 100MG BASE		A200263	003	Jun 19, 2012		Feb	CAHN

TADALAFIL

TABLET; ORAL
TADALAFIL

AB		ACCORD HLTHCARE	10MG		A209167	003	Oct 23, 2019		Jul	NEWA
----	--	-----------------	------	--	---------	-----	--------------	--	-----	------

TAMOXIFEN CITRATE

TABLET; ORAL
TAMOXIFEN CITRATE

>A>	AB	EUGIA PHARMA	EQ 10MG BASE		A213358	001	Aug 14, 2020		Aug	NEWA
>A>	AB		EQ 20MG BASE		A213358	002	Aug 14, 2020		Aug	NEWA

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL
TAMSULOSIN HYDROCHLORIDE

	@	ANBISON LAB	0.4MG		A211885	001	Oct 17, 2019		Apr	DISC
--	---	-------------	-------	--	---------	-----	--------------	--	-----	------

TAPENTADOL HYDROCHLORIDE

SOLUTION;ORAL

NUCYNTA

+	@ COLLEGIUM PHARM INC	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012	Feb CAHN
---	-----------------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

NUCYNTA

+	COLLEGIUM PHARM INC	EQ 50MG BASE	N022304	001	Nov 20, 2008	Feb CAHN
---	---------------------	--------------	---------	-----	--------------	----------

+		EQ 75MG BASE	N022304	002	Nov 20, 2008	Feb CAHN
---	--	--------------	---------	-----	--------------	----------

+	!	EQ 100MG BASE	N022304	003	Nov 20, 2008	Feb CAHN
---	---	---------------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

NUCYNTA ER

+	COLLEGIUM PHARM INC	EQ 50MG BASE	N200533	001	Aug 25, 2011	Feb CAHN
---	---------------------	--------------	---------	-----	--------------	----------

+		EQ 100MG BASE	N200533	002	Aug 25, 2011	Feb CAHN
---	--	---------------	---------	-----	--------------	----------

+		EQ 150MG BASE	N200533	003	Aug 25, 2011	Feb CAHN
---	--	---------------	---------	-----	--------------	----------

+		EQ 200MG BASE	N200533	004	Aug 25, 2011	Feb CAHN
---	--	---------------	---------	-----	--------------	----------

+	!	EQ 250MG BASE	N200533	005	Aug 25, 2011	Feb CAHN
---	---	---------------	---------	-----	--------------	----------

TAZEMETOSTAT HYDROBROMIDE

TABLET;ORAL

TAZVERIK

+	!	EPIZYME INC	EQ 200MG BASE	N211723	001	Jan 23, 2020	Jan NEWA
---	---	-------------	---------------	---------	-----	--------------	----------

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE;INJECTION

HEPATOLITE

@	SUN PHARM INDS INC	N/A	N018467	001	Mar 16, 1982	Apr CAHN
---	--------------------	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE;INJECTION

TECHNETIUM TC-99M MEBROFENIN

AP		SUN PHARM INDS INC	N/A	A078242	001	Jan 29, 2008	Apr CAHN
----	--	--------------------	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE;INJECTION

CIS-MDP

	SUN PHARM INDS INC	N/A	N018124	001		Apr CAHN
--	--------------------	-----	---------	-----	--	----------

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE;INJECTION

TECHNETIUM TC99M MERTIATIDE KIT

AP		SOMMER PHARMS II LLC	N/A	A206489	001	Feb 06, 2020	Jan NEWA
----	--	----------------------	-----	---------	-----	--------------	----------

AP		SUN PHARM INDS INC	N/A	A208994	001	Jul 12, 2019	Apr CAHN
----	--	--------------------	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE;INJECTION

CIS-PYRO

AP		SUN PHARM INDS INC	N/A	N019039	001	Jun 30, 1987	Apr CAHN
----	--	--------------------	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE;INJECTION

TECHNETIUM TC 99M SESTAMIBI

AP		CURIUM	N/A	A078098	001	Sep 22, 2008	Feb CAHN
----	--	--------	-----	---------	-----	--------------	----------

AP		SUN PHARM INDS INC	10-30mCi	A079157	001	Jul 10, 2009	Apr CAHN
----	--	--------------------	----------	---------	-----	--------------	----------

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION;INJECTION, ORAL

AN-SULFUR COLLOID

+	!	SUN PHARM INDS INC	N/A	N017858	001		Apr CAHN
---	---	--------------------	-----	---------	-----	--	----------

TELMISARTAN

TABLET;ORAL

TELMISARTAN

@	CELLTRION	20MG	A078710	001	Jan 08, 2014	Jul CAHN
---	-----------	------	---------	-----	--------------	----------

@		40MG	A078710	002	Jan 08, 2014	Jul CAHN
---	--	------	---------	-----	--------------	----------

@		80MG	A078710	003	Jan 08, 2014	Jul CAHN
---	--	------	---------	-----	--------------	----------

@	JUBILANT GENERICS	20MG	A204164	001	Aug 22, 2016	Jan DISC
---	-------------------	------	---------	-----	--------------	----------

@		40MG	A204164	002	Aug 22, 2016	Jan DISC
---	--	------	---------	-----	--------------	----------

@		80MG	A204164	003	Aug 22, 2016	Jan DISC
---	--	------	---------	-----	--------------	----------

AB		MICRO LABS	20MG	A207016	001	Oct 03, 2017	Apr CMFD
----	--	------------	------	---------	-----	--------------	----------

AB			40MG	A207016	002	Oct 03, 2017	Apr CMFD
----	--	--	------	---------	-----	--------------	----------

AB			80MG	A207016	003	Oct 03, 2017	Apr CMFD
----	--	--	------	---------	-----	--------------	----------

TEMOZOLOMIDE

CAPSULE;ORAL							
TEMOZOLOMIDE							
AB	CHARTWELL	5MG	A206413	001	Apr 12, 2016	Jun	CAHN
AB		20MG	A206413	002	Apr 12, 2016	Jun	CAHN
AB		100MG	A206413	003	Apr 12, 2016	Jun	CAHN
AB		140MG	A206413	004	Apr 12, 2016	Jun	CAHN
AB		180MG	A206413	005	Apr 12, 2016	Jun	CAHN
AB		250MG	A206413	006	Apr 12, 2016	Jun	CAHN

TENAPANOR HYDROCHLORIDE

TABLET;ORAL							
IBSRELA							
+	@ ARDELYX INC	EQ 50MG BASE	N211801	001	Sep 12, 2019	Mar	DISC

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL							
TENOFOVIR DISOPROXIL FUMARATE							
@	MYLAN	150MG	A206569	001	Nov 27, 2018	Feb	DISC
@		200MG	A206569	002	Nov 27, 2018	Feb	DISC
@		250MG	A206569	003	Nov 27, 2018	Feb	DISC
@		300MG	A206569	004	Nov 27, 2018	Feb	DISC

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL							
TERAZOSIN HYDROCHLORIDE							
@	HERITAGE PHARMA	EQ 1MG BASE	A075614	002	Jan 30, 2001	Feb	DISC
@		EQ 2MG BASE	A075614	001	Jan 30, 2001	Feb	DISC
@		EQ 5MG BASE	A075614	003	Jan 30, 2001	Feb	DISC
@		EQ 10MG BASE	A075614	004	Jan 30, 2001	Feb	DISC

TERBUTALINE SULFATE

TABLET;ORAL							
TERBUTALINE SULFATE							
AB	TWI PHARMS	2.5MG	A211832	001	Jun 19, 2020	Jun	NEWA
AB		5MG	A211832	002	Jun 19, 2020	Jun	NEWA

TERIFLUNOMIDE

TABLET;ORAL							
TERIFLUNOMIDE							
AB	IMPAX	14MG	A209677	001	Jun 17, 2020	Jun	NEWA
	@ MYLAN	7MG	A209702	001	Feb 28, 2020	Mar	DISC
AB		7MG	A209702	001	Feb 28, 2020	Feb	NEWA
	@	14MG	A209702	002	Feb 28, 2020	Mar	DISC
AB		14MG	A209702	002	Feb 28, 2020	Feb	NEWA

TERIPARATIDE

INJECTABLE;SUBCUTANEOUS							
FORTEO							
+	! LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318	002	Jun 25, 2008	Jan	CAIN
	@	0.75MG/3ML (0.25MG/ML)	N021318	001	Nov 26, 2002	Jan	CAIN
SOLUTION;SUBCUTANEOUS							
BONSITY							
	ALVOGEN	0.62MG/2.48ML (0.25MG/ML)	N211939	001	Oct 04, 2019	Jan	CAIN
FORTEO							
+	! LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318	002	Jun 25, 2008	Jan	CDFR
	@	0.75MG/3ML (0.25MG/ML)	N021318	001	Nov 26, 2002	Jan	CDFR

TESTOSTERONE

GEL, METERED;TRANSDERMAL							
ANDROGEL							
+	@ ABBVIE	12.5MG/1.25GM ACTUATION	N021015	003	Sep 26, 2003	Mar	DISC
TESTOSTERONE							
BX	! ACTAVIS LABS UT INC	12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Mar	CHRS
BX		12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Mar	CTEC
AB	XIROMED	1.62% (20.25MG/1.25GM ACTUATION)	A210835	001	Apr 16, 2020	Apr	NEWA

TETRABENAZINE

TABLET; ORAL

TETRABENAZINE

AB	APOTEX	12.5MG	A206093	001	Mar 17, 2020	Mar NEWA
AB		25MG	A206093	002	Mar 17, 2020	Mar NEWA
AB	PIRAMAL HLTHCARE UK	12.5MG	A213316	001	Jan 22, 2020	Jan NEWA
AB		25MG	A213316	002	Jan 22, 2020	Jan NEWA

THALLOUS CHLORIDE TL-201

INJECTABLE; INTRAVENOUS

THALLOUS CHLORIDE TL 201

@	CURIUM	2mCi/ML	A077698	001	Nov 09, 2006	Feb CAHN
---	--------	---------	---------	-----	--------------	----------

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

THEOPHYLLINE

	ALEMBIC PHARMS LTD	300MG	A090430	001	Oct 27, 2010	Jun CTEC
@	HERITAGE PHARMA	300MG	A089763	001	Apr 30, 1990	Jun DISC

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

AB	MYLAN	10MG	A088004	002	Mar 15, 1983	Mar CTEC
AB		25MG	A088004	003	Mar 15, 1983	Mar CTEC
AB		50MG	A088004	004	Mar 15, 1983	Mar CTEC
AB	!	100MG	A088004	001	Nov 18, 1983	Mar CTEC
AB	SUN PHARM INDUSTRIES	10MG	A089953	004	Aug 01, 1986	Mar CMFD
AB		25MG	A089953	003	Aug 01, 1986	Mar CMFD
AB		50MG	A089953	002	Aug 01, 1986	Mar CMFD
AB		100MG	A089953	001	Oct 07, 1988	Mar CMFD

THIOTEPA

POWDER; INTRACAVITARY, INTRAVENOUS, INTRAVESICAL

TEPADINA

AP	+	ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017	May CPOT
AP	+		100MG/VIAL	N208264	002	Jan 26, 2017	May CPOT
		THIOTEPA					
AP		MSN	15MG/VIAL	A213049	001	Mar 04, 2020	May CPOT
AP			100MG/VIAL	A213049	002	Mar 04, 2020	May CPOT

POWDER; INTRAVENOUS

TEPADINA

AP	+	ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017	Feb CFTG
AP	+		100MG/VIAL	N208264	002	Jan 26, 2017	Feb CFTG
		THIOTEPA					
AP		MSN	15MG/VIAL	A213049	001	Mar 04, 2020	Feb NFTG
AP			100MG/VIAL	A213049	002	Mar 04, 2020	Feb NFTG

TICAGRELOR

TABLET; ORAL

TICAGRELOR

AB		SIGMAPHARM LABS LLC	90MG	A208596	001	Apr 07, 2020	Mar NEWA
----	--	---------------------	------	---------	-----	--------------	----------

TIGECYCLINE

POWDER; INTRAVENOUS

TIGECYCLINE

>D>	AP	FRESENIUS KABI USA	50MG/VIAL	N205645	001	Dec 01, 2016	Aug CRLD
>A>	AP	+	50MG/VIAL	N205645	001	Dec 01, 2016	Aug CHRS
>A>	AP	+	50MG/VIAL	N205645	001	Dec 01, 2016	Aug CRLD

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 2MG BASE	A213544	001	Mar 24, 2020	Mar NEWA
AB		EQ 4MG BASE	A213544	002	Mar 24, 2020	Mar NEWA
AB		EQ 6MG BASE	A213544	003	Mar 24, 2020	Mar NEWA
AB	RUBICON	EQ 2MG BASE	A213798	001	May 27, 2020	May NEWA
AB		EQ 4MG BASE	A213798	002	May 27, 2020	May NEWA
AB		EQ 6MG BASE	A213798	003	May 27, 2020	May NEWA

TOBRAMYCINSOLUTION; INHALATION
TOBRAMYCIN

>D>	@ MYLAN	300MG/5ML	A209554	001	Oct 13, 2017	Feb DISC
>A>	@ TEVA PHARMS USA	300MG/4ML	A210915	001	Jun 26, 2019	Aug CMFD
AN		300MG/4ML	A210915	001	Jun 26, 2019	Aug CMFD

TOBRAMYCIN SULFATEINJECTABLE; INJECTION
TOBRAMYCIN SULFATE

AP	! XGEN PHARMS	EQ 1.2GM BASE/VIAL	A065013	001	Aug 17, 2001	Feb CAHN
----	---------------	--------------------	---------	-----	--------------	----------

TOLAZAMIDETABLET; ORAL
TOLAZAMIDE

	@ MYLAN PHARMS INC	250MG	A070259	001	Jan 02, 1986	Mar DISC
	@	500MG	A070259	003	Mar 17, 1986	Mar DISC

TOLCAPONETABLET; ORAL
TOLCAPONE

AB	ALVOGEN	100MG	A207729	001	Jul 29, 2020	Jul NEWA
----	---------	-------	---------	-----	--------------	----------

TOLTERODINE TARTRATECAPSULE, EXTENDED RELEASE; ORAL
DETROL LA

AB	+ UPJOHN	2MG	N021228	001	Dec 22, 2000	Jul CAHN
AB	+!	4MG	N021228	002	Dec 22, 2000	Jul CAHN

TOLTERODINE TARTRATE

AB	AJANTA PHARMA LTD	2MG	A213397	001	May 19, 2020	May NEWA
AB		4MG	A213397	002	May 19, 2020	May NEWA

TABLET; ORAL
DETROL

AB	+ UPJOHN	1MG	N020771	001	Mar 25, 1998	Jun CAHN
AB	+!	2MG	N020771	002	Mar 25, 1998	Jun CAHN

TOLTERODINE TARTRATE

	@ MYLAN PHARMS INC	1MG	A202641	001	Nov 27, 2012	Jan DISC
	@	2MG	A202641	002	Nov 27, 2012	Jan DISC
AB	UNICHEM LABS LTD	1MG	A205399	001	Aug 05, 2020	Jul NEWA
AB		2MG	A205399	002	Aug 05, 2020	Jul NEWA
AB	UNIQUE PHARM LABS	1MG	A204721	001	Jan 24, 2020	Jan NEWA
AB		2MG	A204721	002	Jan 24, 2020	Jan NEWA

TOLVAPTANTABLET; ORAL
SAMSCA

AB	+! OTSUKA AMERICA PHARM	30MG	N022275	002	May 19, 2009	May CFTG
----	-------------------------	------	---------	-----	--------------	----------

TOLVAPTAN

AB	ALKEM LABS LTD	30MG	A211891	001	May 19, 2020	May NEWA
AB		60MG	A211891	002	May 19, 2020	May NFTG
AB	APOTEX	30MG	A207605	001	May 19, 2020	May NFTG

TOPIRAMATETABLET; ORAL
TOPIRAMATE

AB	VIWIT PHARM	25MG	A077733	001	Mar 27, 2009	Mar CAHN
AB		25MG	A077733	001	Mar 27, 2009	Mar CAHN
AB		50MG	A077733	002	Mar 27, 2009	Mar CAHN
AB		50MG	A077733	002	Mar 27, 2009	Mar CAHN
AB		100MG	A077733	003	Mar 27, 2009	Mar CAHN
AB		100MG	A077733	003	Mar 27, 2009	Mar CAHN
AB		200MG	A077733	004	Mar 27, 2009	Mar CAHN
AB		200MG	A077733	004	Mar 27, 2009	Mar CAHN

TOREMIFENE CITRATETABLET; ORAL
TOREMIFENE CITRATE

>A>	AB MSN	EQ 60MG BASE	A212818	001	Aug 18, 2020	Aug NEWA
-----	--------	--------------	---------	-----	--------------	----------

TORSEMIDETABLET;ORAL
DEMADEX

>D>	AB	+	MYLAN SPECIALITY LP	5MG	N020136	001	Aug 23, 1993	Aug DISC
>A>		+	@	5MG	N020136	001	Aug 23, 1993	Aug DISC
>D>	AB	+		10MG	N020136	002	Aug 23, 1993	Aug DISC
>A>		+	@	10MG	N020136	002	Aug 23, 1993	Aug DISC
>D>	AB	+	!	20MG	N020136	003	Aug 23, 1993	Aug DISC
>A>		+	@	20MG	N020136	003	Aug 23, 1993	Aug DISC
>D>	AB	+		100MG	N020136	004	Aug 23, 1993	Aug DISC
>A>		+	@	100MG	N020136	004	Aug 23, 1993	Aug DISC

TORSEMIDE

	AB		COREPHARMA	5MG	A076894	001	May 31, 2005	Feb CAHN
	AB			10MG	A076894	002	May 31, 2005	Feb CAHN
	AB			20MG	A076894	003	May 31, 2005	Feb CAHN
	AB			100MG	A076894	004	May 31, 2005	Feb CAHN
>D>	AB		PLIVA PHARM IND	20MG	A076346	003	May 30, 2003	Aug CHRS
>A>	AB	!		20MG	A076346	003	May 30, 2003	Aug CHRS

TRAMADOL HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
CONZIP

>D>		+	CIPHER PHARMS INC	150MG	N022370	004	Aug 01, 2011	Aug DISC
>A>		+	@	150MG	N022370	004	Aug 01, 2011	Aug DISC

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

@ MACLEODS PHARMS LTD 50MG

A205702 001 Sep 25, 2015 May DISC

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

		@	CAPLIN	100MG/ML	A212360	001	Jul 17, 2019	Jan DISC
AP			XGEN PHARMS	100MG/ML	A201580	001	Jun 14, 2013	Feb CAHN

TABLET;ORAL

TRANEXAMIC ACID

@ ANI PHARMS INC 650MG

A203256 001 Jul 25, 2016 Jan CAHN

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

AB			AUROLIFE PHARMA LLC	50MG	A204852	001	Feb 05, 2020	Jan NEWA
AB				100MG	A204852	002	Feb 05, 2020	Jan NEWA
AB				150MG	A204852	003	Feb 05, 2020	Jan NEWA
AB				300MG	A204852	004	Feb 05, 2020	Jan NEWA

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS

TREPROSTINIL

AP			DR REDDYS	1MG/ML	A210214	001	May 22, 2020	May NEWA
AP				2.5MG/ML	A210214	002	May 22, 2020	May NEWA
AP				5MG/ML	A210214	003	May 22, 2020	May NEWA
AP				10MG/ML	A210214	004	May 22, 2020	May NEWA

TRIAMCINOLONE ACETONIDE

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

AT			QUAGEN	0.025%	A213559	001	Jul 01, 2020	Jun NEWA
AT				0.1%	A213559	002	Jul 01, 2020	Jun NEWA
AT			SAPTALIS PHARMS	0.1%	A040672	002	Dec 13, 2006	Mar CAHN

OINTMENT;TOPICAL

TRIAMCINOLONE ACETONIDE

AT			MACLEODS PHARMS LTD	0.025%	A209828	001	Nov 23, 2018	Mar CTNA
AT				0.1%	A209828	002	Nov 23, 2018	Mar CTNA
AT				0.5%	A209828	003	Nov 23, 2018	Mar CTNA
AT			STRIDES PHARMA	0.05%	A212356	001	Jun 01, 2020	May NEWA
		@		0.1%	A211315	001	Mar 18, 2020	Jul DISC
AT				0.1%	A211315	001	Mar 18, 2020	Mar NEWA
		@		0.5%	A211315	002	Mar 18, 2020	Jul DISC
AT				0.5%	A211315	002	Mar 18, 2020	Mar NEWA

TRIAZOLAM

TABLET; ORAL

TRIAZOLAM

@ MYLAN PHARMS INC

0.125MG

A074031 001 Mar 25, 1994 Jan DISC

@

0.25MG

A074031 002 Mar 25, 1994 Jan DISC

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

TRIENTINE HYDROCHLORIDE

AB LUPIN LTD

250MG

A211637 001 May 21, 2020 May NEWA

AB RISING

250MG

A212238 001 Feb 20, 2020 Feb NEWA

TRIFAROTENE

CREAM; TOPICAL

AKLIEF

+! GALDERMA LABS LP

0.005%

N211527 001 Oct 04, 2019 May CAHN

TRIEPTANOIN

LIQUID; ORAL

DOJOLVI

+! ULTRAGENYX PHARM INC

100% w/w

N213687 001 Jun 30, 2020 Jul NEWA

>D> TRIMETHOPRIM HYDROCHLORIDE

>D> SOLUTION; ORAL

>D> PRIMISOL

>D> +! ALLEGIS EQ 50MG BASE/5ML

N074973 001 Jan 24, 2000 Aug DISC

>A> + @ EQ 50MG BASE/5ML

N074973 001 Jan 24, 2000 Aug DISC

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR

+! VERITY EQ 3.75MG BASE/VIAL

N020715 001 Jun 15, 2000 Jul CAHN

+! EQ 11.25MG BASE/VIAL

N021288 001 Jun 29, 2001 Jul CAHN

+! EQ 22.5MG BASE/VIAL

N022437 001 Mar 10, 2010 Jul CAHN

TROMETHAMINE

SOLUTION; INJECTION

THAM

+! HOSPIRA 18GM/500ML (3.6GM/100ML)

N013025 002 Jun CMFD

TROSPIMUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TROSPIMUM CHLORIDE

AB GRANULES PHARMS 60MG

A213185 001 Apr 23, 2020 Apr NEWA

TUCATINIB

TABLET; ORAL

TUKYSA

+ SEATTLE GENETICS 50MG

N213411 001 Apr 17, 2020 Apr NEWA

+! 150MG

N213411 002 Apr 17, 2020 Apr NEWA

URSODIOL

CAPSULE; ORAL

URSODIOL

>A> LGM PHARMA 200MG

A205789 001 May 08, 2020 Aug CAHN

>A> 400MG

A205789 002 May 08, 2020 Aug CAHN

>D> NEXGEN PHARMA INC 200MG

A205789 001 May 08, 2020 Aug CAHN

>D> 200MG

A205789 001 May 08, 2020 Apr NFTG

>D> 400MG

A205789 002 May 08, 2020 Aug CAHN

>D> 400MG

A205789 002 May 08, 2020 Apr NFTG

AB RISING 300MG

A213200 001 Feb 12, 2020 Jan NEWA

>A> AB UPSHER SMITH LABS 300MG

A213555 001 Aug 17, 2020 Aug NEWA

TABLET; ORAL

URSODIOL

>D> AB IMPAX LABS INC 250MG

A200826 001 Dec 23, 2011 Aug DISC

>A> @ 250MG

A200826 001 Dec 23, 2011 Aug DISC

>D> AB 500MG

A200826 002 Dec 23, 2011 Aug DISC

>A> @ 500MG

A200826 002 Dec 23, 2011 Aug DISC

>A> AB STRIDES PHARMA 250MG

A213504 001 Aug 20, 2020 Aug NEWA

>A> AB 500MG

A213504 002 Aug 20, 2020 Aug NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

	@ TEVA PHARMS	EQ 500MG BASE	A077655	001	May 24, 2010	Jan DISC
	@	EQ 1GM BASE	A077655	002	May 24, 2010	Jan DISC
AB	YILING	EQ 500MG BASE	A209553	001	Mar 18, 2020	Mar NEWA
AB		EQ 1GM BASE	A209553	002	Mar 18, 2020	Mar NEWA

VALPROIC ACID

SYRUP; ORAL

VALPROIC ACID

>D>	@ APOTEX	250MG/5ML	A077105	001	Jul 29, 2005	Aug CAHN
>A>	@ NOSTRUM LABS INC	250MG/5ML	A077105	001	Jul 29, 2005	Aug CAHN

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL

FIRVANQ KIT

+	!	AZURITY	EQ 25MG BASE/ML	N208910	001	Jan 26, 2018	Jun CAHN
+	!		EQ 50MG BASE/ML	N208910	002	Jan 26, 2018	Jun CAHN

VANCOCIN HYDROCHLORIDE

!	ANI PHARMS INC	EQ 250MG BASE/5ML	A061667	002	Jul 13, 1983	Jul CHRS
---	----------------	-------------------	---------	-----	--------------	----------

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP		HAINAN POLY PHARM	EQ 500MG BASE/VIAL	A212332	001	Jun 12, 2019	Jun CMFD
AP			EQ 1GM BASE/VIAL	A212332	002	Jun 12, 2019	Jun CMFD
AP		HIKMA	EQ 500MG BASE/VIAL	A203300	001	Aug 11, 2020	Jul NEWA
AP			EQ 1GM BASE/VIAL	A203300	002	Aug 11, 2020	Jul NEWA
	!	HOSPIRA	EQ 1.5GM BASE/VIAL	A062912	003	Jul 10, 2020	Jul NFTG
AP	!	MYLAN LABS LTD	EQ 10GM BASE/VIAL	A091554	001	Sep 19, 2011	Jul CHRS
AP		PHARM ASSOC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Jan CAHN
AP			EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Jan CAHN

SOLUTION; INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

+	!	XELLIA PHARMS APS	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N211962	001	Feb 15, 2019	May CPOT
+	!		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N211962	005	May 13, 2020	May NEWA
+	!		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N211962	002	Feb 15, 2019	May CPOT
+	!		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N211962	006	May 13, 2020	May NEWA
+	!		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N211962	003	Feb 15, 2019	May CPOT
+	!		EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML)	N211962	007	May 13, 2020	May NEWA
+	!		EQ 2GM BASE/400ML (EQ 5MG BASE/ML)	N211962	004	Feb 15, 2019	May CPOT

VARDENAFIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL

VARDENAFIL HYDROCHLORIDE

AB		MACLEODS PHARMS LTD	10MG	A205988	001	Mar 10, 2020	Feb NEWA
----	--	---------------------	------	---------	-----	--------------	----------

VASOPRESSIN

SOLUTION; INTRAVENOUS

VASOPRESSIN

>A>	+	!	AM REGENT	20UNITS/ML (20UNITS/ML)	N212593	001	Aug 03, 2020	Aug NEWA
>A>			VASOSTRICT					
	+	!	PAR STERILE PRODUCTS	40UNITS/100ML (0.4UNITS/ML)	N204485	003	Apr 15, 2020	Apr NEWA
	+	!		60UNITS/100ML (0.6UNITS/ML)	N204485	004	Apr 15, 2020	Apr NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

AB	+	UPJOHN	EQ 37.5MG BASE	N020699	001	Oct 20, 1997	Jun CAHN
AB	+		EQ 75MG BASE	N020699	002	Oct 20, 1997	Jun CAHN
		@	EQ 100MG BASE	N020699	003	Oct 20, 1997	Jun CAHN
AB	+	!	EQ 150MG BASE	N020699	004	Oct 20, 1997	Jun CAHN
			VENLAFAXINE HYDROCHLORIDE				
AB		INVENTIA HLTHCARE	EQ 37.5MG BASE	A203332	001	Mar 12, 2020	Mar NEWA
AB			EQ 75MG BASE	A203332	002	Mar 12, 2020	Mar NEWA
AB			EQ 150MG BASE	A203332	003	Mar 12, 2020	Mar NEWA

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
VERAPAMIL HYDROCHLORIDE

	AUROBINDO PHARMA LTD	2.5MG/ML	A212965	001	Jul 06, 2020	Jul NEWA
	SOLUTION; INTRAVENOUS					
	VERAPAMIL HYDROCHLORIDE					
AP	AREVA PHARMS	10MG/4ML (2.5MG/ML)	A213352	001	Mar 17, 2020	Mar NEWA
AP	CAPLIN	5MG/2ML (2.5MG/ML)	A213232	001	Mar 25, 2020	Mar NEWA
AP		10MG/4ML (2.5MG/ML)	A213232	002	Mar 25, 2020	Mar NEWA

TABLET; ORAL
CALAN

@ PFIZER 40MG
+ @ 80MG
+ @ 120MG
@ 160MG

N018817	003	Feb 23, 1988	Jul CAHN
N018817	001	Sep 10, 1984	Jul CAHN
N018817	002	Sep 10, 1984	Jul CAHN
N018817	004	Feb 23, 1988	Jul CAHN

TABLET, EXTENDED RELEASE; ORAL
COVERA-HS

>D>	@ GD SEARLE LLC	180MG	N020552	001	Feb 26, 1996	Aug CAHN
>D>	@	240MG	N020552	002	Feb 26, 1996	Aug CAHN
>A>	@ PFIZER	180MG	N020552	001	Feb 26, 1996	Aug CAHN
>A>	@	240MG	N020552	002	Feb 26, 1996	Aug CAHN

VIGABATRIN

FOR SOLUTION; ORAL
VIGABATRIN

AA	GRANULES PHARMS	500MG/PACKET	A213469	001	Apr 24, 2020	Apr NEWA
----	-----------------	--------------	---------	-----	--------------	----------

VILAZODONE HYDROCHLORIDE

TABLET; ORAL
VILAZODONE HYDROCHLORIDE

@ TEVA PHARMS USA 10MG
@ 20MG
@ 40MG

A208212	001	Sep 30, 2019	Mar DISC
A208212	002	Sep 30, 2019	Mar DISC
A208212	003	Sep 30, 2019	Mar DISC

>A> VILTOLARSEN

>A> SOLUTION; INTRAVENOUS
>A> VILTEPSO

>A>	+! NIPPON SHINYAKU	250MG/5ML (50MG/ML)	N212154	001	Aug 12, 2020	Aug NEWA
-----	--------------------	---------------------	---------	-----	--------------	----------

VINCRISTINE SULFATE

INJECTABLE; INJECTION
VINCRISTINE SULFATE PFS

AP	! HOSPIRA	1MG/ML	A071484	001	Apr 19, 1988	Feb CTEC
AP	TEVA PHARMS USA	1MG/ML	A075493	001	Sep 01, 1999	Feb CMFD

VORICONAZOLE

INJECTABLE; INTRAVENOUS
VORICONAZOLE

AP	GLAND PHARMA LTD	200MG/VIAL	A211099	001	Mar 31, 2020	Mar NEWA
----	------------------	------------	---------	-----	--------------	----------

TABLET; ORAL
VORICONAZOLE

AB	RISING	50MG	A206762	001	May 24, 2016	Jul CAHN
AB		200MG	A206762	002	May 24, 2016	Jul CAHN

ZALEPLON

CAPSULE; ORAL
ZALEPLON

@ TEVA PHARMS 5MG
@ 10MG

A077239	001	Jun 06, 2008	Mar DISC
A077239	002	Jun 06, 2008	Mar DISC

ZIDOVUDINE

SOLUTION; ORAL
RETROVIR

AA	+! VIIV HLTHCARE	50MG/5ML	N019910	001	Sep 28, 1989	Jul CDFR
----	------------------	----------	---------	-----	--------------	----------

ZIDOVUDINE

AA	AUROBINDO	50MG/5ML	A077268	001	Sep 19, 2005	Jul CDFR
AA	CIPLA LTD	50MG/5ML	A077981	001	Jun 26, 2008	Jul CDFR

TABLET; ORAL
ZIDOVUDINE

@ MYLAN LABS LTD 100MG

N200732	001	Feb 23, 2011	Apr CAHN
---------	-----	--------------	----------

ZINC SULFATE

SOLUTION; INTRAVENOUS

ZINC SULFATE

AM REAGENT

EQ 10MG BASE/10ML (EQ 1MG BASE/ML)

N209377 003

Apr 15, 2020

Apr NEWA

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

AB +! UPJOHN

EQ 20MG BASE

N020825 001

Feb 05, 2001

Jun CAHN

AB +

EQ 40MG BASE

N020825 002

Feb 05, 2001

Jun CAHN

AB +

EQ 60MG BASE

N020825 003

Feb 05, 2001

Jun CAHN

AB +

EQ 80MG BASE

N020825 004

Feb 05, 2001

Jun CAHN

ZIPRASIDONE HYDROCHLORIDE

AB CADILA

EQ 20MG BASE

A208988 001

Aug 22, 2017

Mar CMFD

AB

EQ 40MG BASE

A208988 002

Aug 22, 2017

Mar CMFD

AB

EQ 60MG BASE

A208988 003

Aug 22, 2017

Mar CMFD

AB

EQ 80MG BASE

A208988 004

Aug 22, 2017

Mar CMFD

ZIPRASIDONE MESYLATE

INJECTABLE; INTRAMUSCULAR

GEODON

AP +! UPJOHN

EQ 20MG BASE/ML

N020919 001

Jun 21, 2002

Jun CAHN

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS

ZOLEDRONIC ACID

AP @ EMCURE PHARMS LTD

EQ 5MG BASE/100ML

A201801 001

Mar 29, 2013

Apr DISC

AP INGENUS PHARMS LLC

EQ 4MG BASE/5ML

A208968 001

Feb 19, 2020

Feb NEWA

AP PUNISKA

EQ 4MG BASE/100ML

A210174 001

Oct 27, 2017

May CAHN

ZOLMITRIPTAN

TABLET; ORAL

ZOLMITRIPTAN

AB APPCO

2.5MG

A206973 001

Jun 30, 2017

Mar CAHN

AB

5MG

A206973 002

Jun 30, 2017

Mar CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

ZOLMITRIPTAN

AP @ MYLAN

2.5MG

A202855 001

Sep 20, 2019

Feb DISC

AP

5MG

A202855 002

Sep 20, 2019

Feb DISC

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

AP @ VINTAGE

5MG

A078616 001

Nov 21, 2008

Jun DISC

AP

10MG

A078616 002

Nov 21, 2008

Jun DISC

AP @ YUNG SHIN PHARM

5MG

A077990 001

Apr 23, 2007

Apr DISC

AP

10MG

A077990 002

Apr 23, 2007

Apr DISC

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

AB CENTAUR PHARMS PVT

6.25MG

A213592 001

Jun 04, 2020

Jun NEWA

AB

12.5MG

A213592 002

Jun 04, 2020

Jun NEWA

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

AB AUROBINDO PHARMA LTD

25MG

A077645 002

Sep 29, 2006

Mar CMFD

AB

50MG

A077645 003

Sep 29, 2006

Mar CMFD

AB

100MG

A077645 001

Dec 22, 2005

Mar CMFD

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ADVIL DUAL ACTION WITH ACETAMINOPHEN

+	GLAXOSMITHKLINE	250MG;125MG	N211733	001	Feb 28, 2020	Apr CAHN
+	PFIZER INC	250MG;125MG	N211733	001	Feb 28, 2020	Feb NEWA

ADAPALENE

GEL;TOPICAL

ADAPALENE

	GLENMARK GENERICS	0.1%	A091314	001	Jul 01, 2010	Mar CMS1
	P AND L	0.1%	A090962	001	Jun 02, 2010	Apr CMS1

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	PERRIGO R AND D	5MG;120MG	A210719	001	Nov 16, 2018	Mar CMFD
--	-----------------	-----------	---------	-----	--------------	----------

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

>A>	AMNEAL PHARMS	1%	A208077	001	Mar 18, 2016	Aug CMS1
>A>	ENCUBE	1%	A210986	001	Jan 27, 2020	Aug CMS1
>A>	MYLAN	1%	A204306	001	May 06, 2019	Aug CMS1
	PERRIGO UK FINCO	1%	A211253	001	May 16, 2019	Apr CMS1
	VOLTAREN ARTHRITIS PAIN					
+	GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Mar CTNA
+		1%	N022122	001	Oct 17, 2007	Mar CMS1

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

	HETERO LABS LTD III	EQ 20MG BASE	A208939	001	May 28, 2020	May NEWA
		EQ 20MG BASE	A212507	001	Jun 02, 2020	May NEWA
	SUN PHARM	EQ 20MG BASE	A212866	001	May 04, 2020	Apr NEWA

TABLET, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

	DR REDDYS LABS LTD	EQ 20MG BASE	A211571	001	May 14, 2020	May NEWA
	MYLAN	EQ 20MG BASE	A212088	001	Jun 25, 2020	Jun NEWA

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

	DR REDDYS LABS LTD	10MG	A077367	002	Aug 17, 2001	Jan CMS1
@	MYLAN	10MG	A075674	001	Dec 21, 2001	Jan DISC
@	TEVA	10MG	A075312	001	May 31, 2001	Mar DISC

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

@	L PERRIGO CO	60MG	A212971	001	Feb 24, 2020	Jul DISC
		60MG	A212971	001	Feb 24, 2020	Feb NEWA
@		180MG	A212971	002	Feb 24, 2020	Jul DISC
		180MG	A212971	002	Feb 24, 2020	Feb NEWA

FEXOFENADINE HYDROCHLORIDE ALLERGY

@	GRANULES INDIA LTD	60MG	A211075	001	Oct 18, 2019	May DISC
@		180MG	A211075	002	Oct 18, 2019	May DISC

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

	GRANULES INDIA LTD	600MG	A213420	001	May 08, 2020	Apr NEWA
		1.2GM	A213420	002	May 08, 2020	Apr NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

	AUROBINDO PHARMA LTD	600MG;60MG	A213203	001	Mar 25, 2020	Mar NEWA
		1.2GM;120MG	A213203	002	Mar 25, 2020	Mar NEWA
	SUN PHARM INDS INC	600MG;60MG	A212542	001	Apr 28, 2020	Apr NEWA
		1.2GM;120MG	A212542	002	Apr 28, 2020	Apr NEWA

IBUPROFENTABLET; ORAL
ADVIL

>D>	GLAXOSMITHKLINE	200MG	N018989	001	May 18, 1984	Aug CRLD
>A>	+	200MG	N018989	001	May 18, 1984	Aug CHRS
>A>	+	200MG	N018989	001	May 18, 1984	Aug CRLD
	IBUPROFEN					
	@ ULTRATAB LABS INC	200MG	A209076	001	Jan 06, 2020	Jun DISC
	@ VINTAGE PHARMS	200MG	A071639	001	Feb 02, 1988	Jul DISC

KETOTIFEN FUMARATESOLUTION/DROPS; OPHTHALMIC
KETOTIFEN FUMARATE

BAYSHORE PHARMS LLC	EQ 0.025% BASE	A204059	001	Jun 01, 2020	May NEWA
---------------------	----------------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

HETERO LABS LTD III	5MG	A213513	001	Apr 29, 2020	Apr NEWA
PERRIGO R AND D	5MG	A211983	001	Mar 28, 2019	Feb CMFD

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

APOTEX	1.5MG	A205329	001	Sep 18, 2018	Jan CMFD
LABORATOIRE HRA	1.5MG	A204044	001	Jul 03, 2018	Jan CAHN
@ NAARI PTE LTD	1.5MG	A207660	001	May 02, 2019	Jun CAHN
XIROMED	1.5MG	A205329	001	Sep 18, 2018	Feb CAHN

LORATADINE

CAPSULE; ORAL

LORATADINE

BIONPHARMA INC	10MG	A202538	001	Dec 21, 2018	May CMFD
@ STRIDES PHARMA	10MG	A211926	001	Jan 15, 2020	Jul DISC

SYRUP; ORAL

LORATADINE

@ TEVA	1MG/ML	A075505	001	Nov 07, 2003	Apr DISC
--------	--------	---------	-----	--------------	----------

TABLET; ORAL

LORATADINE

@ MYLAN	10MG	A075790	001	Nov 07, 2008	Jan DISC
@	10MG	A078447	001	Aug 12, 2011	Jan DISC

TABLET, ORALLY DISINTEGRATING; ORAL

LORATADINE

@ ACTAVIS LABS FL INC	10MG	A075990	001	Nov 03, 2003	Apr DISC
-----------------------	------	---------	-----	--------------	----------

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

@ YICHANG HUMANWELL	220MG	A212033	001	Aug 30, 2019	Mar DISC
---------------------	-------	---------	-----	--------------	----------

NICOTINE POLACRILEX

TROCHE/LOZENGE; ORAL

NICOTINE POLACRILEX

DR REDDYS LABS SA	EQ 2MG BASE	A212983	001	Feb 21, 2020	Feb NEWA
	EQ 2MG BASE	A213233	001	Aug 04, 2020	Jul NEWA
	EQ 4MG BASE	A212983	002	Feb 21, 2020	Feb NEWA
	EQ 4MG BASE	A213233	002	Aug 04, 2020	Jul NEWA
P AND L	EQ 2MG BASE	A212057	001	May 14, 2020	May NEWA
	EQ 4MG BASE	A212057	002	May 14, 2020	May NEWA

NONOXYNOL-9

SPONGE; VAGINAL

TODAY

+ @ MAYER LABS INC	1GM	N018683	001	Apr 01, 1983	Mar DISC
--------------------	-----	---------	-----	--------------	----------

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

>A>	APOTEX	EQ 0.1% BASE	A078350	001	Dec 07, 2015	Aug CMS1
>A>	AUROBINDO PHARMA LTD	EQ 0.1% BASE	A204812	001	Dec 18, 2015	Aug CMS1
>A>		EQ 0.2% BASE	A209995	001	Apr 04, 2019	Aug CMS1
	GLAND PHARMA LTD	EQ 0.1% BASE	A209619	001	Aug 02, 2019	Jul CMS1
		EQ 0.2% BASE	A209752	001	May 20, 2020	May NFTG
	MICRO LABS LTD INDIA	EQ 0.2% BASE	A204620	001	Jun 16, 2020	Jun NEWA
PATADAY ONCE DAILY RELIEF						
>A>	+! ALCON LABS INC	EQ 0.2% BASE	N021545	001	Dec 22, 2004	Aug CAHN
>A>	+!	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Aug CAHN
>D>	+! NOVARTIS	EQ 0.2% BASE	N021545	001	Dec 22, 2004	Aug CAHN
	+!	EQ 0.2% BASE	N021545	001	Dec 22, 2004	Mar CTNA
	+!	EQ 0.2% BASE	N021545	001	Dec 22, 2004	Mar CMS1
>D>	+!	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Aug CAHN
	+!	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Jul CTNA
	+!	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Jul CMS1
PATADAY TWICE DAILY RELIEF						
>A>	+! ALCON LABS INC	EQ 0.1% BASE	N020688	001	Dec 18, 1996	Aug CAHN
>D>	+! NOVARTIS	EQ 0.1% BASE	N020688	001	Dec 18, 1996	Aug CAHN
	+!	EQ 0.1% BASE	N020688	001	Dec 18, 1996	Mar CTNA
	+!	EQ 0.1% BASE	N020688	001	Dec 18, 1996	Mar CMS1

OMEPRAZOLE MAGNESIUMTABLET, DELAYED RELEASE;ORAL
OMEPRAZOLE MAGNESIUM

	HETERO LABS LTD III	EQ 20MG BASE	A211732	001	Mar 25, 2020	Mar NEWA
	P AND L	EQ 20MG BASE	A206582	001	Jun 01, 2020	May NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

@ ACTAVIS ELIZABETH 20MG;1.1GM

A204137 001 Jul 15, 2016 Mar DISC

POLYETHYLENE GLYCOL 3350FOR SOLUTION;ORAL
GLYCOLAXLANNETT CO INC 17GM/PACKET
17GM/SCOOPFULA090600 001 Oct 06, 2009 Jan CMFD
A090600 002 Oct 06, 2009 Jan CMFD

POLYETHYLENE GLYCOL 3350

>A>	LGM PHARMA	17GM/SCOOPFUL	A090812	001	Oct 07, 2009	Aug CAHN
>D>	NEXGEN PHARMA	17GM/SCOOPFUL	A090812	001	Oct 07, 2009	Aug CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ APOTEX INC EQ 75MG BASE
 @ EQ 150MG BASE
 @ STRIDES PHARMA EQ 75MG BASE
 @ EQ 75MG BASE
 @ EQ 150MG BASE
 @ EQ 150MG BASE

A075167 001 May 04, 2000 May DISC
 A200172 001 May 31, 2012 Apr DISC
 A201745 001 Feb 29, 2012 Apr DISC
 A209160 001 Mar 05, 2018 Apr DISC
 A200536 001 Jun 28, 2011 Apr DISC
 A209161 001 Feb 22, 2018 Apr DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 08 AUGUST 2020

NO AUGUST 2020 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO AUGUST 2020 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	7803770	Apr 28, 2031	U-2009			
<u>ABAMETAPIR - XEGLYZE</u>						
N 206966 001	10292389	Dec 17, 2034	DP U-2863		>A> NCE	Jul 31, 2025
	7812163	Oct 28, 2026	DP U-2863			
	8212038	Jul 16, 2024	DP U-2863			
	9357783	Jul 16, 2024	DP			
	9839631	Jul 16, 2024	DS DP U-2863			
<u>ACETAMINOPHEN; BUTALBITAL - BUTALBITAL AND ACETAMINOPHEN</u>						
A 213115 001					CGT	Jul 28, 2020
<u>ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN</u>						
N 211733 001					NP	Feb 28, 2023
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	10588895	Jul 07, 2020	U-2772		M-256	Mar 29, 2022
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595 001	10588895	Jul 07, 2020	U-2772			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	RE43431	Jan 13, 2026	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	RE43431	Jan 13, 2026	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	RE43431	Jan 13, 2026	DS			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	10561808	Jan 01, 2032	DP			
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
<u>ALCAFTADINE - LASTACFT</u>						
N 022134 001	10617695	Mar 19, 2027	DP U-1493			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001	10350214	Apr 24, 2035	DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	10646456	Jun 17, 2034	U-2808			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	10646456	Jun 17, 2034	U-2808			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 001	10525033	Mar 10, 2031	DP		NCE	Feb 26, 2025
	9084765	Mar 10, 2031	U-1744			
	9084765	Mar 10, 2031	U-2754			
	9545426	Mar 10, 2031	U-1744			
	9545426	Mar 10, 2031	U-2754			
	9889118	Mar 10, 2031	U-1744			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 001	9889118	Mar 10, 2031	U-2754			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	10695329	Oct 16, 2037	DP			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 001	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
	9855221	Feb 14, 2022	DP			
	9931305	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 002	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
	9855221	Feb 14, 2022	DP			
	9931305	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 003	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
	9855221	Feb 14, 2022	DP			
	9931305	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 004	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 004	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
	9855221	Feb 14, 2022	DP			
	9931305	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 005	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
	9855221	Feb 14, 2022	DP			
	9931305	Feb 14, 2022	DP			
<u>APREMILAST - OTEZLA</u>						
N 205437 001					M-257	Apr 10, 2023
<u>APREMILAST - OTEZLA</u>						
N 205437 002					M-257	Apr 10, 2023
<u>APREMILAST - OTEZLA</u>						
N 205437 003					M-257	Apr 10, 2023
<u>APREPITANT - CINVANTI</u>						
N 209296 001	10624850	Sep 18, 2035	U-2161			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA INITIO KIT</u>						
N 209830 001	10688091	Aug 17, 2035	DP			
<u>ARTESUNATE - ARTESUNATE</u>						
N 213036 001					NCE ODE-290	May 26, 2025 May 26, 2027
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID</u>						
A 090145 001					>A> PC	Feb 27, 2021
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENUVU</u>						
N 209381 001	10646512	Mar 25, 2032	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 001	10583121	Jul 25, 2033	DP U-2763			
<u>ASENAPINE - SECUADO</u>						
N 212268 002	10583121	Jul 25, 2033	DP U-2763			
<u>ASENAPINE - SECUADO</u>						
N 212268 003	10583121	Jul 25, 2033	DP U-2763			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 001	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 003	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Jan 07, 2026	DS DP U-2244			
	7112592	Jan 07, 2026	DS DP U-2508			
	7112592	Jan 07, 2026	DS DP U-282			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AXITINIB - INLYTA</u>						
N 202324 001	10570202	Feb 03, 2035	U-2844			
<u>AXITINIB - INLYTA</u>						
N 202324 002	10570202	Feb 03, 2035	U-2844			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE</u>						
A 207712 001					PC	Aug 29, 2020
<u>BACLOFEN - OZOBAX</u>						
N 208193 001	10610502	Aug 30, 2039	U-2779			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	10633397	Apr 27, 2036	U-2816			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	10633397	Apr 27, 2036	U-2816			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001					>A> ODE-307	May 27, 2027
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 002	7498343	Dec 01, 2026	DS DP U-1321		>A> ODE-307	May 27, 2027
	8546428	Mar 19, 2029	DS DP U-1321			
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	10118881	Dec 23, 2023		U-2747	NCE	Feb 21, 2025
	7335799	Dec 03, 2025	DS			
	8497301	Dec 23, 2023		U-2747		
	9000041	Dec 23, 2023		U-2747		
	9624152	Dec 23, 2023		U-2748		
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	10118881	Dec 23, 2023		U-2746	NCE	Feb 21, 2025
	7335799	Dec 03, 2025	DS		NP	Feb 26, 2023
	8497301	Dec 23, 2023		U-2746		
	9000041	Dec 23, 2023		U-2746		
	9624152	Dec 23, 2023		U-2749		
<u>BENOXINATE HYDROCHLORIDE; FLUORESCHEIN SODIUM - FLUORESCHEIN SODIUM AND BENOXINATE HYDROCHLORIDE</u>						
N 211039 001	10293047	Nov 15, 2037	DP U-2755			
	10632197	Nov 15, 2037	DP U-2755			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	10624918	Jun 03, 2029	U-916			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288 001	8784789	Jan 13, 2025	DP			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589 001	10617698	Jun 10, 2031	DP			
	10660908	Jun 10, 2031	DP	U-2627		
	10682364	Jun 10, 2031	DP			
	10688108	Jun 10, 2031		U-2627		
>A>	10716799	Jun 10, 2031	DP			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - WYNZORA</u>						
N 213422 001	>A> 10265265	Sep 27, 2027	DP		>A> NDF	Jul 20, 2023
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	10548846	Nov 08, 2036	DP			
>A>	7390791	Apr 17, 2025	DS DP			
<u>BIMATOPROST - DURYSTA</u>						
N 211911 001	10398707	Apr 30, 2024		U-2759	NP	Mar 04, 2023
	10441543	Dec 19, 2026	DP			
	7033605	Oct 20, 2020	DP			
	7799336	Apr 24, 2029	DP			
	8206737	Apr 07, 2027		U-2759		
	8629185	Jul 15, 2031	DS DP			
	8673341	Feb 19, 2025		U-2759		
	9149428	Dec 19, 2026	DP			
	9492316	Oct 31, 2034	DP			
	9980974	Oct 31, 2034		U-2759		
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	6579968	Jun 28, 2021	DS DP			
	6794489	Jun 28, 2021	DS DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	7888362	Apr 12, 2026	DS		Y	
	RE48059	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	7888362	Apr 12, 2026	DS		Y	
	RE48059	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	7888362	Apr 12, 2026	DS		Y	
	RE48059	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	7888362	Apr 12, 2026	DS		Y	
	RE48059	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	7888362	Apr 12, 2026	DS		Y	
	RE48059	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Apr 12, 2026	DS		Y	
	RE48059	Apr 12, 2026	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	10385078	Nov 10, 2035	DS DP	U-2837	ODE-300	May 22, 2027
	9273077	May 21, 2029		U-2837		
	9611283	Apr 10, 2034		U-2837		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	10385078	Nov 10, 2035	DS DP U-2837		ODE-300	May 22, 2027
	9273077	May 21, 2029	U-2837			
	9611283	Apr 10, 2034	U-2837			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	10385078	Nov 10, 2035	DS DP U-2837		ODE-300	May 22, 2027
	9273077	May 21, 2029	U-2837			
	9611283	Apr 10, 2034	U-2837			
<u>BRILLIANT BLUE G - TISSUEBLUE</u>						
N 209569 001					NCE ODE-282	Dec 20, 2024 Dec 20, 2026
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001 >A>	10729653	Apr 09, 2030	DP			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002 >A>	10729653	Apr 09, 2030	DP			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003 >A>	10729653	Apr 09, 2030	DP			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004 >A>	10729653	Apr 09, 2030	DP			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005 >A>	10729653	Apr 09, 2030	DP			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	10688094	Apr 30, 2032	U-2870			
	10688094	Apr 30, 2032	U-2871			
	10688094	Apr 30, 2032	U-2872			
	10688094	Apr 30, 2032	U-2873			
	10688094	Apr 30, 2032	U-2874			
	10688094	Apr 30, 2032	U-2875			
	10688094	Apr 30, 2032	U-2876			
	10688094	Apr 30, 2032	U-2877			
	10688094	Apr 30, 2032	U-2878			
	10688094	Apr 30, 2032	U-2879			
	10688094	Apr 30, 2032	U-2880			
	10688094	Apr 30, 2032	U-2881			
	10688094	Apr 30, 2032	U-2882			
	10688094	Apr 30, 2032	U-2883			
	10688094	Apr 30, 2032	U-2884			
	10688094	Apr 30, 2032	U-2885			
	10688094	Apr 30, 2032	U-2886			
	10688094	Apr 30, 2032	U-2887			
	10688094	Apr 30, 2032	U-2888			
>A>	10688155	Jun 07, 2030	U-2281			
>A>	10688155	Jun 07, 2030	U-2890			
>A>	10688155	Jun 07, 2030	U-2891			
>A>	10688155	Jun 07, 2030	U-2892			
>A>	10688155	Jun 07, 2030	U-2893			
>A>	10688155	Jun 07, 2030	U-2894			
>A>	10688155	Jun 07, 2030	U-2895			
>A>	10688155	Jun 07, 2030	U-2896			
>A>	10688155	Jun 07, 2030	U-2897			
>A>	10688155	Jun 07, 2030	U-2898			
>A>	10688155	Jun 07, 2030	U-2899			
>A>	10688155	Jun 07, 2030	U-2900			
>A>	10688155	Jun 07, 2030	U-2901			
>A>	10688155	Jun 07, 2030	U-2902			
>A>	10688155	Jun 07, 2030	U-2903			
>A>	10688155	Jun 07, 2030	U-2904			
>A>	10688155	Jun 07, 2030	U-2905			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	>A> 10688155	Jun 07, 2030	U-2906			
	>A> 10688155	Jun 07, 2030	U-2907			
	>A> 10688155	Jun 07, 2030	U-2908			
	>A> 10688155	Jun 07, 2030	U-2909			
	>A> 10688155	Jun 07, 2030	U-2910			
	>A> 10688155	Jun 07, 2030	U-2911			
	>A> 10688155	Jun 07, 2030	U-2912			
	>A> 10688155	Jun 07, 2030	U-2913			
	>A> 10688155	Jun 07, 2030	U-2914			
	>A> 10688155	Jun 07, 2030	U-2915			
	>A> 10688155	Jun 07, 2030	U-2916			
	>A> 10688155	Jun 07, 2030	U-2917			
	>A> 10688155	Jun 07, 2030	U-2918			
	>A> 10688155	Jun 07, 2030	U-2919			
	>A> 10688155	Jun 07, 2030	U-2920			
	>A> 10688155	Jun 07, 2030	U-2921			
	>A> 10688155	Jun 07, 2030	U-2922			
	>A> 10688155	Jun 07, 2030	U-2923			
	>A> 10688155	Jun 07, 2030	U-2924			
	>A> 10688155	Jun 07, 2030	U-2925			
	>A> 10688155	Jun 07, 2030	U-2926			
	>A> 10688155	Jun 07, 2030	U-2927			
	>A> 10688155	Jun 07, 2030	U-2928			
	>A> 10688155	Jun 07, 2030	U-2929			
	>A> 10688155	Jun 07, 2030	U-2930			
	>A> 10688155	Jun 07, 2030	U-2931			
	>A> 10688155	Jun 07, 2030	U-2932			
	>A> 10688155	Jun 07, 2030	U-2933			
	>A> 10688155	Jun 07, 2030	U-2934			
	>A> 10688155	Jun 07, 2030	U-2935			
	>A> 10688155	Jun 07, 2030	U-2936			
	>A> 10688155	Jun 07, 2030	U-2937			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	10660858	Sep 07, 2031	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE</u>						
N 212122 001	>A> 10716753	May 28, 2030	DP U-2889	>A> NC		Jul 23, 2023
	>A> 8324266	May 28, 2030	U-2889			
	>A> 8703806	May 28, 2030	U-2889			
	>A> 8808713	May 28, 2030	DP U-2889			
	>A> 8815258	Mar 17, 2031	U-2889			
	>A> 9415009	May 28, 2030	U-2889			
	>A> 9463161	May 28, 2030	DP U-2889			
<u>BUPIVACAINE HYDROCHLORIDE - XARACOLL</u>						
N 209511 001				>A> NP		Aug 28, 2023
<u>BUPRENORPHINE - BUPRENORPHINE</u>						
A 211586 002					CGT	Oct 13, 2020
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	10558394	Jun 25, 2031	DP			
	10592168	Jun 06, 2031	U-2489			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	10558394	Jun 25, 2031	DP			
	10592168	Jun 06, 2031	U-2489			
	10646484	Jun 22, 2038	U-2489			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	10583110	Oct 27, 2030	U-2753			
	10716777	Oct 27, 2030	U-2856			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563	001				NPP	Nov 05, 2022
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690	001	>A> 10195168	Jan 11, 2033	DP	NP	Jul 21, 2023
		>A> 10213400	Mar 15, 2033	U-2499		
		>A> 10675258	Jan 11, 2033	U-2938		
		>A> 8591922	Jan 11, 2033	DP		
		>A> 8731963	Dec 17, 2022	U-1110		
		>A> 8772306	Mar 15, 2033	U-1532		
		>A> 8901173	Jan 11, 2033	DP		
		>A> 9050302	Mar 15, 2033	U-1532		
		>A> 9132107	Jan 11, 2033	DP		
		>A> 9486426	Mar 15, 2033	U-1532		
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	001	10617668	May 11, 2031	DP U-2441		
		10617668	May 11, 2031	DP U-2632		
		10617668	May 11, 2031	DP U-2794		
		10617668	May 11, 2031	DP U-2795		
		10617668	May 11, 2031	DP U-2796		
		10617668	May 11, 2031	DP U-2797		
		10617668	May 11, 2031	DP U-2798		
		10617668	May 11, 2031	DP U-2799		
		10617668	May 11, 2031	DP U-493		
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	002	10617668	May 11, 2031	DP U-2441		
		10617668	May 11, 2031	DP U-2632		
		10617668	May 11, 2031	DP U-2794		
		10617668	May 11, 2031	DP U-2795		
		10617668	May 11, 2031	DP U-2796		
		10617668	May 11, 2031	DP U-2797		
		10617668	May 11, 2031	DP U-2798		
		10617668	May 11, 2031	DP U-2799		
		10617668	May 11, 2031	DP U-493		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	001	7943582	Feb 26, 2029	DS DP U-2441		
		7943582	Feb 26, 2029	DS DP U-2632		
		7943582	Feb 26, 2029	DS DP U-493		
		8222219	Apr 11, 2025	U-2441		
		8222219	Apr 11, 2025	U-2632		
		8222219	Apr 11, 2025	U-493		
		8513202	Dec 03, 2027	DS DP U-2441		
		8513202	Dec 03, 2027	DS DP U-2632		
		8513202	Dec 03, 2027	DS DP U-493		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	002	7943582	Feb 26, 2029	DS DP U-2441		
		7943582	Feb 26, 2029	DS DP U-2632		
		7943582	Feb 26, 2029	DS DP U-493		
		8222219	Apr 11, 2025	U-2441		
		8222219	Apr 11, 2025	U-2632		
		8222219	Apr 11, 2025	U-493		
		8513202	Dec 03, 2027	DS DP U-2441		
		8513202	Dec 03, 2027	DS DP U-2632		
		8513202	Dec 03, 2027	DS DP U-493		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	003	7943582	Feb 26, 2029	DS DP U-2441		
		7943582	Feb 26, 2029	DS DP U-2632		
		7943582	Feb 26, 2029	DS DP U-493		
		8222219	Apr 11, 2025	U-2441		
		8222219	Apr 11, 2025	U-2632		
		8222219	Apr 11, 2025	U-493		
		8513202	Dec 03, 2027	DS DP U-2441		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	8680052	Mar 09, 2033	U-1715			
	8680052	Mar 09, 2033	U-2869			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10603288	Jun 17, 2035	U-2780		>A> NPP	Jul 31, 2023
	10603288	Jun 17, 2035	U-2781			
	10603288	Jun 17, 2035	U-2782			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10603288	Jun 17, 2035	U-2783			
	10709671	Jun 17, 2035	U-2862			
	10709673	Jun 17, 2035	DP			
	10709674	Jun 17, 2035	U-2780			
	10709674	Jun 17, 2035	U-2781			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 001	10596178	Jul 22, 2035	DS DP		NCE	May 06, 2025
	7767675	Nov 19, 2027	DS DP		ODE-291	May 06, 2027
	8420645	Jun 05, 2031	DS DP			
	8461330	Nov 19, 2027	DS DP			
	8901123	May 20, 2029	U-2813			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 002	10596178	Jul 22, 2035	DS DP		NCE	May 06, 2025
	7767675	Nov 19, 2027	DS DP		ODE-291	May 06, 2027
	8420645	Jun 05, 2031	DS DP			
	8461330	Nov 19, 2027	DS DP			
	8901123	May 20, 2029	U-2813			
<u>CAPSAICIN - QUTENZA</u>						
N 022395 001					I-838	Jul 17, 2023
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001					>A> I-842	Aug 20, 2023
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002					>A> I-842	Aug 20, 2023
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 003					>A> I-842	Aug 20, 2023
<u>CEDAZURIDINE; DECITABINE - INQOVI</u>						
N 212576 001	8268800	Aug 22, 2030	DS	U-2864	NCE	Jul 07, 2025
	8268800	Aug 22, 2030	DS	U-2865		
	8268800	Aug 22, 2030	DS	U-2866		
	8268800	Aug 22, 2030	DS	U-2867		
	8618075	Oct 16, 2028		U-2864		
	8618075	Oct 16, 2028		U-2867		
	9567363	Oct 16, 2028	DS			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001					NPP	Sep 13, 2022
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002					NPP	Sep 13, 2022
<u>CELECOXIB - ELYXYB</u>						
N 212157 001	10376527	May 27, 2036	DP	U-2718	NP	May 05, 2023
	>A> 10722456	May 27, 2036	DP	U-2718		
	9572819	May 27, 2036	DP	U-2718		
	9795620	May 27, 2036	DP	U-2718		
	9949990	May 27, 2036	DP	U-2718		
<u>CENOBAMATE - XCOPRI</u>						
N 212839 001	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 002	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 003	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CENOBAMATE - XCOPRI</u>						
N 212839 004	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 005	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 006	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CERITINIB - ZYKADIA</u>						
N 205755 001 >A>	7964592	Apr 29, 2028	DS DP			
<u>CERITINIB - ZYKADIA</u>						
N 211225 001 >A>	7964592	Apr 29, 2028	DS DP			
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819 001	8487093	Nov 19, 2029	DS DP U-2586			
	8487093	Nov 19, 2029	DS DP U-2587			
	8487093	Nov 19, 2029	DS DP U-2840			
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001					NP	May 22, 2023
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001	10624879	Jun 23, 2034	DP			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001 >A>	10159682	Aug 14, 2028	U-2942			
>A>	8143240	Jan 12, 2023	U-2942			
>A>	8785427	Jul 25, 2030	DP			
>A>	8865690	Jul 24, 2022	U-2942			
>A>	9211295	Jul 24, 2022	DP			
>A>	9433628	Feb 08, 2029	DP			
>A>	9486458	Jul 24, 2028	U-2942			
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001	10588914	Aug 31, 2030	DP U-2771			
<u>CLONIDINE - CLONIDINE</u>						
N 022500 001	8337890	Apr 17, 2027	DP			
	8623409	Sep 08, 2031	DP			
<u>CLONIDINE - CLONIDINE</u>						
N 022500 002	8337890	Apr 17, 2027	DP			
	8623409	Sep 08, 2031	DP			
<u>COBICISTAT - TYBOST</u>						
N 203094 001	10039718	Oct 06, 2032	DP			
<u>COBICISTAT; DARUNAVIR - PREZCOBIX</u>						
N 205395 001	10039718	Oct 06, 2032	DP			
>A>	8148374	Sep 03, 2029	DS DP U-1279			
>A>	8148374	Sep 03, 2029	DS DP U-2939			
<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455 001	10039718	Oct 06, 2032	DP			
	6642245	Nov 04, 2020	U-2352			
	6642245	Nov 04, 2020	U-2765			
>A>	7390791	Apr 17, 2025	DS DP			
	7803788	Feb 02, 2022	U-2352			
	7803788	Feb 02, 2022	U-2765			
	8148374	Sep 03, 2029	DS DP U-2353			
	8148374	Sep 03, 2029	DS DP U-2364			
	8148374	Sep 03, 2029	DS DP U-2365			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455 001	8148374	Sep 03, 2029	DS DP U-2766			
	8148374	Sep 03, 2029	DS DP U-2767			
	8148374	Sep 03, 2029	DS DP U-2768			
	8754065	Aug 15, 2032	DS DP U-2352			
	8754065	Aug 15, 2032	DS DP U-2765			
	9296769	Aug 15, 2032	DS DP U-2352			
	9296769	Aug 15, 2032	DS DP U-2765			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	10039718	Oct 06, 2032	DP			
	>A> 7390791	Apr 17, 2025	DS DP			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	10039718	Oct 06, 2032	DP			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	10590102	Jun 30, 2036	DS DP U-1776			
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	10383820	Nov 22, 2036	DP U-2814			
	10383821	Nov 22, 2036	DP			
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001	8039451	Jun 11, 2026	DS DP		NCE	Dec 14, 2021
	8039451*PED	Dec 11, 2026			NPP	Mar 23, 2023
	8168614	Jan 20, 2030	U-1932		PED	Jun 14, 2022
	8168614*PED	Jul 20, 2030			PED	Sep 23, 2023
	8501712	Feb 16, 2027	U-1932			
	8501712*PED	Aug 16, 2027				
	9682092	Feb 16, 2027	U-1932			
	9682092*PED	Aug 16, 2027				
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 001					NCE	Apr 30, 2024
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	10548859	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	10548859	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 001	10143665	Aug 16, 2036	U-1399		M-216	Dec 22, 2020
	10328037	Aug 16, 2036	U-1399		PED	Jun 22, 2021
	10548859	Aug 16, 2036	U-1399			
	8026284	Sep 22, 2027	U-1399			
	9173851	Jun 17, 2034	DP			
	9192590	Jan 26, 2027	U-1399			
	9198882	Jan 26, 2027	U-1399			
	9233077	Jun 17, 2034	DP			
	9925156	Jan 26, 2027	DP U-1399			
	9925157	Jan 26, 2027	DP U-1399			
	9925158	Jan 26, 2027	DP U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	10143665	Aug 16, 2036	U-1399		M-216	Dec 22, 2020
	10328037	Aug 16, 2036	U-1399		PED	Jun 22, 2021
	10548859	Aug 16, 2036	U-1399			
	8026284	Sep 22, 2027	U-1399			
	9173851	Jun 17, 2034	DP			
	9192590	Jan 26, 2027	U-1399			
	9198882	Jan 26, 2027	U-1399			
	9233077	Jun 17, 2034	DP			
	9925156	Jan 26, 2027	DP U-1399			
	9925157	Jan 26, 2027	DP U-1399			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	9925158	Jan 26, 2027	DP U-1399			
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	10478453	Jan 15, 2039	DP U-2752			
	10583155	Jan 15, 2039	DP U-2752			
	10653719	Jan 15, 2039	DP			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	10478453	Jan 15, 2039	DP U-2752			
	10493051	Mar 15, 2039	DP			
	10543186	Mar 15, 2039	U-2722			
	10583155	Jan 15, 2039	DP U-2752			
	10653719	Jan 15, 2039	DP			
	10702490	Mar 15, 2039	DP			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001					ODE-287	Aug 03, 2024
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001	8329159	Jul 24, 2029	DS			
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002	8329159	Jul 24, 2029	DS			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	>A> 6515117	Oct 04, 2025	DS DP U-2139		I-834	May 05, 2023
	>A> 6515117	Oct 04, 2025	DS DP U-493		>A> I-841	Oct 18, 2022
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	>A> 6515117	Oct 04, 2025	DS DP U-2139		I-834	May 05, 2023
	>A> 6515117	Oct 04, 2025	DS DP U-493		>A> I-841	Oct 18, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001					>A> I-841	Oct 18, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002					>A> I-841	Oct 18, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003					>A> I-841	Oct 18, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004					>A> I-841	Oct 18, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005					>A> I-841	Oct 18, 2022
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	>A> 10711013	Oct 27, 2030	DS DP			
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					>A> M-263	Jul 23, 2023
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					>A> M-263	Jul 23, 2023
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					>A> M-263	Jul 23, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERASIROX - JADENU</u>						
N 206910 001					>A> M-263	Jul 23, 2023
<u>DEFERASIROX - JADENU</u>						
N 206910 002					>A> M-263	Jul 23, 2023
<u>DEFERASIROX - JADENU</u>						
N 206910 003					>A> M-263	Jul 23, 2023
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 001					>A> M-263	Jul 23, 2023
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 002					>A> M-263	Jul 23, 2023
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 003					>A> M-263	Jul 23, 2023
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 002	7049328	Jun 28, 2021	U-735			
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001	7049328	Jun 28, 2021	U-735			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	10695398	Apr 27, 2032	U-1895			
	10729739	Feb 10, 2029	U-1978			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	10695398	Apr 27, 2032	U-1895			
	10729739	Feb 10, 2029	U-1978			
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	10500214	Mar 02, 2030	DP			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	10702539	Jan 09, 2023	U-1597			
	10702539	Jan 09, 2023	U-2868			
	10702539	Jan 09, 2023	U-985			
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	>A> 10022502	Jun 22, 2034	U-2340			
<u>DEXAMETHASONE - HEMADY</u>						
N 211379 001	10537585	Dec 18, 2037	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			
<u>DICYCLOMINE HYDROCHLORIDE - DICYCLOMINE HYDROCHLORIDE</u>						
A 212286 001					CGT	Nov 18, 2020
<u>DIHYDROERGOTAMINE MESYLATE - DIHYDROERGOTAMINE MESYLATE</u>						
A 212907 001					CGT	Nov 19, 2020
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001					M-260	Feb 05, 2023
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002					M-260	Feb 05, 2023
<u>DOLUTEGRAVIR SODIUM - TIVICAY PD</u>						
N 213983 001	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001					>A> I-839	Aug 06, 2023
<u>DORAVIRINE - PIFELTRO</u>						
N 210806 001					I-827	Sep 19, 2022
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807 001	10603282	Nov 29, 2036	DP			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	10548871	Apr 11, 2028	U-620			
	10653660	Jul 20, 2027	U-620			
	10653662	May 18, 2027	U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	10548871	Apr 11, 2028	U-620			
	10653660	Jul 20, 2027	U-620			
	10653662	May 18, 2027	U-620			
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	10603281	Jun 08, 2031	U-2553			
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 001					NPP	Apr 20, 2023
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 002					NPP	Apr 20, 2023
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 004					NPP	Apr 20, 2023
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	10342875	Oct 02, 2034	DP U-2720		NPP	Apr 27, 2023
	10478601	Apr 25, 2035	DP U-2721			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	10537572	Sep 01, 2036	U-2735			
	10682351	Sep 01, 2036	U-2850			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	6872728	Jan 25, 2021	DS DP		NCE	Jul 23, 2023
	7056927	Sep 10, 2024	DS DP		NP	May 29, 2023
	7179815	Mar 07, 2021	U-2842			
	7419983	Jul 06, 2024	DS DP			
	7462625	Jan 25, 2021	DS DP U-2842			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10646481	Aug 13, 2029	DP			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	7741356	Jun 24, 2026	DS DP			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	7741356	Jun 24, 2026	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	7579449	Aug 01, 2028	DS		>A> M-252	Mar 30, 2023
	8673927	May 04, 2027	U-1652	Y	M-258	Jul 03, 2022
	9173859	May 04, 2027	DP U-1772	Y		
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	7579449	Aug 01, 2028	DS		>A> M-252	Mar 30, 2023
	8673927	May 04, 2027	U-1652	Y	M-258	Jul 03, 2022
	9173859	May 04, 2027	DP U-1772	Y		
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 004	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	10610489	Sep 30, 2030	DP			
	7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	10610489	Sep 30, 2030	DP			
	7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	10610489	Sep 30, 2030	DP			
	7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	10610489	Sep 30, 2030	DP			
	7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	7579449	Aug 01, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	7579449	Aug 01, 2028	DS			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	>A> 7390791	Apr 17, 2025	DS DP			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	>A> 7390791	Apr 17, 2025	DS DP		NPP ODE-284 ODE-285	Sep 25, 2020 Sep 28, 2024 Sep 28, 2024
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 001	10610125	Jun 21, 2030	U-2087			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 002	10610125	Jun 21, 2030	U-2087			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001					I-826	Apr 08, 2023
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	10005761	Aug 27, 2030	U-2335		I-826	Apr 08, 2023
	10005761	Aug 27, 2030	U-2802			
	10005761	Aug 27, 2030	U-2803			
	10258622	Nov 21, 2032	U-2802			
	8541575	Feb 26, 2030	DS DP U-2335			
	8541575	Feb 26, 2030	DS DP U-2802			
	8541575	Feb 26, 2030	DS DP U-2803			
	9314464	Jul 04, 2031	U-2336			
	9314464	Jul 04, 2031	U-2802			
	9314464	Jul 04, 2031	U-2803			
	9474754	Aug 05, 2033	DP U-2802			
	9850230	Aug 27, 2030	U-2334			
	9850230	Aug 27, 2030	U-2802			
	9850230	Aug 27, 2030	U-2803			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	10561651	Feb 19, 2035	U-2745			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	10561651	Feb 19, 2035	U-2745			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	8183274	Aug 24, 2026	U-1281			
	8183274	Aug 24, 2026	U-1588			
	8183274	Aug 24, 2026	U-2345			
	8183274	Aug 24, 2026	U-2708			
	9126941	May 15, 2026	U-1588			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674 001	>A> 7709517	Aug 13, 2027	DS DP			
	>A> 8183274	Aug 24, 2026	U-2345			
	>A> 8183274	Aug 24, 2026	U-2708			
	>A> 9126941	May 15, 2026	U-2345			
	>A> 9126941	May 15, 2026	U-2708			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674 002	>A> 7709517	Aug 13, 2027	DS DP			
	>A> 8183274	Aug 24, 2026		U-2345		
	>A> 8183274	Aug 24, 2026		U-2708		
	>A> 9126941	May 15, 2026		U-2345		
	>A> 9126941	May 15, 2026		U-2708		
<u>EPINEPHRINE - ADRENALIN</u>						
N 020800 003	10166334	Jan 21, 2025	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 020800 004	10166334	Jan 21, 2025	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	>A> 10737028	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	>A> 10737028	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	>A> 10737028	Nov 23, 2024	DP			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001					>A> I-840	Jul 31, 2023
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	10702536	May 06, 2025	U-2501			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	10702536	May 06, 2025	U-2501			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	10702536	May 06, 2025	U-2501			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	10702536	May 06, 2025	U-2501			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10537581	Nov 21, 2032	DP U-2316			
	10537581	Nov 21, 2032	DP U-2317			
	10568891	Jun 18, 2033	U-2316			
	10568891	Jun 18, 2033	U-2317			
	10668082	Jun 18, 2033	U-2316			
	10668082	Jun 18, 2033	U-2317			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10537581	Nov 21, 2032	DP U-2316			
	10537581	Nov 21, 2032	DP U-2317			
	10568891	Jun 18, 2033	U-2316			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10568891	Jun 18, 2033	U-2317			
	10668082	Jun 18, 2033	U-2316			
	10668082	Jun 18, 2033	U-2317			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	10639375	Nov 21, 2032	DP			
	10675288	Nov 21, 2032	U-2439			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001 >A>	8999932	Feb 07, 2031	DS DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002 >A>	8999932	Feb 07, 2031	DS DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003 >A>	8999932	Feb 07, 2031	DS DP U-2014			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	10533174	May 04, 2021	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	10533174	May 04, 2021	DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - TWIRLA</u>						
N 204017 001	7045145	Mar 14, 2021	DP U-2751		NP	Feb 14, 2023
	7384650	Mar 14, 2021	DP			
	8221784	Mar 14, 2021	DP			
	8221785	Mar 14, 2021	DP			
	8246978	Aug 26, 2028	DP			
	8747888	Jul 10, 2028	DP			
	8883196	Nov 22, 2020	DP U-2751			
	9050348	Jul 10, 2028	DP			
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	10632066	Feb 01, 2039	U-2786			
	10632066	Feb 01, 2039	U-2787			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6414126	Oct 04, 2020	DS DP U-2588			
	6515117	Oct 04, 2020	DS DP U-2588			
	6872700	Jan 14, 2020	U-2588			
	6872700	Jan 14, 2020	U-2589			
	6872700	Jan 14, 2020	U-2590			
	6872700	Jan 14, 2020	U-2591			
	6936590	Oct 04, 2020	U-2588			
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8361972	Mar 21, 2028	U-2588			
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2598			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2598			
	8501698	Jun 20, 2027	DP U-2588			
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	9198925	Oct 04, 2020	U-2588			
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6414126	Oct 04, 2020	DS DP U-2588			
	6515117	Oct 04, 2020	DS DP U-2588			
	6872700	Jan 14, 2020	U-2588			
	6872700	Jan 14, 2020	U-2589			
	6872700	Jan 14, 2020	U-2590			
	6872700	Jan 14, 2020	U-2591			
	6936590	Oct 04, 2020	U-2588			
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8361972	Mar 21, 2028	U-2588			
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2598			
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2598			
	8501698	Jun 20, 2027	DP U-2588			
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	9198925	Oct 04, 2020	U-2588			
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	10452815	Oct 22, 2039	U-2859		NP	Jun 25, 2023
	10478441	May 03, 2033	U-2860			
	10478442	May 03, 2033	U-2860			
	10603290	Aug 02, 2037	U-2861			
	9549909	May 03, 2033	U-2858			
	9603814	May 03, 2033	U-2858			
	9603815	May 03, 2033	U-2858			
	9610260	May 03, 2033	U-2858			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	10610523	Jan 25, 2027	DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	10519252	Oct 20, 2023	DS U-2709			
	10519252	Oct 20, 2023	DS U-2710			
	10519252	Oct 20, 2023	DS U-2711			
	10519252	Oct 20, 2023	DS U-2712			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	5753706	Feb 03, 2021	DP U-1577			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 001	10414831	Mar 25, 2029	DS DP			
	8815301	Aug 14, 2029	DS DP U-2734			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC AVNU</u>						
N 212860 001	7816404	Apr 17, 2029	DS U-2801			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	7906489	Mar 04, 2027	U-2741		NPP	Jan 24, 2023
	7906489	Mar 04, 2027	U-319		PED	Jul 24, 2023
	7906489*PED	Sep 04, 2027				
	8859510	Jul 31, 2027	U-2741			
	8859510	Jul 31, 2027	U-319			
	8859510*PED	Jan 31, 2028				
<u>FIDAXOMICIN - DIFICID</u>						
N 213138 001	7378508	Jul 31, 2027	DS DP		NP	Jan 24, 2023
	7378508*PED	Jan 31, 2028			PED	Jul 24, 2023
	7863249	Jul 31, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FIDAXOMICIN - DIFICID</u>						
N 213138 001	7863249*PED	Jan 31, 2028				
	7906489	Mar 04, 2027	U-2741			
	7906489*PED	Sep 04, 2027				
	8586551	Jul 23, 2023	DS DP			
	8586551*PED	Jan 23, 2024				
	8859510	Jul 31, 2027	U-2741			
	8859510*PED	Jan 31, 2028				
	9808530	May 28, 2034	DP			
	9808530*PED	Nov 28, 2034				
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 001	10543179	Dec 25, 2027	U-2719			
<u>FLORTAUCIPIR F-18 - TAUVID</u>						
N 212123 001	8932557	May 19, 2029	DS		NCE	May 28, 2025
<u>FLORTAUCIPIR F-18 - TAUVID</u>						
N 212123 002	8932557	May 19, 2029	DS		NCE	May 28, 2025
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	10716868	Dec 30, 2035	U-2450			
<u>FLUOROESTRADIOL F-18 - CERIANNA</u>						
N 212155 001					NCE	May 20, 2025
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	6715485	Sep 03, 2020	DP			
	8978647	Dec 06, 2030	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	>A> 10716753	May 28, 2030	DP U-2546			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	10624911	Jun 02, 2037	DP			
	>A> 10717721	May 23, 2032	DS			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	10208073	May 23, 2032	U-2301		>A> NCE	Apr 19, 2023
	10624911	Jun 02, 2037	DP			
	>A> 10717721	May 23, 2032	DS			
	8426450	May 23, 2032	DS DP			
	8895586	May 23, 2032	U-2301			
	9186357	Nov 18, 2030	U-2301			
	9403772	May 23, 2032	DS U-2301			
	9908907	May 23, 2032	DS DP			
<u>FOSTEMSAVIR TROMETHAMINE - RUKOBIA</u>						
N 212950 001	7745625	Nov 19, 2027	DS		NCE	Jul 02, 2025
	8168615	Feb 25, 2025	DP			
	8461333	Feb 25, 2025	DS			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001					M-259	Apr 10, 2023
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 001	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 002	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYOPEN</u>						
N 212097 003	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYOPEN</u>						
N 212097 004	9649364	Apr 22, 2036	DP U-2742			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	10668040	Sep 22, 2030	U-1816			
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	10688518	Nov 12, 2036	DP			
	>A> 10744277	Dec 07, 2036	DP U-2941			
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 210361 001	10543192	Feb 28, 2033	DP		>A> NP	Jun 28, 2021
	10548875	Feb 28, 2033	DS DP U-2398			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	10533174	May 04, 2021	DP		ODE-280	Dec 12, 2026
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183 001					>A> NPP	Aug 31, 2023
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	10556010	Dec 19, 2036	U-2250			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	>A> 10722511	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	>A> 10722511	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	>A> 10722511	Jul 25, 2033	U-1810			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004 >A>	10722511	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005 >A>	10722511	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006 >A>	10722511	Jul 25, 2033	U-1810			
<u>HYDROGEN PEROXIDE - ESKATA</u>						
N 209305 001	10493103	Apr 21, 2035	DP			
	10729720	Apr 21, 2035	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10653696	Jun 03, 2031	U-1456			
	10695350	Oct 24, 2034	U-2846			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10653696	Jun 03, 2031	U-1456			
	10695350	Oct 24, 2034	U-2846			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10653696	Jun 03, 2031	U-1456			
	10695350	Oct 24, 2034	U-2846			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10653696	Jun 03, 2031	U-1456			
	10695350	Oct 24, 2034	U-2846			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10653696	Jun 03, 2031	U-1456			
	10695350	Oct 24, 2034	U-2846			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10653696	Jun 03, 2031	U-1456			
	10695350	Oct 24, 2034	U-2846			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	10555924	Jun 28, 2033	U-2743			
	10555925	Jun 28, 2033	U-2744			
	10568861	Jun 28, 2033	U-2756			
	10576054	Jun 28, 2033	U-2762			
	10668042	Jun 28, 2033	U-2841			
	8518929	Feb 09, 2030	U-1287			
	8524698	Feb 09, 2030	U-1287			
	8546372	Feb 09, 2030	U-1287			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	10555924	Jun 28, 2033	U-2743			
	10555925	Jun 28, 2033	U-2744			
	10568861	Jun 28, 2033	U-2756			
	10576054	Jun 28, 2033	U-2762			
	10668042	Jun 28, 2033	U-2841			
	8518929	Feb 09, 2030	U-1287			
	8524698	Feb 09, 2030	U-1287			
	8546372	Feb 09, 2030	U-1287			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001 >A>	10730879	Mar 05, 2033	DS DP			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002 >A>	10730879	Mar 05, 2033	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INDOCYANINE GREEN - SPY AGENT GREEN KIT</u>						
N 211580 001	10631746	Aug 04, 2035	DP U-2815			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001 >A>	10722508	May 02, 2025	DS DP			
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001					ODE-305 GAIN	Mar 06, 2022 Mar 06, 2027
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001					ODE-305 GAIN	Mar 06, 2022 Mar 06, 2027
<u>IVACAFITOR - KALYDECO</u>						
N 203188 001	10646481	Aug 13, 2029	DP			
<u>IVACAFITOR - KALYDECO</u>						
N 207925 001	10646481	Aug 13, 2029	DP			
<u>IVACAFITOR - KALYDECO</u>						
N 207925 002	10646481	Aug 13, 2029	DP			
<u>IVACAFITOR - KALYDECO</u>						
N 207925 003	10646481	Aug 13, 2029	DP			
<u>IVACAFITOR; IVACAFITOR, TEZACAFITOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10646481	Aug 13, 2029	DP			
<u>IVACAFITOR; IVACAFITOR, TEZACAFITOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10646481	Aug 13, 2029	DP			
<u>IVACAFITOR; LUMACAFITOR - ORKAMBI</u>						
N 206038 001	10597384 10646481	Dec 04, 2028 Aug 13, 2029	DS DP U-2777 DP			
<u>IVACAFITOR; LUMACAFITOR - ORKAMBI</u>						
N 206038 002	10597384 10646481	Dec 04, 2028 Aug 13, 2029	DS DP U-2777 DP			
<u>IVACAFITOR; LUMACAFITOR - ORKAMBI</u>						
N 211358 001	10597384 10646481	Dec 04, 2028 Aug 13, 2029	DS DP U-2778 DP			
<u>IVACAFITOR; LUMACAFITOR - ORKAMBI</u>						
N 211358 002	10597384 10646481	Dec 04, 2028 Aug 13, 2029	DS DP U-2778 DP			
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	10610125 10610125	Jun 21, 2030 Jun 21, 2030	U-2784 U-2785			
<u>LACTITOL - PIZENSY</u>						
N 211281 001					NCE	Feb 12, 2025
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	7423050 8748459	Apr 06, 2025 Mar 27, 2023	DS DP U-1719 U-1719		NCE	Jan 31, 2025
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	7423050 8748459	Apr 06, 2025 Mar 27, 2023	DS DP U-1719 U-1719		NCE	Jan 31, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	7423050	Apr 06, 2025	DS DP U-1719		NCE	Jan 31, 2025
	8748459	Mar 27, 2023	U-1719			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10532993	Jul 11, 2026	U-1524			
	10588901	Mar 14, 2034	DS DP U-1524			
	10654844	Nov 10, 2030	DS DP U-1524			
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 001	10188652	Oct 21, 2035	DP U-2791		NCE	Apr 07, 2025
	8268848	Sep 20, 2031	DS DP U-2791			
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 002	10188652	Oct 21, 2035	DP U-2791		NCE	Apr 07, 2025
	8268848	Sep 20, 2031	DS DP U-2791			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001	RE46791	May 22, 2024	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002	RE46791	May 22, 2024	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001	10603384	Feb 28, 2033	DP			
	RE46791	May 22, 2024	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002	10603384	Feb 28, 2033	DP			
	RE46791	May 22, 2024	DS DP			
<u>LEUPROLIDE ACETATE - FENSOLVI KIT</u>						
N 213150 001	>A> 8470359	Oct 15, 2023	DS DP U-2940		I-829	May 01, 2023
	>A> 9539333	Nov 13, 2020	DS DP			
	>A> 9914802	Nov 13, 2020	DS DP U-2940			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 001	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 002	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 003	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 004	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 005	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 006	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 007	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 008	10537538	Feb 28, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 009	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 010	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 011	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 012	10537538	Feb 28, 2037	DP			
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u>						
N 021717 001	10603293	Jan 14, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	10675325	Aug 11, 2031	DP			
	10702576	Aug 11, 2031	U-1516			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	May 04, 2027	U-1503	Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	May 04, 2027	U-1503	Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	May 04, 2027	U-1503	Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	May 04, 2027	U-1503	Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	8673927	May 04, 2027	U-1503	Y	M-252	Mar 30, 2023
	9173859	May 04, 2027	DP U-1503	Y	M-258	Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	8673927	May 04, 2027	U-1503	Y	M-252	Mar 30, 2023
	9173859	May 04, 2027	DP U-1503	Y	M-258	Jul 03, 2022
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	10555938	Mar 07, 2025	U-1316			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001	10596107	Dec 23, 2036	DP U-2764			
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	10646437	May 03, 2033	DP			
	10688045	May 03, 2033	DP			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	10464938	Mar 12, 2028	DP		NCE	Dec 20, 2024
	10695345	Aug 30, 2039	DP U-543			
	7183282	Jun 15, 2020	DS DP			
	8598119	Dec 28, 2029	U-543			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9586960	Mar 12, 2029	DS DP			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE39680	Jun 15, 2020	DS DP U-543			
<u>LURBINECTEDIN - ZEPZELCA</u>						
N 213702 001	7763615	Dec 13, 2024	DS DP U-2836		NCE ODE-304	Jun 15, 2025 Jun 15, 2027
<u>LUTETIUM DOTATATE LU-177 - LUTATHERA</u>						
N 208700 001	10596276	Jul 25, 2038	DP			
	10596278	Jul 25, 2038	DP			
<u>MARAVIROC - SELZENTRY</u>						
N 022128 001	6667314	Aug 06, 2021	DS DP U-824			
	6667314*PED	Feb 06, 2022				
	7368460	Nov 25, 2022	U-824			
	7368460*PED	May 25, 2023				
	7576097	May 25, 2021	DS			
	7576097*PED	Nov 25, 2021				
<u>MARAVIROC - SELZENTRY</u>						
N 022128 002	6667314	Aug 06, 2021	DS DP U-824			
	6667314*PED	Feb 06, 2022				
	7368460	Nov 25, 2022	U-824			
	7368460*PED	May 25, 2023				
	7576097	May 25, 2021	DS			
	7576097*PED	Nov 25, 2021				
<u>MARAVIROC - SELZENTRY</u>						
N 022128 003	6667314	Aug 06, 2021	DS DP U-824			
	6667314*PED	Feb 06, 2022				
	7368460	Nov 25, 2022	U-824			
	7368460*PED	May 25, 2023				
	7576097	May 25, 2021	DS			
	7576097*PED	Nov 25, 2021				
<u>MARAVIROC - SELZENTRY</u>						
N 022128 004	6667314	Aug 06, 2021	DS DP U-824			
	6667314*PED	Feb 06, 2022				
	7368460	Nov 25, 2022	U-824			
	7368460*PED	May 25, 2023				
	7576097	May 25, 2021	DS			
	7576097*PED	Nov 25, 2021				
<u>MARAVIROC - SELZENTRY</u>						
N 208984 001	6667314	Aug 06, 2021	DS DP U-824			
	6667314*PED	Feb 06, 2022				
	7368460	Nov 25, 2022	U-824			
	7368460*PED	May 25, 2023				
	7576097	May 25, 2021	DS			
	7576097*PED	Nov 25, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MARAVIROC - SELZENTRY</u>						
N 208984 001	6667314	Aug 06, 2021	DS DP U-824			
	6667314*PED	Feb 06, 2022				
	7368460	Nov 25, 2022	U-824			
	7368460*PED	May 25, 2023				
	7576097	May 25, 2021	DS			
	7576097*PED	Nov 25, 2021				
<u>MELOXICAM - ANJESO</u>						
N 210583 001	10463673	Feb 24, 2024	DP U-2750		NP	Feb 20, 2023
	10471067	Feb 24, 2024	DP U-2750			
	10709713	May 26, 2030	U-2750			
	8512727	Dec 25, 2022	DP U-2750			
	9974746	May 26, 2030	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	10561675	Aug 08, 2031	U-2490			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001					M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002					M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001					M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002					M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003					M-244	Aug 12, 2022
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	>A> 10709844	Mar 10, 2029	DP			
	>A> 8814834	May 27, 2031	DP			
	>A> 9867949	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	>A> 10709844	Mar 10, 2029	DP			
	>A> 8814834	May 27, 2031	DP			
	>A> 9867949	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	>A> 10709844	Mar 10, 2029	DP			
	>A> 8814834	May 27, 2031	DP			
	>A> 9867949	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	>A> 10709844	Mar 10, 2029	DP			
	>A> 8814834	May 27, 2031	DP			
	>A> 9867949	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	>A> 10709844	Mar 10, 2029	DP			
	>A> 8814834	May 27, 2031	DP			
	>A> 9867949	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	>A> 10709844	Mar 10, 2029	DP			
	>A> 8814834	May 27, 2031	DP			
	>A> 9867949	Mar 10, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	>A> 10709844	Mar 10, 2029	DP			
	>A> 8814834	May 27, 2031	DP			
	>A> 9867949	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	>A> 10709844	Mar 10, 2029	DP			
	>A> 8814834	May 27, 2031	DP			
	>A> 9867949	Mar 10, 2029	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	10610485	Jan 02, 2033	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10617651	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10617651	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10617651	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10617651	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10617651	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001	6770262	Mar 29, 2021	U-2843			
	8334281	May 16, 2030	DP U-2843			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	10596155	Jun 28, 2032	DP			
<u>METYROSINE - METYROSINE</u>						
A 213734 001					CGT	Jan 20, 2021
<u>MEXILETINE HYDROCHLORIDE - MEXILETINE HYDROCHLORIDE</u>						
A 213500 001					CGT	Jan 18, 2021
<u>MEXILETINE HYDROCHLORIDE - MEXILETINE HYDROCHLORIDE</u>						
A 213500 002					CGT	Jan 18, 2021
<u>MEXILETINE HYDROCHLORIDE - MEXILETINE HYDROCHLORIDE</u>						
A 213500 003					CGT	Jan 18, 2021
<u>MICAFUNGIN SODIUM - MICAFUNGIN SODIUM</u>						
A 207344 001					PC	Nov 07, 2020
<u>MICAFUNGIN SODIUM - MICAFUNGIN SODIUM</u>						
A 207344 002					PC	Nov 07, 2020
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 002					I-821 PED	Dec 20, 2022 Jun 20, 2023
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 003					I-821 PED	Dec 20, 2022 Jun 20, 2023
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	10660904	Apr 20, 2036	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10525045	Apr 28, 2028	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - AMZEEQ</u>						
N 212379 001	10517882	Oct 01, 2030	U-2647			
<u>MINOCYCLINE HYDROCHLORIDE - ZILXI</u>						
N 213690 001	10213512	Oct 01, 2030	DP U-1631			
	10265404	Oct 01, 2030	DP			
	10322186	Oct 01, 2030	U-1631			
	8865139	Oct 01, 2030	DP U-1631			
	8945516	Oct 01, 2030	DP			
	8992896	Oct 01, 2030	DP U-1631			
	9675700	Oct 01, 2030	DP U-1631			
<u>MITOMYCIN - JELMYTO</u>						
N 211728 001	9040074	Jan 20, 2031	DP		NP	Apr 15, 2023
	9950069	Jan 20, 2031	DP		ODE-289	Apr 15, 2027
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	10098863	Feb 27, 2035	DP U-1384			
	10105335	Feb 27, 2035	DP			
	10105336	Feb 27, 2035	DP U-1384			
	10105337	Feb 27, 2035	DP			
	9326947	Feb 27, 2035	DP			
	9326965	Feb 27, 2035	U-1384			
	9511043	Feb 27, 2035	U-1384			
	9517209	Feb 27, 2035	DP			
	9566259	Feb 27, 2035	DP			
	9636318	Feb 27, 2035	U-1384			
	9636319	Feb 27, 2035	DP			
	9814691	Feb 27, 2035	U-1384			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	9814692	Feb 27, 2035	U-1384			
	9820960	Feb 27, 2035	DP			
	9820961	Feb 27, 2035	DP U-1384			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001	10695303	Jan 31, 2033	DP			
>A>	10729667	Jan 31, 2033	DP			
<u>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE</u>						
A 213209 001					CGT	Sep 14, 2020
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	>A> 10737028	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	>A> 10737028	Nov 23, 2024	DP			
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001					I-823	Feb 25, 2023
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	10532993	Jul 11, 2026	U-1524			
	10588901	Mar 14, 2034	DS DP U-1524			
	10654844	Nov 10, 2030	DS DP U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	10676440	Sep 25, 2035	DS DP			
	6297375	Mar 17, 2023	DS			
<u>NIFURTIMOX - LAMPIT</u>						
N 213464 001					>A> NCE	Aug 07, 2025
<u>NIFURTIMOX - LAMPIT</u>						
N 213464 002					>A> NCE	Aug 07, 2025
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002	10342787	Apr 16, 2038	DP U-2804			
	10576070	Apr 16, 2038	DP U-2804			
	7070581	Jun 23, 2023	DP			
	8517997	May 14, 2024	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001					I-825	Mar 09, 2023
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002					I-825	Mar 09, 2023
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001					I-833 ODE-295	Apr 29, 2023 Apr 29, 2027
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	10213572	Feb 12, 2036	DP			
>A>	10737051	Oct 20, 2035	DP			
	6758214	Feb 23, 2022	DP			
	7560076	Apr 21, 2027	DP			
	7618594	Oct 17, 2026	DP			
	9604028	Aug 13, 2029	U-2793			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	>A> 10751349	Apr 26, 2036	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002 >A>	10751349	Apr 26, 2036	DP			
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	10238709	Feb 03, 2036	U-2857		NP	Jun 26, 2023
	10695397	Feb 03, 2036	U-2857			
	8329198	Sep 17, 2029	DP			
	8535695	Sep 17, 2029	U-2857			
	9265812	Sep 17, 2029	DP			
	9566246	Sep 17, 2029	DP			
<u>OCTREOTIDE ACETATE - BYNFEZIA PEN</u>						
N 213224 001	10342850	May 15, 2038	DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8071579	Aug 12, 2027	U-2480		I-831	May 08, 2023
	8071579	Aug 12, 2027	U-2819		I-832	May 19, 2023
	8071579	Aug 12, 2027	U-2820		ODE-283	Dec 27, 2026
	8071579	Aug 12, 2027	U-2821		ODE-306	May 08, 2027
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	9169235	Mar 12, 2024	U-2832			
	9169235	Mar 12, 2024	U-2833			
	9566276	Mar 12, 2024	U-2716			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8071579	Aug 12, 2027	U-2480		I-831	May 08, 2023
	8071579	Aug 12, 2027	U-2819		I-832	May 19, 2023
	8071579	Aug 12, 2027	U-2820		ODE-283	Dec 27, 2026
	8071579	Aug 12, 2027	U-2821		ODE-306	May 08, 2027
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	9169235	Mar 12, 2024	U-2832			
	9169235	Mar 12, 2024	U-2833			
	9566276	Mar 12, 2024	U-2716			
<u>OLOPATADINE HYDROCHLORIDE - PATADAY ONCE DAILY RELIEF</u>						
N 206276 001	8791154	May 19, 2032	DP U-1680			
	9533053	May 19, 2032	DP			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	10071085	Mar 31, 2030	DP		NCE	Apr 24, 2025
	10357468	May 27, 2035	U-2812			
	10583130	Mar 31, 2030	U-2811			
	8168793	Apr 02, 2029	DS DP U-2811			
	8524746	Jul 14, 2029	U-2811			
	8907099	May 12, 2027	DS			
	9550759	Jul 26, 2026	U-2811			
	9550759	Jul 26, 2026	U-2817			
	9550759	Jul 26, 2026	U-2818			
	9630955	Dec 12, 2032	DS DP U-2811			
	9745290	Oct 10, 2027	DP U-2811			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	10071085	Mar 31, 2030	DP		NCE	Apr 24, 2025
	10357468	May 27, 2035	U-2812			
	10583130	Mar 31, 2030	U-2811			
	8168793	Apr 02, 2029	DS DP U-2811			
	8524746	Jul 14, 2029	U-2811			
	8907099	May 12, 2027	DS			
	9550759	Jul 26, 2026	U-2811			
	9550759	Jul 26, 2026	U-2817			
	9550759	Jul 26, 2026	U-2818			
	9630955	Dec 12, 2032	DS DP U-2811			
	9745290	Oct 10, 2027	DP U-2811			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002	10071085	Mar 31, 2030	DP		NCE	Apr 24, 2025
	10357468	May 27, 2035	U-2812			
	10583130	Mar 31, 2030	U-2811			
	8168793	Apr 02, 2029	DS DP U-2811			
	8524746	Jul 14, 2029	U-2811			
	8907099	May 12, 2027	DS			
	9550759	Jul 26, 2026	U-2811			
	9550759	Jul 26, 2026	U-2817			
	9550759	Jul 26, 2026	U-2818			
	9630955	Dec 12, 2032	DS DP U-2811			
	9745290	Oct 10, 2027	DP U-2811			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 001					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 002					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 003					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 001					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 002					M-251	Aug 02, 2022
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 001	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	10709691	Oct 12, 2035	U-2770		ODE-286	Mar 06, 2027
	8314097	Mar 27, 2029	DS DP			
	8609862	Jan 13, 2031	U-2770			
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 002	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	10709691	Oct 12, 2035	U-2770		ODE-286	Mar 06, 2027
	8314097	Mar 27, 2029	DS DP			
	8609862	Jan 13, 2031	U-2770			
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 003	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	10709691	Oct 12, 2035	U-2770		ODE-286	Mar 06, 2027
	8314097	Mar 27, 2029	DS DP			
	8609862	Jan 13, 2031	U-2770			
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	10646485	Sep 02, 2036	DP U-1556			
	10668060	Dec 10, 2030	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	10646485	Sep 02, 2036	DP U-1556			
	10668060	Dec 10, 2030	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	10646485	Sep 02, 2036	DP U-1556			
	10668060	Dec 10, 2030	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	10646485	Sep 02, 2036	DP U-1556			
	10668060	Dec 10, 2030	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	10646485	Sep 02, 2036	DP U-1556			
	10668060	Dec 10, 2030	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFAD</u>						
N 208552 001 >A>	10751325	Jun 11, 2035	U-2921			
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ</u>						
N 212520 001	8357714	Aug 26, 2031	U-2849		NP	Jul 08, 2023
	9867808	Aug 26, 2031	U-2849			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u>						
N 021611 001					M-14	Oct 25, 2022
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u>						
N 021611 002					M-14	Oct 25, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	8481573	May 14, 2029	DS DP U-2774		NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	8481573	May 14, 2029	DS DP U-2774		NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	8481573	May 14, 2029	DS DP U-2774		NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2021	DS			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001 >A>	10723730	Feb 08, 2034	DS DP			
	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP	Y		
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002 >A>	10723730	Feb 08, 2034	DS DP			
	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP	Y		
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003 >A>	10723730	Feb 08, 2034	DS DP			
	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP	Y		
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001 >A>	10723730	Feb 08, 2034	DS DP			
	6936612	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002 >A>	10723730	Feb 08, 2034	DS DP			
	6936612	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003 >A>	10723730	Feb 08, 2034	DS DP			
	6936612	Jan 16, 2023	DS DP			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PANTOPRAZOLE SODIUM - PANTOPRAZOLE SODIUM</u>						
A 213725 001					>A> PC	Feb 09, 2021
<u>PEMETREXED - PEMFEXY</u>						
N 209472 001	7772209	May 24, 2022	U-2728			
	7772209	May 24, 2022	U-2729			
	9604990	Oct 28, 2035	DS			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001	10131667	Jun 12, 2033	U-2809		NCE	Apr 17, 2025
	9611267	Jan 30, 2035	DS DP		ODE-292	Apr 17, 2027
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 002	10131667	Jun 12, 2033	U-2809		NCE	Apr 17, 2025
	9611267	Jan 30, 2035	DS DP		ODE-292	Apr 17, 2027
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 003	10131667	Jun 12, 2033	U-2809		NCE	Apr 17, 2025
	9611267	Jan 30, 2035	DS DP		ODE-292	Apr 17, 2027
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	10583207	Dec 28, 2035	U-665			
	10583208	Mar 16, 2037	U-665			
	10588988	May 04, 2037	U-665			
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810 001	>A> 10730876	May 05, 2036	DS			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793 001	10646480	Aug 27, 2038	DP			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001	8354430	Feb 06, 2026	U-1101			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002	8354430	Feb 06, 2026	U-1101			
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	7041786	Jan 30, 2028	DS			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	10555939	May 19, 2030	DP		ODE-296 ODE-297	May 14, 2027 May 14, 2027
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	10555939	May 19, 2030	DP		ODE-296 ODE-297	May 14, 2027 May 14, 2027
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	10555939	May 19, 2030	DP		ODE-296 ODE-297	May 14, 2027 May 14, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	10555939	May 19, 2030	DP		ODE-296 ODE-297	May 14, 2027 May 14, 2027
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	10555939	May 19, 2030	DP		ODE-296 ODE-297	May 14, 2027 May 14, 2027
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES</u>						
N 212121 001	10632150	Apr 19, 2039	DP U-2789			
<u>PROGESTERONE - MILPROSA</u>						
N 201110 001	10537584	Feb 03, 2029	DP		NP	Apr 29, 2023
	10548904	Feb 03, 2029	U-2810			
	8580293	Jan 21, 2030	U-2810			
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001					NCE	Jul 02, 2025
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	10550081	Jul 14, 2030	DS			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	10703763	Feb 27, 2026		U-1708		
	10703763	Feb 27, 2026		U-2847		
	10703763	Feb 27, 2026		U-2848		
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	10314828	Jul 24, 2029		U-1481		
	10335397	Jul 24, 2029		U-2579		
	10703763	Feb 27, 2026		U-1708		
	10703763	Feb 27, 2026		U-2847		
	10703763	Feb 27, 2026		U-2848		
	10709694	Jul 24, 2029		U-2579		
	9421195	Jul 24, 2029		U-1481		
<u>RILUZOLE - EXSERVAN</u>						
N 212640 001	8603514	Apr 03, 2024		DP		
	8765167	Feb 20, 2024		DP		
<u>RIMEGEPANT SULFATE - NURTEC ODT</u>						
N 212728 001	8314117	Feb 22, 2031	DS DP U-2718		NCE	Feb 27, 2025
	8759372	Feb 25, 2033	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	8188113	Jul 27, 2030	DS DP		NCE	May 15, 2025
	8461179	Jun 07, 2032	DS DP		ODE-298	May 15, 2027
	8940756	Jun 07, 2032	U-2829			
<u>RISDIPLAM - EVRYSPI</u>						
N 213535 001					>A> NCE	Aug 07, 2025
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-2142			
	9415053	Nov 13, 2024	DP U-2640			
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
	9539218	Feb 17, 2034	U-2641			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9539218	Feb 17, 2034	U-1953			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
9539218		Feb 17, 2034	U-1955			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 004					I-824	Oct 11, 2021
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	10130636	Aug 17, 2035	U-2012		I-830	May 15, 2023
	10130636	Aug 17, 2035	U-2101			
	10130636	Aug 17, 2035	U-2273			
	10130636	Aug 17, 2035	U-2830			
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2101			
	7351701	Jul 23, 2024	U-2273			
	7351701	Jul 23, 2024	U-2830			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2830			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8071579	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2830			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	8859562	Aug 04, 2031	U-2830			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	10130636	Aug 17, 2035	U-2012		I-830	May 15, 2023
	10130636	Aug 17, 2035	U-2101			
	10130636	Aug 17, 2035	U-2273			
	10130636	Aug 17, 2035	U-2830			
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2101			
7351701		Jul 23, 2024	U-2273			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	7351701	Jul 23, 2024	U-2830			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2830			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8071579	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2830			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	8859562	Aug 04, 2031	U-2830			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	10130636	Aug 17, 2035	U-2012		I-830	May 15, 2023
	10130636	Aug 17, 2035	U-2101			
	10130636	Aug 17, 2035	U-2273			
	10130636	Aug 17, 2035	U-2830			
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2101			
	7351701	Jul 23, 2024	U-2273			
	7351701	Jul 23, 2024	U-2830			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2830			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8071579	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2830			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	8859562	Aug 04, 2031	U-2830			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	10682338	Sep 04, 2035	U-2583			
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	10519139	Aug 14, 2035	DS DP U-2584		I-837	Jun 22, 2023
	10519139	Aug 14, 2035	DS DP U-2855			
	10544108	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-2826		ODE-301	May 08, 2027
	10137124	Oct 10, 2037	U-2827		ODE-302	May 08, 2027
	10137124	Oct 10, 2037	U-2828		ODE-303	May 08, 2027
	10172851	Oct 10, 2037	U-2826			
	10172851	Oct 10, 2037	U-2827			
	10172851	Oct 10, 2037	U-2828			
	10584124	Oct 10, 2038	DS U-2826			
	10584124	Oct 10, 2038	DS U-2827			
	10584124	Oct 10, 2038	DS U-2828			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMQ</u>						
N 213246 002	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-2826		ODE-301	May 08, 2027
	10137124	Oct 10, 2037	U-2827		ODE-302	May 08, 2027
	10137124	Oct 10, 2037	U-2828		ODE-303	May 08, 2027
	10172851	Oct 10, 2037	U-2826			
	10172851	Oct 10, 2037	U-2827			
	10172851	Oct 10, 2037	U-2828			
	10584124	Oct 10, 2038	DS U-2826			
	10584124	Oct 10, 2038	DS U-2827			
	10584124	Oct 10, 2038	DS U-2828			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	7425637	Apr 11, 2024	DS		NCE	Apr 10, 2025
	8178693	Mar 13, 2023	DS DP		ODE-288	Apr 10, 2027
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS U-2800			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	7425637	Apr 11, 2024	DS		NCE	Apr 10, 2025
	8178693	Mar 13, 2023	DS DP		ODE-288	Apr 10, 2027
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS U-2800			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001					I-822	Jan 16, 2023
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002					I-822	Jan 16, 2023
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001					M-252	Jan 16, 2023
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002					M-252	Jan 16, 2023
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003					M-252	Jan 16, 2023
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001					ODE-231 PED	Oct 26, 2025 Apr 26, 2026
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001	10695365	Oct 22, 2033	DS		M-261	Apr 24, 2023
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	10695365	Oct 22, 2033	DS		M-261	Apr 24, 2023
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001					NPP >A> ODE-293	Mar 19, 2023 Mar 19, 2027
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 002	10086011	Jan 30, 2034	U-1470		NS	Mar 19, 2023
	7964580	Mar 26, 2029	DS DP U-1470		>A> ODE-293	Mar 19, 2027
	8334270	Mar 21, 2028	DS DP U-1470			
	8575135	Nov 16, 2032	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8735372	Mar 21, 2028	U-1470			
	8889159	Mar 26, 2029	DP U-1470			
	8921341	Nov 16, 2032	DS DP U-1470			
	8940718	Nov 16, 2032	DS DP U-1470			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 002	9085573	Mar 21, 2028	DS DP U-1470			
	9284342	Sep 13, 2030	DS DP U-1470			
	9757406	Jan 30, 2034	DP			
<u>SOLIFENACIN SUCCINATE - VESICARE LS</u>						
N 209529 001					NP PED	May 26, 2023 Nov 26, 2023
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	10512609	Sep 05, 2037	U-2548			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	10512609	Sep 05, 2037	U-2548			
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	10512620	Aug 18, 2038	U-2769			
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478 001	10624906	Oct 28, 2036	DP			
	10660907	Oct 28, 2036	DP			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	10624855	Nov 26, 2034	DP			
	10682376	Nov 13, 2028	DP			
	10695367	Nov 13, 2028	DP			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	RE44733	Jan 27, 2026	DS DP U-1794		M-262	Jun 09, 2023
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	RE44733	Jan 27, 2026	DS DP U-1794		M-262	Jun 09, 2023
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884 001	10603305	Jun 16, 2030	DP U-1719			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	>A> 10722667	Dec 30, 2028	DP			
<u>SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH</u>						
N 208223 001	10537554	Jan 29, 2036	U-72			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 001					M-253	Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002					M-253	Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003					M-253	Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004					M-253	Jan 29, 2023
<u>TACROLIMUS - PROGRAF</u>						
N 050708 001					ODE-294	May 24, 2025
<u>TACROLIMUS - PROGRAF</u>						
N 050708 002					ODE-294	May 24, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - PROGRAF</u>						
N 050708	003				ODE-294	May 24, 2025
<u>TACROLIMUS - PROGRAF</u>						
N 050709	001				ODE-294	May 24, 2025
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406	001	10548880	Aug 30, 2024	U-2677		
		10548880	Aug 30, 2024	U-2678		
		8664239	Aug 30, 2028	U-1752		
		8664239	Aug 30, 2028	U-2677		
		8664239	Aug 30, 2028	U-2678		
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406	002	10548880	Aug 30, 2024	U-2677		
		10548880	Aug 30, 2024	U-2678		
		8664239	Aug 30, 2028	U-1752		
		8664239	Aug 30, 2028	U-2677		
		8664239	Aug 30, 2028	U-2678		
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406	003	10548880	Aug 30, 2024	U-2677		
		10548880	Aug 30, 2024	U-2678		
		8664239	Aug 30, 2028	U-1752		
		8664239	Aug 30, 2028	U-2677		
		8664239	Aug 30, 2028	U-2678		
<u>TASIMELTEON - HETLIOZ</u>						
N 205677	001	10610510	Jan 25, 2033	U-2805		
		10610511	Oct 10, 2034	U-2806		
<u>TAZAROTENE - FABIOR</u>						
N 202428	001	10568859	Feb 24, 2030	DP U-2760		
		10688071	Feb 24, 2030	DP U-2760		
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723	001	10155002	Apr 13, 2032	U-2736	I-835	Jun 18, 2023
		10245269	Apr 11, 2033	U-2737	I-836	Jun 18, 2023
		10245269	Apr 11, 2033	U-2851	NCE	Jan 23, 2025
		10245269	Apr 11, 2033	U-2854	ODE-299	Jan 23, 2027
		10369155	Oct 16, 2035	U-2736		
		10369155	Oct 16, 2035	U-2852		
		10369155	Oct 16, 2035	U-2853		
		10420775	Apr 13, 2032	U-2736		
		10420775	Apr 13, 2032	U-2852		
		10420775	Apr 13, 2032	U-2853		
		8410088	Apr 13, 2032	DS DP		
		8691507	Sep 12, 2031	U-2852		
		8765732	Apr 13, 2032	U-2852		
		8765732	Apr 13, 2032	U-2853		
		8895245	Sep 12, 2031	U-2852		
		9090562	Apr 13, 2032	DS DP		
		9175331	Sep 12, 2031	U-2852		
		9333217	Sep 12, 2031	U-2852		
		9334527	Sep 12, 2031	U-2852		
		9394283	Apr 11, 2033	DS DP U-2852		
		9394283	Apr 11, 2033	DS DP U-2853		
		9522152	Apr 13, 2032	U-2738		
		9549931	Apr 13, 2032	U-2736		
		9549931	Apr 13, 2032	U-2852		
		9549931	Apr 13, 2032	U-2853		
		9688665	Aug 22, 2034	U-2736		
		9855275	Apr 13, 2032	U-2736		
		9872862	Apr 11, 2033	U-2738		
		9889138	Oct 16, 2035	U-2736		
		9889138	Oct 16, 2035	U-2852		
		9889138	Oct 16, 2035	U-2853		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	9949999	Sep 12, 2031	U-2851			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001	6409990	May 12, 2025	DS			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001 >A>	7816379	Jun 20, 2028	DS DP U-2507		NPP	Jun 19, 2023
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001 >A>	7816379	Jun 20, 2028	DS DP U-2507		NPP	Jun 19, 2023
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001 >A>	7390791	Apr 17, 2025	DS DP		M-255	Feb 04, 2023
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	10238662	Feb 19, 2035	DP U-2418			
	10279131	Jul 31, 2031	DP			
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10646495	Aug 30, 2038	DP			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	10238662	Feb 19, 2035	DP U-2418			
	10279131	Jul 31, 2031	DP			
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10646495	Aug 30, 2038	DP			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	10238662	Feb 19, 2035	DP U-2418			
	10279131	Jul 31, 2031	DP			
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10646495	Aug 30, 2038	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	10588975	Mar 13, 2026	DP			
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	RE47526	Apr 09, 2024	DP			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 002	7301023	Dec 08, 2020	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	7301023	Dec 08, 2020	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 002	10639309	Mar 14, 2034	DP			
	7301023	Dec 08, 2020	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	10695308	Dec 16, 2024	U-2845			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	10695308	Dec 16, 2024	U-2845			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	10695308	Dec 16, 2024	U-2845			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	10695308	Dec 16, 2024	U-2845			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	10376525	May 14, 2027	U-1849			
	10716793	May 14, 2027	U-1849			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	8747897	Aug 11, 2031	DP U-2724		>A> ODE-308	Dec 20, 2020
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	8747897	Aug 11, 2031	DP U-2724		>A> ODE-308	Dec 20, 2020
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	8747897	Aug 11, 2031	DP U-2724		>A> ODE-308	Dec 20, 2020
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	8747897	Aug 11, 2031	DP U-2724		>A> ODE-308	Dec 20, 2020
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	8747897	Aug 11, 2031	DP U-2724		>A> ODE-308	Dec 20, 2020
	8747897	Aug 11, 2031	DP U-2725			
<u>TRETINOIN - ALTRENO</u>						
N 209353 001	10653656	Aug 22, 2038	DP U-2368			
<u>TRIHEPTANOIN - DOJOLVI</u>						
N 213687 001					NCE	Jun 30, 2025
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437 001	10166181	Jun 30, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001	10166181	Jun 30, 2029	DP			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	7452895	Nov 16, 2024	DS DP U-2788		NCE	Apr 17, 2025
	8648087	Apr 12, 2031	DS DP			
	9457093	Oct 12, 2032	DP U-2788			
	9693989	May 09, 2027	DP U-2788			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	7452895	Nov 16, 2024	DS DP U-2788		NCE	Apr 17, 2025
	8648087	Apr 12, 2031	DS DP			
	9457093	Oct 12, 2032	DP U-2788			
	9693989	May 09, 2027	DP U-2788			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	10117836	Jan 30, 2035	DP			
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Nov 10, 2031	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	10117836	Jan 30, 2035	DP			
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Nov 10, 2031	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001					M-245	Jun 09, 2022
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	10519164	Oct 17, 2036	DP			
	10597400	Oct 17, 2036	U-2616			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 001	10688046	Mar 13, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 002	10688046	Mar 13, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 005	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 006	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 007	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 003	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 004	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001 >A>	10730873	Nov 21, 2031	DS			
	8722657	Jan 29, 2032	DS			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002 >A>	10730873	Nov 21, 2031	DS			
	8722657	Jan 29, 2032	DS			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003 >A>	10730873	Nov 21, 2031	DS			
	8722657	Jan 29, 2032	DS			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022	U-839			
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022	U-839			
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022	U-839			
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
<u>VILTOLARSEN - VILTEPSO</u>						
N 212154 001 >A>	9079934	Aug 31, 2031	DS DP		>A> NCE	Aug 12, 2025
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	10017491	Dec 28, 2032	DP		ODE-281	Nov 25, 2026
	10034879	Dec 28, 2032	DS DP			
	10493035	Oct 12, 2037	DP			
>A>	10722502	Feb 06, 2035	DP			
	9018210	Dec 28, 2032	DS DP			
	9248199	Jan 29, 2034	U-2676			
	9248199	Jan 29, 2034	U-2715			
	9447071	Feb 06, 2035	DS DP			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 40th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm